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A B S T R A C T
Background
Respiratory morbidity including respiratory distress syndrome (RDS) is a serious complication of preterm birth and the primary cause
of early neonatal mortality and disability. While researching the effects of the steroid dexamethasone on premature parturition in fetal
sheep in 1969, Liggins found that there was some inflation of the lungs of lambs born at gestations at which the lungs would be expected
to be airless. Liggins and Howie published the first randomised controlled trial in humans in 1972 and many others followed.
Objectives
To assess the effects of administering a course of corticosteroids to the mother prior to anticipated preterm birth on fetal and neonatal
morbidity and mortality, maternal mortality and morbidity, and on the child in later life.
Search methods
We searched Cochrane Pregnancy and Childbirth’s Trials Register (17 February 2016) and reference lists of retrieved studies.
Selection criteria
We considered all randomised controlled comparisons of antenatal corticosteroid administration (betamethasone, dexamethasone, or
hydrocortisone) with placebo, or with no treatment, given to women with a singleton or multiple pregnancy, prior to anticipated
preterm delivery (elective, or following spontaneous labour), regardless of other co-morbidity, for inclusion in this review. Most women
in this review received a single course of steroids; however, nine of the included trials allowed for women to have weekly repeats.
Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. The
quality of the evidence was assessed using the GRADE approach.
Main results
This update includes 30 studies (7774 women and 8158 infants). Most studies are of low or unclear risk for most bias domains. An
assessment of high risk usually meant a trial had potential for performance bias due to lack of blinding. Two trials had low risks of bias
for all risk of bias domains.
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Treatment with antenatal corticosteroids (compared with placebo or no treatment) is associated with a reduction in the most serious
adverse outcomes related to prematurity, including: perinatal death (average risk ratio (RR) 0.72, 95% confidence interval (CI) 0.58
to 0.89; participants = 6729; studies = 15; Tau² = 0.05, I² = 34%; moderate-quality); neonatal death (RR 0.69, 95% CI 0.59 to 0.81;
participants = 7188; studies = 22), RDS (average RR 0.66, 95% CI 0.56 to 0.77; participants = 7764; studies = 28; Tau² = 0.06, I²
= 48%; moderate-quality); moderate/severe RDS (average RR 0.59, 95% CI 0.38 to 0.91; participants = 1686; studies = 6; Tau² =
0.14, I² = 52%); intraventricular haemorrhage (IVH) (average RR 0.55, 95% CI 0.40 to 0.76; participants = 6093; studies = 16;
Tau² = 0.10, I² = 33%; moderate-quality), necrotising enterocolitis (RR 0.50, 95% CI 0.32 to 0.78; participants = 4702; studies =
10); need for mechanical ventilation (RR 0.68, 95% CI 0.56 to 0.84; participants = 1368; studies = 9); and systemic infections in
the first 48 hours of life (RR 0.60, 95% CI 0.41 to 0.88; participants = 1753; studies = 8).
There was no obvious benefit for: chronic lung disease (average RR 0.86, 95% CI 0.42 to 1.79; participants = 818; studies = 6; Tau²
= 0.38 I² = 65%); mean birthweight (g) (MD -18.47, 95% CI -40.83 to 3.90; participants = 6182; studies = 16; moderate-quality);
death in childhood (RR 0.68, 95% CI 0.36 to 1.27; participants = 1010; studies = 4); neurodevelopment delay in childhood (RR
0.64, 95% CI 0.14 to 2.98; participants = 82; studies = 1); or death into adulthood (RR 1.00, 95% CI 0.56 to 1.81; participants =
988; studies = 1).
Treatment with antenatal corticosteroids does not increase the risk of chorioamnionitis (RR 0.83, 95% CI 0.66 to 1.06; participants
= 5546; studies = 15; moderate-quality evidence) or endometritis (RR 1.20, 95% CI 0.87 to 1.63; participants = 4030; studies = 10;
Tau² = 0.11, I² = 28%; moderate-quality). No increased risk in maternal death was observed. However, the data on maternal death
is based on data from a single trial with two deaths; four other trials reporting maternal death had zero events (participants = 3392;
studies = 5; moderate-quality).
There is no definitive evidence to suggest that antenatal corticosteroids work differently in any pre-specified subgroups (singleton versus
multiple pregnancy; membrane status; presence of hypertension) or for different study protocols (type of corticosteroid; single course
or weekly repeats).
GRADE outcomes were downgraded to moderate-quality. Downgrading decisions (for perinatal death, RDS, IVH, and mean birth-
weight) were due to limitations in study design or concerns regarding precision (chorioamnionitis, endometritis). Maternal death was
downgraded for imprecision due to few events.
Authors’ conclusions
Evidence from this update supports the continued use of a single course of antenatal corticosteroids to accelerate fetal lung maturation
in women at risk of preterm birth. A single course of antenatal corticosteroids could be considered routine for preterm delivery. It is
important to note that most of the evidence comes from high income countries and hospital settings; therefore, the results may not be
applicable to low-resource settings with high rates of infections.
There is little need for further trials of a single course of antenatal corticosteroids versus placebo in singleton pregnancies in higher
income countries and hospital settings. However, data are sparse in lower income settings. There are also few data regarding risks and
benefits of antenatal corticosteroids in multiple pregnancies and other high-risk obstetric groups. Further information is also required
concerning the optimal dose-to-delivery interval, and the optimal corticosteroid to use.
We encourage authors of previous studies to provide further information, which may answer any remaining questions about the use of
antenatal corticosteroids in such pregnancies without the need for further randomised controlled trials. Individual patient data meta-
analysis from published trials is likely to answer some of the evidence gaps. Follow-up studies into childhood and adulthood, particularly
in the late preterm gestation and repeat courses groups, are needed. We have not examined the possible harmful effects of antenatal
corticosteroids in low-resource settings in this review. It would be particularly relevant to explore this finding in adequately powered
prospective trials.
P L A I N L A N G U A G E S U M M A R Y
Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
What is the issue?
Babies born very early, or very preterm, are at risk of having breathing difficulties and other serious health problems at birth, as a child
and later in life. Some babies born very early do not survive these difficulties. Some babies have health problems that prevent them
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from developing as they should and can lead to problems with movement or learning. Corticosteroids are medicines given to women in
early labour to help the babies’ lungs to mature more quickly and so reduce the number of babies who die or suffer breathing problems
at birth.
Why is this important?
Breathing problems are the main cause of death and serious health problems for babies born very early. Pregnant women who have
rupturedmembranes or spontaneous preterm labour can take corticosteroids to helpmature the baby’s lungs. In this review, we compared
women and babies who had these medicines to women and babies who did not.
What evidence did we find?
We searched Cochrane Pregnancy and Childbirth’s Trials Register (17 February 2016).
We looked at 30 trials where corticosteroids were given to women at risk of preterm birth (7774 women and 8158 infants). The trials
were all carried out in hospitals in high-income countries. Our review shows that a single course of a corticosteroids, given to the
mother in preterm labour and before the baby is born, helps to develop the baby’s lungs and reduces complications such as breathing
problems. Furthermore, this treatment results in fewer babies dying at birth, and fewer babies having other serious health problems
that commonly affect babies born very early (such as bleeding in the brain or damage to the baby’s intestines).
For the mother, having a single course of corticosteroids did not appear to impact on the number of women who had infections of the
womb (chorioamnionitis or endometritis). There were too few data available to fully assess the outcome of maternal death.
The quality of the trial evidence was moderate, which means that we can be reasonably confident that future studies of corticosteroids
in similar hospital settings will come to the same conclusions about the benefits and safety of treatment for women and babies.
What does this mean?
Most pregnant women who are at risk of giving birth very early or very preterm will benefit from having a corticosteroid medicine.
These medicines appear to be safe for pregnant women and babies when given in hospital settings in high-income countries, and they
improve the chance that the preterm baby will survive and avoid immediate health problems.We have less information about the impact
of steroids on women with multiple pregnancy and on women with other problems during pregnancy such as high blood pressure or
ruptured membranes. We are uncertain whether a specific steroid or dosage is best for women and babies.
Evidence in this review comes from high-income countries and hospital settings; therefore, the results may not be applicable to low-
resource settings with high rates of infections.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Cort icosteroids versus placebo or no treatment
Patient or population: pregnant women at high risk of preterm birth receiving a cort icosteroid or placebo/ no treatment; women with singleton and mult iple pregnancy and
intact and ruptured membranes
Setting: hospital sett ings in high-income countries. For example, data for RDS come f rom 28 trials in 15 dif ferent countries, but only one of these countries is of lower income
(Tunisia)
Intervention: cort icosteroids (dexamethasone or betamethasone) according to various doses and regimens; some trials with weekly repeats
Comparison: placebo (usually normal saline) or no treatment
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Few events and wide conf idence interval led to a downgrade for imprecision (-1). Because maternal death is a rare event and
the total populat ion is over 3000 women, we have opted for (-1) rather than (-2).
2Wide conf idence interval crossing the line of no ef fect (-1).
3Value of I2 = 34%with random-ef fects model. We have not downgraded evidence for heterogeneity.
4Value of I2 = 37%with random-ef fects model. We have not downgraded for heterogeneity. Result downgraded once for risks
of bias in included trials (-1).
5Value of I2 = 47%with random-ef fects model. We have not downgraded for heterogeneity. Result downgraded once for risks
of bias in included trials (-1).
6Value of I2 = 33%with random-ef fects model. We have not downgraded for heterogeneity. Result downgraded once for risks




















































































































7The conf idence interval showed a dif ference at most on average of 40 g in weight; because this is less than 10% of the
lightest average for babies in any trial, we have not downgraded evidence for imprecision. We have downgraded the result for





















































































































B A C K G R O U N D
Description of the condition
Respiratory distress syndrome (RDS) is a serious complication of
preterm birth and the primary cause of early neonatal death and
disability (Rodriguez 2002). It affects up to half of babies born
before 28 weeks and a third of babies born before 32 weeks. Ap-
proximately 42% of extremely low birthweight babies have RDS
(less than 1500 g) (Hintz 2007).
Respiratory failure in these infants occurs as a result of surfactant
deficiency, poor lung anatomical development and immaturity in
other organs. Neonatal survival after preterm birth improves with
gestation (Doyle 2001a), reflecting improved maturity of organ
systems. However, those who survive early neonatal care are at
increased risk of long-term neurological disability (Doyle 2001b).
Some understanding of fetal lung development may be useful in
understanding why RDS occurs and why corticosteroids work.
Fetal lung development can be divided into five stages: embry-
onic, pseudoglandular, canalicular, terminal sac and alveolar. The
lung first appears as an outgrowth of the primitive foregut at 22 to
26 days after conception. By 34 days, the outgrowth has divided
into left and right sides and further to form the major units of
the lung. Mature lungs contain more than 40 different cell types
derived from this early tissue. From eight to 16 weeks’ gestation,
the major bronchial airways and associated respiratory units of the
lung are progressively formed. At this time the lung blood vessels
also begin to grow in parallel. From 17 to 25 weeks’ gestation, the
airways grow, widen and lengthen (canalisation). Terminal bron-
chioles with enlargements that subsequently give rise to terminal
sacs (the primitive alveoli) are formed. These are the functional
units of the lung (respiratory lobules). It is at this stage that the in-
creasing proximity of blood capillaries begins the air-blood inter-
face, required for effective air exchange. This can only take place at
the terminal bronchioles. At the end of the canalicular stage, type
I and II pneumocytes can be seen in the alveoli. From 28 to 35
weeks’ gestation, the alveoli can be counted and with increasing
age they become more mature. Lung volume increases four-fold
between 29 weeks and term. Alveolar number shows a curvilinear
increase with age but a linear relationship with bodyweight. At
birth there are an average of 150 million alveoli (half the expected
adult number). The alveoli produce surfactant. The alveolar stage
continues for one to two years after birth. In the preterm infant,
low alveolar numbers probably contribute to respiratory dysfunc-
tion.
The fetal lung also matures biochemically with increasing ges-
tation. Lamellar bodies, which store surfactant, appear at 22 to
24 weeks. Surfactant is a complex mixture of lipids and apopro-
teins, the main constituents of which are dipalmitoylphosphatidyl
choline, phosphatidylglycerol and apoproteins A, B, C and D.
Surfactant is needed to maintain stability when breathing out, to
prevent collapse of the alveoli. Premature infants have a qualita-
tive and quantitative deficiency of surfactant, which predisposes to
RDS. At the low lung volume associated with expiration, surface
tension becomes very high, leading to atelectasis with subsequent
intrapulmonary shunting, ventilation perfusion inequalities, and
ultimately respiratory failure. Capillary leakage allows inhibitors
fromplasma to reach alveoli and inactivate any surfactant that may
be present. Hypoxia, acidosis and hypothermia (common prob-
lems in the very preterm infant) can reduce surfactant synthesis
required to replenish surfactant lost from the system. The pul-
monary antioxidant system develops in parallel to the surfactant
system and deficiency in this also puts the preterm infant at risk
of chronic lung disease.
Description of the intervention
While researching the effects of the steroid dexamethasone on
premature parturition in fetal sheep in 1969, Liggins found that
there was some inflation of the lungs of lambs born at gestations
at which the lungs would be expected to be airless (Liggins 1969).
Liggins andHowie performed the first randomised controlled trial
in humans of betamethasone for the prevention of RDS in 1972
(Liggins 1972a).
Several clinical trials have been performed on the effects of cor-
ticosteroids before preterm birth since the original Liggins study.
The first structured review on corticosteroids in preterm birth was
published in 1990 (Crowley 1990). This review showed that corti-
costeroids given prior to pretermbirth (as a result of either preterm
labour or planned preterm delivery) are effective in preventing
RDS and neonatal mortality. Corticosteroid treatment was also
associated with a significant reduction in the risk of intraventric-
ular haemorrhage (IVH). Corticosteroids appear to exert major
vasoconstrictive effects on fetal cerebral blood flow, protecting the
fetus against IVH at rest and when challenged by conditions caus-
ing vasodilatation such as hypercapnia (Schwab 2000). Crowley
found no effect on necrotising enterocolitis or chronic lung disease
from antenatal corticosteroid administration. The influence of the
results of the original trial and Crowley’s review was the subject of
a Wellcome Witness Seminar (Wellcome 2005) held in 2004.
Corticosteroids have become the mainstay of prophylactic treat-
ment in preterm birth, as a result of these findings and subsequent
work. However, there have remained a number of outstanding is-
sues regarding the use of antenatal corticosteroids. The original
trial by Liggins suggested an increased rate of stillbirth in women
with hypertension syndromes (Liggins 1976). There is concern
about using corticosteroids in women with premature rupture of
membranes due to the possible increased risk of neonatal and ma-
ternal infection (Imseis 1996; NIH 1994). The efficacy of this
treatment in multiple births has only been addressed retrospec-
tively (Turrentine 1996). From the time of the original Liggins
paper, debate has continued around whether the treatment is ef-
fective at lower gestations and at differing treatment-to-delivery
intervals. Recently, debate has also centred around whether treat-
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ment is effective at latter gestations, up to and including term
delivery (Sotiriadis 2009). These issues will be addressed in this
review in subgroup analyses. The effectiveness and safety of repeat
doses of corticosteroids for womenwho remain undelivered, but at
increased risk of preterm birth after an initial course of treatment,
is addressed in a separate Cochrane Review (Crowther 2015).
Recent epidemiological evidence and animal work suggests that
there may be adverse long-term consequences of antenatal expo-
sure to corticosteroids (Seckl 2000). Exposure to excess corticos-
teroids before birth is hypothesised to be a key mechanism under-
lying the fetal origins of adult disease hypothesis (Barker 1998;
Benediktsson 1993). This hypothesis postulates a link between
impaired fetal growth, and cardiovascular disease and type 2 dia-
betes in later life along with their risk factors of impaired glucose
tolerance, dyslipidaemia, and hypertension (Barker 1998). A large
body of animal experimental work has documented impaired glu-
cose tolerance and increased blood pressure in adult animals after
antenatal exposure to corticosteroids (Clark 1998; Dodic 1999;
Edwards 2001). Thus, this review has considered blood pressure,
glucose intolerance, dyslipidaemia, and hypothalamo-pituitary-
adrenal axis function in childhood and adulthood.
Experimental animal studies have also shown decreased brain
growth in preterm and term infants exposed to single courses of
corticosteroid (Huang 1999; Jobe 1998). This reviewhas therefore
also addressed long-term neurodevelopment and other childhood
and adult outcomes after antenatal corticosteroid exposure.
How the intervention might work
Liggins 1972a theorised that dexamethasone might have accel-
erated the appearance of pulmonary surfactant. The hypothesis
is that corticosteroids act to trigger the synthesis of ribonucleic
acid that codes for particular proteins involved in the biosynthesis
of phospholipids or in the breakdown of glycogen. Subsequent
work has suggested that, in animal models, corticosteroids mature
a number of organ systems (Padbury 1996; Vyas 1997).
Why it is important to do this review
There was a need for an updated systematic review of the effects
of prophylactic corticosteroids for preterm birth, as a result of cur-
rent interest and due to further published trials. In the previous
review we were able to re-analyse the Auckland Steroid Study by
intention-to-treat. This study contributes 15% of the participants
to the review so this was an important development for the review.
This update is needed because it has been some time since the pre-
vious version was published, review methodology for Cochrane
Reviews has changed, and we attempted to standardise the review
with the Cochrane Review on ’Repeat doses of prenatal corticos-
teroids for women at risk of preterm birth for improving neonatal
health outcomes’ (Crowther 2015).
O B J E C T I V E S
To assess the effects of administering a course of corticosteroids to
themother prior to anticipated pretermbirth on fetal and neonatal
morbidity and mortality, maternal mortality and morbidity, and
on the child in later life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised controlled comparisons of antena-
tal corticosteroid administration (betamethasone, dexamethasone,
or hydrocortisone) with placebo, or with no treatment, given to
women prior to anticipated preterm delivery (elective, or follow-
ing spontaneous labour), regardless of other co-morbidity, for in-
clusion in this review. Quasi-randomised (e.g. allocation by date
of birth or record number), cross-over and cluster-randomised tri-
als were not eligible for inclusion. We included trials where the
method of randomisation was not specified in detail in the expec-
tation that their inclusion in this reviewwould encourage the study
authors to make available further information on the method of
randomisation. We excluded trials where non-randomised cohorts
were amalgamated with randomised participants if the results of
the randomised participants could not be separated out. We also
excluded trials that tested the effect of corticosteroids along with
other co-interventions. We included trials in which placebo was
not used in the control group. We also included published, un-
published and ongoing randomised trials with reported data.
Types of participants
Women, with a singleton or multiple pregnancy, expected to de-
liver preterm as a result of either spontaneous preterm labour,
preterm prelabour rupture of the membranes or planned preterm
delivery.
Types of interventions
Trials tested a corticosteroid capable of crossing the placenta
(betamethasone, dexamethasone, hydrocortisone) compared with
placebo or with no treatment. Most trials tested a single course of
steroid, though some included trials allowed for weekly repeats.
We discarded data from trials involving the use of methyl-pred-
nisolone (Block 1977; Schmidt 1984), as this corticosteroid has
not been shown to induce maturation in animal models and is
known to have altered placental transfer (Block 1977).We planned
predefined subgroups to separately examine primary outcomes in
women and infants depending on the specific drug used. Single
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versus multiple doses of corticosteroids is the subject of another
Cochrane Review (Crowther 2015).
Types of outcome measures
Primary outcomes chosenwere those whichwere thought to be the
most clinically valuable in assessing effectiveness and safety of the
treatment for the woman and her offspring. Secondary outcomes





2. chorioamnionitis (however defined by study authors);








6. chronic lung disease (need for continuous supplemental
oxygen at 28 days postnatal age or 36 weeks’ postmenstrual age,
whichever was later);
7. intraventricular haemorrhage (IVH) (diagnosed by
ultrasound, diagnosed by autopsy);
8. mean birthweight (g).
For the child:
1. death;
2. neurodevelopmental disability at follow-up (blindness,
deafness, moderate/severe cerebral palsy (however defined by
study authors), or development delay/intellectual impairment
(defined as developmental quotient or intelligence quotient less
than -2 standard deviation below population mean)).
For the child as adult:
1. death;
2. neurodevelopmental disability at follow-up (blindness,
deafness, moderate/severe cerebral palsy (however defined by
study authors), or development delay/intellectual impairment
(defined as developmental quotient or intelligence quotient less
than -2 standard deviation below population mean)).
Secondary outcomes
For the woman:
1. fever after trial entry requiring the use of antibiotics;
2. intrapartum fever requiring the use of antibiotics;
3. postnatal fever;
4. admission to intensive care unit;
5. side effects of therapy;
6. glucose intolerance (however defined by study authors);
7. hypertension (however defined by study authors).
For the fetus/neonate:
1. Apgar score less than seven at five minutes;
2. interval between trial entry and birth;
3. mean length at birth (height);
4. mean head circumference at birth;
5. mean skin fold thickness at birth;
6. small-for-gestational age (however defined by study
authors);
7. mean placental weight;
8. neonatal blood pressure;
9. admission to neonatal intensive care unit (NICU);
10. need for inotropic support;
11. mean duration of inotropic support (days);
12. need for mechanical ventilation/continuous positive
airways pressure;
13. mean duration of mechanical ventilation/continuous
positive airways pressure (days);
14. air leak syndrome;
15. duration of oxygen supplementation (days);
16. surfactant use;
17. systemic infection in first 48 hours of life;
18. proven infection while in the NICU)
19. necrotising enterocolitis;
20. hypothalamo-pituitary-adrenal (HPA) axis function
(however defined by study authors).
For the child:
1. mean weight;
2. mean head circumference;
3. mean height;
4. mean skin fold thickness;
5. abnormal lung function (however defined by study
authors);
6. mean blood pressure;
7. glucose intolerance (however defined by study authors);
8. HPA axis function (however defined by study authors);
9. dyslipidaemia (however defined by study authors);
10. visual impairment (however defined by study authors);
11. hearing impairment (however defined by study authors);
12. developmental delay (defined as developmental quotient
less than -2 standard deviation below population mean);
13. intellectual impairment (defined as intelligence quotient
less than -2 standard deviation below population mean);
14. cerebral palsy (however defined by study authors);
15. behavioural/learning difficulties (however defined by study
authors).
For the child as adult:
1. mean weight;
2. mean head circumference;
3. mean height;
4. mean skin fold thickness;
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5. abnormal lung function (however defined by study
authors);
6. mean blood pressure;
7. glucose intolerance (however defined by study authors);
8. HPA axis function (however defined by study authors);
9. dyslipidaemia (however defined by study authors);
10. mean age at puberty;
11. bone density (however defined by study authors);
12. educational achievement (completion of high school, or
however defined by study authors);
13. visual impairment (however defined by study authors);
14. hearing impairment (however defined by study authors);
15. intellectual impairment (defined as intelligence quotient
less than -2 standard deviation below population mean).
For health services:
1. mean length of antenatal hospitalisation for women (days);
2. mean length of postnatal hospitalisation for women (days);
3. mean length of neonatal hospitalisation (days);
4. cost of maternal care (in 10s of 1000s of USD);
5. cost of neonatal care (in 10s of 1000s of USD).
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (17 February 2016).
The Register is a database containing over 22,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about Cochrane Pregnancy and Childbirth in
theCochrane Library and select the ‘Specialized Register ’ section
from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in a more specific search set which has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies).
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
Formethods used in the previous version of this review, see Roberts
2006.
For this update, we used the following methods to assess the new
reports that were identified as a result of the updated search.
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors assessed the trials for eligibility and method-
ological quality without consideration of the results. Reasons for
excluding any trial are detailed in the Characteristics of excluded
studies table. Trials were not assessed blind, as we knew the au-
thor’s name, institution and the source of publication. We resolved
any disagreement by discussion until we reached consensus.
Data extraction and management
Two review authors extracted the data, checked them for discrep-
ancies and processed them as described inHiggins 2011a.We con-
tacted authors of each included trial for further information, if we
thought this to be necessary.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b). We resolved
any disagreement by discussion.
(1) Random sequence generation (checking for possible
selection bias)
Wedescribed for each included study themethods used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
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We assessed the methods as:
• low risk of bias (any truly random process, e.g. random
number table; computer random-number generator; tossing a
coin, minimisation);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number; quasi-randomised
studies were excluded from the review);
• unclear risk of bias (unclear description or no description of
randomisation sequence generation).
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to conceal
the allocation sequence in sufficient detail and determine whether
intervention allocation could have been foreseen in advance of, or
during, recruitment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study all the methods used, if
any, to blind study participants and personnel from knowledge
of which intervention a participant received. We also provided
any information relating to whether the intended blinding was
effective. Where blinding was not possible, we assessed whether
the lack of blinding was likely to have introduced bias.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel;
• low, high or unclear risk of bias for outcome assessors
where low risk of bias was when there was blinding or where we
assessed that the outcome or the outcome measurement was not
likely to have been influenced by lack of blinding.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We have assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We described for each included study the completeness of out-
come data for each main outcome, including attrition and exclu-
sions from the analysis. We stated whether attrition and exclusions
were reported, the numbers included in the analyses at each stage
(compared with the total randomised participants), reasons for at-
trition/exclusion where reported, and any re-inclusions in analyses
undertaken.
We assessed the methods as:
• low risk of bias (e.g. where there were no missing data or
where reasons for missing data were balanced across groups);
• high risk of bias (e.g. where missing data were likely to be
related to outcomes or were not balanced across groups);
• unclear risk of bias (e.g. where there was insufficient
reporting of attrition or exclusions to permit a judgement to be
made).
(5) Selective reporting bias
We described for each included study how we examined the pos-
sibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it was clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review were reported);
• high risk of bias (where not all the study’s pre-specified
outcomes were reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest were
reported incompletely and so could not be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other sources of bias
We described for each included study any important concerns we
had about other possible sources of bias. For example, was there
a potential source of bias related to the specific study design? Was
the trial stopped early due to some data-dependent process? Was
there extreme baseline imbalance? Had the study been claimed to
be fraudulent?
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of bias;
• high risk of bias;
• unclear.
(7) Overall risk of bias
We made explicit judgements about risk of bias for important
outcomes both within and across studies. With reference to (1) to
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(6) above we assessed the likely magnitude and direction of the
bias and whether we considered it likely to impact on the findings.
Assessment of the quality of the evidence using
GRADE
For this update the quality of the evidence was assessed using
the GRADE approach as outlined in the GRADE Handbook in
order to assess the quality of the body of evidence relating to
the following outcomes for the main comparison, corticosteroids
versus placebo or no treatment.
1. Maternal death
2. Chorioamnionitis (however defined by study authors)
3. Endometritis (however defined by study authors and
including infections)
4. Perinatal death
5. Respiratory distress syndrome
6. Intraventricular haemorrhage (IVH) (diagnosed by
ultrasound, diagnosed by autopsy)
7. Mean birthweight (g)
We used the GRADEpro Guideline Development Tool to import
data fromReviewManager 5 (RevMan 5) (RevMan 2014) in order
to create ’Summary of findings’ tables. A summary of the inter-
vention effect and a measure of quality for each of the above out-
comes was produced using the GRADE approach. The GRADE
approach uses five considerations (study limitations, consistency
of effect, imprecision, indirectness and publication bias) to assess
the quality of the body of evidence for each outcome. The ev-
idence can be downgraded from ’high quality’ by one level for
serious (or by two levels for very serious) limitations, depending
on assessments for risk of bias, indirectness of evidence, serious
inconsistency, imprecision of effect estimates or potential publi-
cation bias.
Measures of treatment effect
Dichotomous data
In the original review, a weighted estimate of the typical treat-
ment effect across studies was performed using the ’Peto method’
(i.e. ’the typical odds ratio’: the odds of an unfavourable outcome
among treatment-allocated participants to the corresponding odds
among controls). For this update, we have calculated risk ratios
(RR) and 95% confidence intervals (CI) for dichotomous data.
Although odds ratios have been commonly used in meta-analy-
sis, there is potential for them to be interpreted incorrectly, and
current advice is that risk ratios should be used wherever possible
(Deeks 2011). We analysed outcomes on an intention-to-treat ba-
sis.
Continuous data
For continuous data, we used themean difference (MD)with 95%
CI where outcomes were measured using the same instrument.
Where different instruments were used we planned to use the
standardised mean difference with 95% CI.
Unit of analysis issues
Cluster-randomised trials
Cluster-randomised trials were not considered eligible for inclu-
sion in this review.
Cross-over trials
Cross-over trials were not considered eligible for inclusion in this
review.
Other unit of analysis issues
Where possible for multiple pregnancies, the number of babies
was used as the denominator for fetal and neonatal outcomes.
Dealing with missing data
In cases where trial data were missing, we first sought infor-
mation from the original trial investigators. Details of trial au-
thors contacted and the questions asked of them are contained in
Characteristics of included studies. In addition, and where pos-
sible, we performed analyses on all outcomes on an intention-
to-treat basis. It was our intention to include in the analyses all
women randomly assigned to each group and to analyse all women
in the group to which they were allocated, regardless of whether
or not they received the allocated intervention.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² (Higgins 2003) and Chi² statistics. We regarded het-
erogeneity as substantial if an I² was greater than 30% and either
the Tau² was greater than zero, or there was a low P value (less than
0.10) in the Chi² test for heterogeneity. Where we found substan-
tial heterogeneity we used a random-effects model to conduct the
analysis and attempted to explain possible sources of heterogeneity
(Deeks 2011).
Assessment of reporting biases
If there were 10 or more studies in the meta-analysis we inves-
tigated reporting biases (such as publication bias) using funnel
plots (Sterne 2011). We assessed funnel plot asymmetry visually.
If asymmetry was suggested by a visual assessment, we performed
exploratory analyses to investigate it.
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Data synthesis
We carried out statistical analysis using the RevMan 5 software
(RevMan 2014).We used fixed-effectmeta-analysis for combining
datawhere it was reasonable to assume that studies were estimating
the same underlying treatment effect: that is, where trials were
examining the same intervention, and the trials’ populations and
methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we used random-effects
meta-analysis to produce an overall summary if an average treat-
ment effect across trials was considered clinically meaningful. The
random-effects summary was treated as the average of the range of
possible treatment effects and we have discussed the clinical impli-
cations of treatment effects differing between trials. If the average
treatment effect was not clinically meaningful, we planned not to
combine trials. If we used random-effects analyses, we presented
the results as the average treatment effect with 95% CIs, and the
estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
We performed analysis of clinical groups for primary outcomes
only (where data were available).
We analysed the following clinical groups:
1. singleton versus multiple pregnancy;
2. intact membranes versus ruptured membranes at first dose;
3. pregnancy-induced hypertension syndromes;
4. type of glucocorticoid (betamethasone, dexamethasone,
hydrocortisone);
5. decade of trial (post-hoc, i.e.not pre-specified in the
protocol);
6. protocol with weekly repeats (post hoc, i.e. not pre-
specified in the protocol);
7. gestational age at trial entry (post hoc, i.e. not pre-specified
in the protocol).
All covariates were proposed after deliberation with clinical ex-
perts. We planned to explore potential differences in the effect of
corticosteroids in distinct clinical populations, such as pregnant
women with ruptured membranes or multiple pregnancy, and in
different types of trials.
For the main analysis we did not adjust data for multiple preg-
nancies to take account of non-independence of outcomes for ba-
bies from the same pregnancy. For some outcomes there will be a
higher correlation between babies from the same pregnancy than
between babies from different pregnancies. The degree of non-
independence of outcomes for babies from multiple pregnancies
will vary considerably depending on the outcome and the type
of multiple pregnancy. For some outcomes the risk of an adverse
event will be highly correlated in babies from the same pregnancy
(e.g. preterm birth); while for others the degree of correlation will
be lower (e.g. fetal death) but still higher than for babies from dif-
ferent pregnancies. In view of this non-independence, subgroup
analysis examining fetal and neonatal outcomes in singleton versus
multiple pregnancies must be interpreted with particular caution.
We found that some trials included in this review had a protocol
of weekly repeat doses of corticosteroid if the mother remained
undelivered. None of the trials that allowed weekly repeat doses
reported outcomes separately for those exposed to repeat doses.
We performed a post hoc analysis for primary outcomes of trials
where a single course was used versus those where weekly repeat
doses were allowed in the protocol to determine if the inclusion of
such trials biased our results. Single versus multiple doses of cor-
ticosteroids is the subject of another Cochrane Review (Crowther
2015). The analysis in this update will differ from that of the sin-
gle versus multiple doses review, because the latter review includes
only those studies where the women were randomised to either
single or multiple doses.
Because the case-fatality rate for RDS has decreased with improve-
ments in neonatal care, we postulated that the effect of corticos-
teroids may not be as apparent in more recent trials. This hypoth-
esis was tested in a post-hoc subgroup analysis with trials grouped
by the main decade of recruitment or publication of results.
Many trials did not report outcome data split according to the
listed clinical characteristics (covariates). Due to this missing in-
formation, the total number of events/participants in subgroup
analysis for some outcomes does notmatch the overall analysis.We
have indicated in footnotes on the forest plots where the data are
discrepant between the main analysis and the clinical subgroups.
All analyses by the covariates listed above should be considered
hypothesis-generating.
Finally, it should be noted that we did not conduct subgroup
analysis where there were too few trials reporting data to conduct
meaningful analyses.
Sensitivity analysis
We have not conducted any formal sensitivity analysis based on
risks of bias in included trials. We conducted sensitivity analysis
to determine whether conclusions were robust to decisions made
during the review process - for example, regarding missing data,
the definitions of subgroups or the impact of single trials.
We conducted sensitivity analyses for the following specific cases:
where we found heterogeneity greater than 50% for primary out-
comes (see Comparison 1); where we found small amounts of
missing data reported for subgroups compared with the numbers
reported in the main analyses (see Comparison 3); where specific
trials fitted into multiple potential subgroups for our analysis of
gestational age at trial entry (see Comparison 8); and for analysis
of results according to the decade of the trial (see Analysis 6.6).
R E S U L T S
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Description of studies
Results of the search
A total of 48 studies were identified and 30 met the inclusion
criteria. Twenty-eight were excluded. One study report previously
in ongoing studies was included at this update with the full trial
report (Gyamfi-Bannerman 2016).
Included studies
Thirty studies met our inclusion criteria, with data available for
7774 women and 8158 infants. The included studies were con-
ducted over a wide range of gestational ages, including those of
extreme prematurity and late prematurity. Obstetric indications
for recruitment to trials were premature rupture of membranes,
spontaneous preterm labour and planned preterm delivery. Please
also refer to the Characteristics of included studies tables.
The included studies came from a range of healthcare systems
and treatment eras. Thirteen of the studies were conducted in
the USA (Block 1977; Carlan 1991; Collaborative 1981; Garite
1992; Goodner 1979; Gyamfi-Bannerman 2016; Lewis 1996;
Morales 1989; Nelson 1985; Parsons 1988; Shanks 2010; Silver
1996; Taeusch 1979), two studies each were conducted in Finland
(Kari 1994; Teramo 1980), Iran (Khazardoust 2012; Mansouri
2010), and Brazil (Amorim 1999; Porto 2011), and one study
from each of the following countries, Colombia (Lopez 1989),
Spain (Cararach 1991), South Africa (Dexiprom 1999), Turkey
(Balci 2010), Canada (Doran 1980),Tunisia (Fekih 2002), United
Kingdom (Gamsu 1989), New Zealand (Liggins 1972b), Jor-
dan (Qublan 2001), Thailand (Attawattanakul 2015) and the
Netherlands (Schutte 1980). In this update, nine recent tri-
als since 2000 contribute approximately 51% of the data avail-
able for analysis (Attawattanakul 2015; Balci 2010; Fekih 2002;
Gyamfi-Bannerman 2016; Khazardoust 2012; Mansouri 2010;
Porto 2011; Qublan 2001; Shanks 2010).
It should be noted that Khazardoust 2012 contributes no outcome
data to the review.
Multiple pregnancy
The majority of trials recruited only women with singleton preg-
nancy. Twelve trials Collaborative 1981, Dexiprom 1999, Doran
1980, Fekih 2002, Gamsu 1989, Garite 1992, Kari 1994, Liggins
1972b, Schutte 1980, Silver 1996, Taeusch 1979 and Teramo
1980 recruited women with singleton or multiple pregnancy. Of
these, only Collaborative 1981, Gamsu 1989, Liggins 1972b and
Silver 1996 reported outcome data separately for included women
with multiple pregnancy. For two trials recruitment was unclear,
and we analysed available data with the mixed population clinical
group (Goodner 1979 and Lopez 1989).
Membrane status
Several trials specifically excluded women with premature rupture
of membranes: Amorim 1999, Attawattanakul 2015, Balci 2010,
Garite 1992, Kari 1994 and Shanks 2010. Twelve trials reported
outcome data for women with premature rupture of membranes
(Cararach 1991; Carlan 1991;Dexiprom1999; Fekih 2002; Lewis
1996; Liggins 1972b; Lopez 1989; Morales 1989; Nelson 1985;
Parsons 1988; Qublan 2001; Schutte 1980). The remaining in-
cluded trials reported data for a mixed population or the mem-
brane status of included women was unclear. Only Liggins 1972b
reported outcome data separately for women with intact or rup-
tured membranes.
Type of Steroid
Seven of the included studies used dexamethasone as the corticos-
teroid in the treatment arm (1585women and 1708 infants), while
21 studies used betamethasone (6133 women and 6314 infants).
One study did not specify the corticosteroid used (Cararach 1991;
18 women and infants), and one study used either betamethasone
or dexamethasone (Shanks 2010; 32 women and infants).
Decade of trial
Four included trials were published during the 1970s; nine during
the 1980s; eight during the 1990s; five during the 2000s, and four
during the 2010s. The largest trial contributing the most data to
the review is the recent ALPS study (n = 2831;Gyamfi-Bannerman
2016). Please see the Included studies tables for details.
Gestational age at trial entry
We have attached a table stating the gestational parameters for tri-
als included in the review (Table 1). For the analysis of clinical sub-
groups for this update, we have compared trials recruiting women
at gestational age of less than and including 35 weeks + 0 days with
trials recruiting women 34 weeks + 0 days’ gestation or greater
for the review’s primary outcomes. Most trials fall on either side
of this division, with the exception of four studies; Block 1977,
Collaborative 1981, Liggins 1972b, and Teramo 1980. Data from
Liggins 1972b was available for women receiving their first dose
at less than 35 weeks + 0 days and from between 35 weeks + 0 days
and 37 weeks + 0 days, footnotes detailing this have been added
to the appropriate forest plots. The majority of women in the re-
maining three studies (Block 1977; Collaborative 1981; Teramo
1980) received their first dose prior to 34 weeks + 0 days, therefore
we included these studies in the younger gestational age grouping
for the analysis (women less than, and including, 35 weeks and 0
days), but undertook a sensitivity analysis with the studies’ data
removed.
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Weekly repeats
Most trials included in this review tested a single course of cor-
ticosteroid. Nine of the included studies allowed weekly repeat
courses of study medication in their study protocols (Amorim
1999;Carlan1991; Fekih 2002;Garite 1992; Lewis 1996;Morales
1989; Parsons 1988; Qublan 2001; Silver 1996) (932 women and
946 infants).We conducted post hoc analysis of primary outcomes
comparing studies testing a single course of study medication with
studies allowing weekly repeat courses.
Excluded studies
We excluded 28 studies. Reasons for exclusion included the fol-
lowing.
1. The study did not compare a corticosteroid with placebo or
no treatment (Abuhamad 1999; Althabe 2015; Dola 1997;
Egerman 1998; Garite 1981; Iams 1985; Koivisto 2007; Magee
1997; Minoui 1998; Mulder 1997; Rotmensch 1999; Whitt
1976).
2. The study was not a randomised controlled trial (Grgic
2003; Halac 1990; Maksic 2008).
3. The study was a quasi-randomised trial (Asnafei 2004; Liu
2006; Morales 1986; Morrison 1978; Simpson 1985).
4. Study participants were combined with a non-randomised
cohort and results were not presented separately (Butterfill 1979;
Kuhn 1982).
5. Two studies were excluded from this update because of
greater than 20% post-randomisation exclusions (Papageorgiou
1979; Schmidt 1984).
6. Several studies compared repeat-dose corticosteroids and are
eligible for inclusion in the Crowther 2015 review (Khandelwal
2012; Koivisto 2007; Kurtzman 2008; McEvoy 2010).
Refer to Characteristics of excluded studies table.
Risk of bias in included studies
Three studies that were included in the previous review have been
excluded. Two (Papageorgiou 1979; Schmidt 1984) were excluded
because of greater than 20% post-randomisation exclusions. The
third (Morales 1986) was excluded as it was quasi-randomised.
Figure 1 and Figure 2 illustrate the risks of bias which are explained
in more detail below.
Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
Sequence generation
We have summarised the methods of randomisation used in the
included studies in the Characteristics of included studies table.
Thirteen studies used computer-generated or random number-
generated randomisation sequences (Amorim 1999; Balci 2010;
Block 1977; Dexiprom 1999; Garite 1992; Gyamfi-Bannerman
2016; Khazardoust 2012; Lewis 1996; Liggins 1972b; Nelson
1985; Porto 2011; Qublan 2001; Silver 1996). We considered
these studies at low risk of bias from sequence generation. The
17 remaining studies did not describe the method of sequence
generation in sufficient detail to enable a judgement of low risk.
Allocation concealment
Thirteen studies used coded drug boxes/vials in order to conceal
the randomisation sequence or study treatment. We assessed one
of these studies as having a high risk of bias due to a sealed en-
velope containing the identity of the contents being attached to
each vial “to be opened in emergency only in case of an emer-
gency”; the manuscripts do not state how often these were opened
(Collaborative 1981). We assessed a further two studies as unclear
risk due to insufficient information provided to confirm the boxes
were sequentially numbered (Taeusch 1979; Teramo 1980).
Six studies used sealed envelopes (Garite 1992; Khazardoust 2012;
Lewis 1996; Morales 1989; Nelson 1985; Shanks 2010), only one
of which was described as opaque (Lewis 1996). The remaining
studies did not specify if the envelopes were opaque and we there-
fore assessed them as having an unclear risk of bias.
Eleven studies did not include any description of the method of
allocation concealment and we also assessed them as having an
unclear risk of bias (Attawattanakul 2015; Cararach 1991; Carlan
1991; Fekih 2002;Gamsu 1989;Goodner 1979;Kari 1994; Lopez
1989; Mansouri 2010; Parsons 1988; Qublan 2001).
Blinding
Eighteen of the included trials were placebo controlled with the
majority of these studies using normal saline, or the vehicle of
the corticosteroid preparation, as the placebo (Amorim 1999;
Block 1977; Collaborative 1981; Dexiprom 1999; Doran 1980;
Gamsu 1989; Garite 1992; Goodner 1979; Gyamfi-Bannerman
2016; Kari 1994; Khazardoust 2012; Liggins 1972b; Mansouri
2010; Porto 2011; Schutte 1980; Silver 1996; Taeusch 1979;
Teramo 1980). The remainder of the included trials were not
blinded as they used expectant management in the control arm
(Attawattanakul 2015; Balci 2010; Cararach 1991; Carlan 1991;
Fekih 2002; Lewis 1996; Lopez 1989;Morales 1989;Nelson1985;
Parsons 1988; Qublan 2001; Shanks 2010).
Blinding of outcome assessors was reported in nine of the 30 trials
(Amorim 1999; Doran 1980; Gyamfi-Bannerman 2016; Liggins
1972b; Mansouri 2010; Porto 2011; Schutte 1980; Silver 1996;
Taeusch 1979).
Incomplete outcome data
Nine of the 30 studies reported no losses to follow-up at
birth, which was their only time point for measuring outcome
(Attawattanakul 2015;Cararach 1991;Doran 1980;Gamsu1989;
Mansouri 2010; Nelson 1985; Parsons 1988; Qublan 2001;
Teramo 1980). In the remaining studies, losses to follow-up were
generally small and less than 5%. There was no evidence to sug-
gest that these exclusions occurred preferentially in one arm or
the other of the studies, and we assessed all of them as low risk
of bias. We assessed 11 trials as unclear risk of bias due to lack of
information or unknown impact of stated exclusions. We assessed
two trials as high risk of bias due to loss of over 20% (Shanks
2010) or unclear exclusion (Khazardoust 2012); neither of these
trials conducted intention-to-treat analysis.
The four studies (Collaborative 1981; Kari 1994; Liggins 1972b;
Schutte 1980) that reported long-term follow-up after the neonatal
period had their follow-up data included regardless of the follow-
up rate unless there was evidence of bias in follow-up rates between
the treatment and control groups; this was not found to be the
case. The Collaborative 1981 trial reported 37% loss to follow-
up at three years of age and we judged it to be at unclear risk of
bias. Kari 1994 reported 11% loss to follow-up at two years of
age and we judged it as low risk of bias. Liggins 1972b reported
18% loss to follow-up at four to six years and 44% losses at the
30-year follow-up, we judged risk of bias as unclear. Schutte 1980
reported 12% loss to follow-up at age 10 to 14 years and 21% at
the 20-year follow-up, we judged risk of bias as unclear.
Selective reporting
Pre-specified outcomes appear to have been reported on in 24
of the trials; we assessed these trials as low risk of bias (Amorim
1999; Attawattanakul 2015; Block 1977; Collaborative 1981;
Dexiprom 1999; Doran 1980; Fekih 2002; Gamsu 1989; Garite
1992; Gyamfi-Bannerman 2016; Kari 1994; Khazardoust 2012;
Lewis 1996; Liggins 1972b; Lopez 1989;Mansouri 2010;Morales
1989; Nelson 1985; Parsons 1988; Porto 2011; Schutte 1980;
Silver 1996; Taeusch 1979; Teramo 1980). Three studies were
only available in abstract form and were not published as full-
text articles (Cararach 1991; Carlan 1991; Goodner 1979); we
assessed these trials as unclear risk of bias. One trial reported on
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maternal outcomes that were not pre-specified (Balci 2010) and
one trial pre-specified RDS as an outcome but did not report the
data (Shanks 2010). Shanks 2010 also only reported on maternal
outcomes. A third trial (Goodner 1979) only reported on RDS
and no other maternal or neonatal outcomes; we assessed these
three trials as high risk of bias.
Other potential sources of bias
We assessed Shanks 2010 as high risk of other bias because the
trial was stopped early due to problems with recruitment.
In only ten studies was evidence available to suggest that
sample-size calculations had been performed prospectively (
Attawattanakul 2015; Amorim 1999; Collaborative 1981;
Dexiprom 1999; Gyamfi-Bannerman 2016; Kari 1994; Porto
2011; Shanks 2010; Silver 1996; Taeusch 1979).
In most trials there was insufficient information to asses if other
sources of bias existed. There were no other potential sources of
bias identified in one trial Amorim 1999. We assessed one other
trial (Khazardoust 2012) as being at high risk of bias for the fol-
lowing reason: “data was analysed for 35 women in the interven-
tion arm versus 40 in the control arm because two delivered before
cytokine sampling after the second dose of betamethasone, one
opted out of the study and two developed high blood pressure”.
We were unclear if further translation of Mansouri 2010 would
clarify trial methods and consequent risk of bias domains.
Effects of interventions
See: Summary of findings for the main comparison
Corticosteroids versus placebo or no treatment
1. Antenatal corticosteroids versus placebo or no
treatment (all included studies)
Primary outcomes
Data were not available for all primary outcomes from all included
studies.
For the mother
We found similar rates of maternal death in treatment arms, but
the calculated risk ratio (RR) is based on just two events from a
single trial (one death in each arm); four trials report zero events
in both treatment arms limiting our confidence in this finding
(RR 0.98, 95% CI 0.06 to 15.50; participants = 3392; studies =
5; moderate-quality evidence) (Analysis 1.1). There were similar
rates of maternal infection: chorioamnionitis (RR 0.83, 95% CI
0.66 to 1.06; participants = 5546; studies = 15; moderate-quality
evidence) (Analysis 1.2) and endometritis (RR 1.20, 95% CI 0.87
to 1.63; participants = 4030; studies = 10; I² = 28%; moderate
quality evidence) (Analysis 1.3).
For the fetus or neonate
Treatment with antenatal corticosteroids was associated with an
overall average reduction in perinatal death of 28% (average RR
0.72, 95% CI 0.58 to 0.89; participants = 6729; studies = 15; I²
= 34%; Tau² = 0.05; moderate-quality evidence) (Analysis 1.4).
This reduction is mainly due to a reduction in neonatal death of
31% (RR 0.69, 95% CI 0.59 to 0.81; participants = 7188; studies
= 22) (Analysis 1.5), rather than an impact on fetal death (RR
0.98, 95% CI 0.74 to 1.30; participants = 6729; studies = 15)
(Analysis 1.6) where results are inconclusive.
Treatment with antenatal corticosteroids was associated with an
overall average reduction in RDS of 34% (average RR 0.66, 95%
CI 0.56 to 0.77; participants = 7764; studies = 28; I² = 48%; Tau²
= 0.06; moderate-quality evidence) (Analysis 1.7). Moderate to
severe RDS was reduced by 41% compared with no exposure to
antenatal corticosteroids (average RR 0.59, 95% CI 0.38 to 0.91;
participants = 1686; studies = 6; I² = 52%; Tau² = 0.14) (Analysis
1.8). The impact of corticosteroids on chronic lung disease was
inconclusive (average RR 0.86, 95% CI 0.42 to 1.79; participants
= 818; studies = 6; I² = 65%; Tau² = 0.38) (Analysis 1.9).
Sensitivity analysis
Moderate/severe RDS and chronic lung disease both had hetero-
geneity greater than 50%. For moderate/severe RDS (I² = 52%)
when we removed one trial (Fekih 2002) with dramatic results
favouring steroid use the heterogeneity reduced to 28% for a par-
tial explanation of heterogeneity. Fekih 2002 took place in Tunisia
and tested two doses of IM betamethasone 24 hours apart against
no treatment (with weekly treatment repeats); the trial was re-
ported in French, and there was limited information to assess sev-
eral risk of bias domains. The meta-analysis for chronic lung dis-
ease also had heterogeneity over 50%. All included trials were rela-
tively small; three tested betamethasone and three dexamethasone,
but the drug used did not explain heterogeneity; neither did the
fact that four trials had weekly repeats and two did not (analyses
not shown). None of our covariates (membrane status, multiple
pregnancy, or decade of trial) explained the heterogeneity found.
Treatment with antenatal corticosteroids was associated with an
overall average reduction in IVH of 45% (average RR 0.55, 95%
CI0.40 to 0.76; participants = 6093; studies = 16; I² = 33%;Tau² =
0.10; moderate-quality evidence) (Analysis 1.10). A reduction was
also seen for infants with severe IVH (Grades 3 and 4) (RR 0.26,
95% CI 0.11 to 0.60; participants = 3438; studies = 6; analysis
not shown).
Babies in both treatment groups had similar mean birthweight
(mean difference (MD) -18.47, 95% CI -40.83 to 3.90; partici-
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pants = 6182; studies = 16; I² = 5%; moderate-quality evidence)
(Analysis 1.11).
For the child
The impact of corticosteroid exposure on death in childhood was
inconclusive (RR 0.68, 95%CI 0.36 to 1.27; participants = 1010;
studies = 4) (Analysis 1.12), with a similar result for neurodevel-
opmental delay (RR 0.64, 95% CI 0.14 to 2.98; participants =
82; studies = 1) (Analysis 1.13).
For the child as adult
The impact of corticosteroid exposure on death into adulthood
was also inconclusive (RR 1.00, 95%CI 0.56 to 1.81; participants
= 988; studies = 1) (Analysis 1.14).
Secondary outcomes
Data were available for several of the secondary outcomes that
related to the mother, fetus or neonate, child, adult and health
services.
For the mother
Women in both treatment groups had similar rates of: fever after
trial entry requiring the use of antibiotics (average RR 0.95, 95%
CI 0.43 to 2.06; participants = 481; studies = 4; I² = 61%, Tau²
= 0.35) (Analysis 1.15), intrapartum fever requiring the use of
antibiotics (average RR 0.66, 95% CI 0.09 to 4.89; participants =
319; studies = 2; I² = 36%, Tau² = 0.74) (Analysis 1.16), postnatal
fever (RR 0.92, 95% CI 0.64 to 1.33; participants = 1323; studies
= 5) (Analysis 1.20), admission to adult intensive care unit (RR
0.74, 95% CI 0.26 to 2.05; participants = 319; studies = 2) (
Analysis 1.18), and hypertension (RR 1.00, 95% CI 0.36 to 2.76;
participants = 220; studies = 1) (Analysis 1.19).
Five trials reported no side effects for women in any arm. In a sixth
trial more women receiving antenatal corticosteroids reported side
effects of treatment (RR 0.69, 95% CI 0.59 to 0.82; participants
= 3572; studies = 6; all events from a single trial; Analysis 1.17).
Most side effects were pain or bruising at the injection site (close
to 80% of reported side effects in both arms); other side effects
were local reactions at the injection site, gastrointestinal upset,
headache and other.
One small study (Amorim 1999), reported that women in the cor-
ticosteroid arm were more likely to have glucose intolerance than
in the control arm (RR 2.71, 95% CI 1.14 to 6.46; participants
= 123; studies = 1; Analysis 1.21). This study used a treatment
regimen that included weekly repeat doses of corticosteroids if the
infant remained undelivered.
For the fetus or neonate
Treatment with antenatal corticosteroids was associated with a
reduction in the incidence of necrotising enterocolitis (RR 0.50,
95% CI 0.32 to 0.78; participants = 4702; studies = 10) (Analysis
1.22). Treatment with antenatal corticosteroids was also associated
with fewer infants having systemic infection in the first 48 hours
after birth (RR 0.60, 95% CI 0.41 to 0.88; participants = 1753;
studies = 8) (Analysis 1.23); however, infants in both treatment
arms had similar rates of proven infection while in the NICU
(average RR 0.77, 95% CI 0.55 to 1.08; participants = 5707;
studies = 13; I² = 34%; Tau² = 0.09) (Analysis 1.24).
Treatment with antenatal corticosteroids was associated with less
need for neonatal respiratory support, with a reduction in the need
for mechanical ventilation/CPAP (RR 0.68, 95% CI 0.56 to 0.84;
participants = 1368; studies = 9) (Analysis 1.25). Infants receiving
corticosteroids also required less oxygen supplementation (MD -
2.86 days, 95% CI -5.51 to -0.21 days; one study, 73 infants)
(Analysis 1.27), and fewer infants receiving corticosteroids needed
surfactant (RR 0.68, 95% CI 0.51 to 0.90; participants = 3556;
studies = 5) (Analysis 1.28).
Infants in treatment and control groups had similar results for sev-
eral outcomes: time requiring mechanical ventilation/CPAP (MD
-1.91 days, 95% CI -4.59 to 0.76 days; participants = 471; studies
= 3; I² = 77%; Tau² = 3.28) (Analysis 1.26), air leak syndrome
(RR 0.76, 95% CI 0.32 to 1.80; participants = 2965; studies =
2) (Analysis 1.29), interval between trial entry and delivery (MD
0.23 days, 95%CI -1.86 to 2.32 days; participants = 1513; studies
= 3) (Analysis 1.31), incidence of small-for-gestational-age infants
(RR 1.11, 95% CI 0.96 to 1.28; participants = 3478; studies = 5)
(Analysis 1.32), or HPA axis function (cortisol MD 3.94 , 95%CI
-3.12 to 11.00 log units; participants = 27; studies = 1) (Analysis
1.33).
Fewer infants exposed to antenatal corticosteroids had an Apgar
score less than seven at five minutes of age (RR 0.81, 95% CI
0.67 to 0.98; participants = 2419; studies = 10) (Analysis 1.30),
or required admission into a NICU (RR 0.90, 95% CI 0.84 to
0.97; participants = 3803; studies = 7) (Analysis 1.34).
For the child
Treatment with corticosteroids was associated with less develop-
mental delay in childhood (RR 0.49, 95% CI 0.24 to 1.00; par-
ticipants = 518; studies = 2; age at follow-up three years in one
study and unknown in one study) (Analysis 1.35), but results for
cerebral palsy less conclusive (RR 0.60, 95% CI 0.34 to 1.03; P
= 0.86; participants = 904; studies = 5, age at follow-up was two
to six years in four studies, and unknown in one study) (Analysis
1.36).
Childrenwith andwithout treatment had similar results for: child-
hood weight (MD 0.30 kg, 95% CI -0.39 to 1.00 kg; participants
= 333; studies = 2) (Analysis 1.37), height (MD 1.02 cm, 95% CI
-0.26 to 2.29 cm; participants = 334; studies = 2) (Analysis 1.38),
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head circumference (MD 0.27 cm, 95% CI -0.08 to 0.63 cm; par-
ticipants = 328; studies = 2) (Analysis 1.39), lung function (vital
capacity (VC) MD -1.68 % predicted, 95% CI -5.12 to 1.75 %
predicted; participants = 150; studies = 2) (Analysis 1.40), forced
expiratory volume in one second (FEV1) (MD -4.73 % predicted,
95% CI -10.13 to 0.67 % predicted; participants = 75; studies =
1) (Analysis 1.41); FEV1/VC (MD -0.94, 95% CI -3.63 to 1.76;
participants = 150; studies = 2; I² = 31%; Tau² = 1.78) (Analysis
1.42), systolic blood pressure (MD -1.60 mmHg, 95% CI -4.06
to 0.86 mmHg; participants = 223; studies = 1) (Analysis 1.43),
visual impairment (RR 0.55, 95% CI 0.24 to 1.23; participants =
166; studies = 2) (Analysis 1.44), hearing impairment (RR 0.64,
95% CI 0.04 to 9.87; participants = 166; studies = 2) (Analysis
1.45), behavioural/learning difficulties (RR 0.86, 95% CI 0.35 to
2.09; participants = 90; studies = 1) (Analysis 1.47) or intellectual
impairment (RR 0.86, 95% CI 0.44 to 1.69; participants = 778;
studies = 3) (Analysis 1.46).
For the child as adult
Long-term follow-up in one study (Liggins 1972b) showed in-
creased insulin release 30 minutes following a fasting 75 g oral
glucose tolerance test (MD 0.16 log insulin units, 95% CI 0.04
to 0.28 log insulin units; participants = 412; studies = 1) in 30-
year-olds who had been exposed to antenatal corticosteroid. Re-
sults were inconclusive for fasting glucose concentrations (MD
0.01 mmol/L, 95% CI -0.09 to 0.11 mmol/L; participants = 432;
studies = 1), or 30 minutes following a 75 g oral glucose tolerance
test (MD 0.19 mmol/L, 95% CI -0.14 to 0.52 mmol/L; partic-
ipants = 413; studies = 1). At 120 minutes following a 75 g oral
glucose tolerance test, exposure to antenatal corticosteroids was
associated with a reduction in glucose concentration (MD -0.27
mmol/L; 95% CI -0.52 to -0.02 mmol/L; P = 0.04; participants
= 410; studies = 1) (Analysis 1.48; Analysis 1.49). However, the
study reported no difference between those exposed to antenatal
corticosteroids and those not exposed in the prevalence of diabetes
(results not shown).
The impact of corticosteroids on the following was inconclusive:
weight (MD -0.83 kg, 95% CI -6.41 to 4.76 kg; participants =
538; studies = 2; I² = 60%; Tau² = 14.50) (Analysis 1.50), height
(MD 0.91 cm, 95% CI -0.28 to 2.10 cm; participants = 537;
studies = 2) (Analysis 1.51), head circumference (MD 0.03 cm,
95%CI -0.33 to 0.38 cm; participants = 537; studies = 2) (Analysis
1.52), skin fold thickness (triceps MD -0.02 log units, 95% CI -
0.11 to 0.07 log units; participants = 456; studies = 1) (Analysis
1.53), systolic blood pressure (MD -1.53 mmHg, 95% CI -4.50
to 1.44 mmHg; participants = 545; studies = 2; I² = 47%; Tau² =
3.29) (Analysis 1.54), HPA axis function (cortisol MD 0.06 log
units, 95% CI -0.02 to 0.14 log units; participants = 444; studies
= 1) (Analysis 1.55), cholesterol (MD -0.11 mmol/L, 95% CI -
0.28 to 0.06 mmol/L; participants = 445; studies = 1) (Analysis
1.56), age at puberty (MD for girls 0 years, 95% CI -0.94 to 0.94
years; participants = 38; studies = 1) (Analysis 1.57), educational
achievement (RR 0.94, 95% CI 0.80 to 1.10; participants = 534;
studies = 1) (Analysis 1.58), visual impairment (RR 0.91, 95%
CI 0.53 to 1.55; participants = 192; studies = 1) (Analysis 1.59),
hearing impairment (RR 0.24, 95% CI 0.03 to 2.03; participants
= 192; studies = 1) (Analysis 1.60) or intellectual impairment
(RR 0.24, 95% CI 0.01 to 4.95; participants = 273; studies = 2)
(Analysis 1.61). There was no difference between those exposed to
antenatal corticosteroids and those not exposed for lung function
or bone density at age 30 years in participants followed from one
study (Liggins 1972b).
Results were similar for treatment groups for all of the other child-
as-an-adult outcomes examined (Analysis 1.62; Analysis 1.63;
Analysis 1.64; Analysis 1.65; Analysis 1.66; Analysis 1.67; Analysis
1.68; Analysis 1.69; Analysis 1.70; Analysis 1.71; Analysis 1.72;
Analysis 1.73; Analysis 1.74; Analysis 1.75; Analysis 1.76; Analysis
1.77; Analysis 1.78; Analysis 1.79; Analysis 1.80; Analysis 1.81;
Analysis 1.82; Analysis 1.83).
For the health services
Use of corticosteroids did not appear to shorten antenatal hospi-
talisation in women in a single small trial (MD 0.50 days, 95%
CI -1.40 to 2.40 days; participants = 218; studies = 1) (Analysis
1.84); results were also inconclusive for postnatal hospitalisation
in women (MD 0.00 days, 95% CI -1.72 to 1.72 days; partici-
pants = 218; studies = 1) (Analysis 1.85).
Mansouri 2010 (Iran) reported equal numbers of women in each
group requiring a hospital stay of more than three days (12/100
corticosteroid and 12/100 placebo); Attawattanakul 2015 (Thai-
land) reported a similar overall maternal length of stay for both
treatment groups (corticosteroid mean 3.57 (SD 0.87), n = 96;
control mean 3.58 (SD 0.75), n = 98); and Gyamfi-Bannerman
2016 (USA; n = 2827) reported a median maternal length of hos-
pital stay of three days (IQR3 to 5 days) for both treatment groups.
Infants with and without corticosteroids required similar stays in
hospital (MD0.18 days, 95%CI -0.51 to 0.87 days; participants =
788; studies = 5) (Analysis 1.86). Gyamfi-Bannerman 2016 (USA)
reported a median neonatal hospitalisation of seven days (IQR 4
to 12 days) in the corticosteroid group (n = 1427) and a median
of eight days (IQR 4 to 13 days) for the controls (n = 1400).
Investigation of publication bias
Where more than 10 studies contributed data to the analyses, we
inspected funnel plots for evidence of asymmetry and possible
publication bias (Figure 3; Figure 4; Figure 5; Figure 6; Figure 7;
Figure 8; Figure 9). Funnel plots for two outcomes 1.4 Perinatal
deaths (Figure 4) and 1.11 IVH (Figure 8) both showed asym-
metry. For perinatal deaths, two studies with very low event rates
were the funnel plot outliers; one small study (Parsons 1988) had
no events in the corticosteroid arm and one death in the control
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group, and one large study (Gyamfi-Bannerman 2016) had no
events in the control arm and two deaths in the corticosteroid
group. For IVH, the funnel plot mapped 13 of the 16 studies
due to no events in both arms of three studies (Attawattanakul
2015; Dexiprom 1999;Mansouri 2010). Two small studies (Lewis
1996; Taeusch 1979) had considerably larger effect sizes than the
rest (with no events in the corticosteroid arm), one large study
(Gyamfi-Bannerman 2016) had no events in the control arm, and
these studies contributed to funnel plot asymmetry. Publication
bias could not be excluded as some of the asymmetry for both of
these outcomes appeared attributable to small studies with posi-
tive results.
Figure 3. Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.2
Chorioamnionitis
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Figure 4. Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.4
Perinatal deaths
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Figure 5. Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.5
Neonatal deaths
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Figure 6. Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.6 Fetal
deaths
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Figure 7. Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.7
Respiratory distress syndrome
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Figure 8. Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.10
Intraventricular haemorrhage
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Figure 9. Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.11
Mean birthweight (g)
In addition, we inspected funnel plots for evidence of asymmetry
and possible publication bias in further analyses where exactly 10
trials contributed data: necrotising enterocolitis, need formechan-
ical ventilation/CPAP and Apgar less than seven at five minutes.
For 1.26 need for mechanical ventilation there was asymmetry
(Figure 10); two studies (Attawattanakul 2015; Shanks 2010) with
sparse events and wide confidence intervals were the outliers. For
1.31 Apgar less than seven at five minutes of age (Figure 11), all
studies apart from one (Gyamfi-Bannerman 2016) favoured corti-
costeroids, creating the asymmetry. Due to the limited number of
studies contributing to the funnel plots, and the impact of small
studies and sparse events, we could not confirm or exclude possible
publication bias for these outcomes.
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Figure 10. Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.25
Need for mechanical ventilation/CPAP
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Figure 11. Funnel plot of comparison: 1 Corticosteroids versus placebo or no treatment, outcome: 1.30
Apgar < 7 at 5 minutes
Clinical subgroups
We have analysed the results for prespecified clinical subgroups
(covariates) in the comparisons 2, 3 and 4, and added further post
hoc analyses to explore the possible impact of change in prac-
tice over time (comparison 6), protocols with weekly steroid ad-
ministration (comparison 7), and gestational age at randomisation
(comparison 8). Where there were a sufficient number of trials
reporting data for meaningful analyses, we have explored the evi-
dence for the review primary outcomes for women and neonates.
These analyses are hypothesis-generating only and should not be
interpreted as conclusive.
2. Antenatal corticosteroids versus placebo or no
treatment (singleton and women with multiple
pregnancies)
Discrete outcome data for those women delivering multiple preg-
nancies were available from only four studies (Collaborative 1981;
Gamsu 1989; Liggins 1972b; Silver 1996), with the remainder of
the studies including only singleton pregnancies, or reporting data
from combined singleton and multiple pregnancies. We have been
unable to confirm whether the Mansouri 2010 trial included only
singleton pregnancy, but this is suggested by the equal numbers
of women and infants reported. We have included data from this
study in the singleton subgroup.
For the mother
There is no evidence that singleton or multiple pregnancy led
to different rates of chorioamnionitis (Analysis 2.1) in women
exposed to corticosteroids. Maternal death and endometritis were
not reported separately by multiple pregnancy in any study, and
so we did not conduct these subgroup analysis.
For the child
There is no evidence that singleton or multiple pregnancy led
to different rates of death (perinatal (Analysis 2.2); neonatal (
Analysis 2.3); or fetal (Analysis 2.4)), RDS (Analysis 2.5), IVH
(Analysis 2.6) or birthweight (Analysis 2.7) in infants exposed to
corticosteroids.
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Chronic lung disease and moderate/severe RDS were not reported
separately by multiple pregnancy in any study, and so we did not
conduct these subgroup analysis.
3. Antenatal corticosteroids versus placebo or no
treatment (by presence or absence of ruptured
membranes)
Discrete outcome data from women with intact membranes at
the first dose of study medication were available from six studies
(Amorim 1999; Attawattanakul 2015; Collaborative 1981; Garite
1992; Kari 1994; Liggins 1972b), discrete outcome data from
women with ruptured membranes at the first dose of study med-
ication were available from 12 studies (Cararach 1991; Carlan
1991; Dexiprom 1999; Fekih 2002; Lewis 1996; Liggins 1972b;
Lopez 1989; Morales 1989; Nelson 1985; Parsons 1988; Qublan
2001; Schutte 1980), with the remainder of the studies not re-
porting rupture of membrane status or reporting combined data
from women with intact and ruptured membranes.
Relevant subgroups compared below are: 1. pregnant women with
intact membranes, 2. with ruptured membranes, and 3. pregnant
women for whommembrane status was not reported separately or
mixed populations. Analyses with small amounts of data missing
are the following: 3.2. Endometritis (Schutte 1980); 3.3 Perinatal
death (Liggins 1972b); 3.4. Neonatal death (Liggins 1972b); 3.5.
Fetal death (Liggins 1972b; Schutte 1980); 3.6. RDS (Liggins
1972b); 3.7. IVH (Liggins 1972b); and 3.8. Birthweight (Liggins
1972b). Overall totals for these outcomes will not match our main
analyses in Comparison 1 due tomissing data.We have conducted
sensitivity analysis with imputed data and found no difference
in results for any outcome (analyses not shown). We have added
footnotes to the forest plots where data used for specific trials do
not match those in themain analyses due tomissing data.We were
unable to investigate the impact of missing data for the continuous
outcome of birthweight.
For the mother
Womenwith rupture ofmembranes whowere exposed to corticos-
teroids did not show different rates of chorioamnionitis (Analysis
3.1) or endometritis (Analysis 3.2) from women without rupture
of membranes. Maternal death was zero in the treatment and con-
trol arms in relevant studies of women with ruptured membranes,
thus this subgroup analysis was not undertaken.
For the child
There is no evidence that rupture of membrane status led to dif-
ferent rates of death (perinatal (Analysis 3.3); neonatal (Analysis
3.4); or fetal (Analysis 3.5)), RDS (Analysis 3.6), IVH Analysis
3.7() or birthweight (Analysis 3.8) in infants exposed to corticos-
teroids. Chronic lung disease and moderate/severe RDS were not
reported separately by rupture of membrane status in any study,
and so we did not conduct these subgroup analyses.
4. Antenatal corticosteroids versus placebo or no
treatment (for women with hypertension syndrome)
Meaningful analysis was not possible for several primary outcomes
due to the small number of trials reporting results by presence or
absence of hypertension syndromes.
For the mother
For maternal death, only one trial with events was eligible for the
hypertension group (Amorim 1999); no study that was eligible for
the ’not reported’ or ’no hypertension or hypertension syndromes
excluded’ subgroups had any events, and we did not conduct anal-
ysis.
For chorioamnionitis and endometritis, there were too few trials
reporting on hypertension to produce meaningful subgroup anal-
yses. For chorioamnionitis there were two trials; for endometritis
there was one trial.
For the child
There was no evidence that maternal hypertension status led to
different rates of death (perinatal (Analysis 4.2); fetal (Analysis
4.3); or neonatal (Analysis 4.4)) in infants exposed to corticos-
teroids.
Corticosteroids were effective at preventing RDS in infants of
women with and without hypertension syndromes (Analysis 4.1).
There were too few trials eligible for the hypertension syndrome
subgroup (one study) to conduct subgroup analysis for the out-
come of chronic lung disease.
5. Antenatal corticosteroids versus placebo or no
treatment (by type of corticosteroid)
Seven (Attawattanakul 2015; Collaborative 1981; Dexiprom
1999; Kari 1994; Qublan 2001; Silver 1996; Taeusch 1979)
of the included studies used dexamethasone as the corticos-
teroid in the treatment arm (1585 women and 1708 infants),
while 21 (Amorim 1999; Balci 2010; Block 1977; Carlan 1991;
Doran 1980; Fekih 2002; Gamsu 1989; Garite 1992; Goodner
1979; Gyamfi-Bannerman 2016; Khazardoust 2012; Lewis 1996;
Liggins 1972b; Lopez 1989; Mansouri 2010; Morales 1989;
Nelson 1985; Parsons 1988; Porto 2011; Schutte 1980; Teramo
1980) studies used betamethasone (6133 women and 6314 in-
fants). One study did not specify the corticosteroid used (Cararach
1991; 18 women and infants), and one study used either be-
tamethasone or dexamethasone (Shanks 2010; 32 women and in-
fants).
For the mother
For maternal death, there was insufficient event data to conduct
subgroup analysis by type of corticosteroid.
Therewas no evidence that type of corticosteroid used led todiffer-
ent rates of endometritis (Analysis 5.2). Betamethasone appeared
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to result in less maternal chorioamnionitis (RR 0.67, 95%CI 0.50
to 0.90; participants = 4777; studies = 10) than dexamethasone
(RR 1.35, 95% CI 0.89 to 2.05; participants = 769; studies = 5)
(Test for subgroup differences: Chi² = 7.16, df = 1 (P = 0.007), I²
= 86.0%; Analysis 5.1).
For the child
There was no evidence that type of corticosteroid used led to
different rates of death (perinatal (Analysis 5.3); neonatal (Analysis
5.4); or fetal (Analysis 5.5)), RDS (Analysis 5.6), IVH (Analysis
5.7), birthweight (Analysis 5.8), moderate/severe RDS (Analysis
5.9), or chronic lung disease (Analysis 5.10).
6. Antenatal corticosteroids versus placebo or no
treatment (by decade of trial)
The subgroup tests in RevMan 5 are not ideal to test whether or
not there were trends across decades; the test can only indicate if
decades differ. We advise caution when interpreting the findings
below, especially regarding survival across decades.We alsowonder
if the trials from the 1980s that stand out for having worse findings
are actually first-wave trials with less impressive results that were
published later.
For the mother
There was no evidence that the decade of study enrolment led to
different rates of chorioamnionitis (Analysis 6.1) or endometritis (
Analysis 6.2) inwomen exposed to corticosteroids.Maternal death
was zero in the treatment and control arms of all but one relevant
study, thus we did not undertake this subgroup analysis.
For the child
There was no evidence that the decade of study enrolment led to
different rates of IVH (Analysis 6.7) or birthweight (Analysis 6.8)
in infants exposed to corticosteroids.
There was evidence that the decade of study enrolment may have
led to different rates of perinatal death (perinatal death, with ran-
dom-effects model: test for subgroup differences: Chi² = 10.73, df
= 4 (P = 0.03), I² = 62.7%) (Analysis 6.3). This was predominantly
due to differences in neonatal deaths (neonatal death: test for sub-
group differences: Chi² = 12.40, df = 4 (P = 0.01), I² = 67.8%)
(Analysis 6.4) rather than fetal deaths (Analysis 6.5). Neonatal
deaths were reduced in infants exposed to corticosteroids in studies
conducted in the 1970s, 1990s and 2000s, but not the 1980s or
2010s (Analysis 6.4). Only one study (Gyamfi-Bannerman 2016),
the largest in the review, contributed data to the decade of the
2010s. This study was conducted solely in infants born after 33
weeks, when neonatal deaths are rare, with the control arm hav-
ing zero events in 1400 participants (two deaths in the treatment
arm).
There was evidence that the decade of study enrolment may have
led to different rates of RDS in infants exposed to corticosteroids
(RDS: test for subgroup differences: Chi² = 14.30, df = 4 (P =
0.006), I² = 72.0%) (Analysis 6.6). We carried out a sensitivity
analysis removing each decade from the overall analysis set and
repeating the test for subgroup differences without the decade
removed. Removal of all decades apart from the 2000s resulted in
significant subgroup differences, suggesting that data from studies
conducted in the 2000s contributed significantly to the finding
that the decade of study enrolment led to different rates of RDS in
infants exposed to corticosteroids. Studies conducted during the
2000s had the greatest efficacy in reducing RDS in infants exposed
to corticosteroids (RR 0.39, 95% CI 0.26 to 0.59; participants
= 839; studies = 5; I2 = 22%) (Analysis 6.6). RDS was reduced
in infants exposed to corticosteroids in studies conducted in the
1970s, 1980s, and 1990s, but not in the 2010s (Analysis 6.6).
There was no evidence of a difference in rates of moderate/severe
RDS or chronic lung disease across decades; there were single trials
in many subgroups and therefore we have not shown this analysis.
7. Antenatal corticosteroids versus placebo or no
treatment (by presence or absence in protocol of
weekly repeat doses of corticosteroid)
Nine of the included studies allowedweekly repeat courses of study
medication in their study protocols (Amorim 1999; Carlan 1991;
Fekih 2002; Garite 1992; Lewis 1996; Morales 1989; Parsons
1988; Qublan 2001; Silver 1996) (932 women and 946 infants).
For the mother
There was no evidence that protocols that allowed weekly repeat
doses of corticosteroids led to different rates of chorioamnionitis
(Analysis 7.1) or endometritis (Analysis 7.2) in women exposed
to corticosteroids. Maternal death was zero in the treatment and
control arms of all but one relevant study, thus we did not under-
take this subgroup analysis.
For the child
There was no evidence that protocols that allowed weekly repeat
doses of corticosteroids led to different rates of death (perinatal
(Analysis 7.3); neonatal (Analysis 7.4); fetal (Analysis 7.5)), RDS
(Analysis 7.6), IVH (Analysis 7.7) or birthweight (Analysis 7.8) in
infants exposed to corticosteroids. For chronic lung disease, only
one trial contributed data to the single-course subgroup and we
did not conduct analysis.
8. Gestational age at trial entry (less than or equal to
35 weeks + 0 days; greater than or equal to 34 weeks
+ 0 days)
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We have split studies according to the gestational age at which
pregnantwomen entered trials to receive their first dose of corticos-
teroids and have considered two, slightly overlapping subgroups:
1) women less than, and including, 35 weeks and 0 days and 2)
women greater than, and including, 34 weeks and 0 days. Twenty
studies (Amorim 1999; Cararach 1991; Carlan 1991; Dexiprom
1999; Doran 1980; Fekih 2002; Gamsu 1989; Garite 1992;
Goodner 1979; Kari 1994; Khazardoust 2012; Lewis 1996; Lopez
1989; Morales 1989; Nelson 1985; Parsons 1988; Qublan 2001;
Schutte 1980; Silver 1996; Taeusch 1979) contributed data to
the younger gestational age group and six studies (Attawattanakul
2015; Balci 2010; Gyamfi-Bannerman 2016; Mansouri 2010;
Porto 2011; Shanks 2010) contributed data to the older gestational
age group. Of these 26 studies, 17 (Amorim 1999; Attawattanakul
2015; Balci 2010; Carlan 1991; Dexiprom 1999; Doran 1980;
Fekih 2002; Gamsu 1989;Gyamfi-Bannerman 2016; Lewis 1996;
Khazardoust 2012; Lopez 1989; Morales 1989; Nelson 1985;
Porto 2011; Qublan 2001; Shanks 2010) have data in the overlap-
ping 34 weeks + 0 days to 34 weeks + 6 days gestational age group
between the two groups. A further four studies could be analysed
in either group (Block 1977; Collaborative 1981; Liggins 1972b;
Teramo 1980). We addressed these issues as follows: data from
Liggins 1972b were available for women entering trials at less than
35 weeks + 0 days and from between 35 weeks + 0 days and 37
weeks + 0 days. The majority of women in the remaining three
studies (Block 1977; Collaborative 1981; Teramo 1980) were of
less than 34 weeks + 0 days gestation, therefore we included these
studies in the younger-gestational-age grouping for the analysis
(women less than and including 35 weeks and 0 days), but we
undertook a sensitivity analysis with the studies’ data removed.
For the mother
There was no evidence that gestational age at trial entry led to dif-
ferent rates of chorioamnionitis (Analysis 8.1) in women exposed
to corticosteroids. There were insufficient studies in the later ges-
tational age group to evaluate endometritis. Maternal death was
zero in the treatment and control arms of all but one relevant study,
thus this subgroup analysis was not undertaken.
For the infant
There was no evidence that gestational age at trial entry led to
different rates of death (perinatal (Analysis 8.2); neonatal (Analysis
8.3); fetal (Analysis 8.4)), RDS (Analysis 8.5), IVH (Analysis 8.6)
or birthweight (Analysis 8.7) in infants exposed to corticosteroids.
Chronic lung disease and moderate/severe RDS were not reported
by studies occurring in later gestations, and so we did not conduct
these subgroup analyses.
D I S C U S S I O N
Summary of main results
The results of the 30 studies included in this updated review sup-
port the conclusion of the previous review (Roberts 2006), that
treatment with antenatal corticosteroids reduces perinatal death,
neonatal death, RDS, and IVH in preterm infants. Treatment with
antenatal corticosteroids is not associated with changes in the rates
of maternal death, maternal endometritis or chorioamnionitis, fe-
tal death, neonatal chronic lung disease, or birthweight. Treatment
with antenatal corticosteroids is associated with a reduction in the
incidence of neonatal necrotising enterocolitis and systemic infec-
tions in the first 48 hours of life, as well as a reduction in the need
for respiratory support and NICU admission.
Whether antenatal corticosteroids are beneficial in the current era
of advanced neonatal practice has been questioned on the basis
that previous conclusions concerning their benefits drew on data
from the 1970s. In this update, we have included nine trials pub-
lished since 2000 (Attawattanakul 2015; Balci 2010; Fekih 2002;
Gyamfi-Bannerman 2016; Khazardoust 2012; Mansouri 2010;
Porto 2011; Qublan 2001; Shanks 2010), as well as analyses for
the previous decades. These more recent trials contributed 51%
of the overall data to the review. Overall, the results show con-
sistent benefits of steroid use, without any strong evidence that
antenatal corticosteroids are not beneficial in the current era of
advanced neonatal practice. In subgroup analysis two decades sug-
gested heterogeneity of the results between decades for only one
each of the eight primary outcomes analysed; studies conducted
in the decade of the 2000s appeared to show that corticosteroids
had a greater effect on reducing RDS, the opposite result to that
expected if antenatal corticosteroids are not beneficial in the cur-
rent era of advanced neonatal practice. Studies conducted in the
1980s appeared to show that corticosteroids had no effect in re-
ducing neonatal death (removal of this group in sensitivity anal-
ysis explained subgroup heterogeneity), with no evidence of ef-
fect also seen in the most recent decade (2010s). However, as the
sole study (Gyamfi-Bannerman 2016) conducted in the 2010s was
conducted in near term infants who have very low rates of neona-
tal death, and with studies conducted in the decades of the 1990s
and 2000s showing a clear statistical and clinical benefit in terms
of neonatal death, RDS and IVH, we conclude that antenatal cor-
ticosteroids continue to have a strong role in supporting current
methods of obstetric and neonatal practice.
The gestational age range at which antenatal corticosteroids pro-
vide benefit has been subject to debate. Previous reviews have had
difficulty demonstrating benefit at gestations less than 26 weeks
and beyond 36 weeks (Roberts 2006). Once again it was not possi-
ble to test this adequately using trial level data; ideally this question
should be investigated with individual patient data analysis using a
priori agreed gestational age cut-offs. In this update, we examined
outcomes based on gestational age divisions of up to, and includ-
ing, 35 weeks + 0 days and greater than, and including, 34 weeks
+ 0 days. Although this post hoc analysis is exploratory, and 17
studies have data in the overlapping 34 weeks + 0 days to 35 weeks
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+ 0 days gestational age group, we found no evidence of a differ-
ence in effect of antenatal corticosteroids in the two gestational age
groups for the seven primary outcomes analysed. The most recent
study (Gyamfi-Bannerman 2016) included in this review enrolled
2831 women from 34 weeks + 0 days until 36 weeks + 5 days, and
found a clinical benefit in terms of a primary outcome of require-
ment for respiratory support in the first 72 hours of life (11.6%
versus 14.4%), but with increased neonatal hypoglycaemia (24%
versus 15%) for which the long-term effects remain unknown.
Consistent with this we have demonstrated a clear statistical and
clinical benefit of corticosteroids on RDS in six studies providing
data from 34 weeks + 0 days gestation, but not with other primary
outcomes. Thus in very late preterm gestation women (from 35
weeks + 0 days) the use of antenatal corticosteroids needs to be
considered in light of the balance of risks and benefits.
The relationship between the time interval from first dose to de-
livery and outcome, and how this is influenced by factors such as
whether corticosteroids were given and how many doses a women
received, can only be determined by an individual patient data
analysis. We were not able to do this in this update. We were
able to undertake an analysis comparing outcomes in mothers and
children exposed to studies allowing only a single course versus
study protocols allowing weekly repeats if infants remained unde-
livered.We found no differences between these two study protocol
groups. The effect of repeated doses of antenatal corticosteroids
is the subject of a separate Cochrane Review (Crowther 2015),
which found that although repeated doses reduced the severity
of neonatal lung disease, there were insufficient data to exclude
other beneficial or harmful effects to the mother or infant. The
Crowther review awaits the outcome of trials looking at the long-
term effects of repeated courses of antenatal corticosteroids.
We did not find any evidence that the effect of antenatal corti-
costeroids was different in the subgroups of women with multiple
pregnancies, premature rupture of membranes and hypertension
syndromes. However as discrete RDS data from infants of women
with multiple pregnancies contributed to 4.1% of the total RDS
data, and discrete data from infants of women with hypertension
syndromes and premature rupture of membranes contributed to
4.9% and 14.5% of the total RDS data respectively, there needs
to be caution in the interpretation of these findings. Further cau-
tion is required due to the number of studies in which subgroup
classification data were not available.
In this update, we have included a comparison of studies using
dexamethasone as a trial protocol with studies using betametha-
sone. We found no evidence of a difference in efficacy between the
two types of corticosteroids, apart from less maternal chorioam-
nionitis occurring with betamethasone. Our analysis is subject to
bias as allocation to one type of corticosteroid or the other was
not subject to randomisation. However, consistent with our re-
sults a review by Brownfoot 2013 and colleagues (10 studies; 1089
women and 1161 infants) compared different corticosteroid reg-
imens and found insufficient evidence to support the use of one
corticosteroid over the other.
There are insufficient data from follow-up studies into childhood
(Collaborative 1981; Kari 1994; Liggins 1972b; Schutte 1980)
and into adulthood (Liggins 1972b; Schutte 1980) included in
this review. Just one small study reported neurodevelopmental de-
lay in childhood (Kari 1994; n = 82). There are also limited data
for developmental delay in childhood (two trials; n = 518). Five
trials report potential improvement in rates of cerebral palsy in
childhood, though confidence intervals are wide and cross the line
of no effect. Just two included studies followed up into adulthood
(Liggins 1972b; Schutte 1980) and found no differences in in-
tellectual impairment or educational achievement between those
exposed to a single course of antenatal corticosteroids and those
exposed to placebo. This has largely contributed to dispelling pre-
vious concerns regarding decreased brain growth after antenatal
corticosteroid exposure from animal studies (Huang 1999; Jobe
1998).
Exposure to excess corticosteroids before birth is a postulated
mechanism underlying the fetal origins of adult disease hypothesis
(Barker 1998; Benediktsson 1993). Increased insulin release has
been found 30 minutes following a 75 g oral glucose tolerance
test in one follow-up study conducted at age 30 (Liggins 1972b).
However, the same study found no difference in blood pressure,
fasting lipids, body size, hypothalamo-pituitary-adrenal axis func-
tion or the prevalence of diabetes or cardiovascular disease. Thus,
while the finding of increased insulin resistance in adulthood pro-
vides support for excess corticosteroids as a mechanism underlying
the fetal origins of adult disease hypothesis, it should not be seen
as a reason to withhold antenatal corticosteroids given the large
and clinically substantial benefits seen in the neonatal period.
Overall completeness and applicability of
evidence
We have attempted to identify all available published and unpub-
lished randomised trial data for the use of antenatal corticosteroids
for women at risk of preterm birth. Additional data have been
obtained and included where possible. We feel that the data are
comprehensive and relevant to women at risk of preterm birth.
Comparisons of repeat antenatal corticosteroid regimens, of dif-
ferent antenatal corticosteroids and of the use of antenatal cor-
ticosteroids at term before elective birth are described in other
Cochrane Reviews (Brownfoot 2013; Crowther 2015; Sotiriadis
2009).
The evidence here is applicable to most hospital settings in mid- or
high-income countries. More evidence from low-income settings
would help support the overall applicability of the data. For exam-
ple, data in this review for RDS come from 15 different countries,
but only one of these is a low-income country (Tunisia). The issue
of generalisability of the current evidence has also been highlighted
in the recent cluster-randomised trial (Althabe 2014). This trial
suggested harms from better compliance with antenatal corticos-
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teroid administration in women at risk of delivering preterm in
communities of low-resource settings (Althabe 2014).
Quality of the evidence
The evidence described in this review is based on 30 randomised
controlled trials comparing antenatal corticosteroids with no an-
tenatal corticosteroids. Overall the evidence is consistent. There
are some limitations in 13 of the trials where there was no blind-
ing of the intervention, and there was insufficient information in
14 trials to enable the review authors to make judgements on the
processes of randomisation or allocation concealment. The lack
of information is most likely due to the era in which the trials
were conducted, when this information was not a requirement for
publication.
We assessed seven outcomes with GRADEmethodology, as shown
in the ’Summary of findings’ table (Summary of findings for the
main comparison). For pregnant women, evidence was graded as
ofmoderate quality for three outcomes:maternal death, chorioam-
nionitis and endometritis. Downgrading in each case was for im-
precision due to wide confidence intervals crossing the line of no
effect. There were very few data for maternal death.
For infants, evidence for four outcomes was also graded to be of
moderate quality. We downgraded evidence for perinatal death,
RDS, IVHand birthweight for risks of bias in the included trials. A
grade ofmoderate quality suggestswe have some reservations about
the available data and its quality due specifically to unclear risks
of bias for allocation concealment or randomisation and unclear
or high risks of bias for lack of blinding or incomplete outcome
data in some trials included in the meta-analyses.
Potential biases in the review process
We believe we have made sufficient attempts to reduce the po-
tential bias of the review process. We have attempted to identify
all relevant trials and two or more researchers have independently
appraised the trial and extracted the data required. Where data
were missing, we have contacted the original trialists and some
additional data have been provided that enhances the content of
this review.
Agreements and disagreements with other
studies or reviews
Current systematic reviews of antenatal corticosteroids including
the World Health Organization have used earlier versions of this
review on which to base their recommendations (Hofmeyr 2009).
A systematic review conducted for a bi-national clinical practice
guideline for Australia and New Zealand in 2015 reported on
the same maternal and neonatal benefits as the primary outcomes
of this systematic review (Antenatal Corticosteroid CPG Panel
2015).
A recent systematic review of observational studies has analysed the
use of antenatal corticosteroids in specific populations of pregnant
women at risk of impending pretermbirth (with gestational age 34
to 37weeks); the authors considered evidence for pregnant women
with gestational diabetes mellitus; pregnant women undergoing
elective caesarean section (34 to 37 weeks’ gestation; pregnant
womenwith chorioamnionitis; andpregnant womenwith growth-
restricted fetuses) (Amiya 2016). There was no available evidence
(randomised or observational) forwomenwith gestational diabetes
or for pregnant women undergoing elective caesarean section. For
pregnant women with chorioamnionitis, pooled evidence from
eight studies (1424 women) showed a benefit of steroid use for the
outcomes of neonatal death, RDS, IVH and severe IVH; consis-
tent with the conclusions of this review. There were no data avail-
able from these studies for maternal outcomes for women with
chorioamnionitis. For pregnant women with growth-restricted fe-
tuses, the results were inconclusive. There were no clear bene-
fits for growth-restricted babies for outcomes measuring neonatal
mortality or morbidity, including RDS, and the authors called for
further research in this population. Using GRADE methods, re-
view authors assessed all evidence for individual outcomes in the
review as of low or very low quality, due to observational study
design and, most often, imprecision due to wide confidence inter-
vals (Amiya 2016).
As mentioned above, additional evidence is required to better un-
derstand the potential for adverse effects with steroid use in low-
resource settings (Althabe 2014; Azad 2014).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence from this review update supports the continued use
of a single course of antenatal corticosteroids in women at risk of
preterm birth. Treatment with antenatal corticosteroids reduces
the risk of perinatal death, neonatal death, RDS, IVH, necrotising
enterocolitis, need for respiratory support and NICU admission,
even in the current era of advanced neonatal care.
Antenatal corticosteroids can continue to be used inwomen at high
risk of pretermbirth. Further information is required regarding the
optimal dose-to-delivery interval, the optimal steroid, the effects
in multiple pregnancy and long-term effects into adulthood. We
advise that birth should not be delayed to administer antenatal
corticosteroids when there are serious concerns about maternal
condition that will be alleviated by expedited delivery.
It is important to note that most of the evidence in this review
comes from high-income countries and hospital settings; there-
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fore, the results may not be applicable to low-resource settings
with high rates of infections.
Implications for research
There is little need for further trials of a single course of antenatal
corticosteroids versus placebo in singleton pregnancies in high-
income countries and hospital settings. However, data are sparse
in lower-income settings. There are also few data regarding risks
and benefits of antenatal corticosteroids in multiple pregnancies
and other high-risk obstetric groups. We encourage authors of
previous studies to provide further information, which may an-
swer any remaining questions about the use of antenatal corti-
costeroids in such pregnancies without the need for further ran-
domised controlled trials. Individual patient data meta-analysis
from published trials is likely to answer some of the evidence gaps.
Follow-up studies into childhood and adulthood, particularly in
the late-preterm-gestation and repeat-courses groups are needed.
The possible harmful effects of antenatal corticosteroids in low-
resource settings were not examined in this review. It would be
particularly relevant to explore this finding in adequately powered
prospective trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Amorim 1999
Methods Type of study: RCT
Method of treatment allocation: computer-generated randomisation sequence with ran-
domisation code kept by the chief pharmacist. The pharmacy provided coded drug boxes.
Stratification: none stated
Placebo: yes, same volume of similar appearing vehicle
Sample size calculation: yes
Intention-to-treat analyses: no
Losses to follow-up: yes, 2 (1%) women in the placebo group dropped out after ran-
domisation
Funding: Instituto Materno-Infantil de Pernambuco, Brazil
Participants Location: InstitutoMaterno-Infantil de Pernambuco, Recife, state of Pernambuco, Brazil
Timeframe: April 1997-June 1998
Eligibility criteria: women with severe pre-eclampsia, singleton pregnancy with a live
fetus and gestational age between 26-34 weeks. Likely minimal interval of 24 h between
drug administration and delivery. Lung immaturity was confirmed by the foam test in
fetuses of 30-34 weeks. Gestational age range: 26-34 weeks
Exclusion criteria: indication for immediate delivery, diabetes, PROM, maternal disease,
congenital malformations, perinatal haemolytic disease, Group B streptococcal infection
Total recruited: 220 women and infants. 110 women and infants in each arm
Interventions 12 mg betamethasone IM, repeated after 24 h and weekly thereafter if delivery had not
occurred.
Control group received identical placebo. Delivery was at 34 weeks or in the presence
of maternal or fetal compromise in both groups
Outcomes Maternal outcomes (death, chorioamnionitis, maternal infection, fever after trial en-
try requiring antibiotics, intrapartum fever requiring antibiotics, postnatal fever, admis-
sion to ICU, glucose intolerance, hypertension), fetal/neonatal outcomes (fetal death,
neonatal death, RDS, chronic lung disease, IVH, birthweight, Apgar score < 7, interval
between trial entry and delivery, small-for-gestational age, admission to NICU, need
for mechanical ventilation/CPAP, duration of oxygen supplementation, surfactant use,
systemic infection in the first 48 h of life, proven infection while in the NICU, necrotis-
ing enterocolitis), childhood outcomes (death, developmental delay, cerebral palsy) and
health service outcomes reported (length of antenatal hospitalisation for women, length
of postnatal hospitalisation for women, length of neonatal hospitalisation)
Notes Further information obtained from the study authors, including substantial unpublished
data
Risk of bias
Bias Authors’ judgement Support for judgement
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Amorim 1999 (Continued)
Random sequence generation (selection
bias)
Low risk “Computer-generated randomisation se-
quence.”
Allocation concealment (selection bias) Low risk “Randomisation code kept by the chief
pharmacist.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessors was not de-
scribed, but it is likely as the authors state,
“the data analysis was carried out without
knowledge of which of the treatments cor-
responded to corticosteroid and which to
placebo”. The code was fully broken only
after the analysis was completed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 women (1%) in the placebo group vol-
untarily dropped out after randomisation
Selective reporting (reporting bias) Low risk Study protocol was not available, but study
appears to report on all pre-specified out-
comes
Other bias Low risk The groups were comparable at baseline.
The study appears free of other sources of
bias
Attawattanakul 2015
Methods Type of study: open label RCT
Method of treatment allocation: method of randomisation not stated. Block randomi-
sation used
Stratification: none stated
Placebo: no, comparison was no treatment
Sample size calculation: “Sample size was calculated to have type one error of 5 percent
and 80 percent power to detect a reduction of 50 percent in rate of respiratory distress.
Rate of respiratory distress in late preterm infant was assumed to be 28.9 percent based
onWangML, et al. Accordingly, the number of study population was at least 95 pregnant
women in each group.”
Intention-to-treat analyses: yes
Losses to follow-up: no
Funding: not stated, though authors declare no competing interests
Participants Location: Chonburi Hospital, Thailand
Timeframe: March 2013-March 2014
Eligibility criteria: all pregnant women with singleton pregnancy admitted in labour
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Attawattanakul 2015 (Continued)
(defined as “regular uterine contraction at least 4 times in 20 minutes or 8 times in
60 minutes and cervical dilatation more than 1 cm and cervical effacement at least 80
percent”) with a gestational age of 34 weeks + 0 d to 36 weeks + 6 d
Gestational age range: 34 weeks + 0 d-36 weeks + 6 d
Exclusion criteria: “Participants who had history of corticosteroid administration in cur-
rent pregnancy, history of dexamethasone allergy, systemic infection, multifetal preg-
nancy, complicated pregnancy including overt diabetes mellitus, gestational diabetes
mellitus (GDM), pregnancy induced hypertension (PIH), placenta previa and abruptio
placentae, positive or unknown sexual transmitted disease serology, PROM, evidence of
fetal amniotic membrane leakage confirmed by two of the following test; pooling, ni-
trazine test, fern test or cough test, known fetal intrauterine restriction, oligohydramnios,
non-reassuring fetal heart rate tracing, fetal death, fetal anomaly, suspicious of chorioam-
nionitis (fetal tachycardia >160/min, maternal fever > 37.8°C, uterine tenderness, foul
smelling amniotic fluid), cervical dilatation more than 7 cm, were excluded from our
study.”
Total recruited: 194 women and infants; 96 women and infants in the treatment arm
and 98 women and infants in the control arm
Interventions The treatment group received 6 mg dexamethasone IM, up to 4 doses 12 h apart
The control group received no treatment.
Outcomes Maternal outcomes (chorioamnionitis, side effects of therapy in women)
Fetal/neonatal outcomes (RDS, IVH, birthweight, necrotising enterocolitis, systemic
infection in the first 48 h of life, need for mechanical ventilation/CPAP, Apgar score <
7, admission to NICU)
Notes Labour augmentation performed if needed even if women had not received full course
of steroids
6 (6%) women in the intervention group received a full course of steroids; most women
(75/96 (78%)) in the intervention arm received just 1 dose of dexamethasone
Data for ’maternal local or systemic adverse reactions to treatment’ have been included
in the review under our outcome of maternal side effects
Data from the trial are available for the followingoutcomes: lowbirthweight (not defined)
; hypoglycaemia in infant; need for respiratory support in infant (6/96 treatment and
14/98 control; (these data are in addition to the need for ’positive pressure ventilation’
included in the review outcome ’need for mechanical ventilation’); and maternal length
of stay (not separated into intrapartum and postpartum)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported. Method reported as block
randomisation only
Allocation concealment (selection bias) Unclear risk Not stated
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Attawattanakul 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label, participants would have been
aware of allocation. Delivery nurse not
blinded but all other hospital staff deliver-
ing care were blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The data were retrieved from chart review
and hospital staff were blinded apart from
delivery room nurses
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 women in the dexamethasone delivered
after 1week andwere included in ITT anal-
ysis
Selective reporting (reporting bias) Low risk Relevant outcome data reported
Other bias Low risk The groups were comparable at baseline.
Balci 2010
Methods Type of study: RCT
Method of treatment allocation: computer-generated random number table, sequential
sealed envelopes, not stated if opaque
Stratification: none stated
Placebo: no, comparison was no treatment
Sample size calculation: not stated
Intention-to-treat analyses: yes
Losses to follow-up: 30 infants with fetal distress, meconium-stained liquor and who
delivered within less than 24 h were excluded from the study (14 in control group, 16
in steroid group)
Funding: not stated
Participants Location: Dept of Obstetrics and Gynecology, Hospital of Meram, Faculty of Medicine,
Selcuk University, Konya, Turkey
Timeframe: January 2007 and May 2009.
Eligibility criteria: 34-36 weeks’ gestation based on LMP. If unsure dates, fetal biometric
measurements of 33-36 weeks on abdominal ultrasonography (done on admission). The
mother had had at least 2 contractions lasting more than 30 seconds in 10 min on
cardiotocography, and cervical dilatation > 3 cm with 80% effacement
Gestational age range: 34 + 0-36 + 0 weeks
Exclusion criteria: obstetric complications (severe IUGR, pre-eclampsia, placental abrup-
tion, placenta praevia), multiple pregnancies, those who had already received antenatal
corticosteroid therapy, PROM, or suspicion of chorioamnionitis, fetal anomaly, fetal
distress, severe systemic disease (heart disease, hyperthyroidism, hypothyroidism, renal
disease, diabetes mellitus)
Total recruited: 100 (50 women and babies in each group)
47Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Balci 2010 (Continued)
Interventions The treatment group received a single dose of 12 mg betamethasone IM
The control group received no treatment.
Women who delivered at least 24 h after betamethasone administration were included
in the study
Outcomes Apgar score at 1 and 5 minutes, need for resuscitation, development of RDS
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Generated by a computer”
Allocation concealment (selection bias) Unclear risk “Sequential sealed envelopes” not stated if
opaque or not
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Due to comparison group receiving no
treatment and treatment group receiving
corticosteroids, blinding of participants
and personnel would not have been possi-
ble
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors is not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 30 infants with fetal distress, meconium-
stained liquor andwhodeliveredwithin less
than 24 h were excluded from the study
(14 in control group, 16 in steroid group).
Intention-to-treat analysis was used
Selective reporting (reporting bias) High risk Maternal complications were not pre-spec-
ified but were reported
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
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Block 1977
Methods Type of study: RCT
Method of treatment allocation: computer-generated randomisation sequence. Coded
drug boxes were provided.
Stratification: none stated
Placebo: yes, normal saline
Sample size calculation: no
Intention-to-treat analyses: no
Losses to follow-up: yes, 14 (10%) women delivered elsewhere and were lost to follow-
up. 6 (4%) women were excluded from analyses as they failed to complete the protocol.
Funding: Schering Corporation, Kenilworth, New Jersey, USA; and The Upjohn Com-
pany, Kalamazoo, Michigan, USA
Participants Location: Department of Gynecology and Obstetrics at the University of Oklahoma
College of Medicine, Oklahoma City, Oklahoma, USA
Timeframe: not stated in manuscript, the study is coded as 1970s for the review
Eligibility criteria: women with preterm labour and PROM
Gestational age range: not stated
Exclusion criteria: not stated
Total recruited: the number randomised to each group not stated. Data are available on
114 infants; 60 infants in the treatment arm and 54 infants in the control arm
Interventions 12 mg betamethasone IM repeated after 24 h if delivery had not occurred
Control group received 1 mL normal saline IM repeated after 24 h if delivery had not
occurred
If there was evidence of progressive cervical dilatation an alcohol infusion was given in
order to attempt to delay delivery for at least 48 h. In women with PROM delivery was
induced if serial white blood cell counts or temperatures became elevated regardless of
time elapsed since drug administration
Outcomes Fetal/neonatal outcomes reported (fetal death, neonatal death, RDS, need formechanical
ventilation/CPAP)
Notes This study included a third arm (125 mg methylprednisolone IM repeated after 24 h
if delivery had not occurred). The data for the review report the betamethasone and
control arms only. Overall data were available for 150 living infants, of whom 128 were
preterm. Further information was requested from the study authors but there was no
reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer generated randomisation se-
quence.”
Allocation concealment (selection bias) Low risk “Consecutively numbered boxes contain-
ing randomly selected study drug or
placebo.”
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Block 1977 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Clinicians were never aware of the contents
of the coded box. Placeob was saline so it
is likely that participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 14 (10%) women delivered elsewhere and
were lost to follow-up. 6 (4%) women were
excluded from analyses as they failed to
complete the protocol (1 in the betametha-
sone group, 2 in the methylprednisolone
group, and 3 in the control group)
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to assess if other
sources of bias exist
Cararach 1991
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Stratification:
none stated
Placebo: no
Sample size calculation: no
Intention-to-treat analyses: yes
Losses to follow-up: no
Funding: FIS; Perinatal Section of SEGO
Participants Location: Hospital Clinic, University of Barcelona, Spain
Timeframe: 1987-1990
Eligibility criteria: women with PROM
Gestational age range: 28-30 weeks
Exclusion criteria: none stated
Total recruited: 18 women and infants; 12 women and infants in the treatment arm and
6 women and infants in the control arm
Interventions Type and dose of corticosteroid used in the treatment group is not stated
Control group received expectant management
Outcomes Fetal/neonatal outcome reported (RDS)
Notes Study only available as an abstract. Further information was requested from the study
authors but there was no reply
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Cararach 1991 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and personnel not
stated, although unlikely as placebowas not
used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment was not
stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Selective reporting (reporting bias) Unclear risk Study only available as an abstract
Other bias Unclear risk Studywas only available as an abstract. Fur-
ther information was requested from the
study authors, but there was no reply
Carlan 1991
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Stratification:
none stated
Placebo: no
Sample size calculation: no
Intention-to-treat analyses: no
Losses to follow-up: yes, 2 (8%) infants with documented pulmonary maturity and 5
(17%) women with subsequent sealed membranes were not analysed
Funding: not stated
Participants Location: University of South Florida Medical School, Tampa, Florida, USA
Timeframe: not stated in manuscript, the study is coded as 1990s for the review
Eligibility criteria: women with PROM
Gestational age range: 24-34 weeks
Exclusion criteria: not stated
Total recruited: the number randomised to each group is not stated. Data are available
on 24 women and infants; 13 women and infants in the treatment arm and 11 women
and infants in the control arm
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Carlan 1991 (Continued)
Interventions 12 mg betamethasone IM repeated after 24 h and weekly thereafter until delivery or 34
weeks.
Control group received expectant management.
Outcomes Maternal outcome (chorioamnionitis), fetal/neonatal outcomes (RDS, birthweight, days
of mechanical ventilation/CPAP) and health service outcomes reported (days in NICU,
neonatal days in hospital, neonatal hospital cost). However due to lack of SD data only
chorioamnionitis and RDS data were included in the review
Notes This study included a third arm (12 mg betamethasone IM 24-hourly for 2 doses and
400 mcg methylprednisolone IV 8-hourly for 6 doses, repeated weekly until delivery
or 34 weeks. The data for the review report the betamethasone and control arms only.
Further information was requested from the study authors but there was no reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and personnel not
stated, although unlikely as placebowas not
used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 (8%) infants with documented pul-
monary maturity and 5 (17%) women
with subsequent sealed membranes were
not analysed
Selective reporting (reporting bias) Unclear risk SD data not stated so a number of out-
comes are not able to be included in the
review
Other bias Unclear risk Only available as an abstract. Full paper not
published
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Collaborative 1981
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Coded drug boxes
with sequentially-numbered vials containing study drug were used. Sealed envelope
containing the identity of the contents of was attached to each vial “to be opened in
emergency only in case of an emergency”. The manuscripts do not state how often these
were opened. Stratification: yes, within each hospital
Placebo: yes, identical appearance
Sample size calculation: yes
Intention-to-treat analyses: no
Losses to follow-up: yes, 2 (0%) infants in the control arm were lost to RDS follow-up as
neonates and 240 (37%) children were lost to follow-up at age 3 (124 in the treatment
arm and 116 in the control arm)
Funding: National Institutes of Health, USA
Participants Location: 5 university hospitals in the USA
Timeframe: March 1977-March 1980
Eligibility criteria: women at high risk of preterm delivery. L/S ratio < 2.0 in cases of
uncertain gestation, hyperthyroidism, hypertension, placental insufficiency, drug addic-
tion, methadone use or gestational age > 34 weeks
Gestational age range: 26-37 weeks
Exclusion criteria: > 5 cm of cervical dilatation, anticipated delivery < 24 h or > 7 d,
intrauterine infection, previous glucocorticoid treatment, history of peptic ulcer disease,
active tuberculosis, viral keratitis, severe fetal Rhesus sensitisation, infant unlikely to be
available for follow-up
Total recruited: 696 women and 757 infants; 349 women and 378 infants in the treat-
ment arm and 347 women and 379 infants in the control arm
Interventions 4 doses of 5 mg dexamethasone phosphate IM 12 h apart
Control group received placebo
Outcomes Maternal outcomes (postnatal fever), fetal/neonatal outcomes (fetal death, neonatal
death, RDS, birthweight, interval between trial entry and delivery, systemic infection
in the first 48 h of life, proven infection while in the NICU, necrotising enterocolitis)
, childhood outcomes (death, lung function, developmental delay, intellectual impair-
ment, cerebral palsy) and health service outcomes were reported (length of neonatal
hospitalisation)
Notes Further information was requested from the authors but there was no reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) High risk Sealed envelope containing the identity of
the contents of was attached to each vial “to
be opened in emergency only in case of an
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Collaborative 1981 (Continued)
emergency”. The manuscripts do not state
how often these were opened
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both placebo and steroid were dispensed
as 10 ml clear, colourless solutions which
differed only in that one contained the
steroid”. It is likely that participants were
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 (0.27%) infants in the control arm were
lost to RDS follow-up as neonates. At age
3, 240 (37%) children were lost to follow-
up (124 in the treatment arm and 116 in
the control arm), or had died (47 in the
treatment arm and 46 in the control arm)
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
Dexiprom 1999
Methods Type of study: RCT
Method of treatment allocation: computer-generated randomisation. Sequentially-num-
bered drug boxes were used. Stratification: yes, by hospital
Placebo: yes, normal saline
Sample size calculation: yes
Intention-to-treat analyses: no
Losses to follow-up: yes, 7 (3%) women and infants were excluded from analysis (3
women did not have PROM, 2 women were < 26 weeks at randomisation, 1 woman
received off-protocol corticosteroid, a neonatal bed was not available in 1 case)
Funding: Medical Research Council, South Africa; Donmed Pharmaceuticals, South
Africa
Participants Location: 6 hospitals in South Africa
Timeframe: not stated in the manuscripts, the study is coded as 1990s for the review
Eligibility criteria: women with PROM between 28-34 weeks or with an estimated fetal
weights of 1000 g-2000 g if the gestational age was unknown
Gestational age range: 28-34 weeks
Exclusion criteria: cervical dilatation > 4 cm, evidence of infection, evidence of antepar-
tum haemorrhage, < 19 years old
Total recruited: 204 women and 208 infants; 102 women and 105 infants in the treat-
ment arm and 102 women and 103 infants in the control arm
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Dexiprom 1999 (Continued)
Interventions 2 doses of 12 mg dexamethasone IM 24 h apart
Control group received placebo
All women also received ampicillin, metronidazole and hexoprenaline if contractions
present in < 24 h
Outcomes Maternal outcomes (maternal death, chorioamnionitis, endometritis, postnatal fever),
fetal/neonatal outcomes reported (fetal death, neonatal death, RDS, IVH, birthweight,
need for mechanical ventilation/CPAP, systemic infection in the first 48 h of life, necro-
tising enterocolitis)
Notes Study authors supplied additional data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation. Sequentially-numbered
drug boxes were used
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants likely as identi-
cal looking placebo was used. Blinding of
study personnel was not described, other
than “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7 (3%) women and infants were excluded
from analysis (3 women did not have
PROM, 2 women were < 26 weeks at ran-
domisation, 1 woman received off-proto-
col corticosteroid, a neonatal bed was not
available in 1 case)
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Study was discontinued before target sam-
ple size was reached due to increasing body
of evidence of the use of corticosteroids in
women with PPROM being advantageous
to the infants, and it was felt unnecessary
to conduct further trials of antenatal corti-
costeroids in women with PPROM
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Doran 1980
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Coded drug boxes
were provided. Randomisation code was kept on file at the Pharmacy Department of
Toronto General Hospital. Stratification: yes, by gestational age into 2 subgroups; 24-
32 weeks and 33-34 weeks
Placebo: yes, vehicle of steroid preparation consisting of 0.2 mg benzalkonium chloride
and 0.1 mg disodium edentate per mL
Sample size calculation: no
Intention-to-treat analyses: yes
Losses to follow-up: no
Funding: The Hospital for Sick Children Foundation, Canada; Schering Corporation,
Canada; Ontario Ministry of Health Provincial Research Grant PR 279, Canada
Participants Location: 6 teaching hospitals in Toronto, Canada
Timeframe: January 1975-June 1978
Eligibility criteria: women with PROM, spontaneous preterm labour or planned preterm
delivery
Gestational age range: 24 and 34 weeks.
Exclusion criteria: women with pre-eclampsia or in whom steroids were contraindicated
on medical grounds.
Total recruited: 137 women and 144 infants; 75 women and 81 infants in the treatment
arm and 62 women and 63 infants in the control arm
Interventions 4 doses of 3 mg betamethasone acetate and 3 mg betamethasone sodium phosphate IM
12 h apart
Control group received 4 doses of identical placebo
Outcomes Fetal/neonatal outcomes were reported (fetal death, neonatal death, RDS, IVH, birth-
weight, days of mechanical ventilation)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Low risk Coded drug boxes were provided. Ran-
domisation code was kept on file at the
Pharmacy Department of Toronto General
Hospital
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It is likely that participants were blinded as
both placebo and corticosteroid solutions
were identical. Blinding of study personnel
was not described other than to state “dou-
ble blind”
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Doran 1980 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessors was not de-
scribed, but is likely as the authors state
“The key to the code was not broken until
the whole study was completed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
Fekih 2002
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Stratification:
none stated
Placebo: no
Sample size calculation: no
Intention-to-treat analyses: no
Losses to follow-up: yes, number of post-randomisation exclusions not stated
Funding: not stated
Participants Location: CHU Farhat Hached, Sousse, Tunisia
Timeframe: January 1998-June 1999
Eligibility criteria: women in preterm labour
Gestational age range: 26-34 weeks
Exclusion criteria: gestational diabetes, > 4 cm cervical dilatation, fetal abnormalities,
contraindication to corticosteroids, delivery elsewhere or after 34 weeks (post-randomi-
sation exclusions)
Total recruited: 118 women and 131 infants; 59 women and 63 infants in the treatment
arm and 59 women and 68 infants in the control arm
Interventions Abstract and full report state slightly different protocols for the intervention arm. The
abstract stated that 24 mg betamethasone was given as two 12 mg IM doses at 24 h
apart. The full text states that this regimen was repeated weekly. Women had two doses
of 12 mg given 24 h apart, and this regimen was repeated weekly.
Control group received expectant management
Outcomes Maternal outcomes (chorioamnionitis, postnatal fever) and fetal/neonatal outcomes re-
ported (neonatal death, RDS, IVH)
Notes Article in French, abstract in English. Article translated by review authors (La Tunisie
Medicale, 2002, Vol 80; No. 5: 260-265). Further information was requested from the
study authors but there was no reply
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Fekih 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Method of allocation concealment was not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding is unlikely as placebowas not used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of post-randomisation exclusions
not stated
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
Gamsu 1989
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Stratification: yes,
by hospital
Placebo: yes, vehicle of betamethasone preparation
Sample size calculation: no
Intention-to-treat analyses: yes
Losses to follow-up: no
Funding: Glaxo Group Research Ltd, Greenford, Middlesex, UK
Participants Location: 11 hospitals in the UK
Timeframe: mid 1975-February 1978
Eligibility criteria: women with spontaneous or planned preterm delivery
Gestational age range: < 34 weeks
Exclusion criteria: contraindication to corticosteroids, contraindications to postponing
delivery, diabetes, suspected intrauterine infection
Total recruited: 251 women and 268 infants; 126 women and 131 infants in the treat-
ment arm and 125 women and 137 infants in the control arm
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Gamsu 1989 (Continued)
Interventions 6 doses of 4 mg betamethasone phosphate IM 8 h apart
Control group received 6 doses of placebo
All women with spontaneous labour received IV salbutamol
Outcomes Fetal/neonatal outcomes reported (fetal death, neonatal death, RDS, IVH, birthweight,
systemic infection in the first 48 h of life)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It is likely that participants were blinded as
placebo was used. Blinding of study per-
sonnel was not described other than “dou-
ble-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not
stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
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Garite 1992
Methods Type of study: RCT
Method of treatment allocation: random-number table generated randomisation se-
quence by pharmacy. The pharmacy provided consecutive sealed envelopes. Stratifica-
tion: none stated
Placebo: yes, normal saline
Sample size calculation: no
Intention-to-treat analyses: no
Losses to follow-up: yes, 5 (7%) women delivered elsewhere and were lost to follow-up
(4 in treatment arm and 1 in control arm)
Funding: Long Beach Memorial Foundation, USA
Participants Location: Long Beach Memorial Women’s Hospital, California, USA
Timeframe: December 1984-May 1990
Eligibility criteria: women likely to deliver between 24 h and 7 d with spontaneous
preterm labour or planned preterm delivery
Gestational age range: 24-27 + 6 weeks
Exclusion criteria: PROM, clinical or laboratory evidence of infection, contraindication
to or previously given corticosteroids, diabetes
Total recruited: 76 women and 82 infants; 37 women and 40 infants in the treatment
arm and 39 women and 42 infants in the control arm
Interventions 2 doses of 6 mg betamethasone acetate and 6 mg betamethasone phosphate IM 24 h
apart, repeated weekly if still < 28 weeks and thought likely to deliver within the next
week
Control group received 2doses of placebo.Womenundelivered after 28weeks and 1week
post their last dose of study medication were allowed glucocorticoids at the discretion of
their physicians
Outcomes Maternal outcomes (chorioamnionitis, endometritis), fetal/neonatal outcomes reported
(fetal death, neonatal death, RDS, chronic lung disease, IVH, birthweight, Apgar < 7,
need formechanical ventilation/CPAP, duration ofmechanical ventilation/CPAP, proven
neonatal infection while in NICU)
Notes It is not stated how many women received corticosteroids off protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table generated ran-
domisation sequence by pharmacy
Allocation concealment (selection bias) Unclear risk The pharmacy provided consecutive sealed
envelopes, not stated if envelopes were
opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It is likely that participants were blinded as
placebo was used. Blinding of study per-
sonnel was not described other than “dou-
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Garite 1992 (Continued)
ble-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 (7%) women delivered elsewhere and
were lost to follow-up (4 in treatment arm
and 1 in control arm)
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk It is not stated how many women received
corticosteroids off protocol
Goodner 1979
Methods Type of study: RCT (abstract)
Method of treatment allocation: not described
Stratification: not described
Placebo: yes, saline
Sample size calculation: not stated
Intention-to-treat analyses: not stated
Losses to follow-up: not stated
Funding: not stated
Participants Location: Temple University Hospital, Philadelphia, Pennsylvania, USA
Timeframe: July 1976-July 1978
Eligibility criteria: any pregnant woman expected to deliver prior to 34 weeks’ gestation
between July 1976 and July 1978 at Department of Obs & Gyne at Temple University
Hospital
Gestational age range: prior to 34 weeks
Exclusion criteria: not stated
Total recruited: 45 placebo, 47 steroids
Interventions Treatment group received an IM injection of betamethasone. The control group received
an IM injection of saline as placebo
Outcomes Neonatal mortality, RDS
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Goodner 1979 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not stated other than “randomized”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Likely that participants were blinded and
possible that study personnel were blinded
due to the use of placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessor not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) High risk RDS is the only outcome reported.
Other bias Unclear risk Only available as an abstract - does not ap-
pear to have been published
Gyamfi-Bannerman 2016
Methods Type of study: double-blind, RCT
Method of treatment allocation: simple urn method of randomisation
Stratification: yes, according to clinical site and gestational age (34-35 weeks and 36
weeks)
Placebo: yes, matching placebo
Sample size calculation: yes
Intention-to-treat analyses: yes
Losses to follow-up: yes, 4 (0.11%) lost to follow-up; 2 in each treatment group
Funding: National Heart, Lung, and Blood Institute, USA; Eunice Kennedy Shriver
National Institute of Child Health and Human Development, USA; National Center
for Advancing Translational Sciences, National Institutes of Health, USA
Participants Location: 17 university-based clinics in theUSA. All centres affiliated with theMaternal-
FetalMedicineUnitsNetwork of the Eunice Kennedy ShriverNational Institute of Child
Health and Human Development.
Timeframe: October 2010-February 2015
Eligibility criteria: women with singleton pregnancy 34 weeks + 0 d-36 weeks + 5 d
gestation at “high probability” of preterm delivery. “High probability was defined as
either preterm labor with intact membranes and at least 3 cm dilation or 75% cervical
effacement, or spontaneous rupture of themembranes. If neither of these criteria applied,
a high probability was defined as expected preterm delivery for any other indication
either through induction or cesarean section between 24 h and 7 d after the planned
randomisation, as determined by the obstetrical provider.”
Gestational age range: 34 weeks + 0 d-36 weeks + 5 d
Exclusion criteria: expected delivery < 12 h for any reason, already received antenatal
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Gyamfi-Bannerman 2016 (Continued)
corticosteroids in current pregnancy, chorioamnionitis, 8 cm or more cervical dilation,
non-reassuring fetal status requiring immediate delivery, no gestational age dating by
ultrasound before 32 weeks for women with known date for last menstrual period,
women without ultrasound dating before 24 weeks’ gestation with unknown date of last
menstrual period
Total recruited: 2831 women and 2831 infants; 1429 women and 1429 infants in the
treatment arm and 1402 women and 1402 infants in the control arm
Interventions Treatment group: (n = 1429 randomised) 2 IM injections of 12mg betamethasone (equal
parts betamethasone sodium phosphate and betamethasone acetate) administered 24 h
apart
Control group received matching placebo
“For those enrolled because of an indication for preterm delivery, labor inductions were
expected to start by 36 weeks 5 d, and cesarean deliveries were to be scheduled by 36
weeks 6 days and not before 24 hours after randomization.”
Control: (n = 1402 randomised) placebo IM injections as above
Follow up: to 28 d for oxygen dependency outcome
Outcomes Maternal outcome (maternal death, chorioamnionitis, side effects of therapy in women),
fetal/neonatal outcomes (perinatal death, fetal death, neonatal death, RDS, IVH, birth-
weight, necrotising enterocolitis, proven infection while in NICU, need for mechanical
ventilation/CPAP, surfactant use, air leak syndrome, Apgar score < 7, small for gestation
age, admission to NICU)
We asked study authors to clarify the mechanical ventilation/CPAP data presented in
Table 2 of the publication; we are unsure if outcome categories are exclusive or not. We
have not included data from this trial in the meta-analysis for 1.25 due to these concerns;
data will be included at the next update if confirmed by study authors
Data from trial is available for following non-review outcomes: maternal serious adverse
events, infant serious adverse events, hypoglycaemia in infant. Length of stay (maternal
and infant) reported as median with IQR only. Randomisation to delivery interval re-
ported as median with IQR only
Notes Supplementary appendix published online with data tables and additional information
on trial methods relevant to risk of bias. Contact author confirmed no maternal deaths
and blinding of researchers abstracting data from maternal and neonatal charts (24.2.
2016 by email)
ClinicalTrials.gov number, NCT01222247.
Ruptured membranes occurred in 22.1% intervention and 21.7% controls
1. No stillbirths or deaths within 72 hours
2. “Adverse events that were reported after both injections were less common in the
betamethasone group than in the placebo group (rate after first injection, 14.1% vs. 20.
3%; P<0.001; rate after second injection, 5.5% vs. 9.5%; P<0.007). Almost all adverse
events (95%) were local reactions at the injection site (Table S4 in the Supplementary
Appendix).” These data were used for our review’s side effects outcome
3. “Serious maternal adverse events occurred in 10 women in the betamethasone
group and 12 in the placebo group (Table S7 in the Supplementary Appendix). Apart
from the neonatal deaths, only one serious neonatal adverse event occurred (a case of
thrombocytopenia in the betamethasone group).” These data were reported narratively
above.
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Gyamfi-Bannerman 2016 (Continued)
“A total of 860 of 1429 women (60.2%) in the betamethasone group and 826 of 1402
(58.9%) in the placebo group received the prespecified two doses of study medication.
Of the 1145 women who did not receive a second dose, 1083 (94.6%) delivered before
24 hours; 6 women did not receive any of the assigned study medication. (In the placebo
group, 3 women who consented to participate in the trial subsequently declined the
injection, 1 woman delivered after randomization but before the first dose, and 1 received
open label betamethasone. In the betamethasone group, 1 woman was in active labor
with complete cervical dilation at the time of randomization.)”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Independent data-coordinating centre
with the use of the simple urnmethod, with
stratification according to clinical site and
gestational age category (34 to 35 weeks vs.
36 weeks)”
Allocation concealment (selection bias) Low risk Remote centre performed randomisation
and packaged intervention and placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical treatment and placebo packs pre-
pared remotely. Women and staff blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trained research staff extracted data from
maternal and neonatal staff; authors con-
firmed by email that these researchers were
blinded. Charts of babies admitted to spe-
cial care were reviewed by blinded staff for
respiratory outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two women in each group lost to follow-
up. Data available for 2827 neonates
Selective reporting (reporting bias) Low risk Supplementary outcome data published
online with paper
Other bias Low risk Few baseline imbalances apart from mean
maternal age (28.6 vs. 27.8 years) and His-
panic ethnic background (28.3 vs. 32%)
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Kari 1994
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Stratification: yes,
according to gestational age (24-27.9 weeks and 28-31.9 weeks) at each hospital
Placebo: yes, normal saline
Sample size calculation: yes
Intention-to-treat analyses: yes
Losses to follow-up: yes, 10 (11%) children in the follow-up study at age 2 (2 in the
treatment arm and 8 in the control arm)
Funding: Foundation for Pediatric Research, Finland; Orange County Infant Care Spe-
cialists, Finland; The Orion Corporation Research Foundation, Finland; Instrumentar-
ium Corporation Research Foundation, Finland; Arvo and Lea Ylppo Foundation, Fin-
land; Rinnekoti Foundation, Finland; and Organon Company, Oss, The Netherlands
Participants Location: 5 hospitals in Finland
Timeframe: April 1989-October 1991
Eligibility criteria: women with preterm labour or threatened preterm delivery due to
pre-eclampsia
Gestational age range: 24-31.9 weeks
Exclusion criteria: rupture of membranes, chorioamnionitis, congenital abnormalities,
proven lung maturity, insulin-treated diabetes, previously treated with corticosteroids
Total recruited: 157 women and 190 infants; 77 women and 95 infants in the treatment
arm and 80 women and 95 infants in the control arm
Interventions 4 doses of 6 mg dexamethasone sodium phosphate IM 12 h apart
Control group received 4 doses of placebo. Rescue treatment with exogenous human
surfactant was given to infants born 24-33 weeks, who at 2-24 h of age required me-
chanical ventilation with > 40% oxygen for RDS
Outcomes Maternal outcome (chorioamnionitis), fetal/neonatal outcomes (fetal death, neonatal
death, RDS, chronic lung disease, IVH, birthweight, surfactant use, necrotising entero-
colitis, small-for-gestational age) and childhood outcomes reported (death, neurodevel-
opmental delay)
Notes Efficacy analysis restricted to 91 infants in treatment arm and 88 infants in control arm.
3 infants excluded for protocol violations (1 mother with twins in placebo arm was given
corticosteroid, 1 infant in the treatment arm developedRDS but was not given surfactant
as it was not available) and 6 infants were excluded because of congenital malformations
(2 treatment, 4 placebo)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methodof randomisationnot stated. “Ran-
domisation in each participating hospital
was performed in blocks of 10”
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated
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Kari 1994 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The investigators and those who pro-
vided care were unaware of the treatment
allocation”. It is likely that participants
were blinded as “ampoules containing be-
tamethasone and placebo were identical”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10 (11%) children in the follow-up study
at age 2 (2 in the treatment arm and 8 in
the control arm). 1 female placebo-treated
infant born at 27 weeks’ gestation died 3
months after the expected date of delivery,
4 infants were lost due to parental refusal,
2 were living overseas, and 3 were in other
regions of the country
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Efficacy analysis restricted to 91 infants in
treatment arm and 88 infants in control
arm. 3 infants excluded for protocol viola-
tions (1 mother with twins in placebo arm
was given corticosteroid, 1 infant in the
treatment arm developed RDS but was not
given surfactant as it was not available) and
6 infants were excluded because of congen-
ital malformations (2 treatment, 4 placebo)
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Khazardoust 2012
Methods Type of study: double-blind RCT
Method of treatment allocation: computer generated
Stratification: none stated
Placebo: yes, placebo-controlled
Sample size calculation: not described
Intention-to-treat analyses: no, 5 (13%) of participants in the intervention arm were
excluded from analysis post randomisation
Losses to follow-up: yes, as above
Funding: “The study was supported by Tehran University ofMedial Sciences. The assays
were
performed At Shahed University of Medical Sciences which we would like to thanks the
staff and cooperation of that center in this study.”
Participants Location: Obstetric emergency department of Vali-e-Asr,Hospital, Tehran, Iran
Timeframe: June 2006 to July 2010
Eligibility criteria: patients at risk of preterm labor as determined by routine ultrasound
examination in the first trimester
Gestational age range: 34-37 weeks
Exclusion criteria: only primigravid women with signs of preterm labour were eligible,
including “palpable uterine contractions every 5-8 minutes and Bishop score of 4 and
higher associated with cervical dilatation of more than 1 cm and at least 50% of efface-
ment.”
“Women with systemic diseases, maternal hypertension before or during pregnancy,
uterine tenderness, chorioamnionitis signs, symptomatic vaginal infection, rupture of
membranes, current use of antibiotics, induced pregnancy, and history of smoking were
excluded.”
Total recruited: 80 women and 80 infants; 40 women and 40 infants in the treatment
arm and 40 women and 40 infants in the control arm
Interventions The treatment group received 2 doses of 12 mg betamethasone IM
The control group received placebo of saline as per regimen above
Outcomes No outcomes available for the review
Notes Data are provided on endocervical cytokine levels in women who delivered within and
after 1 week but no outcome data available for the review are presented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence in blocks of 4
Allocation concealment (selection bias) Unclear risk Only 1 person (research assistant) had ac-
cess to the randomisation list. It is unclear
whether this person was part of the team
performing the study
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Khazardoust 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial - saline was used as
the placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
High risk Analysis was not by intention-to-treat. 5
participants in the intervention arm were
excluded for named reasons and their data
were not included
Selective reporting (reporting bias) Low risk All intended outcomes, i.e. cytokine mea-
surements, were reported
Other bias High risk Datawere analysed for 35women in the in-
tervention arm versus 40 in the control arm
because 2 delivered before cytokine sam-
pling after the second dose of betametha-
sone, 1 opted out of the study and 2 devel-
oped high blood pressure
Lewis 1996
Methods Type of study: RCT
Method of treatment allocation: random-number table generated randomisation se-
quence by clinical research nurse uninvolved in clinical care. Sequentially-numbered
sealed opaque envelopes used. Stratification: none stated
Placebo: no
Sample size calculation: no
Intention-to-treat analyses: no
Losses to follow-up: yes, 2 (2%) women left hospital after randomisation and were lost
to follow-up (1 woman in each arm)
Funding: not stated
Participants Location: Louisiana State University Medical Center, Shreveport, Louisiana, USA
Timeframe: not stated in manuscript, the study is coded as 1990s for the review
Eligibility criteria: women with singleton pregnancies with PROM. Women were ran-
domised 12-24 h after receiving IV ampicillin-sulbactam
Gestational age range: 24-34 weeks
Exclusion criteria: evidence of infection, vaginal examination, cerclage, allergic to peni-
cillin, contraindication to expectant management, lung maturity confirmed by L/S ratio
if 32 weeks or more
Total recruited: 79 women and infants; 39 women and infants in the treatment arm and
40 women and infants in the control arm
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Lewis 1996 (Continued)
Interventions The treatment group received 12 mg IM betamethasone repeated at 24 h and weekly if
the women had not delivered.
The control group received expectant management.
Outcomes Maternal outcomes (chorioamnionitis, endometritis), fetal/neonatal outcomes (neonatal
death, RDS, IVH, birthweight, Apgar < 7, interval between trial entry and delivery, ad-
mission to NICU, surfactant use, proven neonatal infection while in NICU, necrotising
enterocolitis) and health service outcome reported (length of neonatal hospitalisation)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Clinical research nurse uninvolved in clini-
cal care generated randomisation sequence
by using random-number table, with a ran-
dom permuted block size of 10
Allocation concealment (selection bias) Low risk Sequentially-numbered sealed opaque en-
velopes were used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comparison was “no treatment” so blind-
ing not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 (2%) women left hospital against medical
advice after randomisation and were lost to
follow-up (1 women in each arm)
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
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Liggins 1972b
Methods Type of study: RCT
Method of treatment allocation: random-number table generated randomisation se-
quence by chief pharmacist. Pharmacy provided coded drug ampoules containing treat-
ment or placebo
Stratification: no
Placebo: yes, of identical appearance
Sample-size calculation: no
Intention-to-treat analyses: yes
Losses to follow-up: yes, 54 (18%) children in the follow-up study at ages 4-6 years (31
in the treatment arm and 23 in the control arm) and 412 (44%) adults in the follow-up
study at age 30 years (219 in the treatment arm and 193 in the control arm)
Funding: Health Research Council of New Zealand, Auckland, New Zealand; Auck-
land Medical Research Foundation, Auckland, New Zealand; and New Zealand Lottery
Grants Board, Wellington, New Zealand
Participants Location: National Women’s Hospital, Auckland, New Zealand
Timeframe: December 1969 and February 1974
Eligibility criteria: women with threatened or planned preterm delivery
Gestational age range: 24-36 weeks
Exclusion criteria: imminent delivery, contraindication to corticosteroids
Total recruited: 1142 women and 1218 infants; 560 women and 601 infants in the
treatment arm and 582 women and 617 infants in the control arm
Interventions The treatment group 2 doses of 6mg betamethasone phosphate and 6mg betamethasone
acetate IM 24 h apart. After the first 717 women had enrolled, the treatment intervention
was doubled to 2 doses of 12 mg betamethasone phosphate and 12 mg betamethasone
acetate IM 24 h apart.
The control group received 6mg cortisone acetate, which has 1/70th of the corticosteroid
potency of the betamethasone
Outcomes Maternal outcome (chorioamnionitis), fetal/neonatal outcomes (fetal death, neonatal
death, RDS, cerebroventricular haemorrhage, mean birthweight, Apgar score < 7, mean
interval between trial entry and delivery, proven infection while in NICU), childhood
outcomes (death, mean weight, mean height, mean head circumference, mean lung
function, mean blood pressure, intellectual impairment, cerebral palsy) and adulthood
outcomes were reported (death, mean weight, mean height, mean head circumference,
mean skin fold thickness, mean blood pressure, glucose impairment, HPA axis function,
mean cholesterol, educational achievement, visual impairment, hearing impairment,
intellectual impairment)
Notes Review includes new intention-to-treat analysis of the complete study and additional
data due to the study authors providing individual participant study records
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table generated ran-
domisation sequence by chief pharmacist
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Liggins 1972b (Continued)
Allocation concealment (selection bias) Low risk Pharmacy provided coded drug ampoules
containing treatment or placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of study personnel was not de-
scribed. It is likely that participants were
blinded as placebo was of identical appear-
ance to the corticosteroid
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk For the diagnosis of RDS, clinical records
and chest radiographs were assessed sepa-
rately and independently, by 1 of the study
authors, and by a radiologist
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Incomplete outcome data for 54 (18%)
children in the follow-up study at ages 4-
6 (31 in the treatment arm and 23 in the
control arm) and 412 (44%) adults in the
follow-up study at age 30 (219 in the treat-
ment arm and 193 in the control arm)
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
Lopez 1989
Methods Type of study: RCT
Method of treatment allocation: not described
Stratification: not stated
Placebo: no.
Sample size calculation: not stated
Intention-to-treat analyses: not stated however, all those randomised were analysed
Losses to follow-up: nil
Funding: not stated
Participants Location: Department of Obstetrics and Gynecology, Faculty of Medicine, National
Univeristy of Colombia
Timeframe: August 1983-December 1985
Eligibility criteria: PROM (confirmed using speculoscopy and ultrasound), no signs of
infection, not in labour at time of hospitalisation
Gestational age range: 27-35 weeks’ gestation
Exclusion criteria: not stated
Total recruited: 20 control group, 20 study group
Interventions The treatment group received 2 doses of 12 mg betamethasone IM, 12 h apart
The control group received no treatment.
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Lopez 1989 (Continued)
Outcomes Neonatal mortality, RDS, Apgar score < 7 at 5 min, systemic infection in first 48 h
Notes Original article in Spanish, translated into English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated other than “patients were classi-
fied randomly into groups”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comparison is “no treatment” so blinding
not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
Mansouri 2010
Methods Type of study: double-blind RCT
Method of treatment allocation: not described
Stratification: not stated
Placebo: yes, placebo-controlled
Sample size calculation: not stated
Intention-to-treat analyses: yes
Losses to follow-up: no
Funding: not stated in translation
Double-blind, randomised controlled trial in Kurdistan University of Medical Sciences,
Sanandaj, Iran
Participants Location: Kurdistan University of Medical Sciences, Sanandaj, Iran
Timeframe: “during 2007” stated
Eligibility criteria: women at high risk of preterm labour, not described
Gestational age range: 35-36 weeks
Exclusion criteria: not stated in our translation
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Mansouri 2010 (Continued)
Total recruited: 200 women and 200 infants; 100 women and 100 infants in the treat-
ment arm and 100 women and 100 infants in the control arm
Interventions The treatment group received 2 doses of 12 mg betamethasone, IM
The control group received a placebo of normal saline.
Outcomes Maternal outcome (maternal death, maternal infections), fetal/neonatal outcomes re-
ported (RDS, birthweight, necrotising enterocolitis, systemic infection in the first 48 h
of life, need for mechanical ventilation/CPAP, Apgar < 7 at 5 min, admission to NICU)
Notes Original article in Persian; we have obtained a truncated translation for this update. Our
translator was unable to translate the definition of respiratory distress syndrome but said
that the outcome was based on defined symptoms and confirmed by a paediatrician
Additonal outcome data for this trial are:
Maternal length of stay > 3 d (equal numbers in treatment arms) is reported narratively
above: mean birthweight and SD in kg has been analysed as g
Data for the trial outcome of ’need for respiratory support’ has been included in the
review analysis 1.26 ’need for mechanical ventilation’
We have been unable to confirm whether the trial included only singleton pregnancy,
but this is suggested by the equal numbers of women and infants reported. We have
included data from this trial in the singleton subgroup
We had no information about membrane status from our translation, and so this trial
has been included in the ’not reported or mixed population subgroup.’
Maternal length of stay > 3 d (equal numbers in both arms) is reported narratively
We emailed study investigators for clarification and additional information with no reply
(2/2016)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of sequence not stated, but
block method specified
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial described as double-blind. Placebo-
controlled trial, and researchers andwomen
were blind to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Neonatal outcomes extracted by blinded
paediatrician.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data reported for all women randomised
Selective reporting (reporting bias) Low risk Relevant outcome data reported
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Mansouri 2010 (Continued)
Other bias Unclear risk We have obtained a basic translation, but
future correspondence with authors may
clarify some of the risk of bias domains
above
Morales 1989
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Sealed envelopes
were used. Stratification: none stated
Placebo: no
Sample size calculation: no
Intention-to-treat analyses: no
Losses to follow-up: no
Funding: not stated
Participants Location: 3 hospitals in Florida, USA
Timeframe: January 1986-March 1988
Eligibility criteria: women with singleton pregnancies with PROM
Gestational age range: 26 and 34 weeks
Exclusion criteria: PROM<12 h before onset of labour, uterine tenderness, foul smelling
lochia, fetal tachycardia, allergy to penicillin, congenital abnormalities, L/S ratio 2 or
more, unable to obtain an L/S ratio, Dubowitz-assigned gestational age different from
obstetric assessment by 3 weeks (post-randomisation exclusion)
Total recruited: 165 women and infants; 87 women and infants in the treatment arm
and 78 women and infants in the control arm
Interventions 4 treatment arms. Group 1, expectant management. Group 2, expectant management
plus 2 doses of 12 mg betamethasone IM 24 h apart, repeated weekly if the women
remained undelivered. Group 3, expectant management plus 2 g ampicillin IV every 6
h until cervical cultures were negative. Group 4, combination of group 2 and 3 manage-
ment. We combined Groups 2 and 4 in the treatment arm for the review, and groups 1
and 3 in the control arm for the review
Outcomes Maternal outcome (chorioamnionitis), fetal/neonatal outcomes reported (neonatal
death, RDS, chronic lung disease, IVH, birthweight, proven neonatal infection while in
NICU, necrotising enterocolitis, duration of mechanical ventilation/CPAP)
Notes Further information requested from study authors but therewas no reply.No information
was available on post-randomisation exclusions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
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Morales 1989 (Continued)
Allocation concealment (selection bias) Unclear risk “Sealed envelopes” were used. Not further
described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk As comparison was expectant manage-
ment, blinding of participants and person-
nel was not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment was not
described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No losses to follow-up noted. No informa-
tion was available on post-randomisation
exclusions as per exclusion criteria
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
Nelson 1985
Methods Type of study: RCT
Method of treatment allocation: random-number table generated randomisation se-
quence with consecutive sealed envelopes used. Stratification: none stated
Placebo: no
Sample size calculation: no
Intention-to-treat analyses: yes
Losses to follow-up: no
Funding: not stated
Participants Location: Wake Forest University Medical Center, North Carolina, USA
Timeframe: not stated in manuscript, the study is coded as 1980s for the review
Eligibility criteria: women with PROM
Gestational age range: 28 and 34 weeks
Exclusion criteria: fetal distress, active labour, cervical dilatation > 3 cm, sensitivity to
tocolytics, PROM > 24 h, existing infection
Total recruited: 44 women and infants; 22 women and infants in each arm
Interventions 3 treatment arms. Group 1, 2 doses of 6 mg or 12 mg betamethasone IM 12 h apart,
delivery 24-48 h after PROM and after 24 h of corticosteroid therapy. Group 2, delivery
24-48 h after PROM. Group 3, expectant management. We did not include Group 3
in the review
Outcomes Fetal/neonatal outcomes (neonatal death, RDS, proven neonatal infection while in
NICU) and health service outcome reported (length of neonatal hospitalisation)
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Nelson 1985 (Continued)
Notes Authors provided further information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table generated ran-
domisation sequence
Allocation concealment (selection bias) Unclear risk Consecutive sealed envelopes were used,
not stated if opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and personnel was
not possible due to the nature of the com-
parison
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up or exclusions
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
Parsons 1988
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Stratification:
none stated
Placebo: no
Sample size calculation: no
Intention-to-treat analyses: yes
Losses to follow-up: no
Funding: not stated
Participants Location: University of Illinois, Chicago, USA
Timeframe: not stated in manuscript, the study is coded as 1980s for the review
Eligibility criteria: women with PROM and < 4 cm of cervical dilatation
Gestational age range: 25-32 weeks
Exclusion criteria: infection, fetal distress, fetal anomalies, contraindication to tocolysis
Total recruited: 45 women and infants; 23 women and infants in the treatment arm and
22 women and infants in the control arm
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Parsons 1988 (Continued)
Interventions The treatment group received 2 doses of 12 mg betamethasone IM 12 h apart repeated
weekly until 32 weeks.
The control group received expectant management.
Outcomes Fetal/neonatal outcomes reported (fetal death, neonatal death, RDS, systemic infection
in the first 48 h of life, proven neonatal infection while in NICU)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and personnel was
not possible due to the nature of the com-
parison
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up or exclusions de-
scribed
Selective reporting (reporting bias) Low risk Pre-specified outcomes were reported.
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
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Porto 2011
Methods Type of study: RCT
Method of treatment allocation: sealed cardboard boxes numbered according to random
number table generated by a statistician not involved in the study
Stratification: not stated
Placebo: yes, identical to corticosteroid in appearance, volume and colour
Sample size calculation: yes
Intention-to-treat analyses: yes
Losses to follow-up: 43 (13%) women (19 in corticosteroid group and 24 in placebo
group) were discharged from hospital still pregnant and were considered post-randomi-
sation loss to follow-ups. 2 (1%) women were excluded from the placebo group as they
were found to be ineligible after randomisation (multiple pregnancy, and term preg-
nancy). Two infant stillbirths were also excluded.
Funding: supported by the Insitiuto de Medicina Integral Prof Fernando Figueira-IMIP,
a private, not for profit healthcare organisation based in Recife, Brazil. The Institute did
not interfere with study design or analysis
Participants Location: Instituto de Medicina Integral Professor Fernando Figueira, Recife, Pernam-
buco, Brazil
Timeframe: April 2008-June 2010
Eligibility criteria: 34-36 + 6 weeks’ gestation at risk of imminent premature delivery
(either spontaneously or if early delivery was recommended as a result of problems with
mother or fetus)
Gestational age range: 34-36 + 6 weeks’ gestation
Exclusion criteria: multiple pregnancy, major congenital malformations, haemorrhage
symptoms with active bleeding, clinical evidence of chorioamnionitis, previous use of
antenatal corticosteroids, need for immediate resolution of pregnancy for maternal or
fetal reasons
Total recruited: 320 women and infants; 163 women and infants in the treatment arm
and 157 women and infants in the control arm
Interventions The treatment group received 2 doses of 12 mg IM betamethasone 24 h apart
The control group received IM saline as placebo.
Outcomes Maternal outcomes (side effects of therapy in women) and fetal/neonatal outcomes (fetal
deaths, neonatal deaths, RDS, birthweight, proven infection while in NICU, need for
mechanical ventilation/CPAP, mean duration of mechanical ventilation/CPAP, surfac-
tant use, small for gestational age, admission to NICU)
Notes For infant outcomes we have used the denominator stated in the published report ex-
cluding women who left the trial pregnant. An intention-to-treat analysis should have
included these women, so for SOF outcomes we carried out a sensitivity analysis to de-
termine if the denominator used made a difference to the overall pooled effect estimate;
it did not (data not shown)
Risk of bias
Bias Authors’ judgement Support for judgement
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Porto 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Random number table was prepared by a
statistician not involved in the study, using
random allocation software
Allocation concealment (selection bias) Low risk The hospital pharmacy prepared sealed
cardboard boxes numbered according to
the random number table, and containing
either betamethasone or placebo, identical
in appearance, volume and colour
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Investigators, physicians caring for the
women, the women themselves and the
statistician were all blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators, physicians caring for the
women, the women themselves and the
statistician were all blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 43 (13%) women (19 in steroid group and
24 in placebo group) were discharged from
hospital still pregnant and were consid-
ered post-randomisation losses to follow-
up. 2 (1%) women were excluded from the
placebo group as they were found to be in-
eligible after randomisation (multiple preg-
nancy, and term pregnancy)
Selective reporting (reporting bias) Low risk All pre-specified outcomes appear to have
been reported.
Other bias Unclear risk States “no significant differences between
groups in most baseline characteristics,”
but does not report where differences exist
Qublan 2001
Methods Type of study: RCT
Method of treatment allocation: random-number table generated randomisation se-
quence Allocation concealment unclear. Stratification: none stated
Placebo: no
Sample size calculation: no
Intention-to-treat analyses: yes
Losses to follow-up: no
Funding: not stated
Participants Location: 2 military hospitals in Jordan
Timeframe: January 1997-February 1999
Eligibility criteria: women with singleton pregnancies and PROM
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Qublan 2001 (Continued)
Gestational age range: 27-34 weeks
Exclusion criteria: lethal congenital anomaly, fetal death, infection, expected delivery
within 12 h
Total recruited: 139 women and infants; 72 women and infants in the treatment arm
and 67 women and infants in the control arm
Interventions The treatment group received 4 doses of 6 mg dexamethasone IM 12 h apart, repeated
if women had not delivered after 1 week.
The control group received expectant management.
Outcomes Maternal outcomes (chorioamnionitis, endometritis), fetal/neonatal outcomes (fetal
death, neonatal death, RDS, IVH, proven neonatal infection while in NICU, necrotis-
ing enterocolitis, Apgar < 7) and health service outcome reported (length of neonatal
hospitalisation)
Notes Study authors contacted for further information but no reply. Discrepancy in number
of infants with necrotising enterocolitis in manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table generated ran-
domisation sequence.
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and personnel was
not possible due to the nature of the com-
parison
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up or exclusions stated
Selective reporting (reporting bias) Unclear risk Discrepancy in number of infants with
necrotising enterocolitis in manuscript
Other bias Unclear risk Funding source not stated
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Schutte 1980
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Coded drug am-
poules were provided. Randomisation code was only known to pharmacist. Stratifica-
tion: none stated
Placebo: yes, normal saline
Sample size calculation: no
Intention-to-treat analyses: no
Losses to follow-up: yes, 12 (12%) children in the follow-up study at ages 10-12 years
(4 in the treatment arm and 8 in the control arm) and 21 (21%) adults in the follow-up
study at age 20 years (10 in the treatment arm and 11 in the control arm)
Funding: Dutch Foundation for Research on Prevention (Praeventiefonds Project 28-
1145), the Netherlands
Participants Location: Department of Obstetrics and Gynaecology and Department of Neonatology,
Wilhelmina Gasthuis, University of Amsterdam, Amsterdam, the Netherlands.
Timeframe: April 1974-April 1977
Eligibility criteria: women with preterm labour in whom it was possible to delay delivery
by at least 12 h
Gestational age range: 26-32 weeks. Exclusion criteria: no contraindications to the use
of corticosteroids or orciprenaline (insulin-treated diabetes, hyperthyroidism, infection,
severe hypertension, cardiac disease, marked fetal growth retardation or fetal distress)
Total recruited: 101 women and 123 infants; 50 women and 65 infants in the treatment
arm and 51 women and 58 infants in the control arm
Interventions The treatment group received 8 mg betamethasone phosphate and 6 mg betamethasone
acetate IM repeated after 24 h.
The control group received an identical placebo.
All women received orciprenaline infusion and bed-rest until 32 weeks
Outcomes Maternal outcomes (death, chorioamnionitis, maternal infections, fever after trial entry
requiring antibiotics, intrapartum fever requiring antibiotics, postnatal fever, admission
to ICU, side effects of therapy), fetal/neonatal outcomes (fetal death, neonatal death,
RDS, IVH, birthweight, Apgar score < 7), childhood outcomes (weight, height, head
circumference, lung function, visual impairment, hearing impairment, intellectual im-
pairment, cerebral palsy, behavioural/learning difficulties) and adulthood outcomes were
reported (weight, height, head circumference, blood pressure, intellectual impairment,
age at puberty)
Notes Initial study report included a third arm of women (n = 133) and infants (n = 164) who
had been excluded from randomisation because they were: 1. already in labour (n = 80)
and could not be prolonged for at least 12 h or were already 33 weeks’ gestation, or;
2. (n = 53) contra-indicated for corticosteroids, or; 3. wrongly excluded (n = 5). These
women and infants are not included in the review
Two perinatal deaths in the corticosteroid treatment arm were excluded for: 1. intrauter-
ine fetal death due to solutio placentae, and 2. death due to prolapsed umbilical cord.
These deaths have been included in the analyses
Infections in infants are listed in Table 6 of the Schutte 1979 original report. There are
deaths associated with these infections, and it is not clear when these infections or deaths
occurred, or if they have been included in the reported numbers for neonatal or perinatal
deaths
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Schutte 1980 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Low risk Coded drug ampoules prepared by phar-
macist
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial described as double blind, with phar-
macist preparing identical treatment and
control ampoules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Staff were blind to treatment group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 perinatal deaths in the corticosteroids
group were excluded. Data for infant in-
fections specify additional deaths, and it
is unclear whether or not these deaths are
counted in the overall total for perinatal
deaths. The inclusion of these deaths will
not change the overall conclusions of meta-
analysis in favour of corticosteroid use
Selective reporting (reporting bias) Low risk Primary outcome of the trial was RDS; this
and other important outcomes are reported
Other bias Unclear risk We are unclear as to the impact of exclu-
sions on results, especially for the outcome
of perinatal deaths
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Shanks 2010
Methods Type of study: RCT
Method of treatment allocation: not stated other than “randomly assigned”
Stratification: not stated
Placebo: no
Sample size calculation: yes
Intention-to-treat analyses: no
Losses to follow-up: 7 (22%) women (3 in the study group and 4 in the control group)
delivered within 7 d of their initial testing for fetal lung maturity and were excluded
from the analysis
Funding: supported in part by a Clinical and Translational Science Award, and by a
grant from the National Centre for Research Resources, a component of the National
Institute of Health and NIH Roadmap for Medical Research
Participants Location: Barnes-Jewish Hospital, St Louis, Missouri, USA
Timeframe: May 2003-May 2008
Eligibility criteria: singleton gestation, between 34 + 0 and 36 + 6 weeks’ gestation,
immature TDx-FLM-II test (< 45 mg/g) (this test measures surfactant to albumin ratio)
after clinically indicated amniocentesis to test for fetal lung maturity.
Gestational age range: 34 + 0 -36 + 6 weeks’ gestation
Exclusion criteria: multiple gestations, ruptured membranes, uncertain gestational ages,
previous steroid treatment in current pregnancy, delivery before completing the steroid
course, those unwilling or unable to comply with study protocol
Total recruited: 32 women and infants; 13 women and infants in the treatment arm and
19 women and infants in the control arm
Interventions The treatment group received either 2 doses of betamethasone 12 mg IM 24 h apart, or
4 doses of dexamethasone 6 mg IM 12 h apart
The control group received no treatment.
Outcomes Maternal outcomes (side effects of therapy in women) and fetal/neonatal outcomes (need
for mechanical ventilation/CPAP, admission to NICU)
Notes This study was stopped early due to difficulties in participant recruitment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned” not further described
Allocation concealment (selection bias) Unclear risk “Sealed envelopes” not further described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Control group received no treatment so
blinding of participants and study person-
nel would not have been possible
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Shanks 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention is made of blinding of out-
come assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk 7 (22%) women (3 in the study group and
4 in the control group) deliveredwithin 7 d
of their initial testing for fetal lungmaturity
and were excluded from the analysis. No
intention-to-treat analysis
Selective reporting (reporting bias) High risk Hyaline membrane disease is listed as an
outcome, but not reported
Other bias High risk This study was stopped early due to diffi-
culties in patient recruitment
Silver 1996
Methods Type of study: RCT
Methodof treatment allocation: computer-generated randomisation sequence usedPhar-
macy provided identical syringes labelled with the woman’s study number. Stratification:
none stated
Placebo: yes, normal saline
Sample size calculation: yes
Intention-to-treat analyses: no
Losses to follow-up: 124 women initially recruited, of whom 49 (40%) remained unde-
livered after 29 weeks and were not included in the review
Funding: not stated
Participants Location: Northwestern University Medical School, Chicago, Illinois, USA
Timeframe: April 1990-June 1994
Eligibility criteria: women at risk of delivery between 24-29 weeks
Gestational age range: 24-29 weeks
Exclusion criteria: infection, maternal or fetal indications for urgent delivery
Total recruited: 75 women and 96 infants; 39 women and 54 infants in the treatment
arm and 36 women and 42 infants in the control arm
Interventions The treatment group received 4 doses of 5 mg dexamethasone IM 12 h apart, repeated
weekly if the women remained undelivered.
The control group received placebo.
All infants born < 30 weeks received prophylactic surfactant at birth
Outcomes Maternal outcomes (chorioamnionitis, endometritis) and fetal/neonatal outcomes re-
ported (neonatal death, RDS, chronic lung disease, IVH, small-for-gestational age, birth-
weight, necrotising enterocolitis)
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Silver 1996 (Continued)
Notes Those women undelivered after 29 weeks were eligible for corticosteroid outside the
study protocol. These women and their infants are not included in the review as it was
not possible to separate out control women who subsequently received corticosteroids
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence used
Allocation concealment (selection bias) Low risk Pharmacy provided identical syringes la-
belled with the woman’s study number
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Clinical personnel and the patient were
effectively blinded to study group assign-
ment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The severity of RDS, and diagnosis of IVH
were “confirmed independently by chart
reviews conducted by 1 of the authors
blinded to study group assignment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 49 (40%) of the 124 women initially
recruited, remained undelivered after 29
weeks and were not included in the review
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
Taeusch 1979
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Coded drug boxes
used
Stratification: yes, by gestational age at entry
Placebo: yes, normal saline
Sample size calculation: yes
Intention-to-treat analyses: no
Losses to follow-up: yes, data not available for maternal outcomes on 4 women (2 in
each treatment arm)
Funding: not stated
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Taeusch 1979 (Continued)
Participants Location: 2 hospitals in Boston, USA
Timeframe: January 1975-March 1977
Eligibility criteria: women with preterm labour, PROM or with cervical dilatation < 5
cm at 33 weeks or less and women with an L/S ratio < 2 if > 33 weeks or who had a
previous infant with RDS
Gestational age range: not stated
Exclusion criteria: indication for immediate delivery, obstetrician objection, pre-eclamp-
sia, previously received corticosteroids
Total recruited: 122 women and 127 infants recruited; 39 women and 54 infants ran-
domised to the treatment arm and 36 women and 42 infants randomised to the control
arm
Interventions The treatment group received 6 doses of 4 mg dexamethasone phosphate IM 8 h apart.
The control group received placebo.
Outcomes Maternal outcomes (endometritis, fever after trial entry requiring antibiotics) and fetal/
neonatal outcomes reported (fetal death, neonatal death, RDS, chronic lung disease,
IVH, proven neonatal infection while in NICU)
Notes Study authors contacted for further information but there was no reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Coded drug boxes were used, but it is not
clear how they were coded, e.g. if they were
sequentially numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It is likely that participants were blinded
due to the use of an identical looking
placebo. Blinding of study personnel was
not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Diagnosis of RDSwas made prior to break-
ing the treatment code
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data not available for maternal outcomes
on 4 (3%) women (2 in each treatment
arm) with no explanation given
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
86Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Taeusch 1979 (Continued)
Other bias Unclear risk Insufficient information to asses if other
sources of bias exist
Teramo 1980
Methods Type of study: RCT
Method of treatment allocation: method of randomisation not stated. Coded drug boxes
used. Stratification: none stated
Placebo: yes, normal saline
Sample size calculation: no
Intention-to-treat analyses: yes
Losses to follow-up: no
Funding: not stated
Participants Location: University of Helsinki, Finland
Timeframe: not stated in manuscript, the study is coded as 1980s for the review
Eligibility criteria: women with preterm labour and cervical dilatation < 4 cm without
progression of labour upon initial observation of up to 12 h
Gestational age range: 28 -35 weeks
Exclusion criteria: pre-eclampsia, diabetes
Total recruited: 74 women and 80 infants; 36 women and 38 infants in the treatment
arm and 38 women and 42 infants in the control arm
Interventions The treatment group received 2 doses of 12 mg betamethasone IM 24 h apart.
The control group received placebo.
Outcomes Fetal/neonatal outcomes reported (RDS, HPA axis function)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Coded drug boxes were used but it is not
clear how they were coded, e.g. if they were
sequentially numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It is likely that participants were blinded
due to the use of a placebo “similar in ap-
pearance” to the corticosteroid. Blinding
of study personnel was not described other
than “ampoules were administered to the
patients using the double-blind principle”
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Teramo 1980 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors was not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up or exclusions stated
Selective reporting (reporting bias) Low risk Study protocol not available, but appears
to report on all pre-specified outcomes
Other bias Unclear risk The study was discontinued early because
the overall incidence of RDS was too low
for anymeaningful conclusions concerning
the efficacy of prevention
CPAP: continuous positive airways pressure
GDM: gestational diabetes mellitus
HPA: hypothalamic-pituitary-adrenal
ICU: intensive care unit
IM: intramuscular
IUGR: Iintrauterine growth restriction
IV: intravenous
IVH: intraventricular haemorrhage
LMP: last menstrual period
NICU: neonatal intensive care unit
PIH: pregnancy induced hypertension
PROM: premature rupture of membranes
PPROM: prolonged premature rupture of membranes
RCT: randomised controlled trial
RDS: respiratory distress syndrome
Rh: Rhesus
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abuhamad 1999 This abstract compares TRH + betamethasone with betamethasone + placebo
Althabe 2015 This is a trial of strategies to optimise use of corticosteroids
Asnafei 2004 This study is quasi-experimental.
88Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Butterfill 1979 Randomised participants are combined with a non-randomised cohort and cannot be analysed sepa-
rately
Dola 1997 This abstract compares TRH + betamethasone with betamethasone + placebo
Egerman 1998 This trial compares oral vs IM dexamethasone in the prevention of RDS. It does not meet our entry
criteria for inclusion of studies for the review
Garite 1981 This trial compares a policy of corticosteroid therapy followed by elective delivery with a policy of
withholding corticosteroids and awaiting delivery so the independent effect of the 2 co-interventions
cannot be evaluated separately
Grgic 2003 Not a randomised trial. Outcomes for women who received steroids were compared with those that
did not. Information obtained from translation sheet. Original article in Bosnian
Halac 1990 Not a randomised trial. Women were allocated to placebo if they were expected to deliver within 24 h
and to betamethasone if labour was not expected within 24 h
Iams 1985 Corticosteroid therapy (hydrocortisone) and co-intervention of elective delivery was compared to
expectantmanagement inPROM.The independent effect of the 2 co-interventions cannot be evaluated
separately
Khandelwal 2012 Compared different doses of corticosteroid: 12-hourly vs 24-hourly. The study includes a repeat dose of
corticosteroids and is eligible for inclusion in a different review, ’Repeat doses of prenatal corticosteroids
for women at risk of preterm birth for improving neonatal health outcomes’ Crowther 2015.
Koivisto 2007 The study includes a repeat dose of corticosteroids and is eligible for inclusion in a different review,
’Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal
health outcomes’ Crowther 2015.
Kuhn 1982 Randomised participants are combined with a non-randomised cohort and cannot be analysed sepa-
rately
Kurtzman 2008 The study includes a repeat dose of corticosteroids and is eligible for inclusion in a different review,
’Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal
health outcomes’ Crowther 2015.
Liu 2006 Quasi-randomised study that allocated women according to the in-patient sequence. Compared the
effect of dexamethasone combined with vitamin K, dexamethasone alone and no dexamethasone or
vitamin K on periventricular/intraventricular haemorrhage
Magee 1997 This study compares the effects of betamethasone vs dexamethasone on antenatal fetal heart rate
Maksic 2008 This study appears to be an observational study of 163 premature infants, 80 of whom were exposed
to antenatal corticosteroids, and 83 of whom were not
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(Continued)
McEvoy 2010 This trial compares repeat dose corticosteroids and is eligible for inclusion a different review, ’Repeat
doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health
outcomes’ Crowther 2015.
Minoui 1998 This study compares the effects of betamethasone vs dexamethasone on antenatal fetal heart rate
Morales 1986 Quasi-randomised using medical record number.
Morrison 1978 This study was included in original review. It is excluded from this update because of > 20% post-
randomisation exclusions and the fact that it was possibly quasi-randomised
Mulder 1997 This study compares the effects of betamethasone vs dexamethasone on antenatal fetal heart rate
Papageorgiou 1979 This study was included in original review. It is excluded from this update because of > 20% post-
randomisation exclusions. Of 146 babies included in the study, the paper only reports outcomes for
61
Romejko-Wolniewicz 2013 This is a head-to-head trial of 2 different regimens and is eligible for the Cochrane review entitled
’Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of
preterm birth’ Brownfoot 2013.
Rotmensch 1999 This study compares the effects of betamethasone vs dexamethasone on antenatal fetal heart rate
Schmidt 1984 This study was included in original review. It is excluded from this update because of > 20% post-
randomisation exclusions. The paper only reports results from 92 of 144 randomised mothers and 97
of 149 randomised babies
Simpson 1985 Quasi-randomised study. Randomised participants are combined with a non-randomised cohort and
cannot be analysed separately
Whitt 1976 This trial compares IM betamethasone with IV cortisol. It does not meet our entry criteria for inclusion
of studies for the review
IM: intramuscular
IV: intravenous
PROM: premature rupture of membranes
RDS: respiratory distress syndrome
TRH: thyrotropin-releasing hormone
vs: versus
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D A T A A N D A N A L Y S E S
Comparison 1. Corticosteroids versus placebo or no treatment




participants Statistical method Effect size
1 Maternal death 5 3392 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.50]
2 Chorioamnionitis 15 5546 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.66, 1.06]
3 Endometritis 10 4030 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.87, 1.63]
4 Perinatal deaths 15 6729 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.58, 0.89]
5 Neonatal deaths 22 7188 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.59, 0.81]
6 Fetal deaths 15 6729 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.74, 1.30]
7 Respiratory distress syndrome 28 7764 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.56, 0.77]
8 Moderate/severe respiratory
distress syndrome
6 1686 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.38, 0.91]
9 Chronic lung disease 6 818 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.42, 1.79]
10 Intraventricular haemorrhage 16 6093 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.40, 0.76]
11 Mean birthweight (g) 16 6182 Mean Difference (IV, Fixed, 95% CI) -18.47 [-40.83, 3.
90]
12 Death in childhood 4 1010 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.36, 1.27]
13 Neurodevelopmental delay in
childhood
1 82 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.14, 2.98]
14 Death into adulthood 1 988 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.56, 1.81]
15 Fever in women after trial entry
requiring the use of antibiotics
4 481 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.43, 2.06]
16 Intrapartum fever in woman
requiring the use of antibiotics
2 319 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.09, 4.89]
17 Side effects of therapy in
women
6 3572 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.59, 0.82]
18 Admission into adult intensive
care unit
2 319 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.26, 2.05]
19 Hypertension 1 220 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.36, 2.76]
20 Postnatal fever in woman 5 1323 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.64, 1.33]
21 Glucose intolerance 1 123 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [1.14, 6.46]
22 Necrotising enterocolitis 10 4702 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.32, 0.78]
23 Systemic infection in the first
48 hours of life
8 1753 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.41, 0.88]
24 Proven infection while in the
neonatal intensive care unit
13 5707 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.55, 1.08]
25 Need for mechanical
ventilation/CPAP
9 1368 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.56, 0.84]
26 Mean duration of mechanical
ventilation/CPAP (days)
3 471 Mean Difference (IV, Random, 95% CI) -1.91 [-4.59, 0.76]
27 Mean duration of oxygen
supplementation (days)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
28 Surfactant use 5 3556 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.51, 0.90]
29 Air leak syndrome 2 2965 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.32, 1.80]
30 Apgar < 7 at 5 minutes 10 2419 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.67, 0.98]
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31 Mean interval between trial
entry and birth (days)
3 1513 Mean Difference (IV, Fixed, 95% CI) 0.23 [-1.86, 2.32]
32 Small-for-gestational age 5 3478 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.96, 1.28]
33 Mean infant HPA axis function
(cortisol)
1 27 Mean Difference (IV, Fixed, 95% CI) 3.94 [-3.12, 11.00]
33.1 In babies born < 24
hours after 1st dose
1 6 Mean Difference (IV, Fixed, 95% CI) 9.0 [-11.93, 29.93]
33.2 In babies born 24-48
hours after 1st dose
1 10 Mean Difference (IV, Fixed, 95% CI) 0.0 [-8.68, 8.68]
33.3 In babies born > 48
hours after 1st dose
1 11 Mean Difference (IV, Fixed, 95% CI) 13.0 [-1.90, 27.90]
34 Admission to neonatal intensive
care unit
7 3803 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.84, 0.97]
35 Developmental delay in
childhood
2 518 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.24, 1.00]
36 Cerebral palsy in childhood 5 904 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.34, 1.03]
37 Mean childhood weight (kg) 2 333 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.39, 1.00]
37.1 Liggins 1 250 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.32, 1.12]
37.2 Schutte (females) 1 39 Mean Difference (IV, Fixed, 95% CI) -2.40 [-6.55, 1.75]
37.3 Schutte (males) 1 44 Mean Difference (IV, Fixed, 95% CI) -0.10 [-3.88, 3.68]
38 Mean childhood height (cm) 2 334 Mean Difference (IV, Fixed, 95% CI) 1.02 [-0.26, 2.29]
38.1 Liggins 1 250 Mean Difference (IV, Fixed, 95% CI) 1.0 [-0.39, 2.39]
38.2 Schutte (females) 1 39 Mean Difference (IV, Fixed, 95% CI) 1.70 [-3.08, 6.48]
38.3 Schutte (males) 1 45 Mean Difference (IV, Fixed, 95% CI) 0.60 [-3.79, 4.99]
39 Mean childhood head
circumference (cm)
2 328 Mean Difference (IV, Fixed, 95% CI) 0.27 [-0.08, 0.63]
39.1 Liggins 1 250 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.11, 0.71]
39.2 Schutte (females) 1 36 Mean Difference (IV, Fixed, 95% CI) -0.10 [-1.05, 0.85]
39.3 Schutte (males) 1 42 Mean Difference (IV, Fixed, 95% CI) 0.60 [-0.51, 1.71]
40 Mean childhood VC (%
predicted)
2 150 Mean Difference (IV, Fixed, 95% CI) -1.68 [-5.12, 1.75]
40.1 Liggins 1 75 Mean Difference (IV, Fixed, 95% CI) 0.70 [-5.12, 6.52]
40.2 Schutte (females) 1 36 Mean Difference (IV, Fixed, 95% CI) -2.60 [-8.65, 3.45]
40.3 Schutte (males) 1 39 Mean Difference (IV, Fixed, 95% CI) -3.30 [-9.27, 2.67]
41 Mean childhood FEV1 (%
predicted)
1 75 Mean Difference (IV, Fixed, 95% CI) -4.73 [-10.13, 0.67]
41.1 Schutte (females) 1 36 Mean Difference (IV, Fixed, 95% CI) -2.5 [-11.24, 6.24]
41.2 Schutte (males) 1 39 Mean Difference (IV, Fixed, 95% CI) -6.10 [-12.96, 0.76]
42 Mean childhood FEV1/VC 2 150 Mean Difference (IV, Random, 95% CI) -0.94 [-3.63, 1.76]
42.1 Liggins 1 75 Mean Difference (IV, Random, 95% CI) 1.0 [-2.57, 4.57]
42.2 Schutte (females) 1 36 Mean Difference (IV, Random, 95% CI) 0.0 [-5.56, 5.56]
42.3 Schutte (males) 1 39 Mean Difference (IV, Random, 95% CI) -3.0 [-6.14, 0.14]
43 Mean childhood systolic blood
pressure (mmHg)
1 223 Mean Difference (IV, Fixed, 95% CI) -1.60 [-4.06, 0.86]
44 Visual impairment in
childhood
2 166 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.24, 1.23]
45 Hearing impairment in
childhood
2 166 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.04, 9.87]
46 Intellectual impairment in
childhood
3 778 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.44, 1.69]
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47 Behavioural/learning
difficulties in childhood
1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.35, 2.09]
48 Mean adult insulin (log values) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
48.1 Fasting 1 435 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.03, 0.19]
48.2 30 minutes following a
75 g oral glucose tolerance test
1 412 Mean Difference (IV, Fixed, 95% CI) 0.16 [0.04, 0.28]
48.3 120 minutes following a
75 g oral glucose tolerance test
1 428 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.27, 0.07]
49 Mean adult glucose (mmol/L) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
49.1 Fasting 1 432 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.09, 0.11]
49.2 30 minutes following a
75 g oral glucose tolerance test
1 413 Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.14, 0.52]
49.3 120 minutes following a
75 g oral glucose tolerance test
1 410 Mean Difference (IV, Fixed, 95% CI) -0.27 [-0.52, -0.02]
50 Mean adult weight (kg) 2 538 Mean Difference (IV, Random, 95% CI) -0.83 [-6.41, 4.76]
50.1 Schutte (females) 1 37 Mean Difference (IV, Random, 95% CI) -6.0 [-12.93, 0.93]
50.2 Schutte (males) 1 43 Mean Difference (IV, Random, 95% CI) -1.0 [-9.91, 7.91]
50.3 Liggins 1 458 Mean Difference (IV, Random, 95% CI) 2.57 [-0.72, 5.86]
51 Mean adult height (cm) 2 537 Mean Difference (IV, Fixed, 95% CI) 0.91 [-0.28, 2.10]
51.1 Schutte (females) 1 36 Mean Difference (IV, Fixed, 95% CI) -1.0 [-5.37, 3.37]
51.2 Schutte (males) 1 43 Mean Difference (IV, Fixed, 95% CI) 3.0 [-2.30, 8.30]
51.3 Liggins (females) 1 234 Mean Difference (IV, Fixed, 95% CI) 1.17 [-0.65, 2.99]
51.4 Liggins (males) 1 224 Mean Difference (IV, Fixed, 95% CI) 0.75 [-1.03, 2.53]
52 Mean adult head circumference
(cm)
2 537 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.33, 0.38]
52.1 Schutte (females) 1 37 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.03, 1.03]
52.2 Schutte (males) 1 42 Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.37, 0.97]
52.3 Liggins 1 458 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.34, 0.46]
53 Mean adult skinfold thickness
(log values)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
53.1 Triceps 1 456 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.11, 0.07]
53.2 Biceps 1 456 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.11, 0.09]
53.3 Subscapular 1 441 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.08, 0.10]
53.4 Suprailiac 1 452 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.12, 0.10]
54 Mean adult systolic blood
pressure (mmHg)
2 545 Mean Difference (IV, Random, 95% CI) -1.53 [-4.50, 1.44]
54.1 Schutte (females) 1 38 Mean Difference (IV, Random, 95% CI) -4.0 [-9.12, 1.12]
54.2 Schutte (males) 1 52 Mean Difference (IV, Random, 95% CI) -3.0 [-7.17, 1.17]
54.3 Liggins 1 455 Mean Difference (IV, Random, 95% CI) 0.55 [-1.88, 2.98]
55 Mean adult HPA axis function
(mean log fasting cortisol)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
56 Mean cholesterol in adulthood
(mmol/L)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
57 Mean age at puberty (years) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
57.1 Schutte (females) 1 38 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.94, 0.94]
58 Educational achievement
by adulthood (university or
polytechnic education)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
59 Visual impairment in
adulthood
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
60 Hearing impairment in
adulthood
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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61 Intellectual impairment in
adulthood
2 273 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.01, 4.95]
62 Mean adult FVC (% predicted) 1 383 Mean Difference (IV, Fixed, 95% CI) -0.70 [-3.16, 1.76]
63 Mean adult FEV1 (%
predicted)
1 383 Mean Difference (IV, Fixed, 95% CI) 0.40 [-2.31, 3.11]
64 Mean adult FEV1/FVC 1 383 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.01, 0.03]
65 Mean adult PEF 1 383 Mean Difference (IV, Fixed, 95% CI) 2.20 [-0.77, 5.17]
66 Mean adult F50 1 383 Mean Difference (IV, Fixed, 95% CI) 3.0 [-1.57, 7.57]
67 Mean adult F25 1 383 Mean Difference (IV, Fixed, 95% CI) 0.40 [-3.82, 4.62]
68 Mean adult FEF 25%-75% 1 383 Mean Difference (IV, Fixed, 95% CI) 2.20 [-2.10, 6.50]
69 FEV1/FVC < 70% 1 383 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.49, 1.57]
70 Asthma diagnosed by Doctor
in lifetime
1 534 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.74, 1.30]
71 Wheezing in last 12 months 1 534 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.84, 1.35]
72 Current Asthma 1 534 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.74, 1.48]




1 534 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.69, 2.59]
74 Spontaneous pneumothorax 1 534 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.07, 17.66]
75 Shortness of breath at anytime
in the last 12 months
1 534 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.80, 1.31]
76 Mean adult lumbar spine
aBMD (g/cm2) areal bone
mineral density
1 174 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.04, 0.04]
77 Mean adult lumbar spine
vBMD (g/cm3) volumetric
bone mineral density
1 174 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.01, 0.01]
78 Mean adult total body BMC
(grams) bone mineral content
1 174 Mean Difference (IV, Fixed, 95% CI) 18.0 [-151.30, 187.
30]
79 Mean adult total body aBMD
(g/cm3) areal bone mineral
density
1 174 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.03, 0.03]
80 Mean adult femoral neck
aBMD (g/cm2) areal bone
mineral density
1 174 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.03, 0.07]
81 Mean adult femoral trochanter
aBMD (g/cm2) areal bone
mineral density
1 174 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.02, 0.06]
82 Mean adult femoral shaft
aBMD (g/cm2) areal bone
mineral density
1 174 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.04, 0.06]
83 Mean total proximal femur
aBMD (g/cm2) areal bone
mineral density
1 174 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.03, 0.07]
84 Mean length of antenatal
hospitalisation (days)
1 218 Mean Difference (IV, Fixed, 95% CI) 0.5 [-1.40, 2.40]
85 Mean length of postnatal
hospitalisation (days)
1 218 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.72, 1.72]
86 Mean length of neonatal
hospitalisation (days)
5 788 Mean Difference (IV, Fixed, 95% CI) 0.18 [-0.51, 0.87]
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Comparison 2. Corticosteroids versus placebo or no treatment - single or multiple pregnancy




participants Statistical method Effect size
1 Chorioamnionitis - single or
multiple pregnancy
15 5546 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.66, 1.06]
1.1 In women delivering
singleton pregnancies
7 4682 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.56, 1.01]
1.2 In women delivering
multiple pregnancies
1 74 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.04, 4.49]
1.3 Mixed population 8 790 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.70, 1.57]
2 Perinatal death - single or
multiple pregnancy
15 6729 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.59, 0.89]
2.1 In babies born from
singleton pregnancies
6 5182 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.54, 1.05]
2.2 In babies born from
multiple pregnancies
2 252 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.37, 1.47]
2.3 Mixed population 9 1295 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.49, 0.94]
3 Neonatal death - single or
multiple pregnancy
22 7188 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.59, 0.81]
3.1 In babies born from
singleton pregnancies
9 5335 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.61, 0.92]
3.2 In babies born from
multiple pregnancies
2 236 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.39, 1.61]
3.3 Mixed population 13 1617 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.46, 0.78]
4 Fetal death - single or multiple
pregnancy
15 6729 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.73, 1.29]
4.1 In babies born from
singleton pregnancies
6 5182 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.75, 1.45]
4.2 In babies born from
multiple pregnancies
2 252 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.20, 1.40]
4.3 Mixed population 9 1295 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.50, 1.99]
5 Respiratory distress syndrome -
single or multiple pregnancy
28 7762 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.59, 0.78]
5.1 In babies born from
singleton pregnancies
15 6081 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.50, 0.77]
5.2 In babies born from
multiple pregnancies
4 320 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.67, 1.22]
5.3 Mixed population 13 1361 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.53, 0.89]
6 IVH - single or multiple
pregnancy
16 6093 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.44, 0.70]
6.1 In babies born from
singleton pregnancies
8 4782 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.36, 0.75]
6.2 In babies born from
multiple pregnancies
1 137 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.07, 2.06]
6.3 Mixed population 8 1174 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.44, 0.81]
7 Birthweight - single or multiple
pregnancy
16 6182 Mean Difference (IV, Fixed, 95% CI) -17.61 [-39.95, 4.
74]
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7.1 In babies born from
singleton pregnancy
9 4948 Mean Difference (IV, Fixed, 95% CI) -24.12 [-48.27, 0.
03]
7.2 In babies born from
multiple pregnancies
1 150 Mean Difference (IV, Fixed, 95% CI) 82.36 [-146.23, 310.
95]
7.3 Mixed population 7 1084 Mean Difference (IV, Fixed, 95% CI) 16.77 [-44.16, 77.
69]
Comparison 3. Corticosteroids versus placebo or no treatment - intact membranes versus ruptured membranes
at first dose




participants Statistical method Effect size
1 Chorioamnionitis - intact or
ruptured membranes
15 5517 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.67, 1.07]
1.1 In women with intact
membranes at 1st dose
5 1437 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.50, 1.40]
1.2 In women with ruptured
membranes at 1st dose
7 959 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.69, 1.40]
1.3 Not reported or mixed
population
4 3121 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.47, 1.06]
2 Endometritis - intact or ruptured
membranes
10 4030 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.80, 1.80]
2.1 In women with intact
membranes at 1st dose
2 289 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.37, 4.01]
2.2 In women with ruptured
membranes at 1st dose
4 477 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.35, 2.97]
2.3 Not reported or mixed
population
5 3264 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.81, 2.13]
3 Perinatal death - intact or
ruptured membranes
15 6700 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.60, 0.90]
3.1 In babies born from
pregnancies with intact
membranes at 1st dose
4 1332 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.70, 1.08]
3.2 In babies born from
pregnancies with ruptured
membranes at 1st dose
4 733 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.39, 0.90]
3.3 Not reported or mixed
population
8 4635 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.49, 1.03]
4 Neonatal deaths - intact or
ruptured membranes
22 7163 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.59, 0.81]
4.1 In babies born from
pregnancies with intact
membranes at 1st dose
4 1236 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.58, 1.03]
4.2 In babies born from
pregnancies with ruptured
membranes at 1st dose
8 1024 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.46, 0.83]
4.3 Not reported or mixed
population
11 4903 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.53, 0.88]
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5 Fetal death - intact or ruptured
membranes
15 6634 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.71, 1.26]
5.1 In babies born from
pregnancies with intact
membranes at 1st dose
4 1332 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.73, 1.64]
5.2 In babies born from
pregnancies with ruptured
membranes at 1st dose
5 790 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.46, 1.61]
5.3 Not reported or mixed
population
7 4512 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.44, 1.35]
6 RDS - intact or ruptured
membranes
28 7738 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.56, 0.76]
6.1 In babies born from
pregnancies with intact
membranes at 1st dose
6 1721 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.50, 0.80]
6.2 In babies born from
pregnancies with ruptured
membranes at 1st dose
12 1129 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.55, 0.90]
6.3 Not reported or mixed
population
14 4888 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.46, 0.81]
7 IVH - intact or ruptured
membranes
15 5868 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.44, 0.70]
7.1 In babies born from
pregnancies with intact
membranes at 1st dose
5 1394 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.35, 0.72]
7.2 In babies born from
pregnancies with ruptured
membranes at 1st dose
5 895 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.28, 0.79]
7.3 Not reported or mixed
population
6 3579 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.49, 1.07]
8 Birthweight - intact or ruptured
membranes
16 6153 Mean Difference (IV, Fixed, 95% CI) -19.52 [-41.81, 2.
78]
8.1 In babies born from
pregnancies with intact
membranes at 1st dose
4 1301 Mean Difference (IV, Fixed, 95% CI) -30.27 [-100.43, 39.
89]
8.2 In babies born from
pregnancies with ruptured
membranes at 1st dose
5 835 Mean Difference (IV, Fixed, 95% CI) -49.72 [-113.91, 14.
46]
8.3 Not reported or mixed
population
8 4017 Mean Difference (IV, Fixed, 95% CI) -13.44 [-38.71, 11.
83]
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Comparison 4. Corticosteroids versus placebo or no treatment - hypertension syndrome versus all other trials




participants Statistical method Effect size
1 RDS 28 7764 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.60, 0.74]




9 2660 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.47, 0.71]
1.3 Hypertension not reported
separately
18 4722 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.66, 0.85]
2 Perinatal deaths 15 6729 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.60, 0.92]




3 1394 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.39, 1.29]
2.3 Hypertension not reported
separately
11 5022 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.52, 0.93]
3 Fetal deaths 15 6729 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.74, 1.30]
3.1Women with hypertension
syndrome




4 1644 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.49, 1.08]
3.3 Hypertension not reported
separately
10 4754 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.67, 1.98]
4 Neonatal deaths 22 7188 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.59, 0.81]




3 1306 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.61, 1.09]
4.3 Hypertension not reported
separately
18 5604 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.54, 0.82]
Comparison 5. Corticosteroids versus placebo or no treatment - type of steroid




participants Statistical method Effect size
1 Chorioamnionitis - type of
steroid
15 5546 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.66, 1.06]
1.1 In women treated with
dexamethasone
5 769 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.89, 2.05]
1.2 In women treated with
betamethasone
10 4777 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.50, 0.90]
2 Endometritis - type of steroid 10 4030 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.81, 1.80]
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2.1 In women treated with
dexamethasone
4 536 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.86, 3.43]
2.2 In women treated with
betamethasone
6 3494 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.63, 1.45]
3 Perinatal death - type of steroid 15 6729 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.58, 0.89]
3.1 In babies treated with
dexamethasone
5 1420 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.46, 1.11]
3.2 In babies treated with
betamethasone
10 5309 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.56, 0.94]
4 Neonatal deaths by steroid type 22 7188 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.59, 0.81]
4.1 In babies treated with
dexamethasone
6 1468 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.55, 0.94]
4.2 In babies treated with
betamethasone
16 5720 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.55, 0.83]
5 Fetal death - type of steroid 15 6729 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.74, 1.30]
5.1 In babies treated with
dexamethasone
5 1420 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.48, 1.60]
5.2 In babies treated with
betamethasone
10 5309 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.73, 1.39]
6 Respiratory distress syndrome -
type of steroid
28 7764 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.56, 0.77]
6.1 In babies treated with
dexamethasone
7 1651 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.61, 0.98]
6.2 In babies treated with
betamethasone
20 6095 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.50, 0.73]
6.3 Steroid type not reported 1 18 Risk Ratio (M-H, Random, 95% CI) 1.62 [0.08, 34.66]
7 IVH - type of steroid 16 6093 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.40, 0.76]
7.1 In babies treated with
dexamethasone
6 897 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.18, 1.26]
7.2 In babies treated with
betamethasone
10 5196 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.40, 0.72]
8 Birthweight - type of steroid 16 6182 Mean Difference (IV, Fixed, 95% CI) -18.47 [-40.83, 3.
90]
8.1 In babies treated with
dexamethasone
4 686 Mean Difference (IV, Fixed, 95% CI) -17.04 [-75.48, 41.
41]
8.2 In babies treated with
betamethasone
12 5496 Mean Difference (IV, Fixed, 95% CI) -18.71 [-42.92, 5.
50]
9 Moderate/severe respiratory
distress syndrome - type of
steroid
6 1686 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.38, 0.91]
9.1 Dexamethasone 2 219 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.46, 1.44]
9.2 Betamethasone 4 1467 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.27, 0.90]
10 Chronic lung disease - type of
steroid
6 818 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.42, 1.79]
10.1 Dexamethasone 2 219 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.72, 1.90]
10.2 Betamethasone 4 599 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.26, 2.28]
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Comparison 6. Corticosteroids versus placebo or no treatment - decade of trial




participants Statistical method Effect size
1 Chorioamnionitis - decade of
trial
15 5546 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.66, 1.06]
1.1 In women from trials
conducted in 1970s
2 1237 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.46, 1.17]
1.2 In women from trials
conducted in 1980s
3 276 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.25, 1.01]
1.3 In women from trials
conducted in 1990s
6 755 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.80, 1.74]
1.4 in women from trials
conducted in the 2000’s
2 257 Risk Ratio (M-H, Fixed, 95% CI) 2.02 [0.59, 6.95]
1.5 In trials from 2010s 2 3021 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.35, 1.07]
2 Endometritis - decade of trial 10 4030 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.87, 1.63]
2.1 In women from trials
conducted in 1970s
2 219 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [0.81, 4.27]
2.2 In women from trials
conducted in 1980s
1 71 Risk Ratio (M-H, Fixed, 95% CI) 2.30 [0.88, 6.06]
2.3 In women from trials
conducted in 1990s
4 574 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.53, 1.44]
2.4 In women from trials
conducted in the 2000’s
3 3166 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.69, 2.01]
3 Perinatal deaths - decade of trial 15 6729 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.58, 0.89]
3.1 In babies from trials
conducted in 1970s
6 1994 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.50, 1.00]
3.2 In babies from trials
conducted in 1980s
3 879 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.74, 1.42]
3.3 In babies from trials
conducted in 1990s
3 615 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.43, 0.93]
3.4 in babies from trials
conducted in 2000’s
2 414 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.31, 0.70]
3.5 In trials conducted in
2010s
1 2827 Risk Ratio (M-H, Random, 95% CI) 4.91 [0.24, 102.09]
4 Neonatal deaths decade of trial 22 7188 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.59, 0.81]
4.1 In babies from trials
conducted in 1970s
7 1968 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.56, 0.92]
4.2 In babies from trials
conducted in 1980s
6 1096 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.70, 1.37]
4.3 In babies from trials
conducted in 1990s
5 758 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.36, 0.84]
4.4 In babies from trials
conducted in 2000s
3 539 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.31, 0.64]
4.5 In trials conducted in
2010s
1 2827 Risk Ratio (M-H, Fixed, 95% CI) 4.91 [0.24, 102.09]
5 Fetal death - decade of trial 15 6729 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.74, 1.30]
5.1 In babies from trials
conducted in 1970s
6 1994 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.67, 1.34]
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5.2 In babies from trials
conducted in 1980s
3 879 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.52, 2.00]
5.3 In babies from trials
conducted in 1990s
3 615 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.49, 2.36]
5.4 In babies from trials
conducted in 2000’s
2 414 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.19, 4.50]
5.5 In trials conducted in
2010s
1 2827 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 RDS - decade of trial 28 7764 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.60, 0.74]
6.1 In babies from trials
conducted in 1970s
7 1939 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.43, 0.69]
6.2 In babies from trials
conducted in 1980s
7 1167 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.59, 0.88]
6.3 In babies from trials
conducted in 1990s
7 798 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.65, 0.91]
6.4 In babies from trials
conducted in 2000s
5 839 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.26, 0.59]
6.5 In trials from 2010s 2 3021 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.61, 1.04]
7 IVH - decade of trial 16 6093 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.44, 0.70]
7.1 In babies from trials
conducted in 1970s
4 1646 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.29, 0.85]
7.2 In babies from trials
conducted in 1980s
2 238 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.39, 0.94]
7.3 In babies from trials
conducted in 1990s
5 722 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.42, 0.87]
7.4 In babies from trials
conducted in 2000s
3 466 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.15, 0.73]
7.5 In trials from 2010s 2 3021 Risk Ratio (M-H, Fixed, 95% CI) 4.91 [0.24, 102.09]
8 Birthweight - decade of trial 16 6182 Mean Difference (IV, Fixed, 95% CI) -18.47 [-40.83, 3.
90]
8.1 In babies from trials
conducted in 1970s
4 1739 Mean Difference (IV, Fixed, 95% CI) -9.54 [-83.55, 64.
47]
8.2 In babies from trials
conducted in 1980s
3 280 Mean Difference (IV, Fixed, 95% CI) -19.60 [-108.55, 69.
35]
8.3 In babies from trials
conducted in 1990s
4 569 Mean Difference (IV, Fixed, 95% CI) -33.13 [-102.39, 36.
13]
8.4 In babies from trials
conducted in 2000s
3 573 Mean Difference (IV, Fixed, 95% CI) -20.77 [-61.95, 20.
41]
8.5 In trials in 2010s 2 3021 Mean Difference (IV, Fixed, 95% CI) -15.18 [-48.66, 18.
29]
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Comparison 7. Corticosteroids versus placebo or no treatment - weekly repeats




participants Statistical method Effect size
1 Chorioamnionitis - Protocol
with weekly repeats
15 5546 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.66, 1.06]
1.1 In women treated with
single courses only
7 4659 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.61, 1.11]
1.2 In women treated with
courses including weekly
repeats
8 887 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.57, 1.25]
2 Endometritis - protocol with
weekly repeats
10 4030 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.81, 1.80]
2.1 In women treated with
single courses only
5 3450 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.66, 1.64]
2.2 In women treated with
courses including weekly
repeats
5 580 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.72, 2.95]
3 Perinatal death - protocol with
weekly repeats
15 6729 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.58, 0.89]
3.1 In babies treated with
single course only
11 6250 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.61, 0.99]
3.2 In babies treated with
courses including weekly
repeats
4 479 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.44, 0.97]
4 Neonatal death - protocol with
weekly repeats
22 7188 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.59, 0.81]
4.1 In babies treated with
single course only
14 6266 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.63, 0.95]
4.2 In babies treated with
courses including weekly
repeats
8 922 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.43, 0.72]
5 Fetal death - protocol with
weekly repeats
15 6729 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.74, 1.30]
5.1 In babies treated with
single course only
11 6250 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.68, 1.25]
5.2 In babies treated with
courses including weekly
repeats
4 479 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.64, 2.87]
6 RDS - protocol with weekly
repeats
28 7764 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.60, 0.74]
6.1 In babies treated with
single course only
19 6818 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.61, 0.79]
6.2 In babies treated with
courses including weekly
repeats
9 946 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.52, 0.72]
7 IVH- protocol with weekly
repeats
16 6093 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.44, 0.70]
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7.1 In babies treated with
single course only
9 5216 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.33, 0.76]
7.2 In babies treated with
courses including weekly
repeats
7 877 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.45, 0.78]
8 Birthweight - protocol with
weekly repeats
16 6182 Mean Difference (IV, Fixed, 95% CI) -18.47 [-40.83, 3.
90]
8.1 In babies treated with
single course only
12 5773 Mean Difference (IV, Fixed, 95% CI) -18.24 [-42.12, 5.
65]
8.2 In babies treated with
courses including weekly
repeats




6 1686 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.38, 0.91]
9.1 Single course 3 1259 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.44, 0.83]
9.2 Weekly repeats 3 427 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.13, 1.32]
Comparison 8. Corticosteroids versus placebo or no treatment - gestational age at trial entry




participants Statistical method Effect size
1 Chorioamnionitis - gestational
age at trial entry
15 5506 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.65, 1.05]
1.1 Less than or equal to 35
weeks + 0 days
13 2304 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.70, 1.19]
1.2 Greater than or equal to
34 weeks + 0 days
3 3202 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.33, 0.99]
2 Perinatal death - gestational age
at trial entry
15 6687 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.59, 0.88]
2.1 Less than or equal to 35
weeks + 0 days
13 3391 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.58, 0.87]
2.2 Greater than or equal to
34 weeks + 0 days
3 3296 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.29, 3.67]
3 Neonatal death - gestational age
at trial engry
22 7146 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.57, 0.79]
3.1 Less than or equal to 35
weeks + 0 days
20 3855 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.57, 0.79]
3.2 Greater than or equal to
34 weeks + 0 days
3 3291 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.22, 3.07]
4 Fetal death - gestational age at
trial entry
15 6687 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.72, 1.27]
4.1 Less than or equal to 35
weeks + 0 days
13 3391 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.71, 1.25]
4.2 Greater than or equal to
34 weeks + 0 days
3 3296 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [0.28, 9.37]
5 RDS- gestational age at trial
entry
28 7722 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.60, 0.73]
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5.1 Less than or equal to 35
weeks + 0 days
23 3939 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.58, 0.73]
5.2 Greater than or equal to
34 weeks + 0 days
6 3783 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.56, 0.91]
6 IVH - gestational age at trial
entry
16 6051 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.44, 0.70]
6.1 Less than or equal to 35
weeks + 0 days
13 2639 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.42, 0.68]
6.2 Greater than or equal to
34 weeks + 0 days
4 3412 Risk Ratio (M-H, Fixed, 95% CI) 4.91 [0.24, 102.09]
7 Birthweight - gestational age at
trial entry
16 6140 Mean Difference (IV, Fixed, 95% CI) -17.45 [-39.76, 4.
86]
7.1 Less than or equal to 35
weeks + 0 days
11 2352 Mean Difference (IV, Fixed, 95% CI) -17.89 [-63.14, 27.
36]
7.2 Greater than or equal to
34 weeks + 0 days
6 3788 Mean Difference (IV, Fixed, 95% CI) -17.31 [-42.96, 8.
34]
Analysis 1.1. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 1 Maternal death.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 1 Maternal death
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gyamfi-Bannerman 2016 0/1427 0/1400 Not estimable
Schutte 1980 0/50 0/51 Not estimable
Dexiprom 1999 0/28 0/18 Not estimable
Mansouri 2010 0/100 0/100 Not estimable
Amorim 1999 1/110 1/108 100.0 % 0.98 [ 0.06, 15.50 ]
Total (95% CI) 1715 1677 100.0 % 0.98 [ 0.06, 15.50 ]
Total events: 1 (Corticosteroids), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 2 Chorioamnionitis.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 2 Chorioamnionitis
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Attawattanakul 2015 0/96 0/98 Not estimable
Fekih 2002 1/59 0/59 0.4 % 3.00 [ 0.12, 72.18 ]
Amorim 1999 (1) 2/110 1/108 0.7 % 1.96 [ 0.18, 21.34 ]
Lopez 1989 0/20 1/20 1.1 % 0.33 [ 0.01, 7.72 ]
Garite 1992 1/33 2/38 1.4 % 0.58 [ 0.05, 6.07 ]
Qublan 2001 6/72 3/67 2.3 % 1.86 [ 0.48, 7.15 ]
Carlan 1991 0/11 3/13 2.4 % 0.17 [ 0.01, 2.91 ]
Schutte 1980 1/50 4/51 2.9 % 0.26 [ 0.03, 2.20 ]
Lewis 1996 6/38 6/39 4.4 % 1.03 [ 0.36, 2.90 ]
Kari 1994 13/77 8/80 5.8 % 1.69 [ 0.74, 3.85 ]
Dexiprom 1999 (2) 11/102 8/102 5.9 % 1.38 [ 0.58, 3.28 ]
Silver 1996 13/39 12/36 9.3 % 1.00 [ 0.53, 1.90 ]
Morales 1989 9/87 16/78 12.5 % 0.50 [ 0.24, 1.08 ]
Gyamfi-Bannerman 2016 20/1427 32/1400 24.0 % 0.61 [ 0.35, 1.07 ]
Liggins 1972b 28/556 37/580 26.9 % 0.79 [ 0.49, 1.27 ]
Total (95% CI) 2777 2769 100.0 % 0.83 [ 0.66, 1.06 ]
Total events: 111 (Corticosteroids), 133 (Control)
Heterogeneity: Chi2 = 12.78, df = 13 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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(1) where did you get the info to split the infections reported in the paper in to types of infections?
(2) Suspicion of clinical chorioamnionitis as reason for delivery in Pattison 1999
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Analysis 1.3. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 3 Endometritis.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 3 Endometritis
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schutte 1980 (1) 1/50 1/51 1.5 % 1.02 [ 0.07, 15.86 ]
Qublan 2001 (2) 9/72 2/67 3.2 % 4.19 [ 0.94, 18.68 ]
Lewis 1996 (3) 2/38 4/39 6.0 % 0.51 [ 0.10, 2.64 ]
Garite 1992 (4) 10/33 5/38 7.1 % 2.30 [ 0.88, 6.06 ]
Silver 1996 (5) 11/39 5/36 8.0 % 2.03 [ 0.78, 5.28 ]
Mansouri 2010 (6) 4/100 6/100 9.2 % 0.67 [ 0.19, 2.29 ]
Taeusch 1979 (7) 11/52 7/66 9.4 % 1.99 [ 0.83, 4.79 ]
Dexiprom 1999 (8) 4/102 7/102 10.7 % 0.57 [ 0.17, 1.89 ]
Amorim 1999 (9) 9/110 13/108 20.1 % 0.68 [ 0.30, 1.52 ]
Gyamfi-Bannerman 2016 (10) 16/1427 16/1400 24.7 % 0.98 [ 0.49, 1.95 ]
Total (95% CI) 2023 2007 100.0 % 1.20 [ 0.87, 1.63 ]
Total events: 77 (Corticosteroids), 66 (Control)
Heterogeneity: Chi2 = 12.51, df = 9 (P = 0.19); I2 =28%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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(6) from translation; have emailed authors to verify type of infection
(7) Endometritis
(8) these are endometritis from pattinson 1999
(9) Infections.
(10) Endometritis
106Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 4 Perinatal deaths.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 4 Perinatal deaths








Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.5 % 4.91 [ 0.24, 102.09 ]
Porto 2011 (2) 1/144 3/131 0.9 % 0.30 [ 0.03, 2.88 ]
Block 1977 4/60 6/54 2.8 % 0.60 [ 0.18, 2.01 ]
Kari 1994 5/95 6/94 3.1 % 0.82 [ 0.26, 2.61 ]
Dexiprom 1999 4/105 10/103 3.2 % 0.39 [ 0.13, 1.21 ]
Doran 1980 5/81 14/63 4.2 % 0.28 [ 0.11, 0.73 ]
Schutte 1980 6/65 12/58 4.6 % 0.45 [ 0.18, 1.11 ]
Taeusch 1979 10/56 12/71 6.1 % 1.06 [ 0.49, 2.27 ]
Garite 1992 12/36 12/41 7.4 % 1.14 [ 0.59, 2.21 ]
Gamsu 1989 15/131 22/137 8.3 % 0.71 [ 0.39, 1.31 ]
Amorim 1999 24/110 36/108 12.1 % 0.65 [ 0.42, 1.02 ]
Qublan 2001 21/72 41/67 13.2 % 0.48 [ 0.32, 0.72 ]
Collaborative 1981 47/378 47/379 14.0 % 1.00 [ 0.69, 1.46 ]
Liggins 1972b 108/601 122/617 19.1 % 0.91 [ 0.72, 1.15 ]
Total (95% CI) 3384 3345 100.0 % 0.72 [ 0.58, 0.89 ]
Total events: 264 (Corticosteroids), 344 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 21.30, df = 14 (P = 0.09); I2 =34%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Not applicable
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(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
(2) The events are 1 stillbirth in each arm, and 2 neonatal deaths due to severe perinatal asphyxia.
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Analysis 1.5. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 5 Neonatal deaths.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 5 Neonatal deaths
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 14/100 28/100 9.1 % 0.50 [ 0.28, 0.89 ]
Block 1977 1/57 5/53 1.7 % 0.19 [ 0.02, 1.54 ]
Collaborative 1981 34/365 32/364 10.4 % 1.06 [ 0.67, 1.68 ]
Dexiprom 1999 4/105 8/101 2.6 % 0.48 [ 0.15, 1.55 ]
Doran 1980 4/80 11/60 4.1 % 0.27 [ 0.09, 0.81 ]
Fekih 2002 9/63 21/68 6.5 % 0.46 [ 0.23, 0.93 ]
Gamsu 1989 14/130 17/132 5.5 % 0.84 [ 0.43, 1.63 ]
Garite 1992 9/33 11/40 3.2 % 0.99 [ 0.47, 2.10 ]
Goodner 1979 4/47 7/45 2.3 % 0.55 [ 0.17, 1.74 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.2 % 4.91 [ 0.24, 102.09 ]
Kari 1994 4/91 6/88 2.0 % 0.64 [ 0.19, 2.21 ]
Lewis 1996 1/38 1/39 0.3 % 1.03 [ 0.07, 15.82 ]
Liggins 1972b 61/554 72/567 23.0 % 0.87 [ 0.63, 1.19 ]
Lopez 1989 6/20 6/20 1.9 % 1.00 [ 0.39, 2.58 ]
Morales 1989 7/87 8/78 2.7 % 0.78 [ 0.30, 2.06 ]
Nelson 1985 1/22 1/22 0.3 % 1.00 [ 0.07, 15.00 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Porto 2011 (2) 0/143 2/130 0.8 % 0.18 [ 0.01, 3.75 ]
Qublan 2001 19/70 39/65 13.1 % 0.45 [ 0.29, 0.70 ]
Schutte 1980 3/62 12/58 4.0 % 0.23 [ 0.07, 0.79 ]
Silver 1996 7/54 8/42 2.9 % 0.68 [ 0.27, 1.73 ]
Taeusch 1979 8/54 10/69 2.8 % 1.02 [ 0.43, 2.41 ]
Total (95% CI) 3625 3563 100.0 % 0.69 [ 0.59, 0.81 ]
Total events: 212 (Corticosteroids), 306 (Control)
Heterogeneity: Chi2 = 24.63, df = 21 (P = 0.26); I2 =15%
Test for overall effect: Z = 4.54 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
(2) Deaths due to severe perinatal asphyxia.
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Analysis 1.6. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 6 Fetal deaths.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 6 Fetal deaths
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 10/110 8/108 8.9 % 1.23 [ 0.50, 2.99 ]
Block 1977 3/60 1/54 1.2 % 2.70 [ 0.29, 25.19 ]
Collaborative 1981 13/378 15/379 16.4 % 0.87 [ 0.42, 1.80 ]
Dexiprom 1999 0/105 2/103 2.8 % 0.20 [ 0.01, 4.04 ]
Doran 1980 1/81 3/63 3.7 % 0.26 [ 0.03, 2.43 ]
Gamsu 1989 1/131 5/137 5.4 % 0.21 [ 0.02, 1.77 ]
Garite 1992 3/36 1/41 1.0 % 3.42 [ 0.37, 31.41 ]
Gyamfi-Bannerman 2016 0/1427 0/1400 Not estimable
Kari 1994 1/95 0/94 0.6 % 2.97 [ 0.12, 71.96 ]
Liggins 1972b 47/601 50/617 54.2 % 0.97 [ 0.66, 1.41 ]
Parsons 1988 0/23 0/22 Not estimable
Porto 2011 (1) 1/144 1/131 1.1 % 0.91 [ 0.06, 14.40 ]
Qublan 2001 2/72 2/67 2.3 % 0.93 [ 0.13, 6.42 ]
Schutte 1980 3/65 0/58 0.6 % 6.26 [ 0.33, 118.64 ]
Taeusch 1979 2/56 2/71 1.9 % 1.27 [ 0.18, 8.72 ]
Total (95% CI) 3384 3345 100.0 % 0.98 [ 0.74, 1.30 ]
Total events: 87 (Corticosteroids), 90 (Control)
Heterogeneity: Chi2 = 8.88, df = 12 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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(1) The outcome measured in this trial was stillbirth.
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Analysis 1.7. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 7 Respiratory
distress syndrome.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 7 Respiratory distress syndrome








Cararach 1991 1/12 0/6 0.2 % 1.62 [ 0.08, 34.66 ]
Porto 2011 2/143 1/130 0.4 % 1.82 [ 0.17, 19.82 ]
Carlan 1991 1/11 4/13 0.5 % 0.30 [ 0.04, 2.27 ]
Teramo 1980 3/38 3/42 0.9 % 1.11 [ 0.24, 5.15 ]
Balci 2010 2/50 8/50 1.0 % 0.25 [ 0.06, 1.12 ]
Parsons 1988 3/23 3/22 1.0 % 0.96 [ 0.22, 4.24 ]
Fekih 2002 3/63 19/68 1.5 % 0.17 [ 0.05, 0.55 ]
Doran 1980 4/80 10/60 1.6 % 0.30 [ 0.10, 0.91 ]
Goodner 1979 5/47 11/45 2.0 % 0.44 [ 0.16, 1.15 ]
Block 1977 5/57 12/53 2.0 % 0.39 [ 0.15, 1.03 ]
Gamsu 1989 7/130 16/132 2.4 % 0.44 [ 0.19, 1.04 ]
Taeusch 1979 7/54 14/69 2.5 % 0.64 [ 0.28, 1.47 ]
Mansouri 2010 8/100 20/100 2.8 % 0.40 [ 0.18, 0.87 ]
Lewis 1996 7/38 17/39 2.9 % 0.42 [ 0.20, 0.90 ]
Attawattanakul 2015 9/96 20/98 3.0 % 0.46 [ 0.22, 0.96 ]
Schutte 1980 11/62 17/58 3.5 % 0.61 [ 0.31, 1.18 ]
Lopez 1989 9/20 10/20 3.6 % 0.90 [ 0.47, 1.73 ]
Nelson 1985 10/22 11/22 3.8 % 0.91 [ 0.49, 1.69 ]
Qublan 2001 14/70 24/65 4.2 % 0.54 [ 0.31, 0.95 ]
Dexiprom 1999 32/102 27/100 5.6 % 1.16 [ 0.75, 1.79 ]
Amorim 1999 23/100 43/100 5.7 % 0.53 [ 0.35, 0.82 ]
Morales 1989 23/87 41/78 5.8 % 0.50 [ 0.33, 0.76 ]
Collaborative 1981 46/361 65/359 6.6 % 0.70 [ 0.50, 1.00 ]
Kari 1994 34/91 46/90 6.8 % 0.73 [ 0.52, 1.02 ]
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(Continued . . . )
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(. . . Continued)








Garite 1992 21/33 28/40 6.9 % 0.91 [ 0.65, 1.26 ]
Liggins 1972b 53/542 89/550 7.0 % 0.60 [ 0.44, 0.83 ]
Gyamfi-Bannerman 2016 79/1427 89/1400 7.3 % 0.87 [ 0.65, 1.17 ]
Silver 1996 43/54 34/42 8.5 % 0.98 [ 0.81, 1.20 ]
Total (95% CI) 3913 3851 100.0 % 0.66 [ 0.56, 0.77 ]
Total events: 465 (Corticosteroids), 682 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 51.46, df = 27 (P = 0.003); I2 =48%
Test for overall effect: Z = 5.33 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 8 Moderate/severe
respiratory distress syndrome.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 8 Moderate/severe respiratory distress syndrome








Amorim 1999 9/100 23/100 18.0 % 0.39 [ 0.19, 0.80 ]
Fekih 2002 1/63 15/68 4.2 % 0.07 [ 0.01, 0.53 ]
Liggins 1972b 41/542 73/550 28.5 % 0.57 [ 0.40, 0.82 ]
Nelson 1985 6/22 6/22 12.9 % 1.00 [ 0.38, 2.62 ]
Silver 1996 18/54 14/42 22.1 % 1.00 [ 0.57, 1.77 ]
Taeusch 1979 6/54 14/69 14.3 % 0.55 [ 0.23, 1.33 ]
Total (95% CI) 835 851 100.0 % 0.59 [ 0.38, 0.91 ]
Total events: 81 (Corticosteroids), 145 (Control)
Heterogeneity: Tau2 = 0.14; Chi2 = 10.49, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 9 Chronic lung
disease.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 9 Chronic lung disease








Amorim 1999 1/100 5/100 8.9 % 0.20 [ 0.02, 1.68 ]
Garite 1992 9/33 9/40 25.2 % 1.21 [ 0.54, 2.70 ]
Kari 1994 6/85 1/76 9.1 % 5.36 [ 0.66, 43.56 ]
Morales 1989 8/87 19/78 25.8 % 0.38 [ 0.18, 0.81 ]
Silver 1996 24/54 16/42 31.1 % 1.17 [ 0.72, 1.90 ]
Taeusch 1979 0/54 0/69 Not estimable
Total (95% CI) 413 405 100.0 % 0.86 [ 0.42, 1.79 ]
Total events: 48 (Corticosteroids), 50 (Control)
Heterogeneity: Tau2 = 0.38; Chi2 = 11.35, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 10 Intraventricular
haemorrhage.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 10 Intraventricular haemorrhage








Mansouri 2010 (1) 0/100 0/100 Not estimable
Attawattanakul 2015 0/96 0/98 Not estimable
Dexiprom 1999 0/105 0/101 Not estimable
Gyamfi-Bannerman 2016 (2) 2/1427 0/1400 1.1 % 4.91 [ 0.24, 102.09 ]
Lewis 1996 (3) 0/38 3/39 1.2 % 0.15 [ 0.01, 2.74 ]
Taeusch 1979 0/54 4/69 1.2 % 0.14 [ 0.01, 2.57 ]
Doran 1980 1/80 4/60 2.1 % 0.19 [ 0.02, 1.63 ]
Gamsu 1989 2/130 4/132 3.3 % 0.51 [ 0.09, 2.72 ]
Qublan 2001 2/70 8/65 4.0 % 0.23 [ 0.05, 1.05 ]
Fekih 2002 5/63 14/68 8.1 % 0.39 [ 0.15, 1.01 ]
Amorim 1999 6/100 17/100 9.0 % 0.35 [ 0.15, 0.86 ]
Kari 1994 8/77 18/66 10.9 % 0.38 [ 0.18, 0.82 ]
Morales 1989 (4) 13/87 20/78 13.6 % 0.58 [ 0.31, 1.09 ]
Garite 1992 (5) 10/33 19/40 13.9 % 0.64 [ 0.35, 1.18 ]
Liggins 1972b 16/554 27/567 14.0 % 0.61 [ 0.33, 1.11 ]
Silver 1996 (6) 25/54 17/42 17.6 % 1.14 [ 0.72, 1.82 ]
Total (95% CI) 3068 3025 100.0 % 0.55 [ 0.40, 0.76 ]
Total events: 90 (Corticosteroids), 155 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 17.89, df = 12 (P = 0.12); I2 =33%
Test for overall effect: Z = 3.63 (P = 0.00028)
Test for subgroup differences: Not applicable
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(4) 3 intervention group and 12 of control group were grade 3-4.
(5) 1 intervention group and 9 placebo were grade 3-4.
(6) 2 intervention and 6 placebo were grade 3-4.
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Analysis 1.11. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 11 Mean
birthweight (g).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 11 Mean birthweight (g)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Garite 1992 33 1242 (678) 38 1071 (597) 0.6 % 171.00 [ -128.23, 470.23 ]
Doran 1980 80 2086 (857) 60 1880.5 (803) 0.7 % 205.50 [ -71.18, 482.18 ]
Nelson 1985 (1) 22 1594 (456.4) 22 1752.5 (415.4) 0.8 % -158.50 [ -416.38, 99.38 ]
Lewis 1996 38 1611 (538) 39 1734 (570) 0.8 % -123.00 [ -370.51, 124.51 ]
Kari 1994 94 1654 (831) 94 1783 (837) 0.9 % -129.00 [ -367.43, 109.43 ]
Schutte 1980 61 1788 (690) 58 1670 (448) 1.2 % 118.00 [ -90.03, 326.03 ]
Gamsu 1989 130 2203 (757) 132 2133 (753) 1.5 % 70.00 [ -112.85, 252.85 ]
Dexiprom 1999 105 1795 (437) 103 1791 (542) 2.8 % 4.00 [ -129.95, 137.95 ]
Porto 2011 143 2640 (445) 130 2627 (452) 4.4 % 13.00 [ -93.57, 119.57 ]
Morales 1989 87 1359 (361) 78 1379 (293) 5.0 % -20.00 [ -119.91, 79.91 ]
Attawattanakul 2015 96 2557.2 (367.6) 98 2558.1 (340) 5.0 % -0.90 [ -100.59, 98.79 ]
Liggins 1972b 601 2181.41 (816.9) 617 2260.78 (832.83) 5.8 % -79.37 [ -172.02, 13.28 ]
Silver 1996 54 917 (238) 42 941 (219) 5.9 % -24.00 [ -115.74, 67.74 ]
Mansouri 2010 100 2500 (300) 100 2600 (300) 7.2 % -100.00 [ -183.15, -16.85 ]
Balci 2010 50 2389 (133) 50 2386 (137) 17.9 % 3.00 [ -49.92, 55.92 ]
Gyamfi-Bannerman 2016 1427 2637 (480) 1400 2654 (484) 39.6 % -17.00 [ -52.54, 18.54 ]
Total (95% CI) 3121 3061 100.0 % -18.47 [ -40.83, 3.90 ]
Heterogeneity: Chi2 = 15.82, df = 15 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Corticosteroids lighter Control lighter
(1) SD for treatment group reported in paper as 4563.7; this must be a typo. Exclude?
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Analysis 1.12. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 12 Death in
childhood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 12 Death in childhood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 1/67 5/39 28.5 % 0.12 [ 0.01, 0.96 ]
Collaborative 1981 6/206 5/211 22.3 % 1.23 [ 0.38, 3.96 ]
Kari 1994 2/87 3/82 13.9 % 0.63 [ 0.11, 3.67 ]
Liggins 1972b 7/177 7/141 35.2 % 0.80 [ 0.29, 2.22 ]
Total (95% CI) 537 473 100.0 % 0.68 [ 0.36, 1.27 ]
Total events: 16 (Corticosteroids), 20 (Control)
Heterogeneity: Chi2 = 3.78, df = 3 (P = 0.29); I2 =21%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 13
Neurodevelopmental delay in childhood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 13 Neurodevelopmental delay in childhood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kari 1994 3/50 3/32 100.0 % 0.64 [ 0.14, 2.98 ]
Total (95% CI) 50 32 100.0 % 0.64 [ 0.14, 2.98 ]
Total events: 3 (Corticosteroids), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 14 Death into
adulthood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 14 Death into adulthood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 21/493 21/495 100.0 % 1.00 [ 0.56, 1.81 ]
Total (95% CI) 493 495 100.0 % 1.00 [ 0.56, 1.81 ]
Total events: 21 (Corticosteroids), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 15 Fever in women
after trial entry requiring the use of antibiotics.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 15 Fever in women after trial entry requiring the use of antibiotics








Amorim 1999 11/110 14/108 32.0 % 0.77 [ 0.37, 1.62 ]
Nelson 1985 1/22 4/22 10.5 % 0.25 [ 0.03, 2.06 ]
Schutte 1980 4/50 6/51 21.7 % 0.68 [ 0.20, 2.27 ]
Taeusch 1979 21/52 13/66 35.8 % 2.05 [ 1.14, 3.69 ]
Total (95% CI) 234 247 100.0 % 0.95 [ 0.43, 2.06 ]
Total events: 37 (Corticosteroids), 37 (Control)
Heterogeneity: Tau2 = 0.35; Chi2 = 7.65, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 16 Intrapartum
fever in woman requiring the use of antibiotics.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 16 Intrapartum fever in woman requiring the use of antibiotics








Amorim 1999 2/110 1/108 46.8 % 1.96 [ 0.18, 21.34 ]
Schutte 1980 1/50 4/51 53.2 % 0.26 [ 0.03, 2.20 ]
Total (95% CI) 160 159 100.0 % 0.66 [ 0.09, 4.89 ]
Total events: 3 (Corticosteroids), 5 (Control)
Heterogeneity: Tau2 = 0.74; Chi2 = 1.55, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 17 Side effects of
therapy in women.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 17 Side effects of therapy in women
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Attawattanakul 2015 0/96 0/98 Not estimable
Balci 2010 0/50 0/50 Not estimable
Gyamfi-Bannerman 2016 (1) 201/1428 283/1397 100.0 % 0.69 [ 0.59, 0.82 ]
Porto 2011 0/163 0/157 Not estimable
Schutte 1980 0/50 0/51 Not estimable
Shanks 2010 0/13 0/19 Not estimable
Total (95% CI) 1800 1772 100.0 % 0.69 [ 0.59, 0.82 ]
Total events: 201 (Corticosteroids), 283 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.32 (P = 0.000015)
Test for subgroup differences: Not applicable
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(1) Side effects include pain or bruising at injection site (close to 80% in both arms), other local reaction at injection site; gastrointestinal upset; headache; other.
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Analysis 1.18. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 18 Admission into
adult intensive care unit.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 18 Admission into adult intensive care unit
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 6/110 8/108 100.0 % 0.74 [ 0.26, 2.05 ]
Schutte 1980 0/50 0/51 Not estimable
Total (95% CI) 160 159 100.0 % 0.74 [ 0.26, 2.05 ]
Total events: 6 (Corticosteroids), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 19 Hypertension.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 19 Hypertension
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 7/110 7/110 100.0 % 1.00 [ 0.36, 2.76 ]
Total (95% CI) 110 110 100.0 % 1.00 [ 0.36, 2.76 ]
Total events: 7 (Corticosteroids), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 20 Postnatal fever
in woman.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 20 Postnatal fever in woman
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 9/110 13/108 24.2 % 0.68 [ 0.30, 1.52 ]
Collaborative 1981 27/342 29/340 53.7 % 0.93 [ 0.56, 1.53 ]
Dexiprom 1999 7/102 7/102 12.9 % 1.00 [ 0.36, 2.75 ]
Fekih 2002 2/59 2/59 3.7 % 1.00 [ 0.15, 6.87 ]
Schutte 1980 5/50 3/51 5.5 % 1.70 [ 0.43, 6.74 ]
Total (95% CI) 663 660 100.0 % 0.92 [ 0.64, 1.33 ]
Total events: 50 (Corticosteroids), 54 (Control)
Heterogeneity: Chi2 = 1.34, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 21 Glucose
intolerance.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 21 Glucose intolerance
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 16/61 6/62 100.0 % 2.71 [ 1.14, 6.46 ]
Total (95% CI) 61 62 100.0 % 2.71 [ 1.14, 6.46 ]
Total events: 16 (Corticosteroids), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours corticosteroids Favours control
123Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.22. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 22 Necrotising
enterocolitis.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 22 Necrotising enterocolitis
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 2/100 4/100 7.2 % 0.50 [ 0.09, 2.67 ]
Collaborative 1981 10/371 24/368 43.4 % 0.41 [ 0.20, 0.85 ]
Dexiprom 1999 6/105 8/101 14.7 % 0.72 [ 0.26, 2.01 ]
Gyamfi-Bannerman 2016 0/1427 1/1400 2.7 % 0.33 [ 0.01, 8.02 ]
Kari 1994 1/28 1/29 1.8 % 1.04 [ 0.07, 15.77 ]
Lewis 1996 0/38 3/39 6.2 % 0.15 [ 0.01, 2.74 ]
Mansouri 2010 2/100 0/100 0.9 % 5.00 [ 0.24, 102.85 ]
Morales 1989 1/87 4/78 7.6 % 0.22 [ 0.03, 1.96 ]
Qublan 2001 1/70 5/65 9.3 % 0.19 [ 0.02, 1.55 ]
Silver 1996 4/54 3/42 6.1 % 1.04 [ 0.25, 4.38 ]
Total (95% CI) 2380 2322 100.0 % 0.50 [ 0.32, 0.78 ]
Total events: 27 (Corticosteroids), 53 (Control)
Heterogeneity: Chi2 = 6.35, df = 9 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 23 Systemic
infection in the first 48 hours of life.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 23 Systemic infection in the first 48 hours of life
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 13/100 28/100 43.6 % 0.46 [ 0.26, 0.84 ]
Attawattanakul 2015 (1) 2/96 1/98 1.5 % 2.04 [ 0.19, 22.15 ]
Collaborative 1981 4/307 10/299 15.8 % 0.39 [ 0.12, 1.23 ]
Dexiprom 1999 11/105 11/101 17.4 % 0.96 [ 0.44, 2.12 ]
Gamsu 1989 4/130 7/132 10.8 % 0.58 [ 0.17, 1.93 ]
Lopez 1989 1/20 1/20 1.6 % 1.00 [ 0.07, 14.90 ]
Mansouri 2010 (2) 4/100 6/100 9.3 % 0.67 [ 0.19, 2.29 ]
Parsons 1988 0/23 0/22 Not estimable
Total (95% CI) 881 872 100.0 % 0.60 [ 0.41, 0.88 ]
Total events: 39 (Corticosteroids), 64 (Control)
Heterogeneity: Chi2 = 3.81, df = 6 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
Test for subgroup differences: Not applicable
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(1) Early onset neonatal sepsis
(2) Outcome is ’early onset neonatal sepsis.’
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Analysis 1.24. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 24 Proven infection
while in the neonatal intensive care unit.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 24 Proven infection while in the neonatal intensive care unit








Amorim 1999 19/100 32/100 18.3 % 0.59 [ 0.36, 0.97 ]
Cararach 1991 0/12 1/6 1.1 % 0.18 [ 0.01, 3.85 ]
Collaborative 1981 6/307 21/299 9.6 % 0.28 [ 0.11, 0.68 ]
Garite 1992 1/33 3/40 2.1 % 0.40 [ 0.04, 3.70 ]
Gyamfi-Bannerman 2016 (1) 9/1427 11/1400 9.8 % 0.80 [ 0.33, 1.93 ]
Lewis 1996 1/38 2/39 1.9 % 0.51 [ 0.05, 5.43 ]
Liggins 1972b 64/554 67/567 23.8 % 0.98 [ 0.71, 1.35 ]
Morales 1989 6/87 6/78 7.2 % 0.90 [ 0.30, 2.67 ]
Nelson 1985 5/22 0/22 1.3 % 11.00 [ 0.64, 187.67 ]
Parsons 1988 0/23 0/22 Not estimable
Porto 2011 6/143 9/130 8.1 % 0.61 [ 0.22, 1.66 ]
Qublan 2001 10/70 9/65 10.5 % 1.03 [ 0.45, 2.38 ]
Taeusch 1979 7/54 4/69 6.4 % 2.24 [ 0.69, 7.25 ]
Total (95% CI) 2870 2837 100.0 % 0.77 [ 0.55, 1.08 ]
Total events: 134 (Corticosteroids), 165 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 16.56, df = 11 (P = 0.12); I2 =34%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 25 Need for
mechanical ventilation/CPAP.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 25 Need for mechanical ventilation/CPAP
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shanks 2010 0/13 2/19 1.2 % 0.29 [ 0.01, 5.51 ]
Attawattanakul 2015 (1) 1/96 5/98 3.0 % 0.20 [ 0.02, 1.72 ]
Block 1977 5/57 12/53 7.4 % 0.39 [ 0.15, 1.03 ]
Balci 2010 (2) 7/50 16/50 9.6 % 0.44 [ 0.20, 0.97 ]
Dexiprom 1999 15/105 16/101 9.8 % 0.90 [ 0.47, 1.73 ]
Garite 1992 14/24 19/29 10.3 % 0.89 [ 0.58, 1.37 ]
Porto 2011 (3) 28/143 24/130 15.0 % 1.06 [ 0.65, 1.73 ]
Mansouri 2010 (4) 16/100 28/100 16.8 % 0.57 [ 0.33, 0.99 ]
Amorim 1999 28/100 45/100 26.9 % 0.62 [ 0.42, 0.91 ]
Total (95% CI) 688 680 100.0 % 0.68 [ 0.56, 0.84 ]
Total events: 114 (Corticosteroids), 167 (Control)
Heterogeneity: Chi2 = 9.97, df = 8 (P = 0.27); I2 =20%
Test for overall effect: Z = 3.67 (P = 0.00024)
Test for subgroup differences: Not applicable
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Analysis 1.26. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 26 Mean duration
of mechanical ventilation/CPAP (days).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 26 Mean duration of mechanical ventilation/CPAP (days)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Garite 1992 14 36.4 (32) 19 32.6 (40) 1.2 % 3.80 [ -20.79, 28.39 ]
Morales 1989 87 2.3 (4.2) 78 5.8 (6.1) 47.1 % -3.50 [ -5.12, -1.88 ]
Porto 2011 143 2.2 (2.8) 130 2.8 (5.9) 51.8 % -0.60 [ -1.71, 0.51 ]
Total (95% CI) 244 227 100.0 % -1.91 [ -4.59, 0.76 ]
Heterogeneity: Tau2 = 3.28; Chi2 = 8.57, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Corticosteroids less Control less
Analysis 1.27. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 27 Mean duration
of oxygen supplementation (days).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 27 Mean duration of oxygen supplementation (days)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Amorim 1999 28 6.14 (2.9) 45 9 (8.3) -2.86 [ -5.51, -0.21 ]
Test for subgroup differences: Not applicable
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Analysis 1.28. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 28 Surfactant use.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 28 Surfactant use
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 17/100 20/100 19.9 % 0.85 [ 0.47, 1.52 ]
Gyamfi-Bannerman 2016 26/1427 43/1400 43.3 % 0.59 [ 0.37, 0.96 ]
Kari 1994 21/91 29/88 29.4 % 0.70 [ 0.43, 1.13 ]
Lewis 1996 3/38 7/39 6.9 % 0.44 [ 0.12, 1.58 ]
Porto 2011 1/143 0/130 0.5 % 2.73 [ 0.11, 66.41 ]
Total (95% CI) 1799 1757 100.0 % 0.68 [ 0.51, 0.90 ]
Total events: 68 (Corticosteroids), 99 (Control)
Heterogeneity: Chi2 = 2.06, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0074)
Test for subgroup differences: Not applicable
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Analysis 1.29. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 29 Air leak
syndrome.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 29 Air leak syndrome
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gyamfi-Bannerman 2016 (1) 5/1427 6/1400 53.0 % 0.82 [ 0.25, 2.67 ]
Kari 1994 4/74 5/64 47.0 % 0.69 [ 0.19, 2.47 ]
Total (95% CI) 1501 1464 100.0 % 0.76 [ 0.32, 1.80 ]
Total events: 9 (Corticosteroids), 11 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours corticosteroids Favours control
(1) Pulmonary air leak
130Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.30. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 30 Apgar < 7 at 5
minutes.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 30 Apgar < 7 at 5 minutes
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Attawattanakul 2015 1/96 2/98 1.0 % 0.51 [ 0.05, 5.54 ]
Porto 2011 1/143 2/130 1.1 % 0.45 [ 0.04, 4.95 ]
Lewis 1996 4/38 7/39 3.5 % 0.59 [ 0.19, 1.84 ]
Mansouri 2010 (1) 2/100 8/100 4.0 % 0.25 [ 0.05, 1.15 ]
Lopez 1989 6/20 8/20 4.0 % 0.75 [ 0.32, 1.77 ]
Schutte 1980 9/61 11/58 5.7 % 0.78 [ 0.35, 1.74 ]
Amorim 1999 10/100 13/100 6.5 % 0.77 [ 0.35, 1.67 ]
Garite 1992 9/33 16/40 7.3 % 0.68 [ 0.35, 1.34 ]
Qublan 2001 18/70 30/65 15.6 % 0.56 [ 0.35, 0.90 ]
Liggins 1972b 101/551 103/557 51.4 % 0.99 [ 0.77, 1.27 ]
Total (95% CI) 1212 1207 100.0 % 0.81 [ 0.67, 0.98 ]
Total events: 161 (Corticosteroids), 200 (Control)
Heterogeneity: Chi2 = 8.18, df = 9 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.23 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 1.31. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 31 Mean interval
between trial entry and birth (days).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 31 Mean interval between trial entry and birth (days)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Amorim 1999 110 19.6 (17.5) 108 19.1 (6.8) 35.5 % 0.50 [ -3.01, 4.01 ]
Lewis 1996 38 14.7 (9.6) 39 15.8 (16) 12.7 % -1.10 [ -6.98, 4.78 ]
Liggins 1972b 601 18.85 (26.08) 617 18.48 (25.67) 51.8 % 0.37 [ -2.54, 3.28 ]
Total (95% CI) 749 764 100.0 % 0.23 [ -1.86, 2.32 ]
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 1.32. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 32 Small-for-
gestational age.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 32 Small-for-gestational age
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 21/100 23/100 8.0 % 0.91 [ 0.54, 1.54 ]
Gyamfi-Bannerman 2016 (1) 255/1427 220/1400 76.9 % 1.14 [ 0.96, 1.34 ]
Kari 1994 13/50 9/32 3.8 % 0.92 [ 0.45, 1.91 ]
Porto 2011 35/143 29/130 10.5 % 1.10 [ 0.71, 1.69 ]
Silver 1996 4/54 2/42 0.8 % 1.56 [ 0.30, 8.09 ]
Total (95% CI) 1774 1704 100.0 % 1.11 [ 0.96, 1.28 ]
Total events: 328 (Corticosteroids), 283 (Control)
Heterogeneity: Chi2 = 1.03, df = 4 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.33. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 33 Mean infant
HPA axis function (cortisol).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 33 Mean infant HPA axis function (cortisol)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 In babies born < 24 hours after 1st dose
Teramo 1980 2 30 (14) 4 21 (8) 11.4 % 9.00 [ -11.93, 29.93 ]
Subtotal (95% CI) 2 4 11.4 % 9.00 [ -11.93, 29.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2 In babies born 24-48 hours after 1st dose
Teramo 1980 5 20 (7) 5 20 (7) 66.2 % 0.0 [ -8.68, 8.68 ]
Subtotal (95% CI) 5 5 66.2 % 0.0 [ -8.68, 8.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 In babies born > 48 hours after 1st dose
Teramo 1980 5 37 (13) 6 24 (12) 22.4 % 13.00 [ -1.90, 27.90 ]
Subtotal (95% CI) 5 6 22.4 % 13.00 [ -1.90, 27.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
Total (95% CI) 12 15 100.0 % 3.94 [ -3.12, 11.00 ]
Heterogeneity: Chi2 = 2.44, df = 2 (P = 0.30); I2 =18%
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Chi2 = 2.44, df = 2 (P = 0.30), I2 =18%
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Analysis 1.34. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 34 Admission to
neonatal intensive care unit.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 34 Admission to neonatal intensive care unit
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 35/100 49/100 6.2 % 0.71 [ 0.51, 1.00 ]
Attawattanakul 2015 0/96 2/98 0.3 % 0.20 [ 0.01, 4.20 ]
Gyamfi-Bannerman 2016 (1) 596/1427 629/1400 80.0 % 0.93 [ 0.85, 1.01 ]
Lewis 1996 30/38 33/39 4.1 % 0.93 [ 0.75, 1.15 ]
Mansouri 2010 (2) 16/100 28/100 3.5 % 0.57 [ 0.33, 0.99 ]
Porto 2011 47/143 43/130 5.7 % 0.99 [ 0.71, 1.39 ]
Shanks 2010 0/13 2/19 0.3 % 0.29 [ 0.01, 5.51 ]
Total (95% CI) 1917 1886 100.0 % 0.90 [ 0.84, 0.97 ]
Total events: 724 (Corticosteroids), 786 (Control)
Heterogeneity: Chi2 = 6.93, df = 6 (P = 0.33); I2 =13%
Test for overall effect: Z = 2.62 (P = 0.0089)
Test for subgroup differences: Not applicable
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Analysis 1.35. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 35 Developmental
delay in childhood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 35 Developmental delay in childhood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 4/60 7/34 43.4 % 0.32 [ 0.10, 1.03 ]
Collaborative 1981 7/206 12/218 56.6 % 0.62 [ 0.25, 1.54 ]
Total (95% CI) 266 252 100.0 % 0.49 [ 0.24, 1.00 ]
Total events: 11 (Corticosteroids), 19 (Control)
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Not applicable
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Analysis 1.36. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 36 Cerebral palsy
in childhood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 36 Cerebral palsy in childhood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amorim 1999 1/60 2/34 8.4 % 0.28 [ 0.03, 3.01 ]
Collaborative 1981 9/200 15/206 48.6 % 0.62 [ 0.28, 1.38 ]
Kari 1994 5/50 7/32 28.1 % 0.46 [ 0.16, 1.32 ]
Liggins 1972b 3/129 2/107 7.2 % 1.24 [ 0.21, 7.31 ]
Schutte 1980 2/51 2/35 7.8 % 0.69 [ 0.10, 4.64 ]
Total (95% CI) 490 414 100.0 % 0.60 [ 0.34, 1.03 ]
Total events: 20 (Corticosteroids), 28 (Control)
Heterogeneity: Chi2 = 1.31, df = 4 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.065)
Test for subgroup differences: Not applicable
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Analysis 1.37. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 37 Mean childhood
weight (kg).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 37 Mean childhood weight (kg)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Liggins
Liggins 1972b 139 20.9 (3.1) 111 20.5 (2.7) 93.8 % 0.40 [ -0.32, 1.12 ]
Subtotal (95% CI) 139 111 93.8 % 0.40 [ -0.32, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
2 Schutte (females)
Schutte 1980 21 35.6 (5) 18 38 (7.7) 2.8 % -2.40 [ -6.55, 1.75 ]
Subtotal (95% CI) 21 18 2.8 % -2.40 [ -6.55, 1.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
3 Schutte (males)
Schutte 1980 28 35 (5.3) 16 35.1 (6.6) 3.4 % -0.10 [ -3.88, 3.68 ]
Subtotal (95% CI) 28 16 3.4 % -0.10 [ -3.88, 3.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 188 145 100.0 % 0.30 [ -0.39, 1.00 ]
Heterogeneity: Chi2 = 1.74, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Chi2 = 1.74, df = 2 (P = 0.42), I2 =0.0%
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Analysis 1.38. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 38 Mean childhood
height (cm).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 38 Mean childhood height (cm)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Liggins
Liggins 1972b 139 114.8 (6.1) 111 113.8 (5.1) 84.4 % 1.00 [ -0.39, 2.39 ]
Subtotal (95% CI) 139 111 84.4 % 1.00 [ -0.39, 2.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 Schutte (females)
Schutte 1980 21 148.1 (5.7) 18 146.4 (8.9) 7.1 % 1.70 [ -3.08, 6.48 ]
Subtotal (95% CI) 21 18 7.1 % 1.70 [ -3.08, 6.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
3 Schutte (males)
Schutte 1980 29 142.6 (6.6) 16 142 (7.5) 8.4 % 0.60 [ -3.79, 4.99 ]
Subtotal (95% CI) 29 16 8.4 % 0.60 [ -3.79, 4.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 189 145 100.0 % 1.02 [ -0.26, 2.29 ]
Heterogeneity: Chi2 = 0.11, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Chi2 = 0.11, df = 2 (P = 0.94), I2 =0.0%
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Analysis 1.39. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 39 Mean childhood
head circumference (cm).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 39 Mean childhood head circumference (cm)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Liggins
Liggins 1972b 139 52 (1.6) 111 51.7 (1.7) 75.3 % 0.30 [ -0.11, 0.71 ]
Subtotal (95% CI) 139 111 75.3 % 0.30 [ -0.11, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
2 Schutte (females)
Schutte 1980 20 53.2 (1.7) 16 53.3 (1.2) 14.3 % -0.10 [ -1.05, 0.85 ]
Subtotal (95% CI) 20 16 14.3 % -0.10 [ -1.05, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
3 Schutte (males)
Schutte 1980 28 54 (1.6) 14 53.4 (1.8) 10.4 % 0.60 [ -0.51, 1.71 ]
Subtotal (95% CI) 28 14 10.4 % 0.60 [ -0.51, 1.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 187 141 100.0 % 0.27 [ -0.08, 0.63 ]
Heterogeneity: Chi2 = 0.94, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 0.94, df = 2 (P = 0.62), I2 =0.0%
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Analysis 1.40. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 40 Mean childhood
VC (% predicted).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 40 Mean childhood VC (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Liggins
Liggins 1972b 39 104.2 (13.9) 36 103.5 (11.8) 34.8 % 0.70 [ -5.12, 6.52 ]
Subtotal (95% CI) 39 36 34.8 % 0.70 [ -5.12, 6.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 Schutte (females)
Schutte 1980 18 86.1 (8.8) 18 88.7 (9.7) 32.2 % -2.60 [ -8.65, 3.45 ]
Subtotal (95% CI) 18 18 32.2 % -2.60 [ -8.65, 3.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
3 Schutte (males)
Schutte 1980 23 93.8 (9) 16 97.1 (9.6) 33.0 % -3.30 [ -9.27, 2.67 ]
Subtotal (95% CI) 23 16 33.0 % -3.30 [ -9.27, 2.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 80 70 100.0 % -1.68 [ -5.12, 1.75 ]
Heterogeneity: Chi2 = 1.01, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 1.01, df = 2 (P = 0.60), I2 =0.0%
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Analysis 1.41. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 41 Mean childhood
FEV1 (% predicted).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 41 Mean childhood FEV1 (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Schutte (females)
Schutte 1980 18 86.1 (14.3) 18 88.6 (12.4) 38.1 % -2.50 [ -11.24, 6.24 ]
Subtotal (95% CI) 18 18 38.1 % -2.50 [ -11.24, 6.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 Schutte (males)
Schutte 1980 23 92 (12) 16 98.1 (9.8) 61.9 % -6.10 [ -12.96, 0.76 ]
Subtotal (95% CI) 23 16 61.9 % -6.10 [ -12.96, 0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 41 34 100.0 % -4.73 [ -10.13, 0.67 ]
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
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Analysis 1.42. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 42 Mean childhood
FEV1/VC.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 42 Mean childhood FEV1/VC





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Liggins
Liggins 1972b 39 88.4 (7.5) 36 87.4 (8.2) 37.2 % 1.00 [ -2.57, 4.57 ]
Subtotal (95% CI) 39 36 37.2 % 1.00 [ -2.57, 4.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Schutte (females)
Schutte 1980 18 85 (9) 18 85 (8) 19.2 % 0.0 [ -5.56, 5.56 ]
Subtotal (95% CI) 18 18 19.2 % 0.0 [ -5.56, 5.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Schutte (males)
Schutte 1980 23 82 (6) 16 85 (4) 43.6 % -3.00 [ -6.14, 0.14 ]
Subtotal (95% CI) 23 16 43.6 % -3.00 [ -6.14, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.061)
Total (95% CI) 80 70 100.0 % -0.94 [ -3.63, 1.76 ]
Heterogeneity: Tau2 = 1.78; Chi2 = 2.89, df = 2 (P = 0.24); I2 =31%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 2.89, df = 2 (P = 0.24), I2 =31%
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Analysis 1.43. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 43 Mean childhood
systolic blood pressure (mmHg).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 43 Mean childhood systolic blood pressure (mmHg)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 121 109.3 (9.1) 102 110.9 (9.5) 100.0 % -1.60 [ -4.06, 0.86 ]
Total (95% CI) 121 102 100.0 % -1.60 [ -4.06, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.44. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 44 Visual
impairment in childhood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 44 Visual impairment in childhood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kari 1994 2/50 3/32 27.8 % 0.43 [ 0.08, 2.41 ]
Schutte 1980 7/50 8/34 72.2 % 0.60 [ 0.24, 1.49 ]
Total (95% CI) 100 66 100.0 % 0.55 [ 0.24, 1.23 ]
Total events: 9 (Corticosteroids), 11 (Control)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.45. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 45 Hearing
impairment in childhood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 45 Hearing impairment in childhood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kari 1994 1/50 1/32 100.0 % 0.64 [ 0.04, 9.87 ]
Schutte 1980 0/50 0/34 Not estimable
Total (95% CI) 100 66 100.0 % 0.64 [ 0.04, 9.87 ]
Total events: 1 (Corticosteroids), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 1.46. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 46 Intellectual
impairment in childhood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 46 Intellectual impairment in childhood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Collaborative 1981 8/211 13/219 71.6 % 0.64 [ 0.27, 1.51 ]
Liggins 1972b 5/144 4/114 25.1 % 0.99 [ 0.27, 3.60 ]
Schutte 1980 3/54 0/36 3.4 % 4.71 [ 0.25, 88.52 ]
Total (95% CI) 409 369 100.0 % 0.86 [ 0.44, 1.69 ]
Total events: 16 (Corticosteroids), 17 (Control)
Heterogeneity: Chi2 = 1.80, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 1.47. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 47
Behavioural/learning difficulties in childhood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 47 Behavioural/learning difficulties in childhood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schutte 1980 9/54 7/36 100.0 % 0.86 [ 0.35, 2.09 ]
Total (95% CI) 54 36 100.0 % 0.86 [ 0.35, 2.09 ]
Total events: 9 (Corticosteroids), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 1.48. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 48 Mean adult
insulin (log values).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 48 Mean adult insulin (log values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Fasting
Liggins 1972b 212 2.1 (0.57) 223 2.02 (0.62) 100.0 % 0.08 [ -0.03, 0.19 ]
Subtotal (95% CI) 212 223 100.0 % 0.08 [ -0.03, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 30 minutes following a 75 g oral glucose tolerance test
Liggins 1972b 198 4.11 (0.61) 214 3.95 (0.62) 100.0 % 0.16 [ 0.04, 0.28 ]
Subtotal (95% CI) 198 214 100.0 % 0.16 [ 0.04, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0083)
3 120 minutes following a 75 g oral glucose tolerance test
Liggins 1972b 211 3.05 (0.85) 217 3.15 (0.95) 100.0 % -0.10 [ -0.27, 0.07 ]
Subtotal (95% CI) 211 217 100.0 % -0.10 [ -0.27, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
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Analysis 1.49. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 49 Mean adult
glucose (mmol/L).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 49 Mean adult glucose (mmol/L)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Fasting
Liggins 1972b 211 4.85 (0.54) 221 4.84 (0.49) 100.0 % 0.01 [ -0.09, 0.11 ]
Subtotal (95% CI) 211 221 100.0 % 0.01 [ -0.09, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
2 30 minutes following a 75 g oral glucose tolerance test
Liggins 1972b 202 7.46 (1.68) 211 7.27 (1.69) 100.0 % 0.19 [ -0.14, 0.52 ]
Subtotal (95% CI) 202 211 100.0 % 0.19 [ -0.14, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
3 120 minutes following a 75 g oral glucose tolerance test
Liggins 1972b 195 4.63 (1.13) 215 4.9 (1.49) 100.0 % -0.27 [ -0.52, -0.02 ]
Subtotal (95% CI) 195 215 100.0 % -0.27 [ -0.52, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.038)
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Analysis 1.50. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 50 Mean adult
weight (kg).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 50 Mean adult weight (kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Schutte (females)
Schutte 1980 21 61 (6.4) 16 67 (13) 30.0 % -6.00 [ -12.93, 0.93 ]
Subtotal (95% CI) 21 16 30.0 % -6.00 [ -12.93, 0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
2 Schutte (males)
Schutte 1980 27 71 (10.5) 16 72 (16.3) 23.1 % -1.00 [ -9.91, 7.91 ]
Subtotal (95% CI) 27 16 23.1 % -1.00 [ -9.91, 7.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
3 Liggins
Liggins 1972b 224 79.26 (18.06) 234 76.69 (17.82) 46.9 % 2.57 [ -0.72, 5.86 ]
Subtotal (95% CI) 224 234 46.9 % 2.57 [ -0.72, 5.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 272 266 100.0 % -0.83 [ -6.41, 4.76 ]
Heterogeneity: Tau2 = 14.50; Chi2 = 4.97, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 4.97, df = 2 (P = 0.08), I2 =60%
-20 -10 0 10 20
Corticosteroids lighter Control lighter
149Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.51. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 51 Mean adult
height (cm).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 51 Mean adult height (cm)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Schutte (females)
Schutte 1980 20 169 (6.3) 16 170 (6.9) 7.4 % -1.00 [ -5.37, 3.37 ]
Subtotal (95% CI) 20 16 7.4 % -1.00 [ -5.37, 3.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 Schutte (males)
Schutte 1980 27 180 (8) 16 177 (8.9) 5.0 % 3.00 [ -2.30, 8.30 ]
Subtotal (95% CI) 27 16 5.0 % 3.00 [ -2.30, 8.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
3 Liggins (females)
Liggins 1972b 107 164.59 (6.22) 127 163.42 (7.95) 42.9 % 1.17 [ -0.65, 2.99 ]
Subtotal (95% CI) 107 127 42.9 % 1.17 [ -0.65, 2.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
4 Liggins (males)
Liggins 1972b 117 178.15 (6.93) 107 177.4 (6.67) 44.6 % 0.75 [ -1.03, 2.53 ]
Subtotal (95% CI) 117 107 44.6 % 0.75 [ -1.03, 2.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Total (95% CI) 271 266 100.0 % 0.91 [ -0.28, 2.10 ]
Heterogeneity: Chi2 = 1.44, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 1.44, df = 3 (P = 0.70), I2 =0.0%
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Analysis 1.52. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 52 Mean adult head
circumference (cm).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 52 Mean adult head circumference (cm)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Schutte (females)
Schutte 1980 21 55.7 (1.9) 16 55.7 (1.3) 11.8 % 0.0 [ -1.03, 1.03 ]
Subtotal (95% CI) 21 16 11.8 % 0.0 [ -1.03, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Schutte (males)
Schutte 1980 27 57.3 (2.1) 15 57.5 (1.7) 9.2 % -0.20 [ -1.37, 0.97 ]
Subtotal (95% CI) 27 15 9.2 % -0.20 [ -1.37, 0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
3 Liggins
Liggins 1972b 224 56.27 (2.11) 234 56.21 (2.24) 79.1 % 0.06 [ -0.34, 0.46 ]
Subtotal (95% CI) 224 234 79.1 % 0.06 [ -0.34, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
Total (95% CI) 272 265 100.0 % 0.03 [ -0.33, 0.38 ]
Heterogeneity: Chi2 = 0.17, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Chi2 = 0.17, df = 2 (P = 0.92), I2 =0.0%
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Analysis 1.53. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 53 Mean adult
skinfold thickness (log values).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 53 Mean adult skinfold thickness (log values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Triceps
Liggins 1972b 223 2.63 (0.48) 233 2.65 (0.5) 100.0 % -0.02 [ -0.11, 0.07 ]
Subtotal (95% CI) 223 233 100.0 % -0.02 [ -0.11, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
2 Biceps
Liggins 1972b 223 1.99 (0.55) 233 2 (0.57) 100.0 % -0.01 [ -0.11, 0.09 ]
Subtotal (95% CI) 223 233 100.0 % -0.01 [ -0.11, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
3 Subscapular
Liggins 1972b 215 2.84 (0.46) 226 2.83 (0.5) 100.0 % 0.01 [ -0.08, 0.10 ]
Subtotal (95% CI) 215 226 100.0 % 0.01 [ -0.08, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
4 Suprailiac
Liggins 1972b 220 2.53 (0.58) 232 2.54 (0.63) 100.0 % -0.01 [ -0.12, 0.10 ]
Subtotal (95% CI) 220 232 100.0 % -0.01 [ -0.12, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 0.22, df = 3 (P = 0.97), I2 =0.0%
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Analysis 1.54. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 54 Mean adult
systolic blood pressure (mmHg).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 54 Mean adult systolic blood pressure (mmHg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Schutte (females)
Schutte 1980 21 112 (8) 17 116 (8.02) 22.8 % -4.00 [ -9.12, 1.12 ]
Subtotal (95% CI) 21 17 22.8 % -4.00 [ -9.12, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
2 Schutte (males)
Schutte 1980 27 116 (5.82) 25 119 (9.04) 29.5 % -3.00 [ -7.17, 1.17 ]
Subtotal (95% CI) 27 25 29.5 % -3.00 [ -7.17, 1.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
3 Liggins
Liggins 1972b 221 118.78 (12.29) 234 118.23 (14.09) 47.8 % 0.55 [ -1.88, 2.98 ]
Subtotal (95% CI) 221 234 47.8 % 0.55 [ -1.88, 2.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 269 276 100.0 % -1.53 [ -4.50, 1.44 ]
Heterogeneity: Tau2 = 3.29; Chi2 = 3.75, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 3.75, df = 2 (P = 0.15), I2 =47%
-10 -5 0 5 10
Corticosteroids lower Control lower
153Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.55. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 55 Mean adult HPA
axis function (mean log fasting cortisol).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 55 Mean adult HPA axis function (mean log fasting cortisol)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 217 6.1 (0.42) 227 6.04 (0.41) 0.06 [ -0.02, 0.14 ]
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Corticosteroids lower Control lower
Analysis 1.56. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 56 Mean
cholesterol in adulthood (mmol/L).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 56 Mean cholesterol in adulthood (mmol/L)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 218 4.93 (0.9) 227 5.04 (0.93) -0.11 [ -0.28, 0.06 ]
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Corticosteroids lower Control lower
154Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.57. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 57 Mean age at
puberty (years).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 57 Mean age at puberty (years)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Schutte (females)
Schutte 1980 21 12.8 (1.3) 17 12.8 (1.6) 100.0 % 0.0 [ -0.94, 0.94 ]
Subtotal (95% CI) 21 17 100.0 % 0.0 [ -0.94, 0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.58. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 58 Educational
achievement by adulthood (university or polytechnic education).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 58 Educational achievement by adulthood (university or polytechnic education)
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 133/253 157/281 0.94 [ 0.80, 1.10 ]
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Analysis 1.59. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 59 Visual
impairment in adulthood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 59 Visual impairment in adulthood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 18/87 24/105 0.91 [ 0.53, 1.55 ]
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Analysis 1.60. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 60 Hearing
impairment in adulthood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 60 Hearing impairment in adulthood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 1/87 5/105 0.24 [ 0.03, 2.03 ]
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Analysis 1.61. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 61 Intellectual
impairment in adulthood.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 61 Intellectual impairment in adulthood
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 0/87 2/105 100.0 % 0.24 [ 0.01, 4.95 ]
Schutte 1980 0/48 0/33 Not estimable
Total (95% CI) 135 138 100.0 % 0.24 [ 0.01, 4.95 ]
Total events: 0 (Corticosteroids), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.62. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 62 Mean adult FVC
(% predicted).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 62 Mean adult FVC (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 181 105.9 (12) 202 106.6 (12.6) 100.0 % -0.70 [ -3.16, 1.76 ]
Total (95% CI) 181 202 100.0 % -0.70 [ -3.16, 1.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 1.63. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 63 Mean adult
FEV1 (% predicted).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 63 Mean adult FEV1 (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 181 98.9 (13.4) 202 98.5 (13.6) 100.0 % 0.40 [ -2.31, 3.11 ]
Total (95% CI) 181 202 100.0 % 0.40 [ -2.31, 3.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 1.64. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 64 Mean adult
FEV1/FVC.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 64 Mean adult FEV1/FVC





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 181 0.8 (0.08) 202 0.79 (0.08) 100.0 % 0.01 [ -0.01, 0.03 ]
Total (95% CI) 181 202 100.0 % 0.01 [ -0.01, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 1.65. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 65 Mean adult PEF.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 65 Mean adult PEF





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 181 101.3 (14.3) 202 99.1 (15.4) 100.0 % 2.20 [ -0.77, 5.17 ]
Total (95% CI) 181 202 100.0 % 2.20 [ -0.77, 5.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.66. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 66 Mean adult F50.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 66 Mean adult F50





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 181 80.1 (23.2) 202 77.1 (22.3) 100.0 % 3.00 [ -1.57, 7.57 ]
Total (95% CI) 181 202 100.0 % 3.00 [ -1.57, 7.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours corticosteroids Favours control
159Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.67. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 67 Mean adult F25.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 67 Mean adult F25





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 181 64 (20.5) 202 63.6 (21.6) 100.0 % 0.40 [ -3.82, 4.62 ]
Total (95% CI) 181 202 100.0 % 0.40 [ -3.82, 4.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 1.68. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 68 Mean adult FEF
25%-75%.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 68 Mean adult FEF 25%-75%





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 181 74.9 (21.6) 202 72.7 (21.3) 100.0 % 2.20 [ -2.10, 6.50 ]
Total (95% CI) 181 202 100.0 % 2.20 [ -2.10, 6.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 1.69. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 69 FEV1/FVC <
70%.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 69 FEV1/FVC < 70%
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 18/181 23/202 100.0 % 0.87 [ 0.49, 1.57 ]
Total (95% CI) 181 202 100.0 % 0.87 [ 0.49, 1.57 ]
Total events: 18 (Corticosteroids), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 1.70. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 70 Asthma
diagnosed by Doctor in lifetime.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 70 Asthma diagnosed by Doctor in lifetime
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 68/253 77/281 100.0 % 0.98 [ 0.74, 1.30 ]
Total (95% CI) 253 281 100.0 % 0.98 [ 0.74, 1.30 ]
Total events: 68 (Corticosteroids), 77 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 1.71. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 71 Wheezing in
last 12 months.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 71 Wheezing in last 12 months
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 89/253 93/281 100.0 % 1.06 [ 0.84, 1.35 ]
Total (95% CI) 253 281 100.0 % 1.06 [ 0.84, 1.35 ]
Total events: 89 (Corticosteroids), 93 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.72. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 72 Current Asthma.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 72 Current Asthma
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 50/253 53/281 100.0 % 1.05 [ 0.74, 1.48 ]
Total (95% CI) 253 281 100.0 % 1.05 [ 0.74, 1.48 ]
Total events: 50 (Corticosteroids), 53 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 1.73. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 73 Further
respiratory diagnosis (includes pneumonia, upper airway conditions and bronchitis).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 73 Further respiratory diagnosis (includes pneumonia, upper airway conditions and bronchitis)
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 18/253 15/281 100.0 % 1.33 [ 0.69, 2.59 ]
Total (95% CI) 253 281 100.0 % 1.33 [ 0.69, 2.59 ]
Total events: 18 (Corticosteroids), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 1.74. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 74 Spontaneous
pneumothorax.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 74 Spontaneous pneumothorax
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 1/253 1/281 100.0 % 1.11 [ 0.07, 17.66 ]
Total (95% CI) 253 281 100.0 % 1.11 [ 0.07, 17.66 ]
Total events: 1 (Corticosteroids), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 1.75. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 75 Shortness of
breath at anytime in the last 12 months.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 75 Shortness of breath at anytime in the last 12 months
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b 81/253 88/281 100.0 % 1.02 [ 0.80, 1.31 ]
Total (95% CI) 253 281 100.0 % 1.02 [ 0.80, 1.31 ]
Total events: 81 (Corticosteroids), 88 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 1.76. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 76 Mean adult
lumbar spine aBMD (g/cm2) areal bone mineral density.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 76 Mean adult lumbar spine aBMD (g/cm2) areal bone mineral density





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 80 1.26 (0.15) 94 1.26 (0.15) 100.0 % 0.0 [ -0.04, 0.04 ]
Total (95% CI) 80 94 100.0 % 0.0 [ -0.04, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours corticosteroids Favours control
164Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.77. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 77 Mean adult
lumbar spine vBMD (g/cm3) volumetric bone mineral density.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 77 Mean adult lumbar spine vBMD (g/cm3) volumetric bone mineral density





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 80 0.32 (0.04) 94 0.32 (0.04) 100.0 % 0.0 [ -0.01, 0.01 ]
Total (95% CI) 80 94 100.0 % 0.0 [ -0.01, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.78. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 78 Mean adult total
body BMC (grams) bone mineral content.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 78 Mean adult total body BMC (grams) bone mineral content





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 80 2861 (589) 94 2843 (542) 100.0 % 18.00 [ -151.30, 187.30 ]
Total (95% CI) 80 94 100.0 % 18.00 [ -151.30, 187.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 1.79. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 79 Mean adult total
body aBMD (g/cm3) areal bone mineral density.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 79 Mean adult total body aBMD (g/cm3) areal bone mineral density





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 80 1.22 (0.1) 94 1.22 (0.09) 100.0 % 0.0 [ -0.03, 0.03 ]
Total (95% CI) 80 94 100.0 % 0.0 [ -0.03, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.80. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 80 Mean adult
femoral neck aBMD (g/cm2) areal bone mineral density.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 80 Mean adult femoral neck aBMD (g/cm2) areal bone mineral density





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 80 1.06 (0.16) 94 1.04 (0.14) 100.0 % 0.02 [ -0.03, 0.07 ]
Total (95% CI) 80 94 100.0 % 0.02 [ -0.03, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 1.81. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 81 Mean adult
femoral trochanter aBMD (g/cm2) areal bone mineral density.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 81 Mean adult femoral trochanter aBMD (g/cm2) areal bone mineral density





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 80 0.88 (0.15) 94 0.86 (0.14) 100.0 % 0.02 [ -0.02, 0.06 ]
Total (95% CI) 80 94 100.0 % 0.02 [ -0.02, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 1.82. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 82 Mean adult
femoral shaft aBMD (g/cm2) areal bone mineral density.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 82 Mean adult femoral shaft aBMD (g/cm2) areal bone mineral density





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 80 1.23 (0.19) 94 1.22 (0.16) 100.0 % 0.01 [ -0.04, 0.06 ]
Total (95% CI) 80 94 100.0 % 0.01 [ -0.04, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.83. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 83 Mean total
proximal femur aBMD (g/cm2) areal bone mineral density.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 83 Mean total proximal femur aBMD (g/cm2) areal bone mineral density





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Liggins 1972b 80 1.07 (0.16) 94 1.05 (0.14) 100.0 % 0.02 [ -0.03, 0.07 ]
Total (95% CI) 80 94 100.0 % 0.02 [ -0.03, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours corticosteroids Favours control
Analysis 1.84. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 84 Mean length of
antenatal hospitalisation (days).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 84 Mean length of antenatal hospitalisation (days)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Amorim 1999 110 19.6 (7.5) 108 19.1 (6.8) 100.0 % 0.50 [ -1.40, 2.40 ]
Total (95% CI) 110 108 100.0 % 0.50 [ -1.40, 2.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.85. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 85 Mean length of
postnatal hospitalisation (days).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 85 Mean length of postnatal hospitalisation (days)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Amorim 1999 110 5.74 (5.9) 108 5.74 (7) 100.0 % 0.0 [ -1.72, 1.72 ]
Total (95% CI) 110 108 100.0 % 0.0 [ -1.72, 1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 1.86. Comparison 1 Corticosteroids versus placebo or no treatment, Outcome 86 Mean length of
neonatal hospitalisation (days).
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 1 Corticosteroids versus placebo or no treatment
Outcome: 86 Mean length of neonatal hospitalisation (days)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Amorim 1999 100 12.3 (13.3) 100 10.9 (11.6) 3.9 % 1.40 [ -2.06, 4.86 ]
Attawattanakul 2015 96 4.69 (3.6) 98 4.42 (2.3) 64.9 % 0.27 [ -0.58, 1.12 ]
Lewis 1996 38 24.82 (20.1) 39 29.23 (30.4) 0.4 % -4.41 [ -15.89, 7.07 ]
Nelson 1985 22 23.7 (22.5) 22 25 (21) 0.3 % -1.30 [ -14.16, 11.56 ]
Porto 2011 143 5.1 (6.1) 130 5.2 (4.3) 30.5 % -0.10 [ -1.34, 1.14 ]
Total (95% CI) 399 389 100.0 % 0.18 [ -0.51, 0.87 ]
Heterogeneity: Chi2 = 1.38, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 2.1. Comparison 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy,
Outcome 1 Chorioamnionitis - single or multiple pregnancy.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In women delivering singleton pregnancies
Amorim 1999 2/110 1/108 0.7 % 1.96 [ 0.18, 21.34 ]
Attawattanakul 2015 0/96 0/98 Not estimable
Gyamfi-Bannerman 2016 20/1427 32/1400 24.0 % 0.61 [ 0.35, 1.07 ]
Lewis 1996 6/38 6/39 4.4 % 1.03 [ 0.36, 2.90 ]
Liggins 1972b 27/516 35/546 25.2 % 0.82 [ 0.50, 1.33 ]
Morales 1989 9/87 16/78 12.5 % 0.50 [ 0.24, 1.08 ]
Qublan 2001 6/72 3/67 2.3 % 1.86 [ 0.48, 7.15 ]
Subtotal (95% CI) 2346 2336 69.2 % 0.75 [ 0.56, 1.01 ]
Total events: 70 (Antenatal corticosteroids), 93 (Control)
Heterogeneity: Chi2 = 4.41, df = 5 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
2 In women delivering multiple pregnancies
Liggins 1972b 1/40 2/34 1.6 % 0.43 [ 0.04, 4.49 ]
Subtotal (95% CI) 40 34 1.6 % 0.43 [ 0.04, 4.49 ]
Total events: 1 (Antenatal corticosteroids), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
3 Mixed population
Carlan 1991 0/11 3/13 2.4 % 0.17 [ 0.01, 2.91 ]
Dexiprom 1999 11/102 8/102 5.9 % 1.38 [ 0.58, 3.28 ]
Fekih 2002 1/59 0/59 0.4 % 3.00 [ 0.12, 72.18 ]
Garite 1992 1/33 2/38 1.4 % 0.58 [ 0.05, 6.07 ]
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kari 1994 13/77 8/80 5.8 % 1.69 [ 0.74, 3.85 ]
Lopez 1989 0/20 1/20 1.1 % 0.33 [ 0.01, 7.72 ]
Schutte 1980 1/50 4/51 2.9 % 0.26 [ 0.03, 2.20 ]
Silver 1996 13/39 12/36 9.3 % 1.00 [ 0.53, 1.90 ]
Subtotal (95% CI) 391 399 29.2 % 1.05 [ 0.70, 1.57 ]
Total events: 40 (Antenatal corticosteroids), 38 (Control)
Heterogeneity: Chi2 = 6.10, df = 7 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 2777 2769 100.0 % 0.83 [ 0.66, 1.06 ]
Total events: 111 (Antenatal corticosteroids), 133 (Control)
Heterogeneity: Chi2 = 13.04, df = 14 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 2.07, df = 2 (P = 0.36), I2 =3%
0.01 0.1 1 10 100
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Analysis 2.2. Comparison 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy,
Outcome 2 Perinatal death - single or multiple pregnancy.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy












1 In babies born from singleton pregnancies
Amorim 1999 24/110 36/108 11.0 % 0.65 [ 0.42, 1.02 ]
Collaborative 1981 41/328 42/327 12.1 % 0.97 [ 0.65, 1.45 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.5 % 4.91 [ 0.24, 102.09 ]
Liggins 1972b 95/520 103/548 16.9 % 0.97 [ 0.76, 1.25 ]
Porto 2011 (2) 1/144 3/131 0.8 % 0.30 [ 0.03, 2.88 ]
Qublan 2001 21/72 41/67 12.0 % 0.48 [ 0.32, 0.72 ]
Subtotal (95% CI) 2601 2581 53.3 % 0.75 [ 0.54, 1.05 ]
Total events: 184 (Antenatal corticosteroids), 225 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 12.40, df = 5 (P = 0.03); I2 =60%
Test for overall effect: Z = 1.65 (P = 0.098)
2 In babies born from multiple pregnancies
Collaborative 1981 6/50 5/52 2.9 % 1.25 [ 0.41, 3.83 ]
Liggins 1972b 13/81 19/69 7.3 % 0.58 [ 0.31, 1.09 ]
Subtotal (95% CI) 131 121 10.2 % 0.74 [ 0.37, 1.47 ]
Total events: 19 (Antenatal corticosteroids), 24 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 1.35, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 0.87 (P = 0.38)
3 Mixed population
Block 1977 4/60 6/54 2.6 % 0.60 [ 0.18, 2.01 ]
Dexiprom 1999 4/105 10/103 2.9 % 0.39 [ 0.13, 1.21 ]
Doran 1980 5/81 14/63 3.8 % 0.28 [ 0.11, 0.73 ]
Gamsu 1989 15/131 22/137 7.6 % 0.71 [ 0.39, 1.31 ]
Garite 1992 12/36 12/41 6.8 % 1.14 [ 0.59, 2.21 ]
Kari 1994 5/95 6/94 2.8 % 0.82 [ 0.26, 2.61 ]
Parsons 1988 0/23 1/22 0.4 % 0.32 [ 0.01, 7.45 ]
Schutte 1980 6/65 12/58 4.1 % 0.45 [ 0.18, 1.11 ]
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Taeusch 1979 10/56 12/71 5.5 % 1.06 [ 0.49, 2.27 ]
Subtotal (95% CI) 652 643 36.5 % 0.68 [ 0.49, 0.94 ]
Total events: 61 (Antenatal corticosteroids), 95 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 9.14, df = 8 (P = 0.33); I2 =12%
Test for overall effect: Z = 2.35 (P = 0.019)
Total (95% CI) 3384 3345 100.0 % 0.72 [ 0.59, 0.89 ]
Total events: 264 (Antenatal corticosteroids), 344 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 23.55, df = 16 (P = 0.10); I2 =32%
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Chi2 = 0.22, df = 2 (P = 0.90), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
(2) The events are 1 stillbirth in each arm, and 2 neonatal deaths due to severe perinatal asphyxia.
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Analysis 2.3. Comparison 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy,
Outcome 3 Neonatal death - single or multiple pregnancy.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy




teroid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies born from singleton pregnancies
Amorim 1999 14/100 28/100 9.1 % 0.50 [ 0.28, 0.89 ]
Collaborative 1981 30/317 28/313 9.1 % 1.06 [ 0.65, 1.73 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.2 % 4.91 [ 0.24, 102.09 ]
Lewis 1996 1/38 1/39 0.3 % 1.03 [ 0.07, 15.82 ]
Liggins 1972b 52/477 62/507 19.4 % 0.89 [ 0.63, 1.26 ]
Morales 1989 7/87 8/78 2.7 % 0.78 [ 0.30, 2.06 ]
Nelson 1985 1/22 1/22 0.3 % 1.00 [ 0.07, 15.00 ]
Porto 2011 (2) 0/143 2/130 0.8 % 0.18 [ 0.01, 3.75 ]
Qublan 2001 19/70 39/65 13.1 % 0.45 [ 0.29, 0.70 ]
Subtotal (95% CI) 2681 2654 55.1 % 0.75 [ 0.61, 0.92 ]
Total events: 126 (Antenatal corticosteroid), 169 (Control)
Heterogeneity: Chi2 = 12.38, df = 8 (P = 0.14); I2 =35%
Test for overall effect: Z = 2.73 (P = 0.0064)
2 In babies born from multiple pregnancies
Collaborative 1981 4/48 4/51 1.3 % 1.06 [ 0.28, 4.01 ]
Liggins 1972b 9/77 10/60 3.6 % 0.70 [ 0.30, 1.62 ]
Subtotal (95% CI) 125 111 4.9 % 0.79 [ 0.39, 1.61 ]
Total events: 13 (Antenatal corticosteroid), 14 (Control)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
3 Mixed population
Block 1977 1/57 5/53 1.7 % 0.19 [ 0.02, 1.54 ]
Dexiprom 1999 4/105 8/101 2.6 % 0.48 [ 0.15, 1.55 ]
Doran 1980 4/80 11/60 4.1 % 0.27 [ 0.09, 0.81 ]
Fekih 2002 9/63 21/68 6.5 % 0.46 [ 0.23, 0.93 ]
Gamsu 1989 14/130 17/132 5.5 % 0.84 [ 0.43, 1.63 ]
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teroid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Garite 1992 9/33 11/40 3.2 % 0.99 [ 0.47, 2.10 ]
Goodner 1979 4/47 7/45 2.3 % 0.55 [ 0.17, 1.74 ]
Kari 1994 4/91 6/88 2.0 % 0.64 [ 0.19, 2.21 ]
Lopez 1989 6/20 6/20 1.9 % 1.00 [ 0.39, 2.58 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Schutte 1980 3/62 12/58 4.0 % 0.23 [ 0.07, 0.79 ]
Silver 1996 7/54 8/42 2.9 % 0.68 [ 0.27, 1.73 ]
Taeusch 1979 8/54 10/69 2.8 % 1.02 [ 0.43, 2.41 ]
Subtotal (95% CI) 819 798 40.1 % 0.60 [ 0.46, 0.78 ]
Total events: 73 (Antenatal corticosteroid), 123 (Control)
Heterogeneity: Chi2 = 11.72, df = 12 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.82 (P = 0.00014)
Total (95% CI) 3625 3563 100.0 % 0.69 [ 0.59, 0.81 ]
Total events: 212 (Antenatal corticosteroid), 306 (Control)
Heterogeneity: Chi2 = 24.76, df = 23 (P = 0.36); I2 =7%
Test for overall effect: Z = 4.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.86, df = 2 (P = 0.39), I2 =0.0%
0.01 0.1 1 10 100
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(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
(2) Deaths due to severe perinatal asphyxia.
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Analysis 2.4. Comparison 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy,
Outcome 4 Fetal death - single or multiple pregnancy.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies born from singleton pregnancies
Amorim 1999 10/110 8/108 8.8 % 1.23 [ 0.50, 2.99 ]
Collaborative 1981 11/328 14/327 15.3 % 0.78 [ 0.36, 1.70 ]
Gyamfi-Bannerman 2016 0/1427 0/1400 Not estimable
Liggins 1972b 43/520 41/548 43.7 % 1.11 [ 0.73, 1.67 ]
Porto 2011 (1) 1/144 1/131 1.1 % 0.91 [ 0.06, 14.40 ]
Qublan 2001 2/72 2/67 2.3 % 0.93 [ 0.13, 6.42 ]
Subtotal (95% CI) 2601 2581 71.3 % 1.04 [ 0.75, 1.45 ]
Total events: 67 (Antenatal corticosteroids), 66 (Control)
Heterogeneity: Chi2 = 0.75, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
2 In babies born from multiple pregnancies
Collaborative 1981 2/50 1/52 1.1 % 2.08 [ 0.19, 22.23 ]
Liggins 1972b 4/81 9/69 10.6 % 0.38 [ 0.12, 1.18 ]
Subtotal (95% CI) 131 121 11.7 % 0.53 [ 0.20, 1.40 ]
Total events: 6 (Antenatal corticosteroids), 10 (Control)
Heterogeneity: Chi2 = 1.62, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 1.27 (P = 0.20)
3 Mixed population
Block 1977 3/60 1/54 1.2 % 2.70 [ 0.29, 25.19 ]
Dexiprom 1999 0/105 2/103 2.8 % 0.20 [ 0.01, 4.04 ]
Doran 1980 1/81 3/63 3.7 % 0.26 [ 0.03, 2.43 ]
Gamsu 1989 1/131 5/137 5.3 % 0.21 [ 0.02, 1.77 ]
Garite 1992 3/36 1/41 1.0 % 3.42 [ 0.37, 31.41 ]
Kari 1994 1/95 0/94 0.5 % 2.97 [ 0.12, 71.96 ]
Parsons 1988 0/23 0/22 Not estimable
Schutte 1980 3/65 0/58 0.6 % 6.26 [ 0.33, 118.64 ]
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Taeusch 1979 2/56 2/71 1.9 % 1.27 [ 0.18, 8.72 ]
Subtotal (95% CI) 652 643 17.0 % 0.99 [ 0.50, 1.99 ]
Total events: 14 (Antenatal corticosteroids), 14 (Control)
Heterogeneity: Chi2 = 8.51, df = 7 (P = 0.29); I2 =18%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 3384 3345 100.0 % 0.97 [ 0.73, 1.29 ]
Total events: 87 (Antenatal corticosteroids), 90 (Control)
Heterogeneity: Chi2 = 12.52, df = 14 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 1.65, df = 2 (P = 0.44), I2 =0.0%
0.01 0.1 1 10 100
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(1) The outcome measured in this trial was stillbirth.
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Analysis 2.5. Comparison 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy,
Outcome 5 Respiratory distress syndrome - single or multiple pregnancy.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy
Outcome: 5 Respiratory distress syndrome - single or multiple pregnancy








1 In babies born from singleton pregnancies
Amorim 1999 23/100 43/100 5.1 % 0.53 [ 0.35, 0.82 ]
Attawattanakul 2015 9/96 20/98 2.7 % 0.46 [ 0.22, 0.96 ]
Balci 2010 2/50 8/50 0.9 % 0.25 [ 0.06, 1.12 ]
Cararach 1991 1/12 0/6 0.2 % 1.62 [ 0.08, 34.66 ]
Collaborative 1981 31/307 48/299 5.1 % 0.63 [ 0.41, 0.96 ]
Gamsu 1989 7/120 14/109 2.1 % 0.45 [ 0.19, 1.08 ]
Gyamfi-Bannerman 2016 79/1427 89/1400 6.5 % 0.87 [ 0.65, 1.17 ]
Lewis 1996 7/38 17/39 2.6 % 0.42 [ 0.20, 0.90 ]
Liggins 1972b 43/465 77/490 5.9 % 0.59 [ 0.41, 0.84 ]
Mansouri 2010 8/100 20/100 2.6 % 0.40 [ 0.18, 0.87 ]
Morales 1989 23/87 41/78 5.2 % 0.50 [ 0.33, 0.76 ]
Nelson 1985 10/22 11/22 3.4 % 0.91 [ 0.49, 1.69 ]
Porto 2011 2/143 1/130 0.4 % 1.82 [ 0.17, 19.82 ]
Qublan 2001 14/70 24/65 3.8 % 0.54 [ 0.31, 0.95 ]
Silver 1996 24/28 25/30 7.4 % 1.03 [ 0.83, 1.28 ]
Subtotal (95% CI) 3065 3016 53.9 % 0.62 [ 0.50, 0.77 ]
Total events: 283 (Treatment), 438 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 32.47, df = 14 (P = 0.003); I2 =57%
Test for overall effect: Z = 4.33 (P = 0.000015)
2 In babies born from multiple pregnancies
Collaborative 1981 15/54 17/60 3.6 % 0.98 [ 0.54, 1.77 ]
Gamsu 1989 0/10 2/23 0.2 % 0.44 [ 0.02, 8.35 ]
Liggins 1972b (1) 10/77 12/58 2.6 % 0.63 [ 0.29, 1.35 ]
Silver 1996 19/26 9/12 5.3 % 0.97 [ 0.65, 1.46 ]
Subtotal (95% CI) 167 153 11.8 % 0.90 [ 0.67, 1.22 ]
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Total events: 44 (Treatment), 40 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.47, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
3 Mixed population
Block 1977 5/57 12/53 1.8 % 0.39 [ 0.15, 1.03 ]
Carlan 1991 1/11 4/13 0.5 % 0.30 [ 0.04, 2.27 ]
Dexiprom 1999 32/102 27/100 5.0 % 1.16 [ 0.75, 1.79 ]
Doran 1980 4/80 10/60 1.5 % 0.30 [ 0.10, 0.91 ]
Fekih 2002 3/63 19/68 1.3 % 0.17 [ 0.05, 0.55 ]
Garite 1992 21/33 28/40 6.1 % 0.91 [ 0.65, 1.26 ]
Goodner 1979 5/47 11/45 1.8 % 0.44 [ 0.16, 1.15 ]
Kari 1994 34/91 46/90 6.1 % 0.73 [ 0.52, 1.02 ]
Lopez 1989 9/20 10/20 3.2 % 0.90 [ 0.47, 1.73 ]
Parsons 1988 3/23 3/22 0.9 % 0.96 [ 0.22, 4.24 ]
Schutte 1980 11/62 17/58 3.1 % 0.61 [ 0.31, 1.18 ]
Taeusch 1979 7/54 14/69 2.3 % 0.64 [ 0.28, 1.47 ]
Teramo 1980 3/38 3/42 0.8 % 1.11 [ 0.24, 5.15 ]
Subtotal (95% CI) 681 680 34.3 % 0.69 [ 0.53, 0.89 ]
Total events: 138 (Treatment), 204 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 20.28, df = 12 (P = 0.06); I2 =41%
Test for overall effect: Z = 2.82 (P = 0.0047)
Total (95% CI) 3913 3849 100.0 % 0.68 [ 0.59, 0.78 ]
Total events: 465 (Treatment), 682 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 56.80, df = 31 (P = 0.003); I2 =45%
Test for overall effect: Z = 5.23 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.86, df = 2 (P = 0.14), I2 =48%
0.1 0.2 0.5 1 2 5 10
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(1) Two babies missing from control group, so that the overall analysis here will not match the primary analysis in the main comparison. This small amount of missing data
does not alter the result or conclusion.
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Analysis 2.6. Comparison 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy,
Outcome 6 IVH - single or multiple pregnancy.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy




teroid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies born from singleton pregnancies
Amorim 1999 6/100 17/100 10.7 % 0.35 [ 0.15, 0.86 ]
Attawattanakul 2015 0/96 0/98 Not estimable
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.3 % 4.91 [ 0.24, 102.09 ]
Lewis 1996 0/38 3/39 2.2 % 0.15 [ 0.01, 2.74 ]
Liggins 1972b 14/477 23/507 14.0 % 0.65 [ 0.34, 1.24 ]
Mansouri 2010 (2) 0/100 0/100 Not estimable
Morales 1989 13/87 20/78 13.3 % 0.58 [ 0.31, 1.09 ]
Qublan 2001 2/70 8/65 5.2 % 0.23 [ 0.05, 1.05 ]
Subtotal (95% CI) 2395 2387 45.7 % 0.52 [ 0.36, 0.75 ]
Total events: 37 (Antenatal corticosteroid), 71 (Control)
Heterogeneity: Chi2 = 5.20, df = 5 (P = 0.39); I2 =4%
Test for overall effect: Z = 3.45 (P = 0.00057)
2 In babies born from multiple pregnancies
Liggins 1972b 2/77 4/60 2.8 % 0.39 [ 0.07, 2.06 ]
Subtotal (95% CI) 77 60 2.8 % 0.39 [ 0.07, 2.06 ]
Total events: 2 (Antenatal corticosteroid), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
3 Mixed population
Dexiprom 1999 0/105 0/101 Not estimable
Doran 1980 1/80 4/60 2.9 % 0.19 [ 0.02, 1.63 ]
Fekih 2002 5/63 14/68 8.5 % 0.39 [ 0.15, 1.01 ]
Gamsu 1989 2/130 4/132 2.5 % 0.51 [ 0.09, 2.72 ]
Garite 1992 10/33 19/40 10.8 % 0.64 [ 0.35, 1.18 ]
Kari 1994 8/77 18/66 12.2 % 0.38 [ 0.18, 0.82 ]
Silver 1996 25/54 17/42 12.0 % 1.14 [ 0.72, 1.82 ]
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teroid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Taeusch 1979 0/54 4/69 2.5 % 0.14 [ 0.01, 2.57 ]
Subtotal (95% CI) 596 578 51.4 % 0.60 [ 0.44, 0.81 ]
Total events: 51 (Antenatal corticosteroid), 80 (Control)
Heterogeneity: Chi2 = 11.71, df = 6 (P = 0.07); I2 =49%
Test for overall effect: Z = 3.31 (P = 0.00093)
Total (95% CI) 3068 3025 100.0 % 0.56 [ 0.44, 0.70 ]
Total events: 90 (Antenatal corticosteroid), 155 (Control)
Heterogeneity: Chi2 = 18.21, df = 13 (P = 0.15); I2 =29%
Test for overall effect: Z = 4.90 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.53, df = 2 (P = 0.77), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) Grade 3-4 IVH reported
(2) Grade 3 - 4
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Analysis 2.7. Comparison 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy,
Outcome 7 Birthweight - single or multiple pregnancy.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 2 Corticosteroids versus placebo or no treatment - single or multiple pregnancy
Outcome: 7 Birthweight - single or multiple pregnancy





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 In babies born from singleton pregnancy
Attawattanakul 2015 96 2557.2 (367.6) 98 2558.1 (340) 5.0 % -0.90 [ -100.59, 98.79 ]
Balci 2010 50 2389 (133) 50 2386 (137) 17.8 % 3.00 [ -49.92, 55.92 ]
Gyamfi-Bannerman 2016 1427 2637 (480) 1400 2654 (484) 39.5 % -17.00 [ -52.54, 18.54 ]
Lewis 1996 38 1611 (538) 39 1734 (570) 0.8 % -123.00 [ -370.51, 124.51 ]
Liggins 1972b 520 2228.02 (840.39) 548 2318.81 (817.28) 5.0 % -90.79 [ -190.29, 8.71 ]
Mansouri 2010 100 2500 (300) 100 2600 (300) 7.2 % -100.00 [ -183.15, -16.85 ]
Morales 1989 87 1359 (361) 78 1379 (293) 5.0 % -20.00 [ -119.91, 79.91 ]
Nelson 1985 (1) 22 1594 (456.4) 22 1752.5 (415.4) 0.8 % -158.50 [ -416.38, 99.38 ]
Porto 2011 143 2640 (445) 130 2627 (452) 4.4 % 13.00 [ -93.57, 119.57 ]
Subtotal (95% CI) 2483 2465 85.6 % -24.12 [ -48.27, 0.03 ]
Heterogeneity: Chi2 = 8.42, df = 8 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.96 (P = 0.050)
2 In babies born from multiple pregnancies
Liggins 1972b 81 1882.22 (564.21) 69 1799.86 (816.96) 1.0 % 82.36 [ -146.23, 310.95 ]
Subtotal (95% CI) 81 69 1.0 % 82.36 [ -146.23, 310.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
3 Mixed population
Dexiprom 1999 105 1795 (437) 103 1791 (542) 2.8 % 4.00 [ -129.95, 137.95 ]
Doran 1980 80 2086 (857) 60 1880.5 (803) 0.7 % 205.50 [ -71.18, 482.18 ]
Gamsu 1989 130 2203 (757) 132 2133 (753) 1.5 % 70.00 [ -112.85, 252.85 ]
Garite 1992 33 1242 (678) 38 1071 (597) 0.6 % 171.00 [ -128.23, 470.23 ]
Kari 1994 94 1654 (831) 94 1783 (837) 0.9 % -129.00 [ -367.43, 109.43 ]
Schutte 1980 61 1788 (690) 58 1670 (448) 1.2 % 118.00 [ -90.03, 326.03 ]
Silver 1996 54 917 (238) 42 941 (219) 5.9 % -24.00 [ -115.74, 67.74 ]
Subtotal (95% CI) 557 527 13.4 % 16.77 [ -44.16, 77.69 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 6.27, df = 6 (P = 0.39); I2 =4%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 3121 3061 100.0 % -17.61 [ -39.95, 4.74 ]
Heterogeneity: Chi2 = 16.93, df = 16 (P = 0.39); I2 =6%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Chi2 = 2.24, df = 2 (P = 0.33), I2 =11%
-500 -250 0 250 500
Corticosteroids lighter Control lighter
(1) The trial reports the SD as 4,563.7 which much be a typo; we have used 456.4.
Analysis 3.1. Comparison 3 Corticosteroids versus placebo or no treatment - intact membranes versus
ruptured membranes at first dose, Outcome 1 Chorioamnionitis - intact or ruptured membranes.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 3 Corticosteroids versus placebo or no treatment - intact membranes versus ruptured membranes at first dose




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In women with intact membranes at 1st dose
Amorim 1999 2/110 1/108 0.8 % 1.96 [ 0.18, 21.34 ]
Attawattanakul 2015 0/96 0/98 Not estimable
Garite 1992 1/33 2/38 1.4 % 0.58 [ 0.05, 6.07 ]
Kari 1994 13/77 8/80 5.9 % 1.69 [ 0.74, 3.85 ]
Liggins 1972b 8/391 19/406 14.0 % 0.44 [ 0.19, 0.99 ]
Subtotal (95% CI) 707 730 22.1 % 0.83 [ 0.50, 1.40 ]
Total events: 24 (Antenatal corticosteroids), 30 (Control)
Heterogeneity: Chi2 = 5.83, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 0.69 (P = 0.49)
2 In women with ruptured membranes at 1st dose
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carlan 1991 0/11 3/13 2.4 % 0.17 [ 0.01, 2.91 ]
Dexiprom 1999 11/102 8/102 6.0 % 1.38 [ 0.58, 3.28 ]
Lewis 1996 6/38 6/39 4.5 % 1.03 [ 0.36, 2.90 ]
Liggins 1972b (1) 20/150 16/160 11.7 % 1.33 [ 0.72, 2.47 ]
Lopez 1989 0/20 1/20 1.1 % 0.33 [ 0.01, 7.72 ]
Morales 1989 9/87 16/78 12.7 % 0.50 [ 0.24, 1.08 ]
Qublan 2001 6/72 3/67 2.3 % 1.86 [ 0.48, 7.15 ]
Subtotal (95% CI) 480 479 40.8 % 0.98 [ 0.69, 1.40 ]
Total events: 52 (Antenatal corticosteroids), 53 (Control)
Heterogeneity: Chi2 = 7.30, df = 6 (P = 0.29); I2 =18%
Test for overall effect: Z = 0.11 (P = 0.91)
3 Not reported or mixed population
Fekih 2002 1/59 0/59 0.4 % 3.00 [ 0.12, 72.18 ]
Gyamfi-Bannerman 2016 20/1427 32/1400 24.3 % 0.61 [ 0.35, 1.07 ]
Schutte 1980 1/50 4/51 3.0 % 0.26 [ 0.03, 2.20 ]
Silver 1996 13/39 12/36 9.4 % 1.00 [ 0.53, 1.90 ]
Subtotal (95% CI) 1575 1546 37.1 % 0.71 [ 0.47, 1.06 ]
Total events: 35 (Antenatal corticosteroids), 48 (Control)
Heterogeneity: Chi2 = 3.03, df = 3 (P = 0.39); I2 =1%
Test for overall effect: Z = 1.66 (P = 0.096)
Total (95% CI) 2762 2755 100.0 % 0.85 [ 0.67, 1.07 ]
Total events: 111 (Antenatal corticosteroids), 131 (Control)
Heterogeneity: Chi2 = 17.27, df = 14 (P = 0.24); I2 =19%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Chi2 = 1.41, df = 2 (P = 0.49), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) Ruptured membrane status was missing for 29 (3%) women. The small amount of missing data did not alter the results.
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Analysis 3.2. Comparison 3 Corticosteroids versus placebo or no treatment - intact membranes versus
ruptured membranes at first dose, Outcome 2 Endometritis - intact or ruptured membranes.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 3 Corticosteroids versus placebo or no treatment - intact membranes versus ruptured membranes at first dose












1 In women with intact membranes at 1st dose
Amorim 1999 9/110 13/108 14.9 % 0.68 [ 0.30, 1.52 ]
Garite 1992 10/33 5/38 11.8 % 2.30 [ 0.88, 6.06 ]
Subtotal (95% CI) 143 146 26.6 % 1.21 [ 0.37, 4.01 ]
Total events: 19 (Antenatal corticosteroids), 18 (Control)
Heterogeneity: Tau2 = 0.54; Chi2 = 3.61, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.32 (P = 0.75)
2 In women with ruptured membranes at 1st dose
Dexiprom 1999 4/102 7/102 8.6 % 0.57 [ 0.17, 1.89 ]
Lewis 1996 2/38 4/39 5.2 % 0.51 [ 0.10, 2.64 ]
Qublan 2001 9/72 2/67 6.0 % 4.19 [ 0.94, 18.68 ]
Schutte 1980 1/30 1/27 2.1 % 0.90 [ 0.06, 13.70 ]
Subtotal (95% CI) 242 235 21.9 % 1.02 [ 0.35, 2.97 ]
Total events: 16 (Antenatal corticosteroids), 14 (Control)
Heterogeneity: Tau2 = 0.48; Chi2 = 5.09, df = 3 (P = 0.17); I2 =41%
Test for overall effect: Z = 0.04 (P = 0.96)
3 Not reported or mixed population
Gyamfi-Bannerman 2016 16/1427 16/1400 17.7 % 0.98 [ 0.49, 1.95 ]
Mansouri 2010 4/100 6/100 8.2 % 0.67 [ 0.19, 2.29 ]
Schutte 1980 0/20 0/24 Not estimable
Silver 1996 11/39 5/36 12.0 % 2.03 [ 0.78, 5.28 ]
Taeusch 1979 11/52 7/66 13.4 % 1.99 [ 0.83, 4.79 ]
Subtotal (95% CI) 1638 1626 51.4 % 1.31 [ 0.81, 2.13 ]
Total events: 42 (Antenatal corticosteroids), 34 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 3.53, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 2023 2007 100.0 % 1.20 [ 0.80, 1.80 ]
Total events: 77 (Antenatal corticosteroids), 66 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 12.54, df = 9 (P = 0.18); I2 =28%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 0.17, df = 2 (P = 0.92), I2 =0.0%
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Analysis 3.3. Comparison 3 Corticosteroids versus placebo or no treatment - intact membranes versus
ruptured membranes at first dose, Outcome 3 Perinatal death - intact or ruptured membranes.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 3 Corticosteroids versus placebo or no treatment - intact membranes versus ruptured membranes at first dose












1 In babies born from pregnancies with intact membranes at 1st dose
Amorim 1999 24/110 36/108 11.1 % 0.65 [ 0.42, 1.02 ]
Garite 1992 12/36 12/41 6.5 % 1.14 [ 0.59, 2.21 ]
Kari 1994 5/95 6/94 2.6 % 0.82 [ 0.26, 2.61 ]
Liggins 1972b 75/418 83/430 16.6 % 0.93 [ 0.70, 1.23 ]
Subtotal (95% CI) 659 673 36.8 % 0.87 [ 0.70, 1.08 ]
Total events: 116 (Antenatal corticosteorids), 137 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.44, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
2 In babies born from pregnancies with ruptured membranes at 1st dose
Dexiprom 1999 4/105 10/103 2.7 % 0.39 [ 0.13, 1.21 ]
Liggins 1972b (1) 30/168 36/173 11.3 % 0.86 [ 0.56, 1.33 ]
Parsons 1988 0/23 1/22 0.4 % 0.32 [ 0.01, 7.45 ]
Qublan 2001 21/72 41/67 12.1 % 0.48 [ 0.32, 0.72 ]
Subtotal (95% CI) 368 365 26.5 % 0.59 [ 0.39, 0.90 ]
Total events: 55 (Antenatal corticosteorids), 88 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 4.53, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 2.46 (P = 0.014)
3 Not reported or mixed population
Block 1977 4/60 6/54 2.4 % 0.60 [ 0.18, 2.01 ]
Collaborative 1981 47/378 47/379 13.0 % 1.00 [ 0.69, 1.46 ]
Doran 1980 5/81 14/63 3.6 % 0.28 [ 0.11, 0.73 ]
Gamsu 1989 15/131 22/137 7.4 % 0.71 [ 0.39, 1.31 ]
Gyamfi-Bannerman 2016 (2) 2/1427 0/1400 0.4 % 4.91 [ 0.24, 102.09 ]
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Porto 2011 (3) 1/144 3/131 0.7 % 0.30 [ 0.03, 2.88 ]
Schutte 1980 6/65 12/58 3.9 % 0.45 [ 0.18, 1.11 ]
Taeusch 1979 10/56 12/71 5.3 % 1.06 [ 0.49, 2.27 ]
Subtotal (95% CI) 2342 2293 36.7 % 0.71 [ 0.49, 1.03 ]
Total events: 90 (Antenatal corticosteorids), 116 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 10.48, df = 7 (P = 0.16); I2 =33%
Test for overall effect: Z = 1.80 (P = 0.071)
Total (95% CI) 3369 3331 100.0 % 0.74 [ 0.60, 0.90 ]
Total events: 261 (Antenatal corticosteorids), 341 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.31, df = 15 (P = 0.13); I2 =30%
Test for overall effect: Z = 3.04 (P = 0.0023)
Test for subgroup differences: Chi2 = 2.84, df = 2 (P = 0.24), I2 =30%
0.2 0.5 1 2 5
Favours corticosteroids Favours control
(1) Ruptured membrane status was missing for 29 (2%) mothers. The small amount of missing data did not alter the results.
(2) One due to septic shock and one to cardiac anomaly and arrhythmia.
(3) The events are 1 stillbirth in each arm, and 2 neonatal deaths due to severe perinatal asphyxia.
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Analysis 3.4. Comparison 3 Corticosteroids versus placebo or no treatment - intact membranes versus
ruptured membranes at first dose, Outcome 4 Neonatal deaths - intact or ruptured membranes.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 3 Corticosteroids versus placebo or no treatment - intact membranes versus ruptured membranes at first dose




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies born from pregnancies with intact membranes at 1st dose
Amorim 1999 14/100 28/100 9.1 % 0.50 [ 0.28, 0.89 ]
Garite 1992 9/33 11/40 3.2 % 0.99 [ 0.47, 2.10 ]
Kari 1994 4/91 6/88 2.0 % 0.64 [ 0.19, 2.21 ]
Liggins 1972b 44/387 50/397 16.0 % 0.90 [ 0.62, 1.32 ]
Subtotal (95% CI) 611 625 30.3 % 0.77 [ 0.58, 1.03 ]
Total events: 71 (Antenatal corticosteroids), 95 (Control)
Heterogeneity: Chi2 = 3.32, df = 3 (P = 0.34); I2 =10%
Test for overall effect: Z = 1.77 (P = 0.077)
2 In babies born from pregnancies with ruptured membranes at 1st dose
Dexiprom 1999 4/105 8/101 2.6 % 0.48 [ 0.15, 1.55 ]
Lewis 1996 1/38 1/39 0.3 % 1.03 [ 0.07, 15.82 ]
Liggins 1972b (1) 16/154 21/158 6.7 % 0.78 [ 0.42, 1.44 ]
Lopez 1989 6/20 6/20 1.9 % 1.00 [ 0.39, 2.58 ]
Morales 1989 7/87 8/78 2.7 % 0.78 [ 0.30, 2.06 ]
Nelson 1985 1/22 1/22 0.3 % 1.00 [ 0.07, 15.00 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Qublan 2001 19/70 39/65 13.1 % 0.45 [ 0.29, 0.70 ]
Subtotal (95% CI) 519 505 28.3 % 0.61 [ 0.46, 0.83 ]
Total events: 54 (Antenatal corticosteroids), 85 (Control)
Heterogeneity: Chi2 = 4.38, df = 7 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.22 (P = 0.0013)
3 Not reported or mixed population
Block 1977 1/57 5/53 1.7 % 0.19 [ 0.02, 1.54 ]
Collaborative 1981 34/365 32/364 10.4 % 1.06 [ 0.67, 1.68 ]
Doran 1980 4/80 11/60 4.1 % 0.27 [ 0.09, 0.81 ]
Fekih 2002 9/63 21/68 6.6 % 0.46 [ 0.23, 0.93 ]
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gamsu 1989 14/130 17/132 5.5 % 0.84 [ 0.43, 1.63 ]
Goodner 1979 4/47 7/45 2.3 % 0.55 [ 0.17, 1.74 ]
Gyamfi-Bannerman 2016 (2) 2/1427 0/1400 0.2 % 4.91 [ 0.24, 102.09 ]
Porto 2011 (3) 0/143 2/130 0.9 % 0.18 [ 0.01, 3.75 ]
Schutte 1980 3/62 12/58 4.0 % 0.23 [ 0.07, 0.79 ]
Silver 1996 7/54 8/42 2.9 % 0.68 [ 0.27, 1.73 ]
Taeusch 1979 8/54 10/69 2.9 % 1.02 [ 0.43, 2.41 ]
Subtotal (95% CI) 2482 2421 41.3 % 0.68 [ 0.53, 0.88 ]
Total events: 86 (Antenatal corticosteroids), 125 (Control)
Heterogeneity: Chi2 = 15.54, df = 10 (P = 0.11); I2 =36%
Test for overall effect: Z = 2.95 (P = 0.0032)
Total (95% CI) 3612 3551 100.0 % 0.69 [ 0.59, 0.81 ]
Total events: 211 (Antenatal corticosteroids), 305 (Control)
Heterogeneity: Chi2 = 24.76, df = 22 (P = 0.31); I2 =11%
Test for overall effect: Z = 4.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.25, df = 2 (P = 0.53), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) Ruptured membrane status was missing for 25 (2%) mothers. The small amount of missing data did not alter the results.
(2) One due to septic shock and one to cardiac anomaly and arrhythmia.
(3) Deaths due to severe perinatal asphyxia.
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Analysis 3.5. Comparison 3 Corticosteroids versus placebo or no treatment - intact membranes versus
ruptured membranes at first dose, Outcome 5 Fetal death - intact or ruptured membranes.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 3 Corticosteroids versus placebo or no treatment - intact membranes versus ruptured membranes at first dose




teroid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies born from pregnancies with intact membranes at 1st dose
Amorim 1999 10/110 8/108 9.1 % 1.23 [ 0.50, 2.99 ]
Garite 1992 3/36 1/41 1.1 % 3.42 [ 0.37, 31.41 ]
Kari 1994 1/95 0/94 0.6 % 2.97 [ 0.12, 71.96 ]
Liggins 1972b 31/418 33/430 36.7 % 0.97 [ 0.60, 1.55 ]
Subtotal (95% CI) 659 673 47.5 % 1.09 [ 0.73, 1.64 ]
Total events: 45 (Antenatal corticosteroid), 42 (Control)
Heterogeneity: Chi2 = 1.72, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
2 In babies born from pregnancies with ruptured membranes at 1st dose
Dexiprom 1999 0/105 2/103 2.9 % 0.20 [ 0.01, 4.04 ]
Liggins 1972b (1) 14/168 15/173 16.7 % 0.96 [ 0.48, 1.93 ]
Parsons 1988 0/23 0/22 Not estimable
Qublan 2001 2/72 2/67 2.3 % 0.93 [ 0.13, 6.42 ]
Schutte 1980 (2) 0/30 0/27 Not estimable
Subtotal (95% CI) 398 392 21.9 % 0.86 [ 0.46, 1.61 ]
Total events: 16 (Antenatal corticosteroid), 19 (Control)
Heterogeneity: Chi2 = 1.02, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.63)
3 Not reported or mixed population
Block 1977 3/60 1/54 1.2 % 2.70 [ 0.29, 25.19 ]
Collaborative 1981 13/378 15/379 16.9 % 0.87 [ 0.42, 1.80 ]
Doran 1980 1/81 3/63 3.8 % 0.26 [ 0.03, 2.43 ]
Gamsu 1989 1/131 5/137 5.5 % 0.21 [ 0.02, 1.77 ]
Gyamfi-Bannerman 2016 0/1427 0/1400 Not estimable
Porto 2011 (3) 1/144 1/131 1.2 % 0.91 [ 0.06, 14.40 ]
Taeusch 1979 2/56 2/71 2.0 % 1.27 [ 0.18, 8.72 ]
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teroid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 2277 2235 30.6 % 0.77 [ 0.44, 1.35 ]
Total events: 21 (Antenatal corticosteroid), 27 (Control)
Heterogeneity: Chi2 = 3.93, df = 5 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 3334 3300 100.0 % 0.94 [ 0.71, 1.26 ]
Total events: 82 (Antenatal corticosteroid), 88 (Control)
Heterogeneity: Chi2 = 7.36, df = 12 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Chi2 = 1.10, df = 2 (P = 0.58), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) Ruptured membrane status was missing for 29 (2%) mothers. The small amount of missing data did not alter the results.
(2) Data for the Schutte 1980 and the Liggins 1972 reported here do not add up to the numbers used in our primary analyses. The small amount of missing data does
not change the result.
(3) The outcome measured in this trial was stillbirth.
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Analysis 3.6. Comparison 3 Corticosteroids versus placebo or no treatment - intact membranes versus
ruptured membranes at first dose, Outcome 6 RDS - intact or ruptured membranes.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 3 Corticosteroids versus placebo or no treatment - intact membranes versus ruptured membranes at first dose












1 In babies born from pregnancies with intact membranes at 1st dose
Amorim 1999 23/100 43/100 5.3 % 0.53 [ 0.35, 0.82 ]
Attawattanakul 2015 9/96 20/98 2.9 % 0.46 [ 0.22, 0.96 ]
Collaborative 1981 13/147 29/160 3.6 % 0.49 [ 0.26, 0.90 ]
Garite 1992 21/33 28/40 6.4 % 0.91 [ 0.65, 1.26 ]
Kari 1994 34/91 46/90 6.3 % 0.73 [ 0.52, 1.02 ]
Liggins 1972b 34/381 65/385 5.7 % 0.53 [ 0.36, 0.78 ]
Subtotal (95% CI) 848 873 30.1 % 0.63 [ 0.50, 0.80 ]
Total events: 134 (Antenatal corticosteroids), 231 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 9.04, df = 5 (P = 0.11); I2 =45%
Test for overall effect: Z = 3.81 (P = 0.00014)
2 In babies born from pregnancies with ruptured membranes at 1st dose
Cararach 1991 1/12 0/6 0.2 % 1.62 [ 0.08, 34.66 ]
Carlan 1991 1/11 4/13 0.5 % 0.30 [ 0.04, 2.27 ]
Dexiprom 1999 32/102 27/100 5.2 % 1.16 [ 0.75, 1.79 ]
Fekih 2002 0/14 4/8 0.3 % 0.07 [ 0.00, 1.10 ]
Lewis 1996 7/38 17/39 2.7 % 0.42 [ 0.20, 0.90 ]
Liggins 1972b (1) 17/148 24/152 3.9 % 0.73 [ 0.41, 1.30 ]
Lopez 1989 9/20 10/20 3.3 % 0.90 [ 0.47, 1.73 ]
Morales 1989 23/87 41/78 5.4 % 0.50 [ 0.33, 0.76 ]
Nelson 1985 10/22 11/22 3.6 % 0.91 [ 0.49, 1.69 ]
Parsons 1988 3/23 3/22 0.9 % 0.96 [ 0.22, 4.24 ]
Qublan 2001 14/70 24/65 4.0 % 0.54 [ 0.31, 0.95 ]
Schutte 1980 9/30 11/27 3.0 % 0.74 [ 0.36, 1.50 ]
Subtotal (95% CI) 577 552 33.0 % 0.70 [ 0.55, 0.90 ]
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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Total events: 126 (Antenatal corticosteroids), 176 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 15.53, df = 11 (P = 0.16); I2 =29%
Test for overall effect: Z = 2.81 (P = 0.0049)
3 Not reported or mixed population
Balci 2010 2/50 8/50 0.9 % 0.25 [ 0.06, 1.12 ]
Block 1977 5/57 12/53 1.9 % 0.39 [ 0.15, 1.03 ]
Collaborative 1981 33/214 36/199 5.2 % 0.85 [ 0.55, 1.31 ]
Doran 1980 4/80 10/60 1.5 % 0.30 [ 0.10, 0.91 ]
Fekih 2002 3/49 15/60 1.4 % 0.24 [ 0.08, 0.80 ]
Gamsu 1989 7/130 16/132 2.3 % 0.44 [ 0.19, 1.04 ]
Goodner 1979 5/47 11/45 1.9 % 0.44 [ 0.16, 1.15 ]
Gyamfi-Bannerman 2016 79/1427 89/1400 6.8 % 0.87 [ 0.65, 1.17 ]
Mansouri 2010 8/100 20/100 2.7 % 0.40 [ 0.18, 0.87 ]
Porto 2011 2/143 1/130 0.4 % 1.82 [ 0.17, 19.82 ]
Schutte 1980 2/32 6/31 0.9 % 0.32 [ 0.07, 1.48 ]
Silver 1996 43/54 34/42 7.9 % 0.98 [ 0.81, 1.20 ]
Taeusch 1979 7/54 14/69 2.4 % 0.64 [ 0.28, 1.47 ]
Teramo 1980 3/38 3/42 0.9 % 1.11 [ 0.24, 5.15 ]
Subtotal (95% CI) 2475 2413 36.9 % 0.61 [ 0.46, 0.81 ]
Total events: 203 (Antenatal corticosteroids), 275 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 28.66, df = 13 (P = 0.01); I2 =55%
Test for overall effect: Z = 3.43 (P = 0.00060)
Total (95% CI) 3900 3838 100.0 % 0.65 [ 0.56, 0.76 ]
Total events: 463 (Antenatal corticosteroids), 682 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 56.17, df = 31 (P = 0.004); I2 =45%
Test for overall effect: Z = 5.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.63, df = 2 (P = 0.73), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) Ruptured membrane status was missing for 26 (2%) mothers. The small amount of missing data did not alter the results.
193Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.7. Comparison 3 Corticosteroids versus placebo or no treatment - intact membranes versus
ruptured membranes at first dose, Outcome 7 IVH - intact or ruptured membranes.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 3 Corticosteroids versus placebo or no treatment - intact membranes versus ruptured membranes at first dose




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies born from pregnancies with intact membranes at 1st dose
Amorim 1999 6/100 17/100 10.7 % 0.35 [ 0.15, 0.86 ]
Attawattanakul 2015 0/96 0/98 Not estimable
Garite 1992 10/33 19/40 10.8 % 0.64 [ 0.35, 1.18 ]
Kari 1994 8/77 18/66 12.2 % 0.38 [ 0.18, 0.82 ]
Liggins 1972b 12/387 20/397 12.4 % 0.62 [ 0.31, 1.24 ]
Subtotal (95% CI) 693 701 46.2 % 0.50 [ 0.35, 0.72 ]
Total events: 36 (Antenatal corticosteroids), 74 (Control)
Heterogeneity: Chi2 = 2.03, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.76 (P = 0.00017)
2 In babies born from pregnancies with ruptured membranes at 1st dose
Dexiprom 1999 0/105 0/101 Not estimable
Lewis 1996 0/38 3/39 2.2 % 0.15 [ 0.01, 2.74 ]
Liggins 1972b (1) 4/154 7/158 4.4 % 0.59 [ 0.18, 1.96 ]
Morales 1989 13/87 20/78 13.3 % 0.58 [ 0.31, 1.09 ]
Qublan 2001 2/70 8/65 5.2 % 0.23 [ 0.05, 1.05 ]
Subtotal (95% CI) 454 441 25.1 % 0.47 [ 0.28, 0.79 ]
Total events: 19 (Antenatal corticosteroids), 38 (Control)
Heterogeneity: Chi2 = 2.01, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.88 (P = 0.0040)
3 Not reported or mixed population
Doran 1980 1/80 4/60 2.9 % 0.19 [ 0.02, 1.63 ]
Fekih 2002 5/63 14/68 8.5 % 0.39 [ 0.15, 1.01 ]
Gamsu 1989 2/130 4/132 2.5 % 0.51 [ 0.09, 2.72 ]
Gyamfi-Bannerman 2016 (2) 2/1427 0/1400 0.3 % 4.91 [ 0.24, 102.09 ]
Silver 1996 25/54 17/42 12.1 % 1.14 [ 0.72, 1.82 ]
Taeusch 1979 0/54 4/69 2.5 % 0.14 [ 0.01, 2.57 ]
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 1808 1771 28.7 % 0.72 [ 0.49, 1.07 ]
Total events: 35 (Antenatal corticosteroids), 43 (Control)
Heterogeneity: Chi2 = 9.77, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 2955 2913 100.0 % 0.56 [ 0.44, 0.70 ]
Total events: 90 (Antenatal corticosteroids), 155 (Control)
Heterogeneity: Chi2 = 17.90, df = 13 (P = 0.16); I2 =27%
Test for overall effect: Z = 4.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.49, df = 2 (P = 0.29), I2 =20%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) Ruptured membrane status was missing for 25 (2%) mothers. The small amount of missing data did not alter the results.
(2) Grade 3-4 IVH reported
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Analysis 3.8. Comparison 3 Corticosteroids versus placebo or no treatment - intact membranes versus
ruptured membranes at first dose, Outcome 8 Birthweight - intact or ruptured membranes.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 3 Corticosteroids versus placebo or no treatment - intact membranes versus ruptured membranes at first dose









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 In babies born from pregnancies with intact membranes at 1st dose
Attawattanakul 2015 96 2557.2 (367.6) 98 2558.1 (340) 5.0 % -0.90 [ -100.59, 98.79 ]
Garite 1992 33 1242 (678) 38 1071 (597) 0.6 % 171.00 [ -128.23, 470.23 ]
Kari 1994 94 1654 (831) 94 1783 (837) 0.9 % -129.00 [ -367.43, 109.43 ]
Liggins 1972b (1) 418 2282.61 (844.04) 430 2359.86 (885.65) 3.7 % -77.25 [ -193.67, 39.17 ]
Subtotal (95% CI) 641 660 10.1 % -30.27 [ -100.43, 39.89 ]
Heterogeneity: Chi2 = 3.36, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 0.85 (P = 0.40)
2 In babies born from pregnancies with ruptured membranes at 1st dose
Dexiprom 1999 105 1795 (437) 103 1791 (542) 2.8 % 4.00 [ -129.95, 137.95 ]
Lewis 1996 38 1611 (538) 39 1734 (570) 0.8 % -123.00 [ -370.51, 124.51 ]
Liggins 1972b 168 1897.86 (641.36) 173 2004.22 (623.43) 2.8 % -106.36 [ -240.66, 27.94 ]
Morales 1989 87 1359 (361) 78 1379 (293) 5.0 % -20.00 [ -119.91, 79.91 ]
Nelson 1985 (2) 22 1594 (456.4) 22 1752.5 (415.4) 0.7 % -158.50 [ -416.38, 99.38 ]
Subtotal (95% CI) 420 415 12.1 % -49.72 [ -113.91, 14.46 ]
Heterogeneity: Chi2 = 2.66, df = 4 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
3 Not reported or mixed population
Balci 2010 50 2389 (133) 50 2386 (137) 17.7 % 3.00 [ -49.92, 55.92 ]
Doran 1980 80 2086 (857) 60 1880.5 (803) 0.6 % 205.50 [ -71.18, 482.18 ]
Gamsu 1989 130 2203 (757) 132 2133 (753) 1.5 % 70.00 [ -112.85, 252.85 ]
Gyamfi-Bannerman 2016 1427 2637 (480) 1400 2654 (484) 39.3 % -17.00 [ -52.54, 18.54 ]
Mansouri 2010 100 2500 (300) 100 2600 (300) 7.2 % -100.00 [ -183.15, -16.85 ]
Porto 2011 143 2640 (445) 130 2627 (452) 4.4 % 13.00 [ -93.57, 119.57 ]
Schutte 1980 61 1788 (690) 58 1670 (448) 1.1 % 118.00 [ -90.03, 326.03 ]
Silver 1996 54 917 (238) 42 941 (219) 5.9 % -24.00 [ -115.74, 67.74 ]
Subtotal (95% CI) 2045 1972 77.8 % -13.44 [ -38.71, 11.83 ]
-100 -50 0 50 100
Corticosteroids lighter Control lighter
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 9.60, df = 7 (P = 0.21); I2 =27%
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 3106 3047 100.0 % -19.52 [ -41.81, 2.78 ]
Heterogeneity: Chi2 = 16.78, df = 16 (P = 0.40); I2 =5%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Chi2 = 1.16, df = 2 (P = 0.56), I2 =0.0%
-100 -50 0 50 100
Corticosteroids lighter Control lighter
(1) Ruptured membrane status was missing for 29 (2%) mothers. The small amount of missing data did not alter the results.
(2) The trial reports the SD as 4,563.7 which much be a typo; we have used 456.4.
Analysis 4.1. Comparison 4 Corticosteroids versus placebo or no treatment - hypertension syndrome
versus all other trials, Outcome 1 RDS.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth





teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hypertension syndrome
Amorim 1999 23/100 43/100 6.3 % 0.53 [ 0.35, 0.82 ]
Collaborative 1981 7/33 9/33 1.3 % 0.78 [ 0.33, 1.84 ]
Fekih 2002 0/13 2/8 0.4 % 0.13 [ 0.01, 2.38 ]
Gamsu 1989 0/12 1/6 0.3 % 0.18 [ 0.01, 3.85 ]
Liggins 1972b 3/33 13/44 1.6 % 0.31 [ 0.10, 0.99 ]
Subtotal (95% CI) 191 191 9.9 % 0.50 [ 0.35, 0.72 ]
Total events: 33 (Antenatal corticosteroids), 68 (Control)
Heterogeneity: Chi2 = 3.02, df = 4 (P = 0.55); I2 =0.0%
0.2 0.5 1 2 5
Favours corticosteroids Favours control
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 3.81 (P = 0.00014)
2 No hypertension syndrome or hypertension syndromes excluded
Attawattanakul 2015 9/96 20/98 2.9 % 0.46 [ 0.22, 0.96 ]
Balci 2010 2/50 8/50 1.2 % 0.25 [ 0.06, 1.12 ]
Collaborative 1981 39/328 56/326 8.2 % 0.69 [ 0.47, 1.01 ]
Doran 1980 4/80 10/60 1.7 % 0.30 [ 0.10, 0.91 ]
Fekih 2002 3/50 17/60 2.2 % 0.21 [ 0.07, 0.68 ]
Gamsu 1989 7/118 15/126 2.1 % 0.50 [ 0.21, 1.18 ]
Liggins 1972b 50/509 76/506 11.1 % 0.65 [ 0.47, 0.91 ]
Taeusch 1979 7/54 14/69 1.8 % 0.64 [ 0.28, 1.47 ]
Teramo 1980 3/38 3/42 0.4 % 1.11 [ 0.24, 5.15 ]
Subtotal (95% CI) 1323 1337 31.5 % 0.58 [ 0.47, 0.71 ]
Total events: 124 (Antenatal corticosteroids), 219 (Control)
Heterogeneity: Chi2 = 8.01, df = 8 (P = 0.43); I2 =0%
Test for overall effect: Z = 5.23 (P < 0.00001)
3 Hypertension not reported separately
Block 1977 5/57 12/53 1.8 % 0.39 [ 0.15, 1.03 ]
Cararach 1991 1/12 0/6 0.1 % 1.62 [ 0.08, 34.66 ]
Carlan 1991 1/11 4/13 0.5 % 0.30 [ 0.04, 2.27 ]
Dexiprom 1999 32/102 27/100 4.0 % 1.16 [ 0.75, 1.79 ]
Garite 1992 21/33 28/40 3.7 % 0.91 [ 0.65, 1.26 ]
Goodner 1979 5/47 11/45 1.6 % 0.44 [ 0.16, 1.15 ]
Gyamfi-Bannerman 2016 79/1427 89/1400 13.1 % 0.87 [ 0.65, 1.17 ]
Kari 1994 34/91 46/90 6.7 % 0.73 [ 0.52, 1.02 ]
Lewis 1996 7/38 17/39 2.4 % 0.42 [ 0.20, 0.90 ]
Lopez 1989 9/20 10/20 1.5 % 0.90 [ 0.47, 1.73 ]
Mansouri 2010 8/100 20/100 2.9 % 0.40 [ 0.18, 0.87 ]
Morales 1989 23/87 41/78 6.3 % 0.50 [ 0.33, 0.76 ]
Nelson 1985 10/22 11/22 1.6 % 0.91 [ 0.49, 1.69 ]
Parsons 1988 3/23 3/22 0.4 % 0.96 [ 0.22, 4.24 ]
Porto 2011 2/143 1/130 0.2 % 1.82 [ 0.17, 19.82 ]
Qublan 2001 14/70 24/65 3.6 % 0.54 [ 0.31, 0.95 ]
Schutte 1980 11/62 17/58 2.6 % 0.61 [ 0.31, 1.18 ]
0.2 0.5 1 2 5
Favours corticosteroids Favours control
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Silver 1996 43/54 34/42 5.6 % 0.98 [ 0.81, 1.20 ]
Subtotal (95% CI) 2399 2323 58.6 % 0.75 [ 0.66, 0.85 ]
Total events: 308 (Antenatal corticosteroids), 395 (Control)
Heterogeneity: Chi2 = 28.93, df = 17 (P = 0.04); I2 =41%
Test for overall effect: Z = 4.65 (P < 0.00001)
Total (95% CI) 3913 3851 100.0 % 0.67 [ 0.60, 0.74 ]
Total events: 465 (Antenatal corticosteroids), 682 (Control)
Heterogeneity: Chi2 = 52.60, df = 31 (P = 0.01); I2 =41%
Test for overall effect: Z = 7.74 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.63, df = 2 (P = 0.02), I2 =74%
0.2 0.5 1 2 5
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Analysis 4.2. Comparison 4 Corticosteroids versus placebo or no treatment - hypertension syndrome
versus all other trials, Outcome 2 Perinatal deaths.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 4 Corticosteroids versus placebo or no treatment - hypertension syndrome versus all other trials
Outcome: 2 Perinatal deaths









Liggins 1972b 14/46 10/49 6.5 % 1.49 [ 0.74, 3.02 ]
Amorim 1999 24/110 36/108 11.3 % 0.65 [ 0.42, 1.02 ]
Subtotal (95% CI) 156 157 17.9 % 0.94 [ 0.42, 2.10 ]
Total events: 38 (Corticosteroids), 46 (Control)
Heterogeneity: Tau2 = 0.25; Chi2 = 3.76, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.15 (P = 0.88)
2 No hypertension syndrome or hypertension syndromes excluded
Doran 1980 5/81 14/63 4.0 % 0.28 [ 0.11, 0.73 ]
Taeusch 1979 10/56 12/71 5.8 % 1.06 [ 0.49, 2.27 ]
Liggins 1972b 94/555 112/568 16.9 % 0.86 [ 0.67, 1.10 ]
Subtotal (95% CI) 692 702 26.7 % 0.71 [ 0.39, 1.29 ]
Total events: 109 (Corticosteroids), 138 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 5.40, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 1.12 (P = 0.26)
3 Hypertension not reported separately
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.5 % 4.91 [ 0.24, 102.09 ]
Porto 2011 (2) 1/144 3/131 0.9 % 0.30 [ 0.03, 2.88 ]
Block 1977 4/60 6/54 2.8 % 0.60 [ 0.18, 2.01 ]
Kari 1994 5/95 6/94 3.0 % 0.82 [ 0.26, 2.61 ]
Dexiprom 1999 4/105 10/103 3.1 % 0.39 [ 0.13, 1.21 ]
Schutte 1980 6/65 12/58 4.4 % 0.45 [ 0.18, 1.11 ]
Garite 1992 12/36 12/41 7.1 % 1.14 [ 0.59, 2.21 ]
Gamsu 1989 15/131 22/137 7.9 % 0.71 [ 0.39, 1.31 ]
Qublan 2001 21/72 41/67 12.2 % 0.48 [ 0.32, 0.72 ]
Collaborative 1981 47/378 47/379 13.0 % 1.00 [ 0.69, 1.46 ]
Subtotal (95% CI) 2536 2486 55.4 % 0.70 [ 0.52, 0.93 ]
0.1 0.2 0.5 1 2 5 10
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Total events: 117 (Corticosteroids), 160 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 13.40, df = 10 (P = 0.20); I2 =25%
Test for overall effect: Z = 2.48 (P = 0.013)
Total (95% CI) 3384 3345 100.0 % 0.74 [ 0.60, 0.92 ]
Total events: 264 (Corticosteroids), 344 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 23.48, df = 15 (P = 0.07); I2 =36%
Test for overall effect: Z = 2.70 (P = 0.0070)
Test for subgroup differences: Chi2 = 0.49, df = 2 (P = 0.78), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours corticosteroids Favours control
(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
(2) The events are 1 stillbirth in each arm, and 2 neonatal deaths due to severe perinatal asphyxia.
Analysis 4.3. Comparison 4 Corticosteroids versus placebo or no treatment - hypertension syndrome
versus all other trials, Outcome 3 Fetal deaths.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 4 Corticosteroids versus placebo or no treatment - hypertension syndrome versus all other trials
Outcome: 3 Fetal deaths
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Women with hypertension syndrome
Amorim 1999 10/110 8/108 8.9 % 1.23 [ 0.50, 2.99 ]
Gamsu 1989 0/12 0/6 Not estimable
Liggins 1972b 12/46 5/49 5.3 % 2.56 [ 0.98, 6.69 ]
Subtotal (95% CI) 168 163 14.2 % 1.73 [ 0.91, 3.28 ]
Total events: 22 (Corticosteroids), 13 (Control)
Heterogeneity: Chi2 = 1.20, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 1.66 (P = 0.096)
2 No hypertension syndrome or hypertension syndromes excluded
Doran 1980 1/81 3/63 3.7 % 0.26 [ 0.03, 2.43 ]
0.1 0.2 0.5 1 2 5 10
Favours corticosteroids Favours control
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Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gamsu 1989 1/119 5/131 5.2 % 0.22 [ 0.03, 1.86 ]
Liggins 1972b 35/555 45/568 48.9 % 0.80 [ 0.52, 1.22 ]
Taeusch 1979 2/56 2/71 1.9 % 1.27 [ 0.18, 8.72 ]
Subtotal (95% CI) 811 833 59.8 % 0.73 [ 0.49, 1.08 ]
Total events: 39 (Corticosteroids), 55 (Control)
Heterogeneity: Chi2 = 2.51, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
3 Hypertension not reported separately
Block 1977 3/60 1/54 1.2 % 2.70 [ 0.29, 25.19 ]
Collaborative 1981 13/378 15/379 16.5 % 0.87 [ 0.42, 1.80 ]
Dexiprom 1999 0/105 2/103 2.8 % 0.20 [ 0.01, 4.04 ]
Garite 1992 3/36 1/41 1.0 % 3.42 [ 0.37, 31.41 ]
Gyamfi-Bannerman 2016 0/1427 0/1400 Not estimable
Kari 1994 1/95 0/94 0.6 % 2.97 [ 0.12, 71.96 ]
Parsons 1988 0/23 0/22 Not estimable
Porto 2011 (1) 1/144 1/131 1.2 % 0.91 [ 0.06, 14.40 ]
Qublan 2001 2/72 2/67 2.3 % 0.93 [ 0.13, 6.42 ]
Schutte 1980 3/65 0/58 0.6 % 6.26 [ 0.33, 118.64 ]
Subtotal (95% CI) 2405 2349 26.0 % 1.15 [ 0.67, 1.98 ]
Total events: 26 (Corticosteroids), 22 (Control)
Heterogeneity: Chi2 = 5.06, df = 7 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 3384 3345 100.0 % 0.98 [ 0.74, 1.30 ]
Total events: 87 (Corticosteroids), 90 (Control)
Heterogeneity: Chi2 = 13.47, df = 13 (P = 0.41); I2 =4%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 5.48, df = 2 (P = 0.06), I2 =64%
0.1 0.2 0.5 1 2 5 10
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(1) The outcome measured in this trial was stillbirth.
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Analysis 4.4. Comparison 4 Corticosteroids versus placebo or no treatment - hypertension syndrome
versus all other trials, Outcome 4 Neonatal deaths.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 4 Corticosteroids versus placebo or no treatment - hypertension syndrome versus all other trials
Outcome: 4 Neonatal deaths
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hypertension syndrome
Amorim 1999 14/100 28/100 9.1 % 0.50 [ 0.28, 0.89 ]
Liggins 1972b 2/34 5/44 1.4 % 0.52 [ 0.11, 2.51 ]
Subtotal (95% CI) 134 144 10.5 % 0.50 [ 0.29, 0.87 ]
Total events: 16 (Corticosteroids), 33 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
2 No hypertension syndrome or hypertension syndromes excluded
Doran 1980 4/80 11/60 4.1 % 0.27 [ 0.09, 0.81 ]
Liggins 1972b 59/520 67/523 21.6 % 0.89 [ 0.64, 1.23 ]
Taeusch 1979 8/54 10/69 2.8 % 1.02 [ 0.43, 2.41 ]
Subtotal (95% CI) 654 652 28.5 % 0.81 [ 0.61, 1.09 ]
Total events: 71 (Corticosteroids), 88 (Control)
Heterogeneity: Chi2 = 4.36, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 1.40 (P = 0.16)
3 Hypertension not reported separately
Block 1977 1/57 5/53 1.7 % 0.19 [ 0.02, 1.54 ]
Collaborative 1981 34/365 32/364 10.4 % 1.06 [ 0.67, 1.68 ]
Dexiprom 1999 4/105 8/101 2.6 % 0.48 [ 0.15, 1.55 ]
Fekih 2002 9/63 21/68 6.5 % 0.46 [ 0.23, 0.93 ]
Gamsu 1989 14/130 17/132 5.5 % 0.84 [ 0.43, 1.63 ]
Garite 1992 9/33 11/40 3.2 % 0.99 [ 0.47, 2.10 ]
Goodner 1979 4/47 7/45 2.3 % 0.55 [ 0.17, 1.74 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.2 % 4.91 [ 0.24, 102.09 ]
Kari 1994 4/91 6/88 2.0 % 0.64 [ 0.19, 2.21 ]
Lewis 1996 1/38 1/39 0.3 % 1.03 [ 0.07, 15.82 ]
Lopez 1989 6/20 6/20 1.9 % 1.00 [ 0.39, 2.58 ]
Morales 1989 7/87 8/78 2.7 % 0.78 [ 0.30, 2.06 ]
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(. . . Continued)
Study or subgroup Corticosteroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 1985 1/22 1/22 0.3 % 1.00 [ 0.07, 15.00 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Porto 2011 0/143 2/130 0.8 % 0.18 [ 0.01, 3.75 ]
Qublan 2001 19/70 39/65 13.1 % 0.45 [ 0.29, 0.70 ]
Schutte 1980 3/62 12/58 4.0 % 0.23 [ 0.07, 0.79 ]
Silver 1996 7/54 8/42 2.9 % 0.68 [ 0.27, 1.73 ]
Subtotal (95% CI) 2837 2767 61.0 % 0.66 [ 0.54, 0.82 ]
Total events: 125 (Corticosteroids), 185 (Control)
Heterogeneity: Chi2 = 17.80, df = 17 (P = 0.40); I2 =4%
Test for overall effect: Z = 3.90 (P = 0.000095)
Total (95% CI) 3625 3563 100.0 % 0.69 [ 0.59, 0.81 ]
Total events: 212 (Corticosteroids), 306 (Control)
Heterogeneity: Chi2 = 25.03, df = 22 (P = 0.30); I2 =12%
Test for overall effect: Z = 4.55 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.63, df = 2 (P = 0.27), I2 =24%
0.1 0.2 0.5 1 2 5 10
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(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
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Analysis 5.1. Comparison 5 Corticosteroids versus placebo or no treatment - type of steroid, Outcome 1
Chorioamnionitis - type of steroid.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 5 Corticosteroids versus placebo or no treatment - type of steroid




teroid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In women treated with dexamethasone
Attawattanakul 2015 0/96 0/98 Not estimable
Dexiprom 1999 11/102 8/102 5.9 % 1.38 [ 0.58, 3.28 ]
Kari 1994 13/77 8/80 5.8 % 1.69 [ 0.74, 3.85 ]
Qublan 2001 6/72 3/67 2.3 % 1.86 [ 0.48, 7.15 ]
Silver 1996 13/39 12/36 9.3 % 1.00 [ 0.53, 1.90 ]
Subtotal (95% CI) 386 383 23.3 % 1.35 [ 0.89, 2.05 ]
Total events: 43 (Antenatal corticosteroid), 31 (Control)
Heterogeneity: Chi2 = 1.35, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
2 In women treated with betamethasone
Amorim 1999 2/110 1/108 0.7 % 1.96 [ 0.18, 21.34 ]
Carlan 1991 0/11 3/13 2.4 % 0.17 [ 0.01, 2.91 ]
Fekih 2002 1/59 0/59 0.4 % 3.00 [ 0.12, 72.18 ]
Garite 1992 1/33 2/38 1.4 % 0.58 [ 0.05, 6.07 ]
Gyamfi-Bannerman 2016 20/1427 32/1400 24.0 % 0.61 [ 0.35, 1.07 ]
Lewis 1996 6/38 6/39 4.4 % 1.03 [ 0.36, 2.90 ]
Liggins 1972b 28/556 37/580 26.9 % 0.79 [ 0.49, 1.27 ]
Lopez 1989 0/20 1/20 1.1 % 0.33 [ 0.01, 7.72 ]
Morales 1989 9/87 16/78 12.5 % 0.50 [ 0.24, 1.08 ]
Schutte 1980 1/50 4/51 2.9 % 0.26 [ 0.03, 2.20 ]
Subtotal (95% CI) 2391 2386 76.7 % 0.67 [ 0.50, 0.90 ]
Total events: 68 (Antenatal corticosteroid), 102 (Control)
Heterogeneity: Chi2 = 5.25, df = 9 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0084)
Total (95% CI) 2777 2769 100.0 % 0.83 [ 0.66, 1.06 ]
Total events: 111 (Antenatal corticosteroid), 133 (Control)
Heterogeneity: Chi2 = 12.78, df = 13 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 7.16, df = 1 (P = 0.01), I2 =86%
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Analysis 5.2. Comparison 5 Corticosteroids versus placebo or no treatment - type of steroid, Outcome 2
Endometritis - type of steroid.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 5 Corticosteroids versus placebo or no treatment - type of steroid
Outcome: 2 Endometritis - type of steroid








1 In women treated with dexamethasone
Dexiprom 1999 4/102 7/102 8.6 % 0.57 [ 0.17, 1.89 ]
Qublan 2001 9/72 2/67 6.0 % 4.19 [ 0.94, 18.68 ]
Silver 1996 11/39 5/36 12.0 % 2.03 [ 0.78, 5.28 ]
Taeusch 1979 11/52 7/66 13.5 % 1.99 [ 0.83, 4.79 ]
Subtotal (95% CI) 265 271 40.1 % 1.71 [ 0.86, 3.43 ]
Total events: 35 (Treatment), 21 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 4.84, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 1.52 (P = 0.13)
2 In women treated with betamethasone
Amorim 1999 9/110 13/108 14.9 % 0.68 [ 0.30, 1.52 ]
Garite 1992 10/33 5/38 11.8 % 2.30 [ 0.88, 6.06 ]
Gyamfi-Bannerman 2016 16/1427 16/1400 17.8 % 0.98 [ 0.49, 1.95 ]
Lewis 1996 2/38 4/39 5.2 % 0.51 [ 0.10, 2.64 ]
Mansouri 2010 4/100 6/100 8.2 % 0.67 [ 0.19, 2.29 ]
Schutte 1980 1/50 1/51 2.0 % 1.02 [ 0.07, 15.86 ]
Subtotal (95% CI) 1758 1736 59.9 % 0.96 [ 0.63, 1.45 ]
Total events: 42 (Treatment), 45 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.75, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 2023 2007 100.0 % 1.20 [ 0.81, 1.80 ]
Total events: 77 (Treatment), 66 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 12.51, df = 9 (P = 0.19); I2 =28%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 1.99, df = 1 (P = 0.16), I2 =50%
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Analysis 5.3. Comparison 5 Corticosteroids versus placebo or no treatment - type of steroid, Outcome 3
Perinatal death - type of steroid.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 5 Corticosteroids versus placebo or no treatment - type of steroid












1 In babies treated with dexamethasone
Collaborative 1981 47/378 47/379 14.0 % 1.00 [ 0.69, 1.46 ]
Dexiprom 1999 4/105 10/103 3.2 % 0.39 [ 0.13, 1.21 ]
Kari 1994 5/95 6/94 3.1 % 0.82 [ 0.26, 2.61 ]
Qublan 2001 21/72 41/67 13.2 % 0.48 [ 0.32, 0.72 ]
Taeusch 1979 10/56 12/71 6.1 % 1.06 [ 0.49, 2.27 ]
Subtotal (95% CI) 706 714 39.6 % 0.72 [ 0.46, 1.11 ]
Total events: 87 (Antenatal corticosteroids), 116 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 9.11, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 1.49 (P = 0.14)
2 In babies treated with betamethasone
Amorim 1999 24/110 36/108 12.1 % 0.65 [ 0.42, 1.02 ]
Block 1977 4/60 6/54 2.8 % 0.60 [ 0.18, 2.01 ]
Doran 1980 5/81 14/63 4.2 % 0.28 [ 0.11, 0.73 ]
Gamsu 1989 15/131 22/137 8.3 % 0.71 [ 0.39, 1.31 ]
Garite 1992 12/36 12/41 7.4 % 1.14 [ 0.59, 2.21 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.5 % 4.91 [ 0.24, 102.09 ]
Liggins 1972b 108/601 122/617 19.1 % 0.91 [ 0.72, 1.15 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Porto 2011 (2) 1/144 3/131 0.9 % 0.30 [ 0.03, 2.88 ]
Schutte 1980 6/65 12/58 4.6 % 0.45 [ 0.18, 1.11 ]
Subtotal (95% CI) 2678 2631 60.4 % 0.73 [ 0.56, 0.94 ]
0.5 0.7 1 1.5 2
Favours corticosteroids Favours control
(Continued . . . )
207Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.












Total events: 177 (Antenatal corticosteroids), 228 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 11.98, df = 9 (P = 0.21); I2 =25%
Test for overall effect: Z = 2.38 (P = 0.017)
Total (95% CI) 3384 3345 100.0 % 0.72 [ 0.58, 0.89 ]
Total events: 264 (Antenatal corticosteroids), 344 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 21.30, df = 14 (P = 0.09); I2 =34%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
0.5 0.7 1 1.5 2
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(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
(2) The events are 1 stillbirth in each arm, and 2 neonatal deaths due to severe perinatal asphyxia.
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Analysis 5.4. Comparison 5 Corticosteroids versus placebo or no treatment - type of steroid, Outcome 4
Neonatal deaths by steroid type.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 5 Corticosteroids versus placebo or no treatment - type of steroid
Outcome: 4 Neonatal deaths by steroid type
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies treated with dexamethasone
Collaborative 1981 34/365 32/364 10.4 % 1.06 [ 0.67, 1.68 ]
Dexiprom 1999 4/105 8/101 2.6 % 0.48 [ 0.15, 1.55 ]
Kari 1994 4/91 6/88 2.0 % 0.64 [ 0.19, 2.21 ]
Qublan 2001 19/70 39/65 13.1 % 0.45 [ 0.29, 0.70 ]
Silver 1996 7/54 8/42 2.9 % 0.68 [ 0.27, 1.73 ]
Taeusch 1979 8/54 10/69 2.8 % 1.02 [ 0.43, 2.41 ]
Subtotal (95% CI) 739 729 33.8 % 0.72 [ 0.55, 0.94 ]
Total events: 76 (Treatment), 103 (Control)
Heterogeneity: Chi2 = 8.29, df = 5 (P = 0.14); I2 =40%
Test for overall effect: Z = 2.43 (P = 0.015)
2 In babies treated with betamethasone
Amorim 1999 14/100 28/100 9.1 % 0.50 [ 0.28, 0.89 ]
Block 1977 1/57 5/53 1.7 % 0.19 [ 0.02, 1.54 ]
Doran 1980 4/80 11/60 4.1 % 0.27 [ 0.09, 0.81 ]
Fekih 2002 9/63 21/68 6.5 % 0.46 [ 0.23, 0.93 ]
Gamsu 1989 14/130 17/132 5.5 % 0.84 [ 0.43, 1.63 ]
Garite 1992 9/33 11/40 3.2 % 0.99 [ 0.47, 2.10 ]
Goodner 1979 4/47 7/45 2.3 % 0.55 [ 0.17, 1.74 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.2 % 4.91 [ 0.24, 102.09 ]
Lewis 1996 1/38 1/39 0.3 % 1.03 [ 0.07, 15.82 ]
Liggins 1972b 61/554 72/567 23.0 % 0.87 [ 0.63, 1.19 ]
Lopez 1989 6/20 6/20 1.9 % 1.00 [ 0.39, 2.58 ]
Morales 1989 7/87 8/78 2.7 % 0.78 [ 0.30, 2.06 ]
Nelson 1985 1/22 1/22 0.3 % 1.00 [ 0.07, 15.00 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Porto 2011 0/143 2/130 0.8 % 0.18 [ 0.01, 3.75 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schutte 1980 3/62 12/58 4.0 % 0.23 [ 0.07, 0.79 ]
Subtotal (95% CI) 2886 2834 66.2 % 0.68 [ 0.55, 0.83 ]
Total events: 136 (Treatment), 203 (Control)
Heterogeneity: Chi2 = 16.52, df = 15 (P = 0.35); I2 =9%
Test for overall effect: Z = 3.84 (P = 0.00012)
Total (95% CI) 3625 3563 100.0 % 0.69 [ 0.59, 0.81 ]
Total events: 212 (Treatment), 306 (Control)
Heterogeneity: Chi2 = 24.63, df = 21 (P = 0.26); I2 =15%
Test for overall effect: Z = 4.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.71), I2 =0.0%
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(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
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Analysis 5.5. Comparison 5 Corticosteroids versus placebo or no treatment - type of steroid, Outcome 5
Fetal death - type of steroid.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 5 Corticosteroids versus placebo or no treatment - type of steroid




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies treated with dexamethasone
Collaborative 1981 13/378 15/379 16.4 % 0.87 [ 0.42, 1.80 ]
Dexiprom 1999 0/105 2/103 2.8 % 0.20 [ 0.01, 4.04 ]
Kari 1994 1/95 0/94 0.6 % 2.97 [ 0.12, 71.96 ]
Qublan 2001 2/72 2/67 2.3 % 0.93 [ 0.13, 6.42 ]
Taeusch 1979 2/56 2/71 1.9 % 1.27 [ 0.18, 8.72 ]
Subtotal (95% CI) 706 714 24.0 % 0.88 [ 0.48, 1.60 ]
Total events: 18 (Antenatal corticosteroids), 21 (Control)
Heterogeneity: Chi2 = 1.65, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
2 In babies treated with betamethasone
Amorim 1999 10/110 8/108 8.9 % 1.23 [ 0.50, 2.99 ]
Block 1977 3/60 1/54 1.2 % 2.70 [ 0.29, 25.19 ]
Doran 1980 1/81 3/63 3.7 % 0.26 [ 0.03, 2.43 ]
Gamsu 1989 1/131 5/137 5.4 % 0.21 [ 0.02, 1.77 ]
Garite 1992 3/36 1/41 1.0 % 3.42 [ 0.37, 31.41 ]
Gyamfi-Bannerman 2016 0/1427 0/1400 Not estimable
Liggins 1972b 47/601 50/617 54.2 % 0.97 [ 0.66, 1.41 ]
Parsons 1988 0/23 0/22 Not estimable
Porto 2011 (1) 1/144 1/131 1.1 % 0.91 [ 0.06, 14.40 ]
Schutte 1980 3/65 0/58 0.6 % 6.26 [ 0.33, 118.64 ]
Subtotal (95% CI) 2678 2631 76.0 % 1.01 [ 0.73, 1.39 ]
Total events: 69 (Antenatal corticosteroids), 69 (Control)
Heterogeneity: Chi2 = 7.13, df = 7 (P = 0.42); I2 =2%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 3384 3345 100.0 % 0.98 [ 0.74, 1.30 ]
Total events: 87 (Antenatal corticosteroids), 90 (Control)
Heterogeneity: Chi2 = 8.88, df = 12 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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(1) The outcome measured in this trial was stillbirth.
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Analysis 5.6. Comparison 5 Corticosteroids versus placebo or no treatment - type of steroid, Outcome 6
Respiratory distress syndrome - type of steroid.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 5 Corticosteroids versus placebo or no treatment - type of steroid
Outcome: 6 Respiratory distress syndrome - type of steroid








1 In babies treated with dexamethasone
Attawattanakul 2015 9/96 20/98 3.0 % 0.46 [ 0.22, 0.96 ]
Collaborative 1981 46/361 65/359 6.6 % 0.70 [ 0.50, 1.00 ]
Dexiprom 1999 32/102 27/100 5.6 % 1.16 [ 0.75, 1.79 ]
Kari 1994 34/91 46/90 6.8 % 0.73 [ 0.52, 1.02 ]
Qublan 2001 14/70 24/65 4.2 % 0.54 [ 0.31, 0.95 ]
Silver 1996 43/54 34/42 8.5 % 0.98 [ 0.81, 1.20 ]
Taeusch 1979 7/54 14/69 2.5 % 0.64 [ 0.28, 1.47 ]
Subtotal (95% CI) 828 823 37.3 % 0.77 [ 0.61, 0.98 ]
Total events: 185 (Treatment), 230 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 13.36, df = 6 (P = 0.04); I2 =55%
Test for overall effect: Z = 2.13 (P = 0.033)
2 In babies treated with betamethasone
Amorim 1999 23/100 43/100 5.7 % 0.53 [ 0.35, 0.82 ]
Balci 2010 2/50 8/50 1.0 % 0.25 [ 0.06, 1.12 ]
Block 1977 5/57 12/53 2.0 % 0.39 [ 0.15, 1.03 ]
Carlan 1991 1/11 4/13 0.5 % 0.30 [ 0.04, 2.27 ]
Doran 1980 4/80 10/60 1.6 % 0.30 [ 0.10, 0.91 ]
Fekih 2002 3/63 19/68 1.5 % 0.17 [ 0.05, 0.55 ]
Gamsu 1989 7/130 16/132 2.4 % 0.44 [ 0.19, 1.04 ]
Garite 1992 21/33 28/40 6.9 % 0.91 [ 0.65, 1.26 ]
Goodner 1979 5/47 11/45 2.0 % 0.44 [ 0.16, 1.15 ]
Gyamfi-Bannerman 2016 79/1427 89/1400 7.3 % 0.87 [ 0.65, 1.17 ]
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Lewis 1996 7/38 17/39 2.9 % 0.42 [ 0.20, 0.90 ]
Liggins 1972b 53/542 89/550 7.0 % 0.60 [ 0.44, 0.83 ]
Lopez 1989 9/20 10/20 3.6 % 0.90 [ 0.47, 1.73 ]
Mansouri 2010 8/100 20/100 2.8 % 0.40 [ 0.18, 0.87 ]
Morales 1989 23/87 41/78 5.8 % 0.50 [ 0.33, 0.76 ]
Nelson 1985 10/22 11/22 3.8 % 0.91 [ 0.49, 1.69 ]
Parsons 1988 3/23 3/22 1.0 % 0.96 [ 0.22, 4.24 ]
Porto 2011 2/143 1/130 0.4 % 1.82 [ 0.17, 19.82 ]
Schutte 1980 11/62 17/58 3.5 % 0.61 [ 0.31, 1.18 ]
Teramo 1980 3/38 3/42 0.9 % 1.11 [ 0.24, 5.15 ]
Subtotal (95% CI) 3073 3022 62.5 % 0.60 [ 0.50, 0.73 ]
Total events: 279 (Treatment), 452 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 28.88, df = 19 (P = 0.07); I2 =34%
Test for overall effect: Z = 5.35 (P < 0.00001)
3 Steroid type not reported
Cararach 1991 1/12 0/6 0.2 % 1.62 [ 0.08, 34.66 ]
Subtotal (95% CI) 12 6 0.2 % 1.62 [ 0.08, 34.66 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 3913 3851 100.0 % 0.66 [ 0.56, 0.77 ]
Total events: 465 (Treatment), 682 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 51.46, df = 27 (P = 0.003); I2 =48%
Test for overall effect: Z = 5.33 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.95, df = 2 (P = 0.23), I2 =32%
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Analysis 5.7. Comparison 5 Corticosteroids versus placebo or no treatment - type of steroid, Outcome 7
IVH - type of steroid.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 5 Corticosteroids versus placebo or no treatment - type of steroid












1 In babies treated with dexamethasone
Attawattanakul 2015 0/96 0/98 Not estimable
Dexiprom 1999 0/105 0/101 Not estimable
Kari 1994 8/77 18/66 10.9 % 0.38 [ 0.18, 0.82 ]
Qublan 2001 2/70 8/65 4.0 % 0.23 [ 0.05, 1.05 ]
Silver 1996 25/54 17/42 17.6 % 1.14 [ 0.72, 1.82 ]
Taeusch 1979 0/54 4/69 1.2 % 0.14 [ 0.01, 2.57 ]
Subtotal (95% CI) 456 441 33.6 % 0.48 [ 0.18, 1.26 ]
Total events: 35 (Antenatal corticosteroid), 47 (Control)
Heterogeneity: Tau2 = 0.60; Chi2 = 10.72, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 1.49 (P = 0.14)
2 In babies treated with betamethasone
Amorim 1999 6/100 17/100 9.0 % 0.35 [ 0.15, 0.86 ]
Doran 1980 1/80 4/60 2.1 % 0.19 [ 0.02, 1.63 ]
Fekih 2002 5/63 14/68 8.1 % 0.39 [ 0.15, 1.01 ]
Gamsu 1989 2/130 4/132 3.3 % 0.51 [ 0.09, 2.72 ]
Garite 1992 10/33 19/40 13.9 % 0.64 [ 0.35, 1.18 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 1.1 % 4.91 [ 0.24, 102.09 ]
Lewis 1996 0/38 3/39 1.2 % 0.15 [ 0.01, 2.74 ]
Liggins 1972b 16/554 27/567 14.0 % 0.61 [ 0.33, 1.11 ]
Mansouri 2010 (2) 0/100 0/100 Not estimable
Morales 1989 13/87 20/78 13.6 % 0.58 [ 0.31, 1.09 ]
Subtotal (95% CI) 2612 2584 66.4 % 0.53 [ 0.40, 0.72 ]
Total events: 55 (Antenatal corticosteroid), 108 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.56, df = 8 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 4.08 (P = 0.000045)
0.2 0.5 1 2 5
Favours corticosteroids Favours control
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Total (95% CI) 3068 3025 100.0 % 0.55 [ 0.40, 0.76 ]
Total events: 90 (Antenatal corticosteroid), 155 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 17.89, df = 12 (P = 0.12); I2 =33%
Test for overall effect: Z = 3.63 (P = 0.00028)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
0.2 0.5 1 2 5
Favours corticosteroids Favours control
(1) Grade 3-4 IVH reported
(2) Grade 3 - 4
Analysis 5.8. Comparison 5 Corticosteroids versus placebo or no treatment - type of steroid, Outcome 8
Birthweight - type of steroid.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 5 Corticosteroids versus placebo or no treatment - type of steroid









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 In babies treated with dexamethasone
Attawattanakul 2015 96 2557.2 (367.6) 98 2558.1 (340) 5.0 % -0.90 [ -100.59, 98.79 ]
Dexiprom 1999 105 1795 (437) 103 1791 (542) 2.8 % 4.00 [ -129.95, 137.95 ]
Kari 1994 94 1654 (831) 94 1783 (837) 0.9 % -129.00 [ -367.43, 109.43 ]
Silver 1996 54 917 (238) 42 941 (219) 5.9 % -24.00 [ -115.74, 67.74 ]
Subtotal (95% CI) 349 337 14.6 % -17.04 [ -75.48, 41.41 ]
Heterogeneity: Chi2 = 1.06, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
2 In babies treated with betamethasone
Balci 2010 50 2389 (133) 50 2386 (137) 17.9 % 3.00 [ -49.92, 55.92 ]
-100 -50 0 50 100
Corticosteroids lighter Control lighter
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Doran 1980 80 2086 (857) 60 1880.5 (803) 0.7 % 205.50 [ -71.18, 482.18 ]
Gamsu 1989 130 2203 (757) 132 2133 (753) 1.5 % 70.00 [ -112.85, 252.85 ]
Garite 1992 33 1242 (678) 38 1071 (597) 0.6 % 171.00 [ -128.23, 470.23 ]
Gyamfi-Bannerman 2016 1427 2637 (480) 1400 2654 (484) 39.6 % -17.00 [ -52.54, 18.54 ]
Lewis 1996 38 1611 (538) 39 1734 (570) 0.8 % -123.00 [ -370.51, 124.51 ]
Liggins 1972b 601 2181.41 (816.9) 617 2260.78 (832.83) 5.8 % -79.37 [ -172.02, 13.28 ]
Mansouri 2010 100 2500 (300) 100 2600 (300) 7.2 % -100.00 [ -183.15, -16.85 ]
Morales 1989 87 1359 (361) 78 1379 (293) 5.0 % -20.00 [ -119.91, 79.91 ]
Nelson 1985 (1) 22 1594 (456.4) 22 1752.5 (415.4) 0.8 % -158.50 [ -416.38, 99.38 ]
Porto 2011 143 2640 (445) 130 2627 (452) 4.4 % 13.00 [ -93.57, 119.57 ]
Schutte 1980 61 1788 (690) 58 1670 (448) 1.2 % 118.00 [ -90.03, 326.03 ]
Subtotal (95% CI) 2772 2724 85.4 % -18.71 [ -42.92, 5.50 ]
Heterogeneity: Chi2 = 14.75, df = 11 (P = 0.19); I2 =25%
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 3121 3061 100.0 % -18.47 [ -40.83, 3.90 ]
Heterogeneity: Chi2 = 15.82, df = 15 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
-100 -50 0 50 100
Corticosteroids lighter Control lighter
(1) The trial reports the SD as 4,563.7 which much be a typo; we have used 456.4.
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Analysis 5.9. Comparison 5 Corticosteroids versus placebo or no treatment - type of steroid, Outcome 9
Moderate/severe respiratory distress syndrome - type of steroid.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 5 Corticosteroids versus placebo or no treatment - type of steroid
Outcome: 9 Moderate/severe respiratory distress syndrome - type of steroid









Silver 1996 18/54 14/42 22.1 % 1.00 [ 0.57, 1.77 ]
Taeusch 1979 6/54 14/69 14.3 % 0.55 [ 0.23, 1.33 ]
Subtotal (95% CI) 108 111 36.4 % 0.82 [ 0.46, 1.44 ]
Total events: 24 (Corticosteroids), 28 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.29, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Betamethasone
Amorim 1999 9/100 23/100 18.0 % 0.39 [ 0.19, 0.80 ]
Fekih 2002 1/63 15/68 4.2 % 0.07 [ 0.01, 0.53 ]
Liggins 1972b 41/542 73/550 28.5 % 0.57 [ 0.40, 0.82 ]
Nelson 1985 6/22 6/22 12.9 % 1.00 [ 0.38, 2.62 ]
Subtotal (95% CI) 727 740 63.6 % 0.49 [ 0.27, 0.90 ]
Total events: 57 (Corticosteroids), 117 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 6.62, df = 3 (P = 0.09); I2 =55%
Test for overall effect: Z = 2.32 (P = 0.020)
Total (95% CI) 835 851 100.0 % 0.59 [ 0.38, 0.91 ]
Total events: 81 (Corticosteroids), 145 (Control)
Heterogeneity: Tau2 = 0.14; Chi2 = 10.49, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Chi2 = 1.43, df = 1 (P = 0.23), I2 =30%
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Analysis 5.10. Comparison 5 Corticosteroids versus placebo or no treatment - type of steroid, Outcome 10
Chronic lung disease - type of steroid.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 5 Corticosteroids versus placebo or no treatment - type of steroid
Outcome: 10 Chronic lung disease - type of steroid









Silver 1996 24/54 16/42 31.1 % 1.17 [ 0.72, 1.90 ]
Taeusch 1979 0/54 0/69 Not estimable
Subtotal (95% CI) 108 111 31.1 % 1.17 [ 0.72, 1.90 ]
Total events: 24 (Corticosteroids), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
2 Betamethasone
Amorim 1999 1/100 5/100 8.9 % 0.20 [ 0.02, 1.68 ]
Garite 1992 9/33 9/40 25.2 % 1.21 [ 0.54, 2.70 ]
Kari 1994 6/85 1/76 9.1 % 5.36 [ 0.66, 43.56 ]
Morales 1989 8/87 19/78 25.8 % 0.38 [ 0.18, 0.81 ]
Subtotal (95% CI) 305 294 68.9 % 0.78 [ 0.26, 2.28 ]
Total events: 24 (Corticosteroids), 34 (Control)
Heterogeneity: Tau2 = 0.73; Chi2 = 9.26, df = 3 (P = 0.03); I2 =68%
Test for overall effect: Z = 0.46 (P = 0.65)
Total (95% CI) 413 405 100.0 % 0.86 [ 0.42, 1.79 ]
Total events: 48 (Corticosteroids), 50 (Control)
Heterogeneity: Tau2 = 0.38; Chi2 = 11.35, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours corticosteroids Favours control
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Analysis 6.1. Comparison 6 Corticosteroids versus placebo or no treatment - decade of trial, Outcome 1
Chorioamnionitis - decade of trial.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 6 Corticosteroids versus placebo or no treatment - decade of trial




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In women from trials conducted in 1970s
Liggins 1972b 28/556 37/580 26.9 % 0.79 [ 0.49, 1.27 ]
Schutte 1980 1/50 4/51 2.9 % 0.26 [ 0.03, 2.20 ]
Subtotal (95% CI) 606 631 29.8 % 0.74 [ 0.46, 1.17 ]
Total events: 29 (Antenatal corticosteroids), 41 (Control)
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.31); I2 =1%
Test for overall effect: Z = 1.30 (P = 0.20)
2 In women from trials conducted in 1980s
Garite 1992 1/33 2/38 1.4 % 0.58 [ 0.05, 6.07 ]
Lopez 1989 0/20 1/20 1.1 % 0.33 [ 0.01, 7.72 ]
Morales 1989 9/87 16/78 12.5 % 0.50 [ 0.24, 1.08 ]
Subtotal (95% CI) 140 136 15.0 % 0.50 [ 0.25, 1.01 ]
Total events: 10 (Antenatal corticosteroids), 19 (Control)
Heterogeneity: Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.052)
3 In women from trials conducted in 1990s
Amorim 1999 2/110 1/108 0.7 % 1.96 [ 0.18, 21.34 ]
Carlan 1991 0/11 3/13 2.4 % 0.17 [ 0.01, 2.91 ]
Dexiprom 1999 11/102 8/102 5.9 % 1.38 [ 0.58, 3.28 ]
Kari 1994 13/77 8/80 5.8 % 1.69 [ 0.74, 3.85 ]
Lewis 1996 6/38 6/39 4.4 % 1.03 [ 0.36, 2.90 ]
Silver 1996 13/39 12/36 9.3 % 1.00 [ 0.53, 1.90 ]
Subtotal (95% CI) 377 378 28.5 % 1.18 [ 0.80, 1.74 ]
Total events: 45 (Antenatal corticosteroids), 38 (Control)
Heterogeneity: Chi2 = 3.15, df = 5 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
4 in women from trials conducted in the 2000’s
Fekih 2002 1/59 0/59 0.4 % 3.00 [ 0.12, 72.18 ]
Qublan 2001 6/72 3/67 2.3 % 1.86 [ 0.48, 7.15 ]
0.5 0.7 1 1.5 2
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 131 126 2.7 % 2.02 [ 0.59, 6.95 ]
Total events: 7 (Antenatal corticosteroids), 3 (Control)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
5 In trials from 2010s
Attawattanakul 2015 0/96 0/98 Not estimable
Gyamfi-Bannerman 2016 20/1427 32/1400 24.0 % 0.61 [ 0.35, 1.07 ]
Subtotal (95% CI) 1523 1498 24.0 % 0.61 [ 0.35, 1.07 ]
Total events: 20 (Antenatal corticosteroids), 32 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.083)
Total (95% CI) 2777 2769 100.0 % 0.83 [ 0.66, 1.06 ]
Total events: 111 (Antenatal corticosteroids), 133 (Control)
Heterogeneity: Chi2 = 12.78, df = 13 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 8.49, df = 4 (P = 0.08), I2 =53%
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Analysis 6.2. Comparison 6 Corticosteroids versus placebo or no treatment - decade of trial, Outcome 2
Endometritis - decade of trial.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 6 Corticosteroids versus placebo or no treatment - decade of trial




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In women from trials conducted in 1970s
Schutte 1980 1/50 1/51 1.5 % 1.02 [ 0.07, 15.86 ]
Taeusch 1979 11/52 7/66 9.4 % 1.99 [ 0.83, 4.79 ]
Subtotal (95% CI) 102 117 11.0 % 1.86 [ 0.81, 4.27 ]
Total events: 12 (Antenatal corticosteroids), 8 (Control)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
2 In women from trials conducted in 1980s
Garite 1992 10/33 5/38 7.1 % 2.30 [ 0.88, 6.06 ]
Subtotal (95% CI) 33 38 7.1 % 2.30 [ 0.88, 6.06 ]
Total events: 10 (Antenatal corticosteroids), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
3 In women from trials conducted in 1990s
Amorim 1999 9/110 13/108 20.1 % 0.68 [ 0.30, 1.52 ]
Dexiprom 1999 4/102 7/102 10.7 % 0.57 [ 0.17, 1.89 ]
Lewis 1996 2/38 4/39 6.0 % 0.51 [ 0.10, 2.64 ]
Silver 1996 11/39 5/36 8.0 % 2.03 [ 0.78, 5.28 ]
Subtotal (95% CI) 289 285 44.8 % 0.87 [ 0.53, 1.44 ]
Total events: 26 (Antenatal corticosteroids), 29 (Control)
Heterogeneity: Chi2 = 4.26, df = 3 (P = 0.24); I2 =30%
Test for overall effect: Z = 0.54 (P = 0.59)
4 In women from trials conducted in the 2000’s
Gyamfi-Bannerman 2016 16/1427 16/1400 24.7 % 0.98 [ 0.49, 1.95 ]
Mansouri 2010 4/100 6/100 9.2 % 0.67 [ 0.19, 2.29 ]
Qublan 2001 9/72 2/67 3.2 % 4.19 [ 0.94, 18.68 ]
Subtotal (95% CI) 1599 1567 37.1 % 1.18 [ 0.69, 2.01 ]
Total events: 29 (Antenatal corticosteroids), 24 (Control)
Heterogeneity: Chi2 = 3.85, df = 2 (P = 0.15); I2 =48%
Test for overall effect: Z = 0.60 (P = 0.55)
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 2023 2007 100.0 % 1.20 [ 0.87, 1.63 ]
Total events: 77 (Antenatal corticosteroids), 66 (Control)
Heterogeneity: Chi2 = 12.51, df = 9 (P = 0.19); I2 =28%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 4.38, df = 3 (P = 0.22), I2 =32%
0.01 0.1 1 10 100
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Analysis 6.3. Comparison 6 Corticosteroids versus placebo or no treatment - decade of trial, Outcome 3
Perinatal deaths - decade of trial.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 6 Corticosteroids versus placebo or no treatment - decade of trial












1 In babies from trials conducted in 1970s
Block 1977 4/60 6/54 2.8 % 0.60 [ 0.18, 2.01 ]
Doran 1980 5/81 14/63 4.2 % 0.28 [ 0.11, 0.73 ]
Gamsu 1989 15/131 22/137 8.3 % 0.71 [ 0.39, 1.31 ]
Liggins 1972b 108/601 122/617 19.1 % 0.91 [ 0.72, 1.15 ]
Schutte 1980 6/65 12/58 4.6 % 0.45 [ 0.18, 1.11 ]
Taeusch 1979 10/56 12/71 6.1 % 1.06 [ 0.49, 2.27 ]
Subtotal (95% CI) 994 1000 45.1 % 0.71 [ 0.50, 1.00 ]
Total events: 148 (Antenatal corticosteroids), 188 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 8.18, df = 5 (P = 0.15); I2 =39%
Test for overall effect: Z = 1.96 (P = 0.050)
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2 In babies from trials conducted in 1980s
Collaborative 1981 47/378 47/379 14.0 % 1.00 [ 0.69, 1.46 ]
Garite 1992 12/36 12/41 7.4 % 1.14 [ 0.59, 2.21 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Subtotal (95% CI) 437 442 21.9 % 1.02 [ 0.74, 1.42 ]
Total events: 59 (Antenatal corticosteroids), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
3 In babies from trials conducted in 1990s
Amorim 1999 24/110 36/108 12.1 % 0.65 [ 0.42, 1.02 ]
Dexiprom 1999 4/105 10/103 3.2 % 0.39 [ 0.13, 1.21 ]
Kari 1994 5/95 6/94 3.1 % 0.82 [ 0.26, 2.61 ]
Subtotal (95% CI) 310 305 18.4 % 0.63 [ 0.43, 0.93 ]
Total events: 33 (Antenatal corticosteroids), 52 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
4 in babies from trials conducted in 2000’s
Porto 2011 (1) 1/144 3/131 0.9 % 0.30 [ 0.03, 2.88 ]
Qublan 2001 21/72 41/67 13.2 % 0.48 [ 0.32, 0.72 ]
Subtotal (95% CI) 216 198 14.0 % 0.47 [ 0.31, 0.70 ]
Total events: 22 (Antenatal corticosteroids), 44 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.69 (P = 0.00022)
5 In trials conducted in 2010s
Gyamfi-Bannerman 2016 (2) 2/1427 0/1400 0.5 % 4.91 [ 0.24, 102.09 ]
Subtotal (95% CI) 1427 1400 0.5 % 4.91 [ 0.24, 102.09 ]
Total events: 2 (Antenatal corticosteroids), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 3384 3345 100.0 % 0.72 [ 0.58, 0.89 ]
Total events: 264 (Antenatal corticosteroids), 344 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 21.30, df = 14 (P = 0.09); I2 =34%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Chi2 = 10.73, df = 4 (P = 0.03), I2 =63%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) The events are 1 stillbirth in each arm, and 2 neonatal deaths due to severe perinatal asphyxia.
(2) One due to septic shock and one to cardiac anomaly and arrhythmia.
223Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.4. Comparison 6 Corticosteroids versus placebo or no treatment - decade of trial, Outcome 4
Neonatal deaths decade of trial.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 6 Corticosteroids versus placebo or no treatment - decade of trial
Outcome: 4 Neonatal deaths decade of trial
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies from trials conducted in 1970s
Block 1977 1/57 5/53 1.7 % 0.19 [ 0.02, 1.54 ]
Doran 1980 4/80 11/60 4.1 % 0.27 [ 0.09, 0.81 ]
Gamsu 1989 14/130 17/132 5.5 % 0.84 [ 0.43, 1.63 ]
Goodner 1979 4/47 7/45 2.3 % 0.55 [ 0.17, 1.74 ]
Liggins 1972b 61/554 72/567 23.0 % 0.87 [ 0.63, 1.19 ]
Schutte 1980 3/62 12/58 4.0 % 0.23 [ 0.07, 0.79 ]
Taeusch 1979 8/54 10/69 2.8 % 1.02 [ 0.43, 2.41 ]
Subtotal (95% CI) 984 984 43.4 % 0.72 [ 0.56, 0.92 ]
Total events: 95 (Treatment), 134 (Control)
Heterogeneity: Chi2 = 10.27, df = 6 (P = 0.11); I2 =42%
Test for overall effect: Z = 2.67 (P = 0.0077)
2 In babies from trials conducted in 1980s
Collaborative 1981 34/365 32/364 10.4 % 1.06 [ 0.67, 1.68 ]
Garite 1992 9/33 11/40 3.2 % 0.99 [ 0.47, 2.10 ]
Lopez 1989 6/20 6/20 1.9 % 1.00 [ 0.39, 2.58 ]
Morales 1989 7/87 8/78 2.7 % 0.78 [ 0.30, 2.06 ]
Nelson 1985 1/22 1/22 0.3 % 1.00 [ 0.07, 15.00 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Subtotal (95% CI) 550 546 19.1 % 0.98 [ 0.70, 1.37 ]
Total events: 57 (Treatment), 59 (Control)
Heterogeneity: Chi2 = 0.80, df = 5 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
3 In babies from trials conducted in 1990s
Amorim 1999 14/100 28/100 9.1 % 0.50 [ 0.28, 0.89 ]
Dexiprom 1999 4/105 8/101 2.6 % 0.48 [ 0.15, 1.55 ]
Kari 1994 4/91 6/88 2.0 % 0.64 [ 0.19, 2.21 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lewis 1996 1/38 1/39 0.3 % 1.03 [ 0.07, 15.82 ]
Silver 1996 7/54 8/42 2.9 % 0.68 [ 0.27, 1.73 ]
Subtotal (95% CI) 388 370 16.9 % 0.55 [ 0.36, 0.84 ]
Total events: 30 (Treatment), 51 (Control)
Heterogeneity: Chi2 = 0.62, df = 4 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.75 (P = 0.0059)
4 In babies from trials conducted in 2000s
Fekih 2002 9/63 21/68 6.5 % 0.46 [ 0.23, 0.93 ]
Porto 2011 0/143 2/130 0.8 % 0.18 [ 0.01, 3.75 ]
Qublan 2001 19/70 39/65 13.1 % 0.45 [ 0.29, 0.70 ]
Subtotal (95% CI) 276 263 20.5 % 0.44 [ 0.31, 0.64 ]
Total events: 28 (Treatment), 62 (Control)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 4.30 (P = 0.000017)
5 In trials conducted in 2010s
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.2 % 4.91 [ 0.24, 102.09 ]
Subtotal (95% CI) 1427 1400 0.2 % 4.91 [ 0.24, 102.09 ]
Total events: 2 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 3625 3563 100.0 % 0.69 [ 0.59, 0.81 ]
Total events: 212 (Treatment), 306 (Control)
Heterogeneity: Chi2 = 24.63, df = 21 (P = 0.26); I2 =15%
Test for overall effect: Z = 4.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 12.40, df = 4 (P = 0.01), I2 =68%
0.1 0.2 0.5 1 2 5 10
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(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
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Analysis 6.5. Comparison 6 Corticosteroids versus placebo or no treatment - decade of trial, Outcome 5
Fetal death - decade of trial.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 6 Corticosteroids versus placebo or no treatment - decade of trial




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies from trials conducted in 1970s
Block 1977 3/60 1/54 1.2 % 2.70 [ 0.29, 25.19 ]
Doran 1980 1/81 3/63 3.7 % 0.26 [ 0.03, 2.43 ]
Gamsu 1989 1/131 5/137 5.4 % 0.21 [ 0.02, 1.77 ]
Liggins 1972b 47/601 50/617 54.2 % 0.97 [ 0.66, 1.41 ]
Schutte 1980 3/65 0/58 0.6 % 6.26 [ 0.33, 118.64 ]
Taeusch 1979 2/56 2/71 1.9 % 1.27 [ 0.18, 8.72 ]
Subtotal (95% CI) 994 1000 66.9 % 0.95 [ 0.67, 1.34 ]
Total events: 57 (Antenatal corticosteroids), 61 (Control)
Heterogeneity: Chi2 = 5.73, df = 5 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.29 (P = 0.77)
2 In babies from trials conducted in 1980s
Collaborative 1981 13/378 15/379 16.4 % 0.87 [ 0.42, 1.80 ]
Garite 1992 3/36 1/41 1.0 % 3.42 [ 0.37, 31.41 ]
Parsons 1988 0/23 0/22 Not estimable
Subtotal (95% CI) 437 442 17.5 % 1.02 [ 0.52, 2.00 ]
Total events: 16 (Antenatal corticosteroids), 16 (Control)
Heterogeneity: Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 0.05 (P = 0.96)
3 In babies from trials conducted in 1990s
Amorim 1999 10/110 8/108 8.9 % 1.23 [ 0.50, 2.99 ]
Dexiprom 1999 0/105 2/103 2.8 % 0.20 [ 0.01, 4.04 ]
Kari 1994 1/95 0/94 0.6 % 2.97 [ 0.12, 71.96 ]
Subtotal (95% CI) 310 305 12.2 % 1.07 [ 0.49, 2.36 ]
Total events: 11 (Antenatal corticosteroids), 10 (Control)
Heterogeneity: Chi2 = 1.69, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
4 In babies from trials conducted in 2000’s
Porto 2011 (1) 1/144 1/131 1.1 % 0.91 [ 0.06, 14.40 ]
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Qublan 2001 2/72 2/67 2.3 % 0.93 [ 0.13, 6.42 ]
Subtotal (95% CI) 216 198 3.4 % 0.92 [ 0.19, 4.50 ]
Total events: 3 (Antenatal corticosteroids), 3 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
5 In trials conducted in 2010s
Gyamfi-Bannerman 2016 0/1427 0/1400 Not estimable
Subtotal (95% CI) 1427 1400 Not estimable
Total events: 0 (Antenatal corticosteroids), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 3384 3345 100.0 % 0.98 [ 0.74, 1.30 ]
Total events: 87 (Antenatal corticosteroids), 90 (Control)
Heterogeneity: Chi2 = 8.88, df = 12 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.10, df = 3 (P = 0.99), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) The outcome measured in this trial was stillbirth.
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Analysis 6.6. Comparison 6 Corticosteroids versus placebo or no treatment - decade of trial, Outcome 6
RDS - decade of trial.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 6 Corticosteroids versus placebo or no treatment - decade of trial




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies from trials conducted in 1970s
Block 1977 5/57 12/53 1.8 % 0.39 [ 0.15, 1.03 ]
Doran 1980 4/80 10/60 1.7 % 0.30 [ 0.10, 0.91 ]
Gamsu 1989 7/130 16/132 2.3 % 0.44 [ 0.19, 1.04 ]
Goodner 1979 5/47 11/45 1.6 % 0.44 [ 0.16, 1.15 ]
Liggins 1972b 53/542 89/550 12.8 % 0.60 [ 0.44, 0.83 ]
Schutte 1980 11/62 17/58 2.6 % 0.61 [ 0.31, 1.18 ]
Taeusch 1979 7/54 14/69 1.8 % 0.64 [ 0.28, 1.47 ]
Subtotal (95% CI) 972 967 24.6 % 0.54 [ 0.43, 0.69 ]
Total events: 92 (Antenatal corticosteroids), 169 (Control)
Heterogeneity: Chi2 = 2.65, df = 6 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 5.05 (P < 0.00001)
2 In babies from trials conducted in 1980s
Collaborative 1981 46/361 65/359 9.5 % 0.70 [ 0.50, 1.00 ]
Garite 1992 21/33 28/40 3.7 % 0.91 [ 0.65, 1.26 ]
Lopez 1989 9/20 10/20 1.5 % 0.90 [ 0.47, 1.73 ]
Morales 1989 23/87 41/78 6.3 % 0.50 [ 0.33, 0.76 ]
Nelson 1985 10/22 11/22 1.6 % 0.91 [ 0.49, 1.69 ]
Parsons 1988 3/23 3/22 0.4 % 0.96 [ 0.22, 4.24 ]
Teramo 1980 3/38 3/42 0.4 % 1.11 [ 0.24, 5.15 ]
Subtotal (95% CI) 584 583 23.4 % 0.72 [ 0.59, 0.88 ]
Total events: 115 (Antenatal corticosteroids), 161 (Control)
Heterogeneity: Chi2 = 6.34, df = 6 (P = 0.39); I2 =5%
Test for overall effect: Z = 3.30 (P = 0.00096)
3 In babies from trials conducted in 1990s
Amorim 1999 23/100 43/100 6.3 % 0.53 [ 0.35, 0.82 ]
Cararach 1991 1/12 0/6 0.1 % 1.62 [ 0.08, 34.66 ]
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carlan 1991 1/11 4/13 0.5 % 0.30 [ 0.04, 2.27 ]
Dexiprom 1999 32/102 27/100 4.0 % 1.16 [ 0.75, 1.79 ]
Kari 1994 34/91 46/90 6.7 % 0.73 [ 0.52, 1.02 ]
Lewis 1996 7/38 17/39 2.4 % 0.42 [ 0.20, 0.90 ]
Silver 1996 43/54 34/42 5.6 % 0.98 [ 0.81, 1.20 ]
Subtotal (95% CI) 408 390 25.6 % 0.77 [ 0.65, 0.91 ]
Total events: 141 (Antenatal corticosteroids), 171 (Control)
Heterogeneity: Chi2 = 15.72, df = 6 (P = 0.02); I2 =62%
Test for overall effect: Z = 3.08 (P = 0.0021)
4 In babies from trials conducted in 2000s
Balci 2010 2/50 8/50 1.2 % 0.25 [ 0.06, 1.12 ]
Fekih 2002 3/63 19/68 2.7 % 0.17 [ 0.05, 0.55 ]
Mansouri 2010 8/100 20/100 2.9 % 0.40 [ 0.18, 0.87 ]
Porto 2011 2/143 1/130 0.2 % 1.82 [ 0.17, 19.82 ]
Qublan 2001 14/70 24/65 3.6 % 0.54 [ 0.31, 0.95 ]
Subtotal (95% CI) 426 413 10.5 % 0.39 [ 0.26, 0.59 ]
Total events: 29 (Antenatal corticosteroids), 72 (Control)
Heterogeneity: Chi2 = 5.11, df = 4 (P = 0.28); I2 =22%
Test for overall effect: Z = 4.57 (P < 0.00001)
5 In trials from 2010s
Attawattanakul 2015 9/96 20/98 2.9 % 0.46 [ 0.22, 0.96 ]
Gyamfi-Bannerman 2016 79/1427 89/1400 13.1 % 0.87 [ 0.65, 1.17 ]
Subtotal (95% CI) 1523 1498 15.9 % 0.80 [ 0.61, 1.04 ]
Total events: 88 (Antenatal corticosteroids), 109 (Control)
Heterogeneity: Chi2 = 2.51, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 3913 3851 100.0 % 0.67 [ 0.60, 0.74 ]
Total events: 465 (Antenatal corticosteroids), 682 (Control)
Heterogeneity: Chi2 = 51.46, df = 27 (P = 0.003); I2 =48%
Test for overall effect: Z = 7.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 14.30, df = 4 (P = 0.01), I2 =72%
0.01 0.1 1 10 100
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Analysis 6.7. Comparison 6 Corticosteroids versus placebo or no treatment - decade of trial, Outcome 7
IVH - decade of trial.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 6 Corticosteroids versus placebo or no treatment - decade of trial




orids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies from trials conducted in 1970s
Doran 1980 1/80 4/60 2.9 % 0.19 [ 0.02, 1.63 ]
Gamsu 1989 2/130 4/132 2.5 % 0.51 [ 0.09, 2.72 ]
Liggins 1972b 16/554 27/567 16.8 % 0.61 [ 0.33, 1.11 ]
Taeusch 1979 0/54 4/69 2.5 % 0.14 [ 0.01, 2.57 ]
Subtotal (95% CI) 818 828 24.7 % 0.50 [ 0.29, 0.85 ]
Total events: 19 (Antenatal corticosteorids), 39 (Control)
Heterogeneity: Chi2 = 1.90, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.54 (P = 0.011)
2 In babies from trials conducted in 1980s
Garite 1992 10/33 19/40 10.8 % 0.64 [ 0.35, 1.18 ]
Morales 1989 13/87 20/78 13.3 % 0.58 [ 0.31, 1.09 ]
Subtotal (95% CI) 120 118 24.1 % 0.61 [ 0.39, 0.94 ]
Total events: 23 (Antenatal corticosteorids), 39 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.027)
3 In babies from trials conducted in 1990s
Amorim 1999 6/100 17/100 10.7 % 0.35 [ 0.15, 0.86 ]
Dexiprom 1999 0/105 0/101 Not estimable
Kari 1994 8/77 18/66 12.2 % 0.38 [ 0.18, 0.82 ]
Lewis 1996 0/38 3/39 2.2 % 0.15 [ 0.01, 2.74 ]
Silver 1996 25/54 17/42 12.1 % 1.14 [ 0.72, 1.82 ]
Subtotal (95% CI) 374 348 37.2 % 0.61 [ 0.42, 0.87 ]
Total events: 39 (Antenatal corticosteorids), 55 (Control)
Heterogeneity: Chi2 = 10.87, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.74 (P = 0.0062)
4 In babies from trials conducted in 2000s
Fekih 2002 5/63 14/68 8.5 % 0.39 [ 0.15, 1.01 ]
Mansouri 2010 (1) 0/100 0/100 Not estimable
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orids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Qublan 2001 2/70 8/65 5.2 % 0.23 [ 0.05, 1.05 ]
Subtotal (95% CI) 233 233 13.7 % 0.33 [ 0.15, 0.73 ]
Total events: 7 (Antenatal corticosteorids), 22 (Control)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.71 (P = 0.0067)
5 In trials from 2010s
Attawattanakul 2015 0/96 0/98 Not estimable
Gyamfi-Bannerman 2016 (2) 2/1427 0/1400 0.3 % 4.91 [ 0.24, 102.09 ]
Subtotal (95% CI) 1523 1498 0.3 % 4.91 [ 0.24, 102.09 ]
Total events: 2 (Antenatal corticosteorids), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 3068 3025 100.0 % 0.56 [ 0.44, 0.70 ]
Total events: 90 (Antenatal corticosteorids), 155 (Control)
Heterogeneity: Chi2 = 17.89, df = 12 (P = 0.12); I2 =33%
Test for overall effect: Z = 4.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.16, df = 4 (P = 0.39), I2 =4%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) Grade 3 - 4
(2) Grade 3-4 IVH reported
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Analysis 6.8. Comparison 6 Corticosteroids versus placebo or no treatment - decade of trial, Outcome 8
Birthweight - decade of trial.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 6 Corticosteroids versus placebo or no treatment - decade of trial









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 In babies from trials conducted in 1970s
Doran 1980 80 2086 (857) 60 1880.5 (803) 0.7 % 205.50 [ -71.18, 482.18 ]
Gamsu 1989 130 2203 (757) 132 2133 (753) 1.5 % 70.00 [ -112.85, 252.85 ]
Liggins 1972b 601 2181.41 (816.9) 617 2260.78 (832.83) 5.8 % -79.37 [ -172.02, 13.28 ]
Schutte 1980 61 1788 (690) 58 1670 (448) 1.2 % 118.00 [ -90.03, 326.03 ]
Subtotal (95% CI) 872 867 9.1 % -9.54 [ -83.55, 64.47 ]
Heterogeneity: Chi2 = 6.67, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 0.25 (P = 0.80)
2 In babies from trials conducted in 1980s
Garite 1992 33 1242 (678) 38 1071 (597) 0.6 % 171.00 [ -128.23, 470.23 ]
Morales 1989 87 1359 (361) 78 1379 (293) 5.0 % -20.00 [ -119.91, 79.91 ]
Nelson 1985 (1) 22 1594 (456.4) 22 1752.5 (415.4) 0.8 % -158.50 [ -416.38, 99.38 ]
Subtotal (95% CI) 142 138 6.3 % -19.60 [ -108.55, 69.35 ]
Heterogeneity: Chi2 = 2.67, df = 2 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.43 (P = 0.67)
3 In babies from trials conducted in 1990s
Dexiprom 1999 105 1795 (437) 103 1791 (542) 2.8 % 4.00 [ -129.95, 137.95 ]
Kari 1994 94 1654 (831) 94 1783 (837) 0.9 % -129.00 [ -367.43, 109.43 ]
Lewis 1996 38 1611 (538) 39 1734 (570) 0.8 % -123.00 [ -370.51, 124.51 ]
Silver 1996 54 917 (238) 42 941 (219) 5.9 % -24.00 [ -115.74, 67.74 ]
Subtotal (95% CI) 291 278 10.4 % -33.13 [ -102.39, 36.13 ]
Heterogeneity: Chi2 = 1.46, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
4 In babies from trials conducted in 2000s
Balci 2010 50 2389 (133) 50 2386 (137) 17.9 % 3.00 [ -49.92, 55.92 ]
Mansouri 2010 100 2500 (300) 100 2600 (300) 7.2 % -100.00 [ -183.15, -16.85 ]
Porto 2011 143 2640 (445) 130 2627 (452) 4.4 % 13.00 [ -93.57, 119.57 ]
Subtotal (95% CI) 293 280 29.5 % -20.77 [ -61.95, 20.41 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 4.65, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.99 (P = 0.32)
5 In trials in 2010s
Attawattanakul 2015 96 2557.2 (367.6) 98 2558.1 (340) 5.0 % -0.90 [ -100.59, 98.79 ]
Gyamfi-Bannerman 2016 1427 2637 (480) 1400 2654 (484) 39.6 % -17.00 [ -52.54, 18.54 ]
Subtotal (95% CI) 1523 1498 44.6 % -15.18 [ -48.66, 18.29 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Total (95% CI) 3121 3061 100.0 % -18.47 [ -40.83, 3.90 ]
Heterogeneity: Chi2 = 15.82, df = 15 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Chi2 = 0.28, df = 4 (P = 0.99), I2 =0.0%
-100 -50 0 50 100
Corticosteroids lighter Control lighter
(1) The trial reports the SD as 4,563.7 which much be a typo; we have used 456.4.
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Analysis 7.1. Comparison 7 Corticosteroids versus placebo or no treatment - weekly repeats, Outcome 1
Chorioamnionitis - Protocol with weekly repeats.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 7 Corticosteroids versus placebo or no treatment - weekly repeats




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In women treated with single courses only
Attawattanakul 2015 0/96 0/98 Not estimable
Dexiprom 1999 11/102 8/102 5.9 % 1.38 [ 0.58, 3.28 ]
Gyamfi-Bannerman 2016 20/1427 32/1400 24.0 % 0.61 [ 0.35, 1.07 ]
Kari 1994 13/77 8/80 5.8 % 1.69 [ 0.74, 3.85 ]
Liggins 1972b 28/556 37/580 26.9 % 0.79 [ 0.49, 1.27 ]
Lopez 1989 0/20 1/20 1.1 % 0.33 [ 0.01, 7.72 ]
Schutte 1980 1/50 4/51 2.9 % 0.26 [ 0.03, 2.20 ]
Subtotal (95% CI) 2328 2331 66.6 % 0.83 [ 0.61, 1.11 ]
Total events: 73 (Antenatal corticosteroids), 90 (Control)
Heterogeneity: Chi2 = 6.83, df = 5 (P = 0.23); I2 =27%
Test for overall effect: Z = 1.26 (P = 0.21)
2 In women treated with courses including weekly repeats
Amorim 1999 2/110 1/108 0.7 % 1.96 [ 0.18, 21.34 ]
Carlan 1991 0/11 3/13 2.4 % 0.17 [ 0.01, 2.91 ]
Fekih 2002 1/59 0/59 0.4 % 3.00 [ 0.12, 72.18 ]
Garite 1992 1/33 2/38 1.4 % 0.58 [ 0.05, 6.07 ]
Lewis 1996 6/38 6/39 4.4 % 1.03 [ 0.36, 2.90 ]
Morales 1989 9/87 16/78 12.5 % 0.50 [ 0.24, 1.08 ]
Qublan 2001 6/72 3/67 2.3 % 1.86 [ 0.48, 7.15 ]
Silver 1996 13/39 12/36 9.3 % 1.00 [ 0.53, 1.90 ]
Subtotal (95% CI) 449 438 33.4 % 0.84 [ 0.57, 1.25 ]
Total events: 38 (Antenatal corticosteroids), 43 (Control)
Heterogeneity: Chi2 = 5.94, df = 7 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Total (95% CI) 2777 2769 100.0 % 0.83 [ 0.66, 1.06 ]
Total events: 111 (Antenatal corticosteroids), 133 (Control)
Heterogeneity: Chi2 = 12.78, df = 13 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 7.2. Comparison 7 Corticosteroids versus placebo or no treatment - weekly repeats, Outcome 2
Endometritis - protocol with weekly repeats.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 7 Corticosteroids versus placebo or no treatment - weekly repeats












1 In women treated with single courses only
Dexiprom 1999 4/102 7/102 8.6 % 0.57 [ 0.17, 1.89 ]
Gyamfi-Bannerman 2016 16/1427 16/1400 17.8 % 0.98 [ 0.49, 1.95 ]
Mansouri 2010 4/100 6/100 8.2 % 0.67 [ 0.19, 2.29 ]
Schutte 1980 1/50 1/51 2.0 % 1.02 [ 0.07, 15.86 ]
Taeusch 1979 11/52 7/66 13.5 % 1.99 [ 0.83, 4.79 ]
Subtotal (95% CI) 1731 1719 50.1 % 1.04 [ 0.66, 1.64 ]
Total events: 36 (Antenatal corticosteroids), 37 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.62, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.85)
2 In women treated with courses including weekly repeats
Amorim 1999 9/110 13/108 14.9 % 0.68 [ 0.30, 1.52 ]
Garite 1992 10/33 5/38 11.8 % 2.30 [ 0.88, 6.06 ]
Lewis 1996 2/38 4/39 5.2 % 0.51 [ 0.10, 2.64 ]
Qublan 2001 9/72 2/67 6.0 % 4.19 [ 0.94, 18.68 ]
Silver 1996 11/39 5/36 12.0 % 2.03 [ 0.78, 5.28 ]
Subtotal (95% CI) 292 288 49.9 % 1.46 [ 0.72, 2.95 ]
Total events: 41 (Antenatal corticosteroids), 29 (Control)
Heterogeneity: Tau2 = 0.32; Chi2 = 8.19, df = 4 (P = 0.09); I2 =51%
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 2023 2007 100.0 % 1.20 [ 0.81, 1.80 ]
Total events: 77 (Antenatal corticosteroids), 66 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 12.51, df = 9 (P = 0.19); I2 =28%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 0.61, df = 1 (P = 0.44), I2 =0.0%
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Analysis 7.3. Comparison 7 Corticosteroids versus placebo or no treatment - weekly repeats, Outcome 3
Perinatal death - protocol with weekly repeats.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 7 Corticosteroids versus placebo or no treatment - weekly repeats












1 In babies treated with single course only
Block 1977 4/60 6/54 2.8 % 0.60 [ 0.18, 2.01 ]
Collaborative 1981 47/378 47/379 14.0 % 1.00 [ 0.69, 1.46 ]
Dexiprom 1999 4/105 10/103 3.2 % 0.39 [ 0.13, 1.21 ]
Doran 1980 5/81 14/63 4.2 % 0.28 [ 0.11, 0.73 ]
Gamsu 1989 15/131 22/137 8.3 % 0.71 [ 0.39, 1.31 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.5 % 4.91 [ 0.24, 102.09 ]
Kari 1994 5/95 6/94 3.1 % 0.82 [ 0.26, 2.61 ]
Liggins 1972b 108/601 122/617 19.1 % 0.91 [ 0.72, 1.15 ]
Porto 2011 (2) 1/144 3/131 0.9 % 0.30 [ 0.03, 2.88 ]
Schutte 1980 6/65 12/58 4.6 % 0.45 [ 0.18, 1.11 ]
Taeusch 1979 10/56 12/71 6.1 % 1.06 [ 0.49, 2.27 ]
Subtotal (95% CI) 3143 3107 66.8 % 0.77 [ 0.61, 0.99 ]
Total events: 207 (Antenatal corticosteroids), 254 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 12.94, df = 10 (P = 0.23); I2 =23%
Test for overall effect: Z = 2.07 (P = 0.039)
2 In babies treated with courses including weekly repeats
Amorim 1999 24/110 36/108 12.1 % 0.65 [ 0.42, 1.02 ]
Garite 1992 12/36 12/41 7.4 % 1.14 [ 0.59, 2.21 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Qublan 2001 21/72 41/67 13.2 % 0.48 [ 0.32, 0.72 ]
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Subtotal (95% CI) 241 238 33.2 % 0.65 [ 0.44, 0.97 ]
Total events: 57 (Antenatal corticosteroids), 90 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 5.06, df = 3 (P = 0.17); I2 =41%
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 3384 3345 100.0 % 0.72 [ 0.58, 0.89 ]
Total events: 264 (Antenatal corticosteroids), 344 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 21.30, df = 14 (P = 0.09); I2 =34%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
(2) The events are 1 stillbirth in each arm, and 2 neonatal deaths due to severe perinatal asphyxia.
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Analysis 7.4. Comparison 7 Corticosteroids versus placebo or no treatment - weekly repeats, Outcome 4
Neonatal death - protocol with weekly repeats.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 7 Corticosteroids versus placebo or no treatment - weekly repeats




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies treated with single course only
Block 1977 1/57 5/53 1.7 % 0.19 [ 0.02, 1.54 ]
Collaborative 1981 34/365 32/364 10.4 % 1.06 [ 0.67, 1.68 ]
Dexiprom 1999 4/105 8/101 2.6 % 0.48 [ 0.15, 1.55 ]
Doran 1980 4/80 11/60 4.1 % 0.27 [ 0.09, 0.81 ]
Gamsu 1989 14/130 17/132 5.5 % 0.84 [ 0.43, 1.63 ]
Goodner 1979 4/47 7/45 2.3 % 0.55 [ 0.17, 1.74 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.2 % 4.91 [ 0.24, 102.09 ]
Kari 1994 4/91 6/88 2.0 % 0.64 [ 0.19, 2.21 ]
Liggins 1972b 61/554 72/567 23.0 % 0.87 [ 0.63, 1.19 ]
Lopez 1989 6/20 6/20 1.9 % 1.00 [ 0.39, 2.58 ]
Nelson 1985 1/22 1/22 0.3 % 1.00 [ 0.07, 15.00 ]
Porto 2011 0/143 2/130 0.8 % 0.18 [ 0.01, 3.75 ]
Schutte 1980 3/62 12/58 4.0 % 0.23 [ 0.07, 0.79 ]
Taeusch 1979 8/54 10/69 2.8 % 1.02 [ 0.43, 2.41 ]
Subtotal (95% CI) 3157 3109 61.6 % 0.78 [ 0.63, 0.95 ]
Total events: 146 (Antenatal corticosteroids), 189 (Control)
Heterogeneity: Chi2 = 15.37, df = 13 (P = 0.28); I2 =15%
Test for overall effect: Z = 2.46 (P = 0.014)
2 In babies treated with courses including weekly repeats
Amorim 1999 14/100 28/100 9.1 % 0.50 [ 0.28, 0.89 ]
Fekih 2002 9/63 21/68 6.5 % 0.46 [ 0.23, 0.93 ]
Garite 1992 9/33 11/40 3.2 % 0.99 [ 0.47, 2.10 ]
Lewis 1996 1/38 1/39 0.3 % 1.03 [ 0.07, 15.82 ]
Morales 1989 7/87 8/78 2.7 % 0.78 [ 0.30, 2.06 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Qublan 2001 19/70 39/65 13.1 % 0.45 [ 0.29, 0.70 ]
Silver 1996 7/54 8/42 2.9 % 0.68 [ 0.27, 1.73 ]
Subtotal (95% CI) 468 454 38.4 % 0.55 [ 0.43, 0.72 ]
Total events: 66 (Antenatal corticosteroids), 117 (Control)
Heterogeneity: Chi2 = 4.53, df = 7 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 4.42 (P < 0.00001)
Total (95% CI) 3625 3563 100.0 % 0.69 [ 0.59, 0.81 ]
Total events: 212 (Antenatal corticosteroids), 306 (Control)
Heterogeneity: Chi2 = 24.63, df = 21 (P = 0.26); I2 =15%
Test for overall effect: Z = 4.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.95, df = 1 (P = 0.05), I2 =75%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) One due to septic shock and one to cardiac anomaly and arrhythmia.
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Analysis 7.5. Comparison 7 Corticosteroids versus placebo or no treatment - weekly repeats, Outcome 5
Fetal death - protocol with weekly repeats.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 7 Corticosteroids versus placebo or no treatment - weekly repeats




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies treated with single course only
Block 1977 3/60 1/54 1.2 % 2.70 [ 0.29, 25.19 ]
Collaborative 1981 13/378 15/379 16.4 % 0.87 [ 0.42, 1.80 ]
Dexiprom 1999 0/105 2/103 2.8 % 0.20 [ 0.01, 4.04 ]
Doran 1980 1/81 3/63 3.7 % 0.26 [ 0.03, 2.43 ]
Gamsu 1989 1/131 5/137 5.4 % 0.21 [ 0.02, 1.77 ]
Gyamfi-Bannerman 2016 0/1427 0/1400 Not estimable
Kari 1994 1/95 0/94 0.6 % 2.97 [ 0.12, 71.96 ]
Liggins 1972b 47/601 50/617 54.2 % 0.97 [ 0.66, 1.41 ]
Porto 2011 (1) 1/144 1/131 1.1 % 0.91 [ 0.06, 14.40 ]
Schutte 1980 3/65 0/58 0.6 % 6.26 [ 0.33, 118.64 ]
Taeusch 1979 2/56 2/71 1.9 % 1.27 [ 0.18, 8.72 ]
Subtotal (95% CI) 3143 3107 87.8 % 0.92 [ 0.68, 1.25 ]
Total events: 72 (Antenatal corticosteroids), 79 (Control)
Heterogeneity: Chi2 = 7.31, df = 9 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 In babies treated with courses including weekly repeats
Amorim 1999 10/110 8/108 8.9 % 1.23 [ 0.50, 2.99 ]
Garite 1992 3/36 1/41 1.0 % 3.42 [ 0.37, 31.41 ]
Parsons 1988 0/23 0/22 Not estimable
Qublan 2001 2/72 2/67 2.3 % 0.93 [ 0.13, 6.42 ]
Subtotal (95% CI) 241 238 12.2 % 1.36 [ 0.64, 2.87 ]
Total events: 15 (Antenatal corticosteroids), 11 (Control)
Heterogeneity: Chi2 = 0.86, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 3384 3345 100.0 % 0.98 [ 0.74, 1.30 ]
Total events: 87 (Antenatal corticosteroids), 90 (Control)
Heterogeneity: Chi2 = 8.88, df = 12 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.87, df = 1 (P = 0.35), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) The outcome measured in this trial was stillbirth.
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Analysis 7.6. Comparison 7 Corticosteroids versus placebo or no treatment - weekly repeats, Outcome 6
RDS - protocol with weekly repeats.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 7 Corticosteroids versus placebo or no treatment - weekly repeats




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies treated with single course only
Attawattanakul 2015 9/96 20/98 2.9 % 0.46 [ 0.22, 0.96 ]
Balci 2010 2/50 8/50 1.2 % 0.25 [ 0.06, 1.12 ]
Block 1977 5/57 12/53 1.8 % 0.39 [ 0.15, 1.03 ]
Cararach 1991 1/12 0/6 0.1 % 1.62 [ 0.08, 34.66 ]
Collaborative 1981 46/361 65/359 9.5 % 0.70 [ 0.50, 1.00 ]
Dexiprom 1999 32/102 27/100 4.0 % 1.16 [ 0.75, 1.79 ]
Doran 1980 4/80 10/60 1.7 % 0.30 [ 0.10, 0.91 ]
Gamsu 1989 7/130 16/132 2.3 % 0.44 [ 0.19, 1.04 ]
Goodner 1979 5/47 11/45 1.6 % 0.44 [ 0.16, 1.15 ]
Gyamfi-Bannerman 2016 79/1427 89/1400 13.1 % 0.87 [ 0.65, 1.17 ]
Kari 1994 34/91 46/90 6.7 % 0.73 [ 0.52, 1.02 ]
Liggins 1972b 53/542 89/550 12.8 % 0.60 [ 0.44, 0.83 ]
Lopez 1989 9/20 10/20 1.5 % 0.90 [ 0.47, 1.73 ]
Mansouri 2010 8/100 20/100 2.9 % 0.40 [ 0.18, 0.87 ]
Nelson 1985 10/22 11/22 1.6 % 0.91 [ 0.49, 1.69 ]
Porto 2011 2/143 1/130 0.2 % 1.82 [ 0.17, 19.82 ]
Schutte 1980 11/62 17/58 2.6 % 0.61 [ 0.31, 1.18 ]
Taeusch 1979 7/54 14/69 1.8 % 0.64 [ 0.28, 1.47 ]
Teramo 1980 3/38 3/42 0.4 % 1.11 [ 0.24, 5.15 ]
Subtotal (95% CI) 3434 3384 68.5 % 0.69 [ 0.61, 0.79 ]
Total events: 327 (Antenatal corticosteroids), 469 (Control)
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 21.88, df = 18 (P = 0.24); I2 =18%
Test for overall effect: Z = 5.63 (P < 0.00001)
2 In babies treated with courses including weekly repeats
Amorim 1999 23/100 43/100 6.3 % 0.53 [ 0.35, 0.82 ]
Carlan 1991 1/11 4/13 0.5 % 0.30 [ 0.04, 2.27 ]
Fekih 2002 3/63 19/68 2.7 % 0.17 [ 0.05, 0.55 ]
Garite 1992 21/33 28/40 3.7 % 0.91 [ 0.65, 1.26 ]
Lewis 1996 7/38 17/39 2.4 % 0.42 [ 0.20, 0.90 ]
Morales 1989 23/87 41/78 6.3 % 0.50 [ 0.33, 0.76 ]
Parsons 1988 3/23 3/22 0.4 % 0.96 [ 0.22, 4.24 ]
Qublan 2001 14/70 24/65 3.6 % 0.54 [ 0.31, 0.95 ]
Silver 1996 43/54 34/42 5.6 % 0.98 [ 0.81, 1.20 ]
Subtotal (95% CI) 479 467 31.5 % 0.61 [ 0.52, 0.72 ]
Total events: 138 (Antenatal corticosteroids), 213 (Control)
Heterogeneity: Chi2 = 34.76, df = 8 (P = 0.00003); I2 =77%
Test for overall effect: Z = 5.93 (P < 0.00001)
Total (95% CI) 3913 3851 100.0 % 0.67 [ 0.60, 0.74 ]
Total events: 465 (Antenatal corticosteroids), 682 (Control)
Heterogeneity: Chi2 = 51.46, df = 27 (P = 0.003); I2 =48%
Test for overall effect: Z = 7.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.26, df = 1 (P = 0.26), I2 =21%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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Analysis 7.7. Comparison 7 Corticosteroids versus placebo or no treatment - weekly repeats, Outcome 7
IVH- protocol with weekly repeats.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 7 Corticosteroids versus placebo or no treatment - weekly repeats




orids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In babies treated with single course only
Attawattanakul 2015 0/96 0/98 Not estimable
Dexiprom 1999 0/105 0/101 Not estimable
Doran 1980 1/80 4/60 2.9 % 0.19 [ 0.02, 1.63 ]
Gamsu 1989 2/130 4/132 2.5 % 0.51 [ 0.09, 2.72 ]
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.3 % 4.91 [ 0.24, 102.09 ]
Kari 1994 8/77 18/66 12.2 % 0.38 [ 0.18, 0.82 ]
Liggins 1972b 16/554 27/567 16.8 % 0.61 [ 0.33, 1.11 ]
Mansouri 2010 (2) 0/100 0/100 Not estimable
Taeusch 1979 0/54 4/69 2.5 % 0.14 [ 0.01, 2.57 ]
Subtotal (95% CI) 2623 2593 37.2 % 0.50 [ 0.33, 0.76 ]
Total events: 29 (Antenatal corticosteorids), 57 (Control)
Heterogeneity: Chi2 = 4.56, df = 5 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.21 (P = 0.0013)
2 In babies treated with courses including weekly repeats
Amorim 1999 6/100 17/100 10.7 % 0.35 [ 0.15, 0.86 ]
Fekih 2002 5/63 14/68 8.5 % 0.39 [ 0.15, 1.01 ]
Garite 1992 10/33 19/40 10.8 % 0.64 [ 0.35, 1.18 ]
Lewis 1996 0/38 3/39 2.2 % 0.15 [ 0.01, 2.74 ]
Morales 1989 13/87 20/78 13.3 % 0.58 [ 0.31, 1.09 ]
Qublan 2001 2/70 8/65 5.2 % 0.23 [ 0.05, 1.05 ]
Silver 1996 25/54 17/42 12.1 % 1.14 [ 0.72, 1.82 ]
Subtotal (95% CI) 445 432 62.8 % 0.59 [ 0.45, 0.78 ]
Total events: 61 (Antenatal corticosteorids), 98 (Control)
Heterogeneity: Chi2 = 12.19, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 3.69 (P = 0.00022)
Total (95% CI) 3068 3025 100.0 % 0.56 [ 0.44, 0.70 ]
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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orids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 90 (Antenatal corticosteorids), 155 (Control)
Heterogeneity: Chi2 = 17.89, df = 12 (P = 0.12); I2 =33%
Test for overall effect: Z = 4.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) Grade 3-4 IVH reported
(2) Grade 3 - 4
Analysis 7.8. Comparison 7 Corticosteroids versus placebo or no treatment - weekly repeats, Outcome 8
Birthweight - protocol with weekly repeats.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 7 Corticosteroids versus placebo or no treatment - weekly repeats









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 In babies treated with single course only
Attawattanakul 2015 96 2557.2 (367.6) 98 2558.1 (340) 5.0 % -0.90 [ -100.59, 98.79 ]
Balci 2010 50 2389 (133) 50 2386 (137) 17.9 % 3.00 [ -49.92, 55.92 ]
Dexiprom 1999 105 1795 (437) 103 1791 (542) 2.8 % 4.00 [ -129.95, 137.95 ]
Doran 1980 80 2086 (857) 60 1880.5 (803) 0.7 % 205.50 [ -71.18, 482.18 ]
Gamsu 1989 130 2203 (757) 132 2133 (753) 1.5 % 70.00 [ -112.85, 252.85 ]
Gyamfi-Bannerman 2016 1427 2637 (480) 1400 2654 (484) 39.6 % -17.00 [ -52.54, 18.54 ]
Kari 1994 94 1654 (831) 94 1783 (837) 0.9 % -129.00 [ -367.43, 109.43 ]
Liggins 1972b 601 2181.41 (816.9) 617 2260.78 (832.83) 5.8 % -79.37 [ -172.02, 13.28 ]
Mansouri 2010 100 2500 (300) 100 2600 (300) 7.2 % -100.00 [ -183.15, -16.85 ]
-100 -50 0 50 100
Corticosteroids lighter Control lighter
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nelson 1985 (1) 22 1594 (456.4) 22 1752.5 (415.4) 0.8 % -158.50 [ -416.38, 99.38 ]
Porto 2011 143 2640 (445) 130 2627 (452) 4.4 % 13.00 [ -93.57, 119.57 ]
Schutte 1980 61 1788 (690) 58 1670 (448) 1.2 % 118.00 [ -90.03, 326.03 ]
Subtotal (95% CI) 2909 2864 87.7 % -18.24 [ -42.12, 5.65 ]
Heterogeneity: Chi2 = 13.58, df = 11 (P = 0.26); I2 =19%
Test for overall effect: Z = 1.50 (P = 0.13)
2 In babies treated with courses including weekly repeats
Garite 1992 33 1242 (678) 38 1071 (597) 0.6 % 171.00 [ -128.23, 470.23 ]
Lewis 1996 38 1611 (538) 39 1734 (570) 0.8 % -123.00 [ -370.51, 124.51 ]
Morales 1989 87 1359 (361) 78 1379 (293) 5.0 % -20.00 [ -119.91, 79.91 ]
Silver 1996 54 917 (238) 42 941 (219) 5.9 % -24.00 [ -115.74, 67.74 ]
Subtotal (95% CI) 212 197 12.3 % -20.10 [ -83.79, 43.60 ]
Heterogeneity: Chi2 = 2.24, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
Total (95% CI) 3121 3061 100.0 % -18.47 [ -40.83, 3.90 ]
Heterogeneity: Chi2 = 15.82, df = 15 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
-100 -50 0 50 100
Corticosteroids lighter Control lighter
(1) The trial reports the SD as 4,563.7 which much be a typo; we have used 456.4.
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Analysis 7.9. Comparison 7 Corticosteroids versus placebo or no treatment - weekly repeats, Outcome 9
Moderate/severe respiratory distress syndrome.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 7 Corticosteroids versus placebo or no treatment - weekly repeats
Outcome: 9 Moderate/severe respiratory distress syndrome









Liggins 1972b 41/542 73/550 28.5 % 0.57 [ 0.40, 0.82 ]
Nelson 1985 6/22 6/22 12.9 % 1.00 [ 0.38, 2.62 ]
Taeusch 1979 6/54 14/69 14.3 % 0.55 [ 0.23, 1.33 ]
Subtotal (95% CI) 618 641 55.7 % 0.60 [ 0.44, 0.83 ]
Total events: 53 (Corticosteroids), 93 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.20, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 3.12 (P = 0.0018)
2 Weekly repeats
Amorim 1999 9/100 23/100 18.0 % 0.39 [ 0.19, 0.80 ]
Fekih 2002 1/63 15/68 4.2 % 0.07 [ 0.01, 0.53 ]
Silver 1996 18/54 14/42 22.1 % 1.00 [ 0.57, 1.77 ]
Subtotal (95% CI) 217 210 44.3 % 0.41 [ 0.13, 1.32 ]
Total events: 28 (Corticosteroids), 52 (Control)
Heterogeneity: Tau2 = 0.76; Chi2 = 10.04, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 1.49 (P = 0.14)
Total (95% CI) 835 851 100.0 % 0.59 [ 0.38, 0.91 ]
Total events: 81 (Corticosteroids), 145 (Control)
Heterogeneity: Tau2 = 0.14; Chi2 = 10.49, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.54), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours corticosteroids Favours control
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Analysis 8.1. Comparison 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry,
Outcome 1 Chorioamnionitis - gestational age at trial entry.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Less than or equal to 35 weeks + 0 days
Amorim 1999 2/110 1/108 0.7 % 1.96 [ 0.18, 21.34 ]
Carlan 1991 0/11 3/13 2.4 % 0.17 [ 0.01, 2.91 ]
Dexiprom 1999 11/102 8/102 5.9 % 1.38 [ 0.58, 3.28 ]
Fekih 2002 1/59 0/59 0.4 % 3.00 [ 0.12, 72.18 ]
Garite 1992 1/33 2/38 1.4 % 0.58 [ 0.05, 6.07 ]
Kari 1994 13/77 8/80 5.8 % 1.69 [ 0.74, 3.85 ]
Lewis 1996 6/38 6/39 4.4 % 1.03 [ 0.36, 2.90 ]
Liggins 1972b 28/459 34/456 25.1 % 0.82 [ 0.50, 1.33 ]
Lopez 1989 0/20 1/20 1.1 % 0.33 [ 0.01, 7.72 ]
Morales 1989 9/87 16/78 12.4 % 0.50 [ 0.24, 1.08 ]
Qublan 2001 6/72 3/67 2.3 % 1.86 [ 0.48, 7.15 ]
Schutte 1980 1/50 4/51 2.9 % 0.26 [ 0.03, 2.20 ]
Silver 1996 13/39 12/36 9.2 % 1.00 [ 0.53, 1.90 ]
Subtotal (95% CI) 1157 1147 73.9 % 0.91 [ 0.70, 1.19 ]
Total events: 91 (Antenatal corticosteroids), 98 (Control)
Heterogeneity: Chi2 = 10.93, df = 12 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
2 Greater than or equal to 34 weeks + 0 days
Attawattanakul 2015 (1) 0/96 0/98 Not estimable
Gyamfi-Bannerman 2016 (2) 20/1427 32/1400 23.8 % 0.61 [ 0.35, 1.07 ]
Liggins 1972b (3) 0/81 3/100 2.3 % 0.18 [ 0.01, 3.36 ]
Subtotal (95% CI) 1604 1598 26.1 % 0.57 [ 0.33, 0.99 ]
Total events: 20 (Antenatal corticosteroids), 35 (Control)
Heterogeneity: Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
Total (95% CI) 2761 2745 100.0 % 0.82 [ 0.65, 1.05 ]
0.01 0.1 1 10 100
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 111 (Antenatal corticosteroids), 133 (Control)
Heterogeneity: Chi2 = 13.83, df = 14 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Chi2 = 2.26, df = 1 (P = 0.13), I2 =56%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) 34 weeks + 0 days - 36 weeks + 6 days
(2) 34 weeks + 0 days - 36 weeks + 6 days
(3) 35 weeks + 0 days - 36 weeks + 6 days
Analysis 8.2. Comparison 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry,
Outcome 2 Perinatal death - gestational age at trial entry.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry












1 Less than or equal to 35 weeks + 0 days
Amorim 1999 24/110 36/108 12.0 % 0.65 [ 0.42, 1.02 ]
Block 1977 4/60 6/54 2.5 % 0.60 [ 0.18, 2.01 ]
Collaborative 1981 47/378 47/379 14.4 % 1.00 [ 0.69, 1.46 ]
Dexiprom 1999 4/105 10/103 2.8 % 0.39 [ 0.13, 1.21 ]
Doran 1980 5/81 14/63 3.7 % 0.28 [ 0.11, 0.73 ]
Gamsu 1989 15/131 22/137 7.8 % 0.71 [ 0.39, 1.31 ]
Garite 1992 12/36 12/41 6.9 % 1.14 [ 0.59, 2.21 ]
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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Kari 1994 5/95 6/94 2.7 % 0.82 [ 0.26, 2.61 ]
Liggins 1972b 102/496 119/486 21.2 % 0.84 [ 0.67, 1.06 ]
Parsons 1988 0/23 1/22 0.4 % 0.32 [ 0.01, 7.45 ]
Qublan 2001 21/72 41/67 13.3 % 0.48 [ 0.32, 0.72 ]
Schutte 1980 6/65 12/58 4.1 % 0.45 [ 0.18, 1.11 ]
Taeusch 1979 10/56 12/71 5.5 % 1.06 [ 0.49, 2.27 ]
Subtotal (95% CI) 1708 1683 97.3 % 0.71 [ 0.58, 0.87 ]
Total events: 255 (Antenatal corticosteroids), 338 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 17.61, df = 12 (P = 0.13); I2 =32%
Test for overall effect: Z = 3.24 (P = 0.0012)
2 Greater than or equal to 34 weeks + 0 days
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.4 % 4.91 [ 0.24, 102.09 ]
Liggins 1972b (2) 3/87 3/107 1.5 % 1.23 [ 0.25, 5.94 ]
Porto 2011 (3) 1/144 3/131 0.8 % 0.30 [ 0.03, 2.88 ]
Subtotal (95% CI) 1658 1638 2.7 % 1.03 [ 0.29, 3.67 ]
Total events: 6 (Antenatal corticosteroids), 6 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 2.20, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 3366 3321 100.0 % 0.72 [ 0.59, 0.88 ]
Total events: 261 (Antenatal corticosteroids), 344 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 20.09, df = 15 (P = 0.17); I2 =25%
Test for overall effect: Z = 3.24 (P = 0.0012)
Test for subgroup differences: Chi2 = 0.32, df = 1 (P = 0.57), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) 34 weeks + 0 days - 36 weeks + 6 days. One due to septic shock and one to cardiac anomaly and arrhythmia.
(2) 35 weeks + 0 days - 36 weeks + 6 days
(3) The events are 1 stillbirth in each arm, and 2 neonatal deaths due to severe perinatal asphyxia.
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Analysis 8.3. Comparison 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry,
Outcome 3 Neonatal death - gestational age at trial engry.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Less than or equal to 35 weeks + 0 days
Amorim 1999 14/100 28/100 9.0 % 0.50 [ 0.28, 0.89 ]
Block 1977 1/57 5/53 1.7 % 0.19 [ 0.02, 1.54 ]
Collaborative 1981 34/365 32/364 10.3 % 1.06 [ 0.67, 1.68 ]
Dexiprom 1999 4/105 8/101 2.6 % 0.48 [ 0.15, 1.55 ]
Doran 1980 4/80 11/60 4.0 % 0.27 [ 0.09, 0.81 ]
Fekih 2002 9/63 21/68 6.5 % 0.46 [ 0.23, 0.93 ]
Gamsu 1989 14/130 17/132 5.4 % 0.84 [ 0.43, 1.63 ]
Garite 1992 9/33 11/40 3.2 % 0.99 [ 0.47, 2.10 ]
Goodner 1979 4/47 7/45 2.3 % 0.55 [ 0.17, 1.74 ]
Kari 1994 4/91 6/88 2.0 % 0.64 [ 0.19, 2.21 ]
Lewis 1996 1/38 1/39 0.3 % 1.03 [ 0.07, 15.82 ]
Liggins 1972b 57/451 70/437 22.9 % 0.79 [ 0.57, 1.09 ]
Lopez 1989 6/20 6/20 1.9 % 1.00 [ 0.39, 2.58 ]
Morales 1989 7/87 8/78 2.7 % 0.78 [ 0.30, 2.06 ]
Nelson 1985 1/22 1/22 0.3 % 1.00 [ 0.07, 15.00 ]
Parsons 1988 0/23 1/22 0.5 % 0.32 [ 0.01, 7.45 ]
Qublan 2001 19/70 39/65 13.0 % 0.45 [ 0.29, 0.70 ]
Schutte 1980 3/62 12/58 4.0 % 0.23 [ 0.07, 0.79 ]
Silver 1996 7/54 8/42 2.9 % 0.68 [ 0.27, 1.73 ]
Taeusch 1979 8/54 10/69 2.8 % 1.02 [ 0.43, 2.41 ]
Subtotal (95% CI) 1952 1903 98.4 % 0.67 [ 0.57, 0.79 ]
Total events: 206 (Antenatal corticosteroids), 302 (Control)
Heterogeneity: Chi2 = 20.92, df = 19 (P = 0.34); I2 =9%
Test for overall effect: Z = 4.87 (P < 0.00001)
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
2 Greater than or equal to 34 weeks + 0 days
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.2 % 4.91 [ 0.24, 102.09 ]
Liggins 1972b (2) 1/85 2/106 0.6 % 0.62 [ 0.06, 6.76 ]
Porto 2011 0/143 2/130 0.8 % 0.18 [ 0.01, 3.75 ]
Subtotal (95% CI) 1655 1636 1.6 % 0.83 [ 0.22, 3.07 ]
Total events: 3 (Antenatal corticosteroids), 4 (Control)
Heterogeneity: Chi2 = 2.34, df = 2 (P = 0.31); I2 =14%
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 3607 3539 100.0 % 0.67 [ 0.57, 0.79 ]
Total events: 209 (Antenatal corticosteroids), 306 (Control)
Heterogeneity: Chi2 = 23.28, df = 22 (P = 0.39); I2 =6%
Test for overall effect: Z = 4.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) 34 weeks + 0 days - 36 weeks + 6 days. One due to septic shock and one to cardiac anomaly and arrhythmia.
(2) 34 weeks + 0 days - 36 weeks + 6 days
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Analysis 8.4. Comparison 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry,
Outcome 4 Fetal death - gestational age at trial entry.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry




teroid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Less than or equal to 35 weeks + 0 days
Amorim 1999 10/110 8/108 8.8 % 1.23 [ 0.50, 2.99 ]
Block 1977 3/60 1/54 1.1 % 2.70 [ 0.29, 25.19 ]
Collaborative 1981 13/378 15/379 16.3 % 0.87 [ 0.42, 1.80 ]
Dexiprom 1999 0/105 2/103 2.7 % 0.20 [ 0.01, 4.04 ]
Doran 1980 1/81 3/63 3.7 % 0.26 [ 0.03, 2.43 ]
Gamsu 1989 1/131 5/137 5.3 % 0.21 [ 0.02, 1.77 ]
Garite 1992 3/36 1/41 1.0 % 3.42 [ 0.37, 31.41 ]
Kari 1994 1/95 0/94 0.5 % 2.97 [ 0.12, 71.96 ]
Liggins 1972b 45/496 49/486 53.7 % 0.90 [ 0.61, 1.32 ]
Parsons 1988 0/23 0/22 Not estimable
Qublan 2001 2/72 2/67 2.2 % 0.93 [ 0.13, 6.42 ]
Schutte 1980 3/65 0/58 0.6 % 6.26 [ 0.33, 118.64 ]
Taeusch 1979 2/56 2/71 1.9 % 1.27 [ 0.18, 8.72 ]
Subtotal (95% CI) 1708 1683 97.9 % 0.94 [ 0.71, 1.25 ]
Total events: 84 (Antenatal corticosteroid), 88 (Control)
Heterogeneity: Chi2 = 8.99, df = 11 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
2 Greater than or equal to 34 weeks + 0 days
Gyamfi-Bannerman 2016 (1) 0/1427 0/1400 Not estimable
Liggins 1972b (2) 2/87 1/107 1.0 % 2.46 [ 0.23, 26.68 ]
Porto 2011 (3) 1/144 1/131 1.1 % 0.91 [ 0.06, 14.40 ]
Subtotal (95% CI) 1658 1638 2.1 % 1.62 [ 0.28, 9.37 ]
Total events: 3 (Antenatal corticosteroid), 2 (Control)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 3366 3321 100.0 % 0.96 [ 0.72, 1.27 ]
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(Continued . . . )
252Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.




teroid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 87 (Antenatal corticosteroid), 90 (Control)
Heterogeneity: Chi2 = 9.61, df = 13 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Chi2 = 0.36, df = 1 (P = 0.55), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) 34 weeks + 0 days - 36 weeks + 6 days.
(2) 35 weeks + 0 days - 36 weeks + 6 days
(3) The outcome measured in this trial was stillbirth.
Analysis 8.5. Comparison 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry,
Outcome 5 RDS- gestational age at trial entry.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry




orids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Less than or equal to 35 weeks + 0 days
Amorim 1999 23/100 43/100 6.2 % 0.53 [ 0.35, 0.82 ]
Block 1977 5/57 12/53 1.8 % 0.39 [ 0.15, 1.03 ]
Cararach 1991 1/12 0/6 0.1 % 1.62 [ 0.08, 34.66 ]
Carlan 1991 1/11 4/13 0.5 % 0.30 [ 0.04, 2.27 ]
Collaborative 1981 46/361 65/359 9.4 % 0.70 [ 0.50, 1.00 ]
Dexiprom 1999 32/102 27/100 4.0 % 1.16 [ 0.75, 1.79 ]
Doran 1980 4/80 10/60 1.7 % 0.30 [ 0.10, 0.91 ]
Fekih 2002 3/63 19/68 2.6 % 0.17 [ 0.05, 0.55 ]
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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orids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gamsu 1989 7/130 16/132 2.3 % 0.44 [ 0.19, 1.04 ]
Garite 1992 21/33 28/40 3.7 % 0.91 [ 0.65, 1.26 ]
Goodner 1979 5/47 11/45 1.6 % 0.44 [ 0.16, 1.15 ]
Kari 1994 34/91 46/90 6.7 % 0.73 [ 0.52, 1.02 ]
Lewis 1996 7/38 17/39 2.4 % 0.42 [ 0.20, 0.90 ]
Liggins 1972b 51/441 85/420 12.6 % 0.57 [ 0.41, 0.79 ]
Lopez 1989 9/20 10/20 1.4 % 0.90 [ 0.47, 1.73 ]
Morales 1989 23/87 41/78 6.3 % 0.50 [ 0.33, 0.76 ]
Nelson 1985 10/22 11/22 1.6 % 0.91 [ 0.49, 1.69 ]
Parsons 1988 3/23 3/22 0.4 % 0.96 [ 0.22, 4.24 ]
Qublan 2001 14/70 24/65 3.6 % 0.54 [ 0.31, 0.95 ]
Schutte 1980 11/62 17/58 2.5 % 0.61 [ 0.31, 1.18 ]
Silver 1996 43/54 34/42 5.5 % 0.98 [ 0.81, 1.20 ]
Taeusch 1979 7/54 14/69 1.8 % 0.64 [ 0.28, 1.47 ]
Teramo 1980 3/38 3/42 0.4 % 1.11 [ 0.24, 5.15 ]
Subtotal (95% CI) 1996 1943 79.4 % 0.65 [ 0.58, 0.73 ]
Total events: 363 (Antenatal corticosteorids), 540 (Control)
Heterogeneity: Chi2 = 45.95, df = 22 (P = 0.002); I2 =52%
Test for overall effect: Z = 7.63 (P < 0.00001)
2 Greater than or equal to 34 weeks + 0 days
Attawattanakul 2015 9/96 20/98 2.9 % 0.46 [ 0.22, 0.96 ]
Balci 2010 2/50 8/50 1.2 % 0.25 [ 0.06, 1.12 ]
Gyamfi-Bannerman 2016 79/1427 89/1400 13.0 % 0.87 [ 0.65, 1.17 ]
Liggins 1972b (1) 2/85 4/104 0.5 % 0.61 [ 0.11, 3.26 ]
Mansouri 2010 8/100 20/100 2.9 % 0.40 [ 0.18, 0.87 ]
Porto 2011 2/143 1/130 0.2 % 1.82 [ 0.17, 19.82 ]
Subtotal (95% CI) 1901 1882 20.6 % 0.71 [ 0.56, 0.91 ]
Total events: 102 (Antenatal corticosteorids), 142 (Control)
Heterogeneity: Chi2 = 7.81, df = 5 (P = 0.17); I2 =36%
Test for overall effect: Z = 2.70 (P = 0.0069)
Total (95% CI) 3897 3825 100.0 % 0.66 [ 0.60, 0.73 ]
Total events: 465 (Antenatal corticosteorids), 682 (Control)
Heterogeneity: Chi2 = 52.54, df = 28 (P = 0.003); I2 =47%
Test for overall effect: Z = 7.93 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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(1) 34 weeks + 0 days - 36 weeks + 6 days
Analysis 8.6. Comparison 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry,
Outcome 6 IVH - gestational age at trial entry.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Less than or equal to 35 weeks + 0 days
Amorim 1999 6/100 17/100 10.7 % 0.35 [ 0.15, 0.86 ]
Dexiprom 1999 0/105 0/101 Not estimable
Doran 1980 1/80 4/60 2.9 % 0.19 [ 0.02, 1.63 ]
Fekih 2002 5/63 14/68 8.4 % 0.39 [ 0.15, 1.01 ]
Gamsu 1989 2/130 4/132 2.5 % 0.51 [ 0.09, 2.72 ]
Garite 1992 10/33 19/40 10.8 % 0.64 [ 0.35, 1.18 ]
Kari 1994 8/77 18/66 12.2 % 0.38 [ 0.18, 0.82 ]
Lewis 1996 0/38 3/39 2.2 % 0.15 [ 0.01, 2.74 ]
Liggins 1972b 16/451 27/437 17.2 % 0.57 [ 0.31, 1.05 ]
Morales 1989 13/87 20/78 13.2 % 0.58 [ 0.31, 1.09 ]
Qublan 2001 2/70 8/65 5.2 % 0.23 [ 0.05, 1.05 ]
Silver 1996 25/54 17/42 12.0 % 1.14 [ 0.72, 1.82 ]
Taeusch 1979 0/54 4/69 2.5 % 0.14 [ 0.01, 2.57 ]
Subtotal (95% CI) 1342 1297 99.7 % 0.54 [ 0.42, 0.68 ]
Total events: 88 (Antenatal corticosteroids), 155 (Control)
Heterogeneity: Chi2 = 16.29, df = 11 (P = 0.13); I2 =32%
Test for overall effect: Z = 5.15 (P < 0.00001)
2 Greater than or equal to 34 weeks + 0 days
Attawattanakul 2015 0/96 0/98 Not estimable
Gyamfi-Bannerman 2016 (1) 2/1427 0/1400 0.3 % 4.91 [ 0.24, 102.09 ]
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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255Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.




teroids Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liggins 1972b (2) 0/85 0/106 Not estimable
Mansouri 2010 (3) 0/100 0/100 Not estimable
Subtotal (95% CI) 1708 1704 0.3 % 4.91 [ 0.24, 102.09 ]
Total events: 2 (Antenatal corticosteroids), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 3050 3001 100.0 % 0.55 [ 0.44, 0.70 ]
Total events: 90 (Antenatal corticosteroids), 155 (Control)
Heterogeneity: Chi2 = 17.95, df = 12 (P = 0.12); I2 =33%
Test for overall effect: Z = 4.98 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.03, df = 1 (P = 0.15), I2 =51%
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) Grade 3-4 IVH reported
(2) 35 weeks + 0 days - 36 weeks + 6 days
(3) Grade 3 - 4
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Analysis 8.7. Comparison 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry,
Outcome 7 Birthweight - gestational age at trial entry.
Review: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
Comparison: 8 Corticosteroids versus placebo or no treatment - gestational age at trial entry









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Less than or equal to 35 weeks + 0 days
Dexiprom 1999 105 1795 (437) 103 1791 (542) 2.8 % 4.00 [ -129.95, 137.95 ]
Doran 1980 80 2086 (857) 60 1880.5 (803) 0.7 % 205.50 [ -71.18, 482.18 ]
Gamsu 1989 130 2203 (757) 132 2133 (753) 1.5 % 70.00 [ -112.85, 252.85 ]
Garite 1992 33 1242 (678) 38 1071 (597) 0.6 % 171.00 [ -128.23, 470.23 ]
Kari 1994 94 1654 (831) 94 1783 (837) 0.9 % -129.00 [ -367.43, 109.43 ]
Lewis 1996 38 1611 (538) 39 1734 (570) 0.8 % -123.00 [ -370.51, 124.51 ]
Liggins 1972b 496 2100.325 (840.4667) 486 2178.72 (868.0339) 4.4 % -78.40 [ -185.29, 28.50 ]
Morales 1989 87 1359 (361) 78 1379 (293) 5.0 % -20.00 [ -119.91, 79.91 ]
Nelson 1985 (1) 22 1594 (456.4) 22 1752.5 (415.4) 0.7 % -158.50 [ -416.38, 99.38 ]
Schutte 1980 61 1788 (690) 58 1670 (448) 1.2 % 118.00 [ -90.03, 326.03 ]
Silver 1996 54 917 (238) 42 941 (219) 5.9 % -24.00 [ -115.74, 67.74 ]
Subtotal (95% CI) 1200 1152 24.3 % -17.89 [ -63.14, 27.36 ]
Heterogeneity: Chi2 = 10.58, df = 10 (P = 0.39); I2 =6%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Greater than or equal to 34 weeks + 0 days
Attawattanakul 2015 96 2557.2 (367.6) 98 2558.1 (340) 5.0 % -0.90 [ -100.59, 98.79 ]
Balci 2010 50 2389 (133) 50 2386 (137) 17.8 % 3.00 [ -49.92, 55.92 ]
Gyamfi-Bannerman 2016 1427 2637 (480) 1400 2654 (484) 39.4 % -17.00 [ -52.54, 18.54 ]
Liggins 1972b (2) 87 2518.39 (538.91) 107 2531.96 (610.52) 1.9 % -13.57 [ -175.45, 148.31 ]
Mansouri 2010 100 2500 (300) 100 2600 (300) 7.2 % -100.00 [ -183.15, -16.85 ]
Porto 2011 143 2640 (445) 130 2627 (452) 4.4 % 13.00 [ -93.57, 119.57 ]
Subtotal (95% CI) 1903 1885 75.7 % -17.31 [ -42.96, 8.34 ]
Heterogeneity: Chi2 = 4.78, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 3103 3037 100.0 % -17.45 [ -39.76, 4.86 ]
Heterogeneity: Chi2 = 15.36, df = 16 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
-100 -50 0 50 100
Corticosteroids lighter Control lighter
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(1) The trial reports the SD as 4,563.7 which much be a typo; we have used 456.4.
(2) 34 weeks + 0 days - 36 weeks + 6 days
A D D I T I O N A L T A B L E S





Amorim 1999 1999 28+0 34+6
Attawattanakul 2015 2015 34+0 36+6
Balci 2010 2010 34+0 36+6
Block 1977 1976 Not reported 36+6
Carlan 1991 1991 24+0 34+6
Cararach 1991 1994 28+0 30+6
Collaborative 1981 1981 26+0 37+0
Dexiprom 1999 1999 28+0 34+6
Doran 1980 1980 24+0 34+6
Fekih 2002 2002 26+0 34+6
Gamsu 1989 1989 Not reported 34+6
Garite 1992 1992 24+0 27+6
Goodner 1979 1979 Not reported 33+6
Gyamfi-Bannerman 2016 2016 34+0 36+6




Lewis 1996 1996 24+0 34+6
Liggins 1972b 1972 24+0 36+6
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Table 1. Gestational age parameters for included trials (Continued)
Lopez 1989 1989 27+0 35+0
Mansouri 2010 2010 35+0 36+6
Morales 1989 1989 26+0 34+6
Nelson 1985 1985 28+0 34+6
Parsons 1988 1988 25+0 32+6
Porto 2011 2011 34+0 36+6
Qublan 2001 2001 27+0 34+6
Schutte 1980 1980 26+0 32+6
Shanks 2010 2010 34+0 36+6
Silver 1996 1996 24+0 29+6
Taeusch 1979 1979 Not reported 33+6
Teramo 1980 1980 28+0 35+6
F E E D B A C K
Nachum, September 2002
Summary
Are there enough data to indicate the efficacy of antenatal steroids in twins?
(Summary of comment received from Zohar Nachum, September 2002)
Reply
Only two small trials report outcome following a multiple pregnancy. Therefore there is currently not enough evidence to support the
use of corticosteroids in multiple pregnancy. Nevertheless, in view of the strength of the overall evidence, it would seem sensible to
offer a single course of steroids to women with a multiple pregnancy at risk of preterm birth.
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Preston, August 2002
Summary
It is unclear whether quasi-randomised trials should be included. The abstract states they are included, types of studies says they are
excluded, and a quasi-randomised study has been included (Morales 1986).
Also some data appear to be missing from the meta-analysis. Silver 1995 does not contribute any information to the outcome neonatal
death, yet the data are reported in the abstract you reference (7/54 deaths on dexamethasone, 8/42 deaths on placebo).
(Summary of comments received from Carol Preston, August 2002)
Reply
The protocol for the updated review excluded quasi-randomised studies, and Morales 1986 has therefore been excluded. The data for
neonatal deaths in Silver 1995 are now included in the meta-analysis.






The results, and reviewer’s conclusions, are that administering corticosteroids (24 mg betamethasone, or 24 mg dexamethasone) to
women who are expected to give birth at 28-34 weeks’ gestation reduces neonatal morbidity and mortality. However, there is no
clarification of how this should be prescribed. Standard regimens are for 48 hours treatment, using either 12 mg betamethasone IM
every 24 hours, or 6 mg dexamethasone IM every 12 hours. But data in this review show the maximum benefit for corticosteroids is
after 24 hours of treatment.
I have some questions about how to maximise the benefit in clinical practice.
1) For a woman in preterm labor who is being given tocolytic treatment to facilitate steroid administration, how long should tocolytics
be continued, 24 hours or 48 hours?
2) Would the benefit of steroids be the same for a modified regimen over 24 hours, for example 8 mg dexamethasone IM every 8 hours
for 3 doses, or 12 mg dexamethasone IM every 12 hours? Will this affect adrenal suppression and fetal growth like repeated doses?
3) Do we need a review comparing the benefits and adverse events between different regimens of prophylactic corticosteroids?
(Summary of comments from Tippawan Liabsuetrakul, September 2003)
Reply
These questions have all been addressed by sub-group analyses in the updated review.
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Selinger, December 2005
Summary
Why do the corticosteroids need to be administered by intramuscular injection? Is there any evidence that this is preferable to oral
administration?
(Summary of comment from Mark Selinger, December 2005)
Reply
Presumably the original sheep studieswere donewith parenteral steroids, so perhaps the initial extrapolation tohumanswas intramuscular
use. We are not aware of evidence about the effects of oral administration.






There have been two recent reports(1,2) of 30-year follow-up of people recruited whilst in utero to Liggins 1972a. Both used intention-
to-treat analysis, as does this review. One of these reports (1) stated “ that there were similar numbers of neonatal survivors with much
the same perinatal morbidity in both treatment and control groups”. Clearly this means that Liggins 1972a showed no overall benefit
in terms of survival or morbidity, which to me seem the most important end points.
Liggins 1972a forms a major part of this Cochrane review, yet the data from the follow-up reports differ from those in the review.
This new evidence therefore raises questions about the validity of the Cochrane meta-analysis. There are also discrepancies between
this version of the review, and its earlier published versions, for some of the other trials. The version published in Effective care in
Pregnancy and Childbirth (3) contained 12 trials reporting the effect of corticosteroids on early neonatal death (0-7 days). Some of
these 12 are in the analysis presented here of corticosteroids versus placebo for the outcome neonatal death (0-28 days). However, for
Liggins 1972a, Block 1977, Gamsu 1989, and Morales 1989 the data remain unchanged between the two reviews. Does this mean
there were no deaths from 8-28 days? We now know this is not true for Liggins 1972a. There is also something peculiar about the
randomisation in Schmidt 1984. Between appearing in Effective Care in Pregnancy and Childbirth and inclusion in the Cochrane
review 15 women were added to this study, all in the treatment group and with no change in the number of deaths.
I understand an update of the review is in preparation. However, since the early nineties it would have been considered unethical to
carry out a randomised trial of steroids versus placebo and so I do not expect any new trials to have become available since the last
Cochrane review in 2002.
(Summary of feedback from David Hutchon, May 2006)
References
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Reply
Since Effective Care in Pregnancy and Childbirth appeared, nine randomised controlled trials of antenatal corticosteroids have been
published. These trials are now included in the updated Cochrane review. This updated review shows the contribution of each study
to the outcome measures, and describes the methodological quality of each included trial.
For Liggins 1972a, the previous Cochrane review (Crowley 1996) included data that were published at that time Hence, data for
perinatal death (stillbirth or death in the first week of life) were included. However, the updated Cochrane review includes an intention-
to-treat analysis of the original data from Liggins 1972a. These data were not available for the previous review (Crowley 1996). This
updated review therefore now includes data for neonatal death (death in the first 28 days of life) in Liggins 1972a.
Data reported for Schmidt 1984 included a third arm of women and infants who had been excluded from randomisation. This study
is now excluded from the review.






It is good to see the updated review has incorporated intention to treat analysis for all the trials. In the paragraph entitled “Effects of
antenatal corticosteroids for preterm birth” the third sentence referring to the 1990 review by Crowley et al (1) is not strictly correct.
“This review showed that corticosteroids ... are effective in preventing respiratory distress syndrome and neonatal mortality.” In fact
that analysis was for early neonatal deaths (deaths in the first seven days) only. Subsequently the Cochrane review used neonatal deaths
(deaths in the first 28 days) and, as I pointed out in my feedback on the last update, data from some of the trials (Liggins 1972a, Block
1977, Gamsu 1989, and Morales 1989) are still the same as the previous data reported as early neonatal deaths. Therefore, to be correct,
the above sentence should end “...preventing respiratory distress and early neonatal mortality.”
Confusion remains regarding the results of three trials. Differences in the data for neonatal death between this update and the previous
version (Table 1) are unexplained. For Block 1977 and Gamsu 1989 the differences are minor, but for Morales 1986 they are larger.
These changes merit some comment.
Table 1 Differences in the data for neonatal mortality:
Block 1977
Previous update: Treatment (n/N) = 1/69; Control (n/N) = 5/61
This update: Treatment (n/N) = 1/57; Control (n/N) = 5/53
Gamsu 1989
Previous update: Treatment (n/N) = 14/131; Control (n/N) = 20/137
This update: Treatment (n/N) = 14/130; Control (n/N) = 17/132
Morales 1986
Previous update: Treatment (n/N) = 7/121; Control (n/N) = 13/124
This update: Treatment (n/N) = 7/87; Control (n/N) = 8/78
Finally, data from Liggins 1972a has been adjusted and is now presented as an intention to treat analysis. Precise details about the
cause of death are not available. Data for Block 1977, Gamsu 1989 and Morales 1986 are not quite as old as that for Liggins 1972a,
nevertheless, it is surprising that secure reanalysis of these studies was available after all these years.
1.Crowley P, Chalmers I, KeirseMJNC. The effects of corticosteroid administration before pretermdelivery: an overview of the evidence
from controlled trials. British Journal of Obstetrics and Gynaecology 1990; 97:11-25
(Summary of feedback from David Hutchon, January 2007)
Reply
A reply from the authors will be published as soon as it is available.
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Contributors
David Hutchon
Vlassov, 15 March 2008
Summary
The title of the review is misleading; the objectives of the review, as well as the outcomes evaluated, are NOT about fetal lung maturation
only.
(Summary of feedback from Vasiliy Vlassov, March 2008)
Reply
The results of the review do include data for outcomes other than fetal lung maturity. For the update, we did not want to significantly
alter the title of the review. The intention of the original review was to assess the effect on fetal lung maturation. We felt it would be
too radical a change for this first update to have a completely different title. We will consider this comment for future updates.
(Reply from Devender Roberts, June 2008)
Contributors
Devender Roberts
Berghella, 23 January 2013
Summary
This review is one of the best and most comprehensive I have seen. However, I would suggest though adding ‘neonatal hypoglycemia’
as an outcome.
(Comment submitted by Vincenzo Berghella, January 2013)
Reply
Thank you for your comments. We will consider this for the next update.
Contributors
Devender Roberts, August 2016.
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WH A T ’ S N E W
Date Event Description
17 February 2016 New search has been performed Search updated. Themethods updated and the analyses
have been restructured. ’Summary of findings’ table has
been incorporated
17 February 2016 New citation required but conclusions have not
changed
Nine new studies added for this update (Attawattanakul
2015; Balci 2010; Goodner 1979; Gyamfi-Bannerman
2016; Khazardoust 2012; Lopez 1989;Mansouri 2010;
Porto 2011; Shanks 2010). The review now includes a
total of 30 studies. The conclusions remain unchanged
H I S T O R Y
Date Event Description
23 January 2013 Feedback has been incorporated Feedback 8 received from Vincenzo Berghella.
30 April 2010 Amended Search updated. Fourteen reports added to Studies awaiting classification
25 June 2008 Feedback has been incorporated Feedback from Vasiliy Vlassov added with a reply from the review author
23 June 2008 Amended Converted to new review format.
14 March 2007 Feedback has been incorporated Feedback from David Hutchon added.
30 October 2005 New search has been performed The review substantially updates the Crowley 2006 review due to new
Cochrane guidelines for inclusion and exclusion of studies and the need for
the review to be standardised with the repeat courses of prenatal corticos-
teroids review. Six new trials have been included (Amorim 1999; Dexiprom
1999; Fekih 2002; Lewis 1996; Nelson 1985; Qublan 2001). Three studies
that were included in the previous review have been excluded. The results
are now presented as relative risks. Results from recent follow-up studies have
been included. Individual participant data were available from the Liggins
and Howie study and these were analysed completely by intention-to-treat
analysis for the first time. These data contribute nearly a third of the data
to the review. This represents an important development. The review also
provides new information on corticosteroid use in the presence of rupture of
membranes, hypertension syndromes, in multiple pregnancies and according
to gestational age at first corticosteroid dose
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C O N T R I B U T I O N S O F A U T H O R S
P Crowley prepared the first version of the Cochrane Review in 1996.
S Dalziel and D Roberts revised the protocol for the 2005 update. Both review authors identified included and excluded studies,
extracted the data and wrote the discussion. S Dalziel entered the data and re-analysed data from the New Zealand Trial using intention
to treat. D Roberts entered the tables and contacted study authors for additional data.
In 2016 J Brown and N Medley assisted S Dalziel and D Roberts to update the review by entering and re-analysing the data and
drafting text of the review. J Brown created Table 1. N Medley created Summary of findings for the main comparison.
D E C L A R A T I O N S O F I N T E R E S T
Devender Roberts: none known.
Julie Brown: none known.
Nancy Medley: Nancy Medley’s work was financially supported by the a grant to University of Liverpool from the Harris-Wellbeing
Preterm Birth Centre.
Stuart R Dalziel: none known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Auckland, New Zealand.
• The University of Liverpool, UK.
• Liverpool Women’s NHS Foundation Trust, UK.
External sources
• Harris-Wellbeing of Women Preterm Birth Centre, UK.
• Health Research Council of New Zealand (HRC13/556), New Zealand.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The methods have been updated to current standard methods text for the Cochrane Pregnancy and Childbirth Group.
The following subgroups were not pre-specified in the protocol:
1. decade of trial;
2. gestational age at trial entry;
3. protocol with weekly repeats.
In the 2016 update, comparison one has been re-structured to include only the main analysis, with all clinical groups moved to
subsequent comparisons. We have also deleted subgroups from previous versions of the review related to post-randomisation variables
(gestational age to delivery and ruptured membranes at specific time points). A ’Summary of findings’ table has been incorporated in
this update (2016).
We clarified the primary outcome of deaths (fetal/neonatal) to perinatal deaths. Neonatal deaths and fetal deaths are still presented
separately as primary outcomes.
We renamed outcomes of mean length for children and adults as mean height.
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In response to referee feedback we changed the name of the primary outcome ’puerperal sepsis’ to ’endometritis (including infections)’.
Most trials (7/10) in this analysis specifically reported endometritis.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Premature Birth; Adrenal Cortex Hormones [∗administration & dosage]; Betamethasone [administration & dosage]; Dexamethasone
[administration & dosage]; Fetal Organ Maturity [∗drug effects]; Hydrocortisone [administration & dosage]; Lung [drug effects;
∗embryology]; Maternal Death; Perinatal Death; Prenatal Care [∗methods]; Respiratory Distress Syndrome, Newborn [∗prevention &
control]
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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